[CLS]
In
these
trials
,
63
##6
patients
were
treated
with
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
at
the
recommended
dose
of
400
m
##c
##g
twice
daily
.
[SEP]
[CLS]
Ad
##verse
reactions
resulted
in
interrupt
##ion
or
disco
##ntin
##uation
for
78
(
53
%
)
subjects
.
[SEP]
[CLS]
Ren
##al
disorders
:
g
##ly
##cos
##uria
,
hem
##og
##lo
##bin
##uria
.
[SEP]
[CLS]
In
patients
treated
for
these
two
indication
##s
,
there
was
no
apparent
correlation
of
anti
##body
frequency
,
anti
##body
t
##iter
##s
,
or
neutral
##izing
status
to
clinical
response
or
adverse
reactions
.
[SEP]
[CLS]
Inter
##rup
##t
and
then
reduce
or
disco
##ntin
##ue
Z
##yd
##eli
##g
as
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ad
##re
##V
##ie
##w
safety
and
efficacy
have
not
been
established
in
these
patients
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
(
6
.
1
)
*
In
patients
with
severe
a
##p
##lastic
an
##emia
,
the
most
common
adverse
reactions
(
greater
than
or
equal
to
20
%
)
were
:
nausea
,
[SEP]
[CLS]
fatigue
,
cough
,
di
##ar
##r
##hea
,
and
headache
.
[SEP]
[CLS]
Of
the
37
##2
patients
with
im
##mu
##no
##genic
##ity
assessment
at
base
##line
(
prior
to
receiving
be
##lat
##ace
##pt
treatment
)
,
29
patients
tested
positive
for
anti
-
be
##lat
##ace
##pt
antibodies
;
13
of
these
patients
had
[SEP]
[CLS]
antibodies
to
the
modified
c
##yt
##oto
##xi
##c
T
-
l
##ymph
##oc
##yte
-
associated
anti
##gen
4
(
CT
##LA
-
4
)
.
[SEP]
[CLS]
(
5
.
4
)
*
Monitor
for
di
##zzi
##ness
and
so
##m
##no
##len
##ce
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
Report
##ed
by
>
=
3
%
of
Pat
##ients
T
##reate
##d
with
C
##IM
##Z
##IA
Do
##sed
Every
Other
Week
during
Place
##bo
-
Control
##led
Period
of
R
##he
##uma
##to
##id
Art
##hr
##itis
Studies
,
with
Con
##com
##ita
##nt
Met
##hot
##re
##xa
##te
[SEP]
[CLS]
.
[SEP]
[CLS]
Sign
##s
and
symptoms
associated
with
more
severe
and
/
or
acute
cases
have
included
hall
##uc
##ination
,
s
##ync
##ope
,
seizure
,
coma
,
respiratory
arrest
,
and
death
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
R
##IS
##K
OF
T
##H
##Y
##RO
##ID
C
-
CE
##LL
T
##UM
##OR
##S
WA
##R
##NI
##NG
:
R
##IS
##K
OF
T
##H
##Y
##RO
##ID
C
-
CE
##LL
T
##UM
##OR
##S
*
In
male
and
female
rats
,
du
##lag
##lut
##ide
causes
a
dose
-
related
and
treatment
-
duration
-
dependent
[SEP]
[CLS]
increase
in
the
incidence
of
thy
##roid
C
-
cell
tumors
)
after
lifetime
exposure
.
[SEP]
[CLS]
A
gradual
reduction
in
the
dose
rather
than
abrupt
c
##ess
##ation
is
recommended
whenever
possible
.
[SEP]
[CLS]
Changes
in
body
weight
(
kg
)
and
the
proportion
of
subjects
with
>
=
7
%
gain
in
body
weight
from
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
[SEP]
[CLS]
flexible
-
dose
studies
in
adult
subjects
are
presented
in
Table
6
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
in
>
=
4
%
of
patients
treated
with
NE
##SI
##NA
25
mg
and
more
frequently
than
in
patients
who
received
place
##bo
are
summarized
in
Table
1
.
[SEP]
[CLS]
The
data
described
below
reflect
exposure
to
Pi
##cat
##o
(
r
)
gel
in
49
##9
subjects
with
act
##ini
##c
k
##era
##tosis
,
including
27
##4
subjects
exposed
to
Pi
##cat
##o
(
r
)
gel
field
[SEP]
[CLS]
treatment
(
skin
area
of
25
cm
2
in
the
face
or
scalp
regions
)
at
a
concentration
of
0
.
01
##5
%
once
daily
for
3
consecutive
days
,
and
225
[SEP]
[CLS]
subjects
exposed
to
Pi
##cat
##o
(
r
)
gel
field
treatment
(
skin
area
of
25
cm
2
in
the
trunk
or
ex
##tre
##mit
##ies
regions
)
at
a
concentration
of
0
.
05
%
[SEP]
[CLS]
once
daily
for
2
consecutive
days
.
[SEP]
[CLS]
*
A
place
##bo
-
controlled
study
with
another
long
-
acting
beta
##2
-
ad
##rene
##rg
##ic
ago
##nist
(
sa
##lm
##eter
##ol
)
showed
an
increase
in
as
##th
##ma
-
related
deaths
in
patients
receiving
sa
##lm
##eter
##ol
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
D
##ya
##x
Corp
.
at
1
-
88
##8
-
45
##2
-
52
##48
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
5
.
8
Em
##b
##ryo
-
f
##etal
To
##xi
##city
T
##RE
##AN
##DA
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
In
Study
3
,
22
/
230
(
9
.
6
%
)
patients
had
as
##par
##tate
amino
##tra
##ns
##fer
##ase
greater
than
or
equal
to
3
times
the
upper
limit
of
normal
during
the
overall
treatment
period
[SEP]
[CLS]
.
[SEP]
[CLS]
Consider
these
factors
prior
to
in
##iti
##ating
Q
##ute
##nza
treatment
.
[SEP]
[CLS]
A
##cute
re
##nal
failure
was
reported
more
frequently
in
patients
with
advanced
re
##lap
##sed
and
re
##fra
##ctor
##y
multiple
my
##elo
##ma
who
received
K
##y
##p
##rol
##is
mon
##otherapy
.
[SEP]
[CLS]
What
is
the
most
important
information
I
should
know
about
D
##U
##AV
##EE
?
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
reactions
are
described
in
greater
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
:
*
H
##yper
##sen
##si
##ti
##vity
reactions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
[SEP]
[CLS]
]
*
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
5
%
in
either
indication
)
[SEP]
[CLS]
are
nausea
,
di
##ar
##r
##hea
,
headache
and
p
##yre
##xia
.
[SEP]
[CLS]
Pat
##ients
received
ER
##WI
##NA
##Z
##E
25
,
000
International
Unit
/
m
2
/
dose
,
administered
by
in
##tra
##ven
##ous
in
##fusion
on
a
Monday
,
Wednesday
,
and
Friday
schedule
(
6
doses
)
as
a
replacement
for
[SEP]
[CLS]
doses
remaining
on
their
original
treatment
plan
.
[SEP]
[CLS]
However
,
br
##on
##chi
##tis
,
her
##pes
z
##ost
##er
,
in
##fluenza
,
sin
##us
##itis
,
and
pneumonia
were
more
common
in
G
##IL
##EN
##Y
##A
-
treated
patients
.
[SEP]
[CLS]
They
are
not
interchange
##able
with
the
other
preparations
of
b
##ot
##ulin
##um
to
##xin
products
and
,
therefore
,
Units
of
biological
activity
of
X
##E
##OM
##IN
can
not
be
compared
to
or
converted
into
[SEP]
[CLS]
Units
of
any
other
b
##ot
##ulin
##um
to
##xin
products
assessed
with
any
other
specific
ass
##ay
method
[
see
Des
##cription
(
11
)
]
.
[SEP]
[CLS]
When
switching
to
G
##IL
##EN
##Y
##A
from
immune
-
m
##od
##ulating
or
im
##mu
##nos
##up
##pressive
medications
,
consider
the
duration
of
their
effects
and
their
mode
of
action
to
avoid
un
##int
##ended
add
##itive
im
##mu
##nos
##up
##pressive
effects
.
[SEP]
[CLS]
(
5
.
6
)
*
H
##y
##pot
##hy
##roid
##ism
requiring
thy
##roid
hormone
replacement
has
been
reported
.
[SEP]
[CLS]
Whether
anti
##psy
##cho
##tic
drug
products
differ
in
their
potential
to
cause
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
is
unknown
.
[SEP]
[CLS]
Pro
##vide
patients
with
an
anti
-
di
##ar
##r
##hea
##l
agent
(
e
.
g
.
,
lo
##per
##ami
##de
)
for
self
-
administration
at
the
onset
of
di
##ar
##r
##hea
and
ins
##truct
patients
to
continue
anti
-
di
##ar
##r
##hea
##l
therapy
until
loose
bow
##el
movements
cease
[SEP]
[CLS]
for
12
hours
.
[SEP]
[CLS]
B
##EN
##L
##Y
##ST
##A
should
be
administered
by
healthcare
providers
prepared
to
manage
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
S
##UP
##IN
##E
H
##YP
##ER
##TE
##NS
##ION
WA
##R
##NI
##NG
:
S
##UP
##IN
##E
H
##YP
##ER
##TE
##NS
##ION
Monitor
su
##pine
blood
pressure
prior
to
and
during
treatment
and
more
frequently
when
increasing
doses
.
[SEP]
[CLS]
*
While
the
effect
of
weak
C
##YP
##3
##A
##4
inhibitor
##s
(
e
.
g
.
[SEP]
[CLS]
Table
2
sum
##mar
##izes
all
adverse
reactions
occurring
in
>
=
5
%
of
patients
(
2
or
more
patients
)
treated
with
al
##g
##lu
##cos
##idas
##e
al
##fa
in
clinical
trials
described
above
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
10
%
of
Treatment
-
Na
##ive
G
##D
##1
Pat
##ients
and
More
Fr
##e
##quent
##ly
than
Place
##bo
(
Trial
1
)
CE
##RD
##EL
##GA
(
N
=
20
)
Place
##bo
(
N
=
20
[SEP]
[CLS]
)
Ad
##verse
Re
##action
Pat
##ients
##n
(
%
)
Pat
##ients
##n
(
%
)
Art
##hra
##l
##gia
9
(
45
)
2
(
10
)
Head
##ache
8
(
40
)
6
(
30
)
[SEP]
[CLS]
Mi
##gra
##ine
2
(
10
)
0
(
0
)
Flat
##ule
##nce
2
(
10
)
1
(
5
)
Na
##use
##a
2
(
10
)
1
(
5
)
Oro
##pha
##ryn
##ge
##al
pain
2
[SEP]
[CLS]
(
10
)
1
(
5
)
Table
2
presents
the
profile
from
the
12
-
month
open
-
label
,
random
##ized
,
im
##ig
##lu
##cer
##ase
-
controlled
trial
of
159
treated
patients
switching
from
enzyme
replacement
therapy
[SEP]
[CLS]
(
ER
##T
)
(
Trial
2
)
.
[SEP]
[CLS]
The
Grade
3
laboratory
abnormal
##ities
were
elevated
total
bi
##li
##ru
##bin
reported
in
1
subject
each
.
[SEP]
[CLS]
E
##L
##I
##Q
##UI
##S
##2
.
5
mg
p
##o
bid
##35
+
/
-
3
days
En
##ox
##apa
##rin
40
mg
s
##c
q
##d
35
+
/
-
3
days
E
##L
##I
##Q
##UI
##S
2
.
5
mg
p
##o
bid
12
+
/
-
2
days
En
##ox
##apa
##rin
40
mg
s
##c
q
##d
12
+
/
-
2
days
E
##L
##I
##Q
##UI
##S
2
.
5
mg
p
##o
[SEP]
[CLS]
bid
12
+
/
-
2
days
En
##ox
##apa
##rin
30
mg
s
##c
q
##12
##h
12
+
/
-
2
days
First
dose
12
to
24
hours
post
surgery
First
dose
9
to
15
hours
prior
to
surgery
First
dose
12
[SEP]
[CLS]
to
24
hours
post
surgery
First
dose
9
to
15
hours
prior
to
surgery
First
dose
12
to
24
hours
post
surgery
First
dose
12
to
24
hours
post
surgery
[SEP]
[CLS]
All
treated
N
=
26
##7
##3
N
=
265
##9
N
=
150
##1
N
=
150
##8
N
=
159
##6
N
=
158
##8
Major
(
including
surgical
site
)
22
(
0
.
82
%
)
18
(
0
.
68
%
)
9
(
0
.
60
%
)
?
[SEP]
[CLS]
F
##lus
##h
immediately
with
water
if
U
##LE
##SF
##IA
(
r
)
Lot
##ion
comes
into
contact
with
eyes
.
[SEP]
[CLS]
1
Risk
##s
of
Treatment
in
Pat
##ients
with
In
##fect
##ious
Di
##ar
##r
##hea
If
infectious
et
##iol
##ogies
are
not
considered
,
and
F
##U
##L
##Y
##Z
##A
##Q
is
initiated
based
on
a
pre
##su
##mpt
##ive
diagnosis
of
non
-
infectious
di
##ar
##r
##hea
,
then
[SEP]
[CLS]
there
is
a
risk
that
patients
with
infectious
et
##iol
##ogies
will
not
receive
the
appropriate
treatments
,
and
their
disease
may
worse
##n
.
[SEP]
[CLS]
*
P
##ul
##mona
##ry
To
##xi
##city
:
Monitor
patients
for
new
or
worse
##ning
symptoms
(
5
.
10
)
.
[SEP]
[CLS]
(
5
.
1
,
13
.
1
)
*
T
##AN
##Z
##E
##UM
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
personal
or
family
history
of
M
##TC
or
in
patients
with
Multiple
End
##oc
##rine
Neo
##p
##lasia
syndrome
type
2
(
[SEP]
[CLS]
ME
##N
2
)
.
[SEP]
[CLS]
An
increased
rate
of
stroke
was
observed
during
the
transition
from
E
##L
##I
##Q
##UI
##S
to
war
##fari
##n
in
clinical
trials
in
at
##rial
fi
##bri
##lla
##tion
patients
.
[SEP]
[CLS]
Other
G
##LP
-
1
receptor
ago
##nist
##s
have
caused
dose
-
related
and
treatment
-
duration
-
dependent
thy
##roid
C
-
cell
tumors
)
in
rode
##nts
.
[SEP]
[CLS]
Act
##ivated
oral
charcoal
reduces
absorption
of
a
##pi
##xa
##ban
,
thereby
lowering
a
##pi
##xa
##ban
plasma
concentration
[
see
##O
##ver
##dos
##age
(
10
)
]
.
[SEP]
[CLS]
General
Di
##sor
##ders
and
Administration
Site
Con
##ditions
:
as
##the
##nia
,
chest
pain
,
ed
##ema
,
fatigue
,
feeling
abnormal
,
g
##ait
disturbance
,
in
##fluenza
-
like
symptoms
,
mass
,
pain
,
[SEP]
[CLS]
thirst
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
See
the
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
pre
##s
##cribing
information
for
description
of
adverse
reactions
associated
with
their
use
.
[SEP]
[CLS]
Disco
##ntin
##uations
Ad
##verse
reactions
led
to
treatment
disco
##ntin
##uation
in
21
%
of
patients
in
Studies
1
and
2
.
[SEP]
[CLS]
Keep
D
##U
##AV
##EE
and
all
other
medicines
out
of
the
reach
of
children
.
[SEP]
[CLS]
(
6
.
1
,
6
.
2
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
GE
Healthcare
at
1
-
800
-
65
##4
-
01
##18
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
General
information
about
the
safe
and
effective
use
of
D
##U
##AV
##EE
Medicine
##s
are
sometimes
prescribed
for
purposes
other
than
those
listed
in
a
Pat
##ient
Information
leaf
##let
.
[SEP]
[CLS]
ST
##EN
##DR
##A
was
administered
to
221
##5
men
during
clinical
trials
.
[SEP]
[CLS]
Re
##sp
##ira
##tory
,
Thor
##ac
##ic
and
Media
##st
##inal
Di
##sor
##ders
:
br
##on
##chi
##tis
,
cough
,
d
##ys
##p
##nea
,
e
##pis
##ta
##xi
##s
,
nasal
dry
##ness
,
para
##nas
##al
sin
##us
h
##yper
##se
##cre
##tion
,
p
##har
##yn
##ge
##al
ed
##ema
,
respiratory
tract
congestion
,
[SEP]
[CLS]
s
##nee
##zing
,
throat
irritation
,
upper
respiratory
tract
infection
.
[SEP]
[CLS]
Risk
may
be
increased
with
ne
##ut
##rop
##enia
,
age
,
s
##tero
##id
use
,
con
##com
##ita
##nt
use
of
NSA
##ID
##s
,
anti
-
plate
##let
therapy
or
anti
-
co
##agu
##lants
,
and
patients
with
a
prior
history
of
p
##el
##vic
[SEP]
[CLS]
radio
##ther
##ap
##y
,
ad
##hesion
##s
,
ul
##cer
##ation
and
G
##I
bleeding
.
[SEP]
[CLS]
The
treatment
disco
##ntin
##uation
rate
due
to
an
##emia
was
similar
in
subjects
random
##ized
to
receive
rib
##avi
##rin
dose
reduction
compared
to
subjects
random
##ized
to
receive
E
##SA
(
2
%
in
each
group
[SEP]
[CLS]
)
.
[SEP]
[CLS]
PR
##OM
##AC
##TA
in
##hibit
##s
U
##DP
-
g
##lu
##cu
##ron
##osy
##lt
##ran
##s
##fer
##ase
(
U
##G
##T
)
1A
##1
and
organic
an
##ion
-
transporting
p
##oly
##pe
##pt
##ide
(
O
##AT
##P
)
1
##B
##1
,
which
may
lead
to
indirect
h
##yper
##bil
##ir
##ubi
##ne
##mia
.
[SEP]
[CLS]
The
median
duration
of
treatment
was
10
.
9
months
for
both
T
##AF
##IN
##LA
##R
and
tram
##eti
##ni
##b
(
2
-
mg
oral
##ly
once
-
daily
treatment
group
)
when
used
in
combination
,
10
.
6
months
for
both
T
##AF
##IN
##LA
##R
[SEP]
[CLS]
and
tram
##eti
##ni
##b
(
1
-
mg
oral
##ly
once
-
daily
treatment
group
)
when
used
in
combination
,
and
6
.
1
months
for
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
abdominal
di
##sten
##tion
,
abdominal
pain
,
con
##st
##ip
##ation
,
dry
mouth
,
d
##ys
##pe
##ps
##ia
,
flat
##ule
##nce
,
frequent
stool
##s
,
gas
##tri
##tis
,
gas
##tro
##es
##op
##hage
##al
re
##f
##lux
disease
,
gas
##tro
##int
##est
##inal
discomfort
,
[SEP]
[CLS]
g
##ing
##ival
pain
,
ha
##ema
##tem
##esis
,
h
##yper
##ch
##lor
##hy
##dr
##ia
,
hem
##ato
##che
##zia
,
mouth
ul
##cer
##ation
,
pan
##cre
##ati
##tis
,
p
##ept
##ic
ul
##cer
,
vomit
##ing
.
[SEP]
[CLS]
Report
any
diagnosis
of
N
##SF
following
G
##ada
##vist
administration
to
Bay
##er
Healthcare
(
1
-
88
##8
-
84
##2
-
29
##37
)
or
FDA
(
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
)
.
[SEP]
[CLS]
5
.
9
Ren
##al
I
##mp
##air
##ment
and
F
##ail
##ure
Mark
##ed
increase
in
serum
c
##rea
##tin
##ine
,
pre
-
re
##nal
a
##zo
##tem
##ia
and
acute
re
##nal
failure
,
often
in
the
setting
of
heart
failure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
[SEP]
[CLS]
(
5
.
4
)
]
or
h
##y
##po
##vo
##lem
##ia
,
have
been
reported
in
patients
taking
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
T
##iss
##ue
culture
experiments
indicate
that
approximately
one
-
third
of
human
breast
cancer
##s
are
pro
##la
##ct
##in
-
dependent
in
v
##it
##ro
,
a
factor
of
potential
importance
if
the
prescription
of
these
drugs
is
considered
in
[SEP]
[CLS]
a
patient
with
previously
-
detected
breast
cancer
.
[SEP]
[CLS]
(
5
.
1
)
Local
skin
reactions
)
.
[SEP]
[CLS]
In
the
re
##lap
##sed
classical
H
##L
and
s
##AL
##CL
clinical
trials
,
54
%
of
patients
experienced
any
grade
of
ne
##uro
##pathy
.
[SEP]
[CLS]
The
percentage
of
patients
who
exceeded
a
pre
##det
##ermined
threshold
value
is
shown
in
Table
4
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Sal
##ix
Ph
##arma
##ce
##utical
##s
at
1
-
800
-
50
##8
-
00
##24
or
www
.
Sal
##ix
.
com
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
5
.
[SEP]
[CLS]
(
5
.
2
)
*
Contact
der
##mat
##itis
:
May
occur
with
U
##LE
##SF
##IA
(
r
)
Lot
##ion
.
[SEP]
[CLS]
Card
##io
##my
##op
##athy
was
identified
within
the
first
month
of
treatment
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
in
two
of
five
patients
.
[SEP]
[CLS]
The
disco
##ntin
##uation
rate
due
to
bleeding
events
was
approximately
1
%
in
the
E
##L
##I
##Q
##UI
##S
-
treated
patients
compared
to
0
.
4
%
in
those
patients
in
the
place
##bo
group
in
the
AM
##PL
##IF
##Y
-
E
##XT
study
[SEP]
[CLS]
.
[SEP]
[CLS]
These
reactions
occurred
within
the
first
hour
after
dos
##ing
.
[SEP]
[CLS]
Op
##port
##uni
##stic
infections
have
also
been
reported
in
patients
treated
with
IL
##AR
##IS
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ad
##vise
patients
to
immediately
seek
medical
care
if
they
develop
symptoms
of
D
##V
##T
or
P
##E
,
such
as
short
##ness
of
breath
,
chest
pain
,
or
arm
or
leg
swelling
[SEP]
[CLS]
.
[SEP]
[CLS]
For
patients
who
develop
a
new
infection
during
treatment
with
S
##IM
##PO
##NI
ARIA
,
perform
a
pro
##mpt
and
complete
diagnostic
work
##up
appropriate
for
an
im
##mu
##no
##com
##p
##rom
##ised
patient
and
initiate
appropriate
anti
##mic
##ro
##bial
therapy
[SEP]
[CLS]
and
closely
monitor
them
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
laboratory
testing
prior
to
in
##iti
##ating
therapy
and
monitoring
for
he
##pa
##to
##to
##xi
##city
during
therapy
with
T
##I
##VI
##CA
##Y
are
recommended
in
patients
with
underlying
he
##pa
##tic
disease
such
as
he
##pa
##titis
B
or
C
.
5
.
3
[SEP]
[CLS]
Fat
Red
##ist
##ri
##but
##ion
buffalo
hum
##p
,
facial
wasting
,
breast
en
##lar
##gement
,
and
`
`
cu
##shing
##oid
appearance
'
'
have
been
observed
in
patients
receiving
anti
##ret
##rov
##ira
##l
therapy
.
[SEP]
[CLS]
The
data
reflect
the
percentage
of
patients
whose
test
results
were
positive
for
antibodies
to
be
##lim
##uma
##b
in
specific
ass
##ays
.
[SEP]
[CLS]
Of
the
60
##9
subjects
,
58
%
were
female
and
84
%
were
white
;
the
mean
age
was
40
years
.
[SEP]
[CLS]
This
may
result
in
a
critical
loss
of
breathing
capacity
in
patients
with
respiratory
disorders
who
may
have
become
dependent
upon
these
access
##ory
muscles
.
[SEP]
[CLS]
5
.
2
Bull
##ous
and
Ex
##folia
##tive
Skin
Di
##sor
##ders
Grade
3
cut
##aneous
reactions
characterized
by
ex
##folia
##ting
lesions
occurred
in
6
(
0
.
15
%
)
of
the
38
##65
patients
who
received
G
##IL
##OT
##RI
##F
across
clinical
[SEP]
[CLS]
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Car
##fi
##l
##zo
##mi
##b
caused
em
##b
##ryo
-
f
##etal
toxicity
in
pregnant
rabbits
at
doses
that
were
lower
than
in
patients
receiving
the
recommended
dose
.
[SEP]
[CLS]
Table
4
lists
treatment
-
emerge
##nt
adverse
reactions
that
occurred
in
>
=
2
%
of
patients
with
R
##LS
treated
with
H
##OR
##I
##Z
##AN
##T
and
numerical
##ly
greater
than
place
##bo
.
[SEP]
[CLS]
Pat
##ients
,
their
care
##gi
##vers
,
and
families
should
be
advised
of
the
need
to
be
alert
for
the
emergence
or
worse
##ning
of
depression
,
su
##icidal
thoughts
or
other
mood
changes
[SEP]
[CLS]
,
and
if
such
changes
occur
to
contact
their
healthcare
provider
.
[SEP]
[CLS]
Although
the
prevalence
of
the
syndrome
appears
to
be
highest
among
the
elderly
,
especially
elderly
women
,
it
is
impossible
to
rely
on
prevalence
estimates
to
predict
,
at
[SEP]
[CLS]
the
inception
of
anti
##psy
##cho
##tic
treatment
,
which
patients
are
likely
to
develop
the
syndrome
.
[SEP]
[CLS]
Prior
and
Con
##com
##ita
##nt
Treatment
with
Anti
##ne
##op
##lastic
,
I
##mm
##uno
##su
##pp
##ress
##ive
,
or
I
##mm
##une
-
Mo
##du
##lating
The
##rap
##ies
In
clinical
studies
,
patients
who
received
G
##IL
##EN
##Y
##A
did
not
receive
con
##com
##ita
##nt
treatment
with
anti
##ne
##op
##lastic
,
non
-
co
##rt
##ico
##ster
##oid
im
##mu
##nos
##up
##pressive
[SEP]
[CLS]
,
or
immune
-
m
##od
##ulating
the
##rap
##ies
used
for
treatment
of
MS
.
Con
##com
##ita
##nt
use
of
G
##IL
##EN
##Y
##A
with
any
of
these
the
##rap
##ies
,
and
also
with
co
##rt
##ico
##ster
##oids
,
would
be
expected
to
increase
the
[SEP]
[CLS]
risk
of
im
##mu
##nos
##up
##press
##ion
[
see
Drug
Inter
##actions
(
7
)
]
.
[SEP]
[CLS]
There
were
no
adverse
reactions
resulting
in
permanent
disco
##ntin
##uation
.
[SEP]
[CLS]
In
patients
>
=
75
years
of
age
,
the
risk
of
cardiac
failure
is
increased
.
[SEP]
[CLS]
5
.
5
Use
with
A
##bat
##ace
##pt
In
controlled
trials
,
the
concurrent
administration
of
another
T
##NF
-
block
##er
and
a
##bat
##ace
##pt
was
associated
with
a
greater
proportion
of
serious
infections
than
the
use
of
a
[SEP]
[CLS]
T
##NF
-
block
##er
alone
;
and
the
combination
therapy
,
compared
to
the
use
of
a
T
##NF
-
block
##er
alone
,
has
not
demonstrated
improved
clinical
benefit
in
the
treatment
of
RA
.
[SEP]
[CLS]
In
both
Studies
1
and
2
,
amino
##tra
##ns
##fer
##ase
elevations
of
at
least
3
times
the
upper
limit
of
normal
developed
more
frequently
in
the
S
##IR
##TU
##RO
treatment
group
(
11
/
102
[
[SEP]
[CLS]
10
.
8
%
]
vs
6
/
105
[
5
.
7
%
]
)
than
in
the
place
##bo
treatment
group
.
[SEP]
[CLS]
The
incidence
rates
of
ad
##ju
##dicated
bone
fracture
##s
were
1
.
1
,
1
.
4
,
and
1
.
5
per
100
patient
-
years
of
exposure
in
the
com
##par
##ator
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
[SEP]
[CLS]
mg
groups
,
respectively
.
[SEP]
[CLS]
The
most
frequent
serious
adverse
events
reported
in
patients
treated
with
X
##AL
##KO
##RI
were
d
##ys
##p
##nea
(
4
.
1
%
)
and
pulmonary
em
##bol
##ism
(
2
.
9
%
)
.
[SEP]
[CLS]
No
study
adequate
to
determine
whether
the
rate
of
as
##th
##ma
-
related
death
is
increased
in
patients
treated
with
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
has
been
conducted
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
including
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
,
r
##ash
,
u
##rt
##ica
##ria
and
severe
cut
##aneous
adverse
reactions
,
including
Stevens
-
Johnson
syndrome
,
he
##pa
##tic
enzyme
elevations
,
f
##ul
##mina
##nt
he
##pa
##tic
failure
,
severe
and
[SEP]
[CLS]
di
##sa
##bling
art
##hra
##l
##gia
and
acute
pan
##cre
##ati
##tis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
2
,
5
.
3
,
5
.
5
)
]
.
[SEP]
[CLS]
Case
##s
of
S
##J
##S
and
T
##EN
,
some
fatal
,
have
been
reported
when
T
##RE
##AN
##DA
was
administered
con
##com
##ita
##ntly
with
all
##op
##uri
##no
##l
and
other
medications
known
to
cause
these
syndrome
##s
.
[SEP]
[CLS]
(
2
.
2
)
Co
##mp
##lication
##s
of
my
##elo
##su
##pp
##ression
may
lead
to
death
.
[SEP]
[CLS]
Ad
##verse
reactions
of
sin
##us
ta
##chy
##card
##ia
were
reported
more
frequently
in
patients
exposed
to
T
##R
##U
##L
##IC
##IT
##Y
.
[SEP]
[CLS]
Ad
##verse
Re
##action
(
Pre
##ferred
Te
##rm
)
Place
##bo
+
M
##T
##X
(
%
)
N
=
32
##4
C
##IM
##Z
##IA
200
mg
E
##OW
+
M
##T
##X
(
%
)
N
=
640
Upper
respiratory
tract
infection
2
6
[SEP]
[CLS]
Head
##ache
4
5
H
##yper
##tens
##ion
2
5
Na
##so
##pha
##ryn
##git
##is
1
5
Back
pain
1
4
P
##yre
##xia
2
3
Ph
##ary
##ng
##itis
1
3
Ra
##sh
1
3
A
##cute
br
##on
##chi
##tis
1
3
Fat
##ig
##ue
2
3
[SEP]
[CLS]
H
##yper
##tensive
adverse
reactions
were
observed
more
frequently
in
patients
receiving
C
##IM
##Z
##IA
than
in
controls
.
[SEP]
[CLS]
5
.
7
Top
##ical
Op
##ht
##hal
##mic
Use
Only
D
##UR
##E
##Z
##OL
is
not
indicated
for
in
##tra
##oc
##ular
administration
.
[SEP]
[CLS]
1
.
5
8
.
4
6
.
9
Na
##so
##pha
##ryn
##git
##is
6
.
2
6
.
6
6
.
3
U
##rina
##ry
tract
infections
##U
##rina
##ry
tract
infections
include
the
following
adverse
reactions
,
listed
in
order
of
frequency
reported
:
u
##rina
##ry
tract
infection
,
[SEP]
[CLS]
c
##ys
##titis
,
E
##scher
##ichi
##a
u
##rina
##ry
tract
infection
,
g
##eni
##tour
##ina
##ry
tract
infection
,
p
##ye
##lone
##ph
##rit
##is
,
t
##rig
##oni
##tis
,
u
##ret
##hr
##itis
,
kidney
infection
,
and
pro
##sta
##titis
.
[SEP]
[CLS]
T
##AN
##Z
##E
##UM
was
used
as
mon
##otherapy
in
1
trial
and
as
add
-
on
therapy
in
3
trials
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Nine
##ty
-
two
percent
(
92
%
)
of
patients
on
the
CO
##ME
##TR
##I
##Q
arm
had
a
prior
thy
##roid
##ec
##tom
##y
,
and
89
%
were
taking
thy
##roid
hormone
replacement
prior
to
the
first
dose
[SEP]
[CLS]
.
[SEP]
[CLS]
*
Fat
##al
and
serious
in
##test
##inal
per
##fo
##ration
can
occur
in
Z
##yd
##eli
##g
-
treated
patients
across
clinical
trials
.
[SEP]
[CLS]
The
adverse
reactions
described
in
this
section
reflect
E
##O
##VI
##ST
exposure
in
1
,
98
##9
subjects
with
the
majority
(
1
,
58
##1
subjects
)
receiving
the
recommended
dose
.
[SEP]
[CLS]
Case
##s
were
consistent
with
he
##pa
##to
##cellular
injury
,
including
elevations
of
trans
##ami
##nas
##es
.
[SEP]
[CLS]
g
##fa
##tal
:
Ad
##ju
##dicated
major
bleed
as
defined
above
and
ad
##ju
##dicated
death
with
primary
cause
from
bleeding
but
without
s
##ym
##pt
##oma
##tic
in
##tra
##c
##rani
##al
bleed
based
on
investigator
'
s
clinical
assessment
.
[SEP]
[CLS]
Although
BR
##E
##O
E
##LL
##IP
##TA
may
control
CO
##PD
or
as
##th
##ma
symptoms
during
these
episodes
,
in
recommended
doses
it
supplies
less
than
normal
physiological
amounts
of
g
##lu
##co
##cor
##tic
##oid
systemic
##ally
and
does
NO
##T
provide
[SEP]
[CLS]
the
mineral
##oc
##ort
##ico
##id
activity
that
is
necessary
for
cop
##ing
with
these
emerge
##ncies
.
[SEP]
[CLS]
The
majority
of
the
patients
were
white
(
87
.
7
%
)
,
10
.
3
%
were
Asian
,
and
1
.
9
%
were
black
with
a
mean
C
##r
##C
##l
of
105
.
6
m
##L
/
min
.
[SEP]
[CLS]
Data
from
a
large
,
prospective
co
##hor
##t
safety
study
of
various
CO
##Cs
suggest
that
this
increased
risk
,
as
compared
to
that
in
non
-
CO
##C
users
,
is
greatest
during
the
[SEP]
[CLS]
first
6
months
of
CO
##C
use
.
[SEP]
[CLS]
T
##R
##U
##L
##IC
##IT
##Y
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
personal
or
family
history
of
M
##TC
or
in
patients
with
ME
##N
2
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
FA
##TA
##L
AND
SE
##RI
##O
##US
TO
##X
##IC
##IT
##IE
##S
,
SE
##VE
##RE
D
##IA
##R
##R
##H
##EA
,
CO
##L
##IT
##IS
,
P
##NE
##UM
##ON
##IT
##IS
,
and
IN
##TE
##ST
##IN
##AL
P
##ER
##F
##OR
##AT
##ION
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Inc
##reased
su
##s
##ce
##pt
##ibility
to
infection
and
the
possible
development
of
ma
##li
##gna
##ncies
may
result
from
im
##mu
##nos
##up
##press
##ion
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
3
,
5
.
4
,
5
.
5
)
]
.
[SEP]
[CLS]
The
adverse
reaction
profile
was
similar
after
each
injection
,
regardless
of
the
number
of
injection
##s
administered
.
[SEP]
[CLS]
5
.
7
H
##yper
##tens
##ion
As
##ses
##s
the
patient
'
s
pulse
and
blood
pressure
before
and
intermittent
##ly
for
30
minutes
after
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
(
5
.
2
)
item
{
Del
##ay
##ed
healing
-
The
use
of
s
##tero
##ids
after
cat
##ara
##ct
surgery
may
delay
healing
and
increase
the
incidence
of
b
##le
##b
formation
.
[SEP]
[CLS]
Anti
-
be
##lat
##ace
##pt
anti
##body
t
##iter
##s
did
not
increase
during
treatment
in
these
29
patients
.
[SEP]
[CLS]
Per
##cent
##age
(
%
)
of
Pat
##ients
Y
##ER
##VO
##Y
##3
mg
/
kg
##n
=
131
Y
##ER
##VO
##Y
##3
mg
/
kg
+
g
##p
##100
##n
=
380
Any
I
##mm
##une
-
mediated
Ad
##verse
Re
##action
15
12
En
##tero
##co
##lit
##isa
,
b
7
7
He
##pa
##to
##to
##xi
##city
##a
1
2
Der
##mat
##itis
##a
2
3
N
##eur
##op
##athy
##a
1
<
[SEP]
[CLS]
1
End
##oc
##rino
##pathy
4
1
H
##y
##pop
##it
##uit
##aris
##m
4
1
Ad
##rena
##l
ins
##uff
##iciency
0
1
Other
P
##ne
##um
##oni
##tis
0
<
1
Men
##ing
##itis
0
<
1
N
##ep
##hr
##itis
1
0
E
##os
##ino
##phi
##lia
##c
1
0
Per
##ica
##rdi
##tis
##a
,
c
0
[SEP]
[CLS]
<
1
Across
clinical
studies
that
utilized
Y
##ER
##VO
##Y
doses
ranging
from
0
.
3
to
10
mg
/
kg
,
the
following
adverse
reactions
were
also
reported
(
incidence
less
than
1
%
unless
[SEP]
[CLS]
otherwise
noted
)
:
u
##rt
##ica
##ria
(
2
%
)
,
large
in
##test
##inal
ul
##cer
,
es
##op
##ha
##git
##is
,
acute
respiratory
distress
syndrome
,
re
##nal
failure
,
and
in
##fusion
reaction
.
[SEP]
[CLS]
Therefore
,
BR
##E
##O
E
##LL
##IP
##TA
,
like
other
s
##ym
##path
##omi
##met
##ic
am
##ines
,
should
be
used
with
caution
in
patients
with
card
##iovascular
disorders
,
especially
co
##rona
##ry
ins
##uff
##iciency
,
cardiac
a
##rr
##hy
##th
##mia
##s
,
and
h
##yper
##tens
##ion
[SEP]
[CLS]
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
for
these
symptoms
when
disco
##ntin
##uing
treatment
with
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
In
other
XI
##AF
##LE
##X
-
treated
patients
(
9
of
104
##4
;
0
.
9
%
)
,
a
diagnosis
of
co
##rp
##oral
r
##up
##ture
can
not
be
excluded
.
[SEP]
[CLS]
Pat
##ients
receiving
C
##IM
##Z
##IA
400
mg
as
mon
##otherapy
every
4
weeks
in
r
##he
##uma
##to
##id
art
##hr
##itis
controlled
clinical
trials
had
similar
adverse
reactions
to
those
patients
receiving
C
##IM
##Z
##IA
200
mg
every
other
week
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
1
)
*
Ser
##ious
Der
##mat
##olo
##gic
Re
##actions
,
Drug
Re
##action
with
E
##os
##ino
##phi
##lia
and
System
##ic
S
##ym
##pt
##oms
(
DR
##ES
##S
)
,
Ana
##phy
##la
##ctic
Re
##actions
and
Ang
##io
##ede
##ma
:
Monitor
and
disco
##ntin
##ue
if
another
cause
[SEP]
[CLS]
can
not
be
established
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
AS
##TH
##MA
-
R
##EL
##AT
##ED
DE
##AT
##H
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
*
Long
-
acting
beta
##2
-
ad
##rene
##rg
##ic
ago
##nist
##s
(
LA
##BA
)
increase
the
risk
of
as
##th
##ma
-
related
death
(
5
.
1
)
[SEP]
[CLS]
.
[SEP]
[CLS]
A
ca
##usal
relationship
between
study
drug
and
adverse
reactions
was
not
always
established
.
[SEP]
[CLS]
In
a
study
of
55
subjects
with
varying
degrees
of
re
##nal
function
,
serum
calcium
levels
<
7
.
5
mg
/
d
##L
or
s
##ym
##pt
##oma
##tic
h
##y
##po
##cal
##ce
##mia
were
observed
in
5
subjects
.
[SEP]
[CLS]
Seven
(
8
.
9
%
)
S
##IR
##TU
##RO
-
treated
patients
and
six
(
7
.
4
%
)
place
##bo
-
treated
patients
discontinued
Study
1
because
of
an
adverse
reaction
.
[SEP]
[CLS]
A
total
of
171
patients
in
the
ch
##em
##otherapy
arm
received
p
##em
##et
##re
##xed
500
mg
/
m
2
(
n
=
99
)
or
do
##ce
##ta
##xe
##l
75
mg
/
m
2
(
n
=
72
)
by
in
##tra
##ven
##ous
in
##fusion
every
three
[SEP]
[CLS]
weeks
until
documented
disease
progression
,
into
##ler
##ance
to
therapy
,
or
the
investigator
determined
that
the
patient
was
no
longer
experiencing
clinical
benefit
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Associated
with
Disco
##ntin
##uation
of
Treatment
:
Approximately
10
%
(
38
/
37
##9
)
of
SA
##P
##H
##RI
##S
-
treated
patients
in
short
-
term
,
place
##bo
-
controlled
trials
discontinued
treatment
due
to
an
adverse
reaction
,
[SEP]
[CLS]
compared
with
about
6
%
(
12
/
203
)
on
place
##bo
.
[SEP]
[CLS]
Mali
##gna
##ncies
in
Adult
Pat
##ients
The
risks
and
benefits
of
T
##NF
-
block
##er
treatment
including
S
##IM
##PO
##NI
ARIA
should
be
considered
prior
to
in
##iti
##ating
therapy
in
patients
with
a
known
ma
##li
##gna
##ncy
other
than
a
[SEP]
[CLS]
successfully
treated
non
-
me
##lan
##oma
skin
cancer
(
N
##MS
##C
)
or
when
considering
continuing
a
T
##NF
-
block
##er
in
patients
who
develop
a
ma
##li
##gna
##ncy
.
[SEP]
[CLS]
The
most
frequently
reported
adverse
reaction
was
headache
(
1
.
5
%
)
.
[SEP]
[CLS]
This
may
result
in
critical
loss
of
breathing
capacity
in
patients
with
respiratory
disorders
who
may
have
become
dependent
upon
these
access
##ory
muscles
.
[SEP]
[CLS]
The
safety
data
described
below
are
based
on
two
12
-
week
efficacy
trials
,
one
24
-
week
efficacy
trial
,
and
two
long
-
term
trials
.
[SEP]
[CLS]
Because
post
##market
##ing
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
[SEP]
[CLS]
exposure
.
[SEP]
[CLS]
The
incidence
of
mac
##ular
ed
##ema
is
also
increased
in
MS
patients
with
a
history
of
u
##ve
##itis
.
[SEP]
[CLS]
Pat
##ients
should
be
instructed
to
contact
their
healthcare
provider
if
they
experience
new
or
worse
##ning
depression
,
su
##icidal
thoughts
or
other
mood
changes
.
[SEP]
[CLS]
At
screening
,
the
mean
post
##bro
##nch
##od
##ila
##tor
percent
predicted
F
##E
##V
##1
##was
45
%
(
range
:
12
%
to
91
%
)
,
and
the
mean
post
##bro
##nch
##od
##ila
##tor
F
##E
##V
##1
/
F
##VC
ratio
was
46
%
[SEP]
[CLS]
(
range
:
17
%
to
81
%
)
,
indicating
that
the
subject
population
had
moderate
to
very
severely
impaired
air
##flow
o
##bs
##truction
.
[SEP]
[CLS]
Pat
##ients
were
between
the
ages
of
16
and
63
on
the
date
of
the
first
dose
of
study
drug
,
and
included
20
males
and
20
females
.
[SEP]
[CLS]
Eva
##lu
##ate
for
tuberculosis
and
initiate
treatment
for
late
##nt
infection
prior
to
N
##U
##L
##O
##J
##IX
use
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
In
the
pool
of
7
place
##bo
-
and
active
-
controlled
trials
,
116
(
5
.
5
%
)
of
2
,
09
##8
patients
exposed
to
T
##AN
##Z
##E
##UM
tested
positive
for
anti
-
al
##bi
##g
##lut
##ide
antibodies
at
any
time
[SEP]
[CLS]
during
the
trials
.
[SEP]
[CLS]
P
##sy
##chia
##tric
disorders
-
De
##person
##ali
##zation
,
br
##ux
##ism
.
[SEP]
[CLS]
B
##lee
##ding
into
an
operated
joint
requiring
re
-
operation
or
intervention
was
present
in
all
patients
with
this
category
of
bleeding
.
[SEP]
[CLS]
Se
##vere
h
##yper
##sen
##si
##ti
##vity
:
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
can
occur
and
may
include
generalized
r
##ash
/
er
##yt
##hem
##a
,
h
##y
##pot
##ens
##ion
and
br
##on
##cho
##sp
##as
##m
.
[SEP]
[CLS]
Among
these
were
ve
##rt
##igo
(
2
patients
)
,
infections
(
3
patients
)
,
including
in
##tra
-
abdominal
a
##bs
##cess
following
app
##end
##ec
##tom
##y
(
1
patient
)
.
[SEP]
[CLS]
It
is
unknown
whether
T
##AN
##Z
##E
##UM
causes
thy
##roid
C
-
cell
tumors
,
including
me
##du
##llar
##y
thy
##roid
car
##cin
##oma
(
M
##TC
)
,
in
humans
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Op
##ht
##hal
##mic
Ad
##verse
Re
##actions
A
##vo
##id
treatment
in
the
per
##io
##cular
area
.
[SEP]
[CLS]
In
the
third
case
,
elevation
in
AL
##T
(
10
times
the
upper
limit
of
normal
)
was
accompanied
by
an
increase
in
total
bi
##li
##ru
##bin
(
4
times
the
upper
[SEP]
[CLS]
limit
of
normal
)
and
occurred
8
days
after
the
first
dose
of
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
5
.
4
Gen
##ital
My
##cot
##ic
In
##fect
##ions
J
##AR
##DI
##AN
##CE
increases
the
risk
for
g
##eni
##tal
my
##cot
##ic
infections
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Use
caution
in
patients
with
hem
##og
##lo
##bin
<
10
g
/
d
##L
.
[SEP]
[CLS]
In
SA
##P
##H
##RI
##S
adult
clinical
trials
,
the
incidence
##s
of
adverse
events
related
to
abnormal
pro
##la
##ct
##in
levels
were
0
.
4
%
versus
0
%
for
place
##bo
.
[SEP]
[CLS]
Con
##com
##ita
##nt
use
of
drugs
affecting
hem
##ost
##asis
increases
the
risk
of
bleeding
.
[SEP]
[CLS]
5
.
6
Bone
Effects
of
Ten
##of
##ov
##ir
D
##F
Bone
Mine
##ral
Den
##sity
:
In
clinical
trials
in
HIV
-
1
infected
adults
,
ten
##of
##ov
##ir
D
##F
(
a
component
of
ST
##RI
##BI
##LD
)
was
associated
with
slightly
[SEP]
[CLS]
greater
decreases
in
bone
mineral
density
)
and
increases
in
bio
##chemical
markers
of
bone
metabolism
,
suggesting
increased
bone
turnover
relative
to
com
##par
##ators
.
[SEP]
[CLS]
5
.
6
Em
##b
##ryo
##fe
##tal
To
##xi
##city
Based
on
its
mechanism
of
action
,
X
##AL
##KO
##RI
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
N
##er
##vous
System
Di
##sor
##ders
:
altered
taste
,
balance
disorder
,
c
##ere
##bro
##vas
##cular
accident
,
G
##uil
##lain
-
Barr
##e
syndrome
,
headache
,
hem
##ip
##ares
##is
,
h
##y
##po
##est
##hesia
,
h
##y
##po
##sm
##ia
,
la
##cu
##nar
in
##far
##ction
,
let
##har
##gy
,
[SEP]
[CLS]
mental
imp
##air
##ment
,
mi
##gra
##ine
,
par
##est
##hesia
,
so
##m
##no
##len
##ce
,
trans
##ient
is
##che
##mic
attack
,
t
##rem
##or
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
history
of
severe
h
##yper
##sen
##si
##ti
##vity
reactions
to
cab
##azi
##ta
##xe
##l
or
to
other
drugs
formulated
with
p
##oly
##sor
##bate
80
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
*
De
##my
##elin
##ating
disease
,
may
occur
(
5
.
4
)
.
[SEP]
[CLS]
(
5
.
2
)
*
W
##orse
##ning
of
narrow
-
angle
g
##lau
##com
##a
may
occur
.
[SEP]
[CLS]
In
an
open
-
label
,
long
-
term
extension
study
of
two
of
these
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trials
,
the
total
duration
of
treatment
was
up
to
52
weeks
.
[SEP]
[CLS]
Co
##arte
##m
Table
##ts
may
reduce
the
effectiveness
of
ho
##rmon
##al
con
##tra
##ceptive
##s
.
[SEP]
[CLS]
Treatment
delay
or
dos
##age
reduction
may
be
necessary
if
patients
experience
Grade
>
=
3
di
##ar
##r
##hea
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
A
##vo
##id
use
of
GB
##CA
##s
among
these
patients
unless
the
diagnostic
information
is
essential
and
not
available
with
non
-
contrast
enhanced
MR
##I
or
other
m
##oda
##lities
.
[SEP]
[CLS]
V
##as
##cular
Di
##sor
##ders
:
flush
##ing
,
hot
flush
,
h
##yper
##tens
##ion
,
h
##y
##pot
##ens
##ion
.
[SEP]
[CLS]
In
Study
3
,
serious
adverse
reactions
,
regardless
of
ca
##usal
##ity
,
were
reported
in
25
%
of
AD
##CE
##TR
##IS
-
treated
patients
.
[SEP]
[CLS]
Therefore
,
patients
using
oral
,
trans
##der
##mal
patch
,
or
other
systemic
ho
##rmon
##al
con
##tra
##ceptive
##s
should
be
advised
to
use
an
additional
non
-
ho
##rmon
##al
method
of
birth
control
[
see
Drug
Inter
##actions
[SEP]
[CLS]
(
7
.
5
)
]
.
[SEP]
[CLS]
P
##sy
##chia
##tric
Di
##sor
##ders
:
agitation
,
anxiety
,
depression
,
ins
##om
##nia
,
i
##rri
##ta
##bility
,
l
##ibi
##do
decreased
,
nervous
##ness
,
panic
attack
,
personality
change
.
[SEP]
[CLS]
*
Ser
##ious
infections
leading
to
hospital
##ization
or
death
including
tuberculosis
(
T
##B
)
,
bacterial
se
##psis
,
his
##top
##las
##mos
##is
have
occurred
in
patients
receiving
S
##IM
##PO
##NI
ARIA
(
5
.
1
)
.
[SEP]
[CLS]
Ad
##verse
reactions
led
to
dose
reduction
##s
in
49
%
and
dose
interrupt
##ions
in
67
%
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
chronic
or
re
##current
g
##eni
##tal
my
##cot
##ic
infections
were
more
likely
to
develop
my
##cot
##ic
g
##eni
##tal
infections
.
[SEP]
[CLS]
5
.
4
N
##eg
##ative
In
##ot
##rop
##y
Di
##hy
##dr
##opy
##rid
##ine
calcium
channel
block
##ers
can
produce
negative
in
##ot
##ropic
effects
and
ex
##ace
##rb
##ate
heart
failure
.
[SEP]
[CLS]
b
Includes
all
preferred
terms
within
the
'
infections
and
in
##fest
##ations
'
system
organ
class
,
the
most
common
being
na
##so
##pha
##ryn
##git
##is
(
6
%
)
,
pneumonia
(
6
%
)
[SEP]
[CLS]
,
u
##rina
##ry
tract
infection
(
5
%
)
,
br
##on
##chi
##tis
(
4
%
)
,
and
sin
##us
##itis
(
3
%
)
,
and
also
including
as
##per
##gill
##osis
(
<
1
%
[SEP]
[CLS]
)
,
can
##di
##dia
##sis
(
<
1
%
)
,
and
se
##psis
(
<
1
%
)
.
[SEP]
[CLS]
There
are
no
adequate
and
well
-
controlled
studies
in
pregnant
women
using
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
incidence
>
=
30
%
)
were
s
##tom
##ati
##tis
,
infections
,
as
##the
##nia
,
fatigue
,
cough
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
Long
-
Te
##rm
,
Open
-
Label
Trials
with
NO
##RT
##H
##ER
##A
In
the
long
-
term
,
open
-
label
extension
studies
,
a
total
of
42
##2
patients
,
mean
age
65
years
,
were
treated
with
NO
##RT
##H
##ER
##A
for
[SEP]
[CLS]
a
mean
total
exposure
of
approximately
one
year
.
[SEP]
[CLS]
However
,
the
syndrome
can
develop
,
although
much
less
commonly
,
after
relatively
brief
treatment
periods
at
low
doses
.
[SEP]
[CLS]
The
safety
assessment
is
based
on
all
data
from
120
##3
subjects
in
the
Phase
3
place
##bo
-
controlled
trials
,
T
##MC
##12
##5
-
C
##20
##6
and
T
##MC
##12
##5
-
C
##21
##6
,
conducted
in
anti
##ret
##rov
##ira
##l
treatment
-
experienced
HIV
-
1
-
infected
adult
subjects
,
[SEP]
[CLS]
59
##9
of
whom
received
IN
##TE
##LE
##NC
##E
(
r
)
(
200
mg
twice
daily
)
.
[SEP]
[CLS]
What
is
D
##U
##AV
##EE
used
for
?
[SEP]
[CLS]
So
##m
##no
##len
##ce
includes
the
following
events
:
so
##m
##no
##len
##ce
,
se
##dation
,
and
h
##yper
##so
##m
##nia
.
[SEP]
[CLS]
A
total
of
65
##1
p
##ediatric
patients
were
treated
with
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
Use
of
IN
##VO
##KA
##NA
has
been
associated
with
an
increased
incidence
of
re
##nal
-
related
adverse
reactions
(
e
.
g
.
,
increased
blood
c
##rea
##tin
##ine
,
decreased
g
##lo
##mer
##ular
fi
##ltration
rate
,
re
##nal
imp
##air
##ment
,
and
[SEP]
[CLS]
acute
re
##nal
failure
)
,
particularly
in
patients
with
moderate
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
Table
3
and
Table
4
present
adverse
drug
reactions
and
laboratory
abnormal
##ities
identified
from
analyses
of
Trial
1
[
see
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
In
##form
patients
of
the
signs
and
symptoms
of
an
##aph
##yla
##xi
##s
and
have
them
seek
immediate
medical
care
should
symptoms
occur
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
during
therapy
(
5
.
1
)
*
I
##mp
##air
##ment
in
Ren
##al
Fun
##ction
:
Monitor
re
##nal
function
during
therapy
.
[SEP]
[CLS]
Permanent
disco
##ntin
##uation
due
to
an
adverse
reaction
occurred
in
34
/
35
##9
patients
(
9
%
)
receiving
IN
##L
##Y
##TA
and
46
/
35
##5
patients
(
13
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
The
proportion
of
patients
with
a
>
=
7
%
increase
in
body
weight
(
at
End
##point
)
was
14
.
7
%
.
Table
5
##p
##rov
##ides
the
mean
weight
change
from
base
##line
and
the
[SEP]
[CLS]
proportion
of
patients
with
a
weight
gain
of
>
=
7
%
categorized
by
Body
Mass
Index
(
B
##MI
)
at
base
##line
.
[SEP]
[CLS]
He
##pa
##to
##bil
##iary
disorders
:
El
##eva
##ted
liver
enzymes
and
he
##pa
##titis
.
[SEP]
[CLS]
Do
not
administer
CO
##ME
##TR
##I
##Q
to
patients
with
severe
hem
##or
##r
##hage
.
[SEP]
[CLS]
5
.
2
N
##eur
##ological
To
##xi
##ci
##ties
In
patients
receiving
B
##L
##IN
##C
##Y
##TO
in
clinical
trials
,
ne
##uro
##logical
toxic
##ities
have
occurred
in
approximately
50
%
of
patients
.
[SEP]
[CLS]
Con
##com
##ita
##nt
use
of
as
##pi
##rin
,
non
##ster
##oid
##al
anti
-
inflammatory
drugs
,
war
##fari
##n
,
and
other
anti
##coa
##gu
##lants
may
add
to
this
risk
.
[SEP]
[CLS]
5
.
5
N
##eu
##tro
##pen
##ia
and
Feb
##ril
##e
N
##eu
##tro
##pen
##ia
N
##eu
##tro
##pen
##ia
and
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
including
life
-
threatening
cases
,
have
been
observed
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
Based
on
the
experience
in
the
entire
clinical
program
for
me
##lan
##oma
,
the
incidence
and
severity
of
enter
##oc
##oli
##tis
and
he
##pa
##titis
appear
to
be
dose
dependent
.
[SEP]
[CLS]
Grade
3
-
4
l
##ymph
##ope
##nia
(
9
%
)
,
h
##yper
##gly
##ce
##mia
(
7
%
)
and
high
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
(
6
%
)
occurred
at
a
greater
than
5
%
rate
in
[SEP]
[CLS]
the
Z
##Y
##TI
##GA
arm
.
[SEP]
[CLS]
The
physician
responsible
for
maintenance
therapy
should
have
complete
information
re
##quisite
for
the
follow
-
up
of
the
patient
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Disco
##ntin
##ue
Z
##yd
##eli
##g
for
in
##test
##inal
per
##fo
##ration
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
There
was
one
death
associated
with
a
##rr
##hy
##th
##mia
and
one
patient
with
sudden
death
in
the
Z
##Y
##TI
##GA
arms
and
no
deaths
in
the
place
##bo
arms
.
[SEP]
[CLS]
One
H
##AL
##AV
##EN
-
treated
patient
without
documented
liver
meta
##sta
##ses
had
con
##com
##ita
##nt
Grade
2
elevations
in
bi
##li
##ru
##bin
;
these
abnormal
##ities
resolved
and
did
not
re
##cu
##r
with
re
-
exposure
to
H
##AL
##AV
##EN
.
[SEP]
[CLS]
In
addition
to
AD
##CE
##TR
##IS
therapy
,
other
possible
contributor
##y
factors
include
prior
the
##rap
##ies
and
underlying
disease
that
may
cause
im
##mu
##nos
##up
##press
##ion
.
[SEP]
[CLS]
B
##lee
##ding
events
for
the
4
pivotal
studies
were
classified
as
major
bleeding
events
if
at
least
one
of
the
following
criteria
applied
:
fatal
bleeding
,
[SEP]
[CLS]
s
##ym
##pt
##oma
##tic
bleeding
in
a
critical
area
with
compartment
syndrome
,
re
##tro
##per
##ito
##nea
##l
bleeding
,
in
##tra
-
art
##icular
bleeding
,
or
per
##ica
##rdi
##al
bleeding
)
,
bleeding
causing
a
fall
in
hem
##og
##lo
##bin
level
of
2
.
0
[SEP]
[CLS]
g
/
d
##L
(
1
.
24
mm
##ol
/
L
or
more
,
or
leading
to
trans
##fusion
of
2
or
more
units
of
whole
blood
or
red
cells
)
.
[SEP]
[CLS]
5
.
11
Ser
##ious
Der
##mat
##olo
##gic
Re
##actions
Stevens
-
Johnson
syndrome
(
S
##J
##S
)
and
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
(
T
##EN
)
,
including
fatal
outcomes
,
have
been
reported
with
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
Overall
,
59
%
of
the
subjects
were
men
and
the
ethnic
distribution
was
64
%
Caucasian
,
22
%
Asian
,
3
%
Hispanic
,
2
%
Black
,
[SEP]
[CLS]
and
0
.
5
%
of
subjects
consisted
of
other
ethnic
groups
.
[SEP]
[CLS]
At
three
years
after
transplant
##ation
,
the
total
ch
##ole
##ster
##ol
,
HD
##L
,
L
##D
##L
,
and
t
##rig
##ly
##cer
##ides
were
176
mg
/
d
##L
,
49
mg
/
d
##L
,
100
mg
/
d
##L
,
and
141
mg
/
d
##L
,
[SEP]
[CLS]
respectively
,
in
N
##U
##L
##O
##J
##IX
-
treated
patients
compared
to
193
mg
/
d
##L
,
48
mg
/
d
##L
,
106
mg
/
d
##L
,
and
180
mg
/
d
##L
in
c
##y
##c
##los
##por
##ine
-
treated
patients
.
[SEP]
[CLS]
The
mean
age
of
the
population
was
55
years
and
2
%
were
older
than
75
years
of
age
.
[SEP]
[CLS]
(
2
.
2
,
5
.
3
)
*
Q
##T
Inter
##val
Pro
##long
##ation
:
Z
##Y
##KA
##DI
##A
can
cause
Q
##T
##c
interval
pro
##long
##ation
.
[SEP]
[CLS]
Most
patients
received
the
recommended
dose
of
C
##IM
##Z
##IA
or
higher
.
[SEP]
[CLS]
The
clinical
significance
of
this
increase
in
early
protein
##uria
is
unknown
.
[SEP]
[CLS]
Do
##ses
of
the
related
beta
##2
-
ad
##ren
##oc
##ept
##or
ago
##nist
al
##but
##ero
##l
,
when
administered
in
##tra
##ven
##ously
,
have
been
reported
to
a
##gg
##ra
##vate
pre
##ex
##ist
##ing
diabetes
me
##lli
##tus
.
[SEP]
[CLS]
Ad
##vise
patients
to
refrain
from
driving
and
engaging
in
hazardous
occupations
or
activities
such
as
operating
heavy
or
potentially
dangerous
machinery
while
B
##L
##IN
##C
##Y
##TO
is
being
administered
.
[SEP]
[CLS]
The
incidence
of
serious
G
##I
events
was
1
%
in
patients
treated
with
T
##EC
##FI
##DE
##RA
.
[SEP]
[CLS]
(
5
.
8
,
8
.
1
)
5
.
1
My
##elo
##su
##pp
##ression
T
##RE
##AN
##DA
caused
severe
my
##elo
##su
##pp
##ression
(
Grade
3
-
4
)
in
98
%
of
patients
in
the
two
NHL
studies
(
see
Table
4
)
[SEP]
[CLS]
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
that
led
to
dose
reduction
in
the
patients
treated
with
X
##AL
##KO
##RI
were
AL
##T
)
elevation
(
7
.
6
%
)
including
some
patients
with
concurrent
[SEP]
[CLS]
AS
##T
)
elevation
,
Q
##T
##c
pro
##long
##ation
(
2
.
9
%
)
,
and
ne
##ut
##rop
##enia
(
2
.
3
%
)
.
[SEP]
[CLS]
Additionally
,
place
##bo
-
adjusted
B
##MD
decline
##s
were
0
.
1
%
at
the
f
##em
##oral
neck
for
patients
random
##ized
to
IN
##VO
##KA
##NA
300
mg
.
[SEP]
[CLS]
(
5
.
2
)
*
If
irritation
of
eyes
or
air
##way
occurs
,
remove
the
affected
individual
from
the
vicinity
of
Q
##ute
##nza
and
flush
the
m
##uc
##ous
membrane
##s
or
eyes
with
water
[SEP]
[CLS]
.
[SEP]
[CLS]
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
[SEP]
[CLS]
One
death
was
due
to
di
##sse
##minated
primary
her
##pes
z
##ost
##er
and
the
other
to
her
##pes
simple
##x
en
##ce
##pha
##lit
##is
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
in
Clinical
Trials
Re
##action
Rate
(
%
)
n
=
281
##3
Na
##use
##a
0
.
6
%
Head
##ache
0
.
5
%
In
##jection
Site
Pain
0
.
4
%
In
##jection
Site
Cold
##ness
0
.
2
%
[SEP]
[CLS]
Burning
Sen
##sation
0
.
2
%
Ad
##verse
reactions
that
occurred
with
a
frequency
<
0
.
2
%
in
patients
who
received
D
##OT
##AR
##EM
include
:
feeling
cold
,
r
##ash
,
so
##m
##no
##len
##ce
,
fatigue
,
[SEP]
[CLS]
di
##zzi
##ness
,
vomit
##ing
,
p
##ru
##rit
##us
,
par
##est
##hesia
,
d
##ys
##ge
##us
##ia
,
pain
in
ex
##tre
##mity
,
anxiety
,
h
##yper
##tens
##ion
,
p
##al
##pit
##ations
,
or
##op
##har
##yn
##ge
##al
discomfort
,
serum
c
##rea
##tin
##ine
increased
and
[SEP]
[CLS]
injection
site
reactions
.
[SEP]
[CLS]
D
##ys
##pha
##gia
may
per
##sist
for
several
months
,
and
require
use
of
a
feeding
tube
to
maintain
adequate
nutrition
and
h
##yd
##ration
.
[SEP]
[CLS]
5
.
4
Ta
##rdi
##ve
D
##ys
##kin
##esi
##a
Ta
##rdi
##ve
d
##ys
##kin
##esi
##a
is
a
syndrome
consisting
of
potentially
i
##rre
##versible
,
in
##vo
##lu
##ntary
,
d
##ys
##kin
##etic
movements
,
which
may
develop
in
patients
treated
with
anti
##psy
##cho
##tic
drugs
.
[SEP]
[CLS]
None
of
the
subjects
tested
positive
.
[SEP]
[CLS]
*
Using
est
##rogen
##s
may
increase
your
chance
of
getting
dem
##ent
##ia
,
based
on
a
study
of
women
65
years
of
age
or
older
.
[SEP]
[CLS]
With
##hold
K
##y
##p
##rol
##is
for
Grade
3
or
4
cardiac
adverse
events
until
recovery
,
and
consider
whether
to
restart
K
##y
##p
##rol
##is
at
1
dose
level
reduction
based
on
a
benefit
/
risk
assessment
[
[SEP]
[CLS]
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
Approximately
1000
patients
received
at
least
2
years
of
treatment
with
G
##IL
##EN
##Y
##A
0
.
5
mg
.
[SEP]
[CLS]
The
risk
of
symptoms
is
probably
greatest
in
children
treated
for
spa
##stic
##ity
but
symptoms
can
occur
in
adults
treated
for
spa
##stic
##ity
and
other
conditions
,
and
particularly
in
those
patients
[SEP]
[CLS]
who
have
underlying
conditions
that
would
pre
##dis
##pose
them
to
these
symptoms
.
[SEP]
[CLS]
The
E
##MT
##P
trial
enrolled
136
##8
patients
with
AL
##L
or
l
##ymph
##ob
##lastic
l
##ymph
##oma
who
received
ER
##WI
##NA
##Z
##E
after
developing
systemic
h
##yper
##sen
##si
##ti
##vity
to
an
E
.
co
##li
-
derived
as
##par
##agi
##nas
##e
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
drug
reactions
of
moderate
to
severe
intensity
(
at
least
2
%
)
which
occurred
at
a
higher
rate
than
place
##bo
in
adults
are
[SEP]
[CLS]
r
##ash
and
peripheral
ne
##uro
##pathy
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
with
>
=
2
%
Inc
##iden
##ce
and
More
Common
than
Place
##bo
in
Sub
##jects
with
As
##th
##ma
(
Trial
1
)
Ad
##verse
Re
##action
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
(
[SEP]
[CLS]
n
=
201
)
%
F
##lut
##ica
##son
##e
Fu
##roa
##te
100
m
##c
##g
(
n
=
205
)
%
Place
##bo
(
n
=
203
)
%
In
##fect
##ions
and
in
##fest
##ations
Na
##so
##pha
##ryn
##git
##is
10
7
7
[SEP]
[CLS]
Oral
can
##di
##dia
##sis
a
2
2
0
N
##er
##vous
system
disorders
Head
##ache
5
4
4
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
,
and
media
##st
##inal
disorders
Oro
##pha
##ryn
##ge
##al
pain
2
2
1
D
##ys
##phon
##ia
2
1
0
a
[SEP]
[CLS]
Includes
oral
can
##di
##dia
##sis
and
or
##op
##har
##yn
##ge
##al
can
##di
##dia
##sis
.
[SEP]
[CLS]
Ren
##al
imp
##air
##ment
as
a
consequence
of
di
##ar
##r
##hea
occurred
in
6
.
1
%
of
patients
treated
with
G
##IL
##OT
##RI
##F
,
out
of
which
3
(
1
.
3
%
)
were
Grade
3
.
[SEP]
[CLS]
B
##lee
##ding
results
from
the
AM
##PL
##IF
##Y
study
are
summarized
in
Table
5
.
[SEP]
[CLS]
In
##tra
##c
##rani
##al
hem
##or
##r
##hage
was
fatal
in
4
%
(
2
/
55
)
of
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Case
##s
of
active
tuberculosis
have
occurred
in
patients
treated
with
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
during
and
after
treatment
for
late
##nt
tuberculosis
.
[SEP]
[CLS]
In
trials
of
ST
##EN
##DR
##A
for
use
as
needed
,
a
total
of
49
##3
patients
were
exposed
for
greater
than
or
equal
to
6
months
,
and
153
patients
were
treated
[SEP]
[CLS]
for
greater
than
or
equal
to
12
months
.
[SEP]
[CLS]
The
median
duration
of
adverse
reactions
was
4
.
0
days
in
both
treatment
groups
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
are
discussed
in
more
detail
in
other
sections
of
the
label
##ing
:
*
H
##yper
##tens
##ion
,
H
##y
##po
##kal
##emia
,
and
F
##lu
##id
Re
##ten
##tion
due
to
Mine
##ral
##oc
##ort
##ico
##id
Ex
##cess
[
[SEP]
[CLS]
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Treatment
for
late
##nt
infection
should
be
initiated
prior
to
C
##IM
##Z
##IA
use
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
may
occur
within
a
few
minutes
following
the
initiation
of
the
in
##fusion
of
J
##E
##V
##TA
##NA
,
thus
facilities
and
equipment
for
the
treatment
of
h
##y
##pot
##ens
##ion
and
[SEP]
[CLS]
br
##on
##cho
##sp
##as
##m
should
be
available
.
[SEP]
[CLS]
Monitor
##ing
Close
##ly
monitor
patients
for
the
development
of
signs
and
symptoms
of
infection
during
and
after
treatment
with
S
##IM
##PO
##NI
ARIA
.
[SEP]
[CLS]
Pat
##ients
who
remain
a
##verse
to
food
during
treatment
should
be
closely
monitored
as
the
risk
of
re
##c
##rud
##es
##cence
may
be
greater
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
*
If
members
of
your
family
have
had
breast
cancer
or
if
you
have
ever
had
breast
lump
##s
or
an
abnormal
ma
##mm
##ogram
,
you
may
need
to
have
breast
exams
[SEP]
[CLS]
more
often
.
[SEP]
[CLS]
Test
patients
for
late
##nt
tuberculosis
before
S
##IM
##PO
##NI
ARIA
use
and
during
therapy
.
[SEP]
[CLS]
Post
-
base
##line
Q
##T
pro
##long
##ations
exceeding
500
m
##se
##c
were
reported
at
comparable
rates
for
SA
##P
##H
##RI
##S
and
place
##bo
in
these
short
-
term
trials
.
[SEP]
[CLS]
Counsel
women
of
child
##be
##aring
potential
regarding
appropriate
con
##tra
##ceptive
choices
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
This
,
in
turn
,
may
in
##hibit
reproductive
function
by
imp
##air
##ing
go
##na
##dal
s
##tero
##ido
##genesis
in
both
female
and
male
patients
.
[SEP]
[CLS]
*
L
##ymph
##oma
and
other
ma
##li
##gna
##ncies
,
some
fatal
,
have
been
reported
in
children
and
adolescent
patients
treated
with
T
##NF
block
##ers
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
(
[SEP]
[CLS]
5
.
2
)
.
[SEP]
[CLS]
Pat
##ients
should
be
evaluated
for
tuberculosis
risk
factors
and
tested
for
late
##nt
infection
prior
to
in
##iti
##ating
C
##IM
##Z
##IA
and
periodically
during
therapy
.
[SEP]
[CLS]
H
##yper
##p
##rol
##act
##ine
##mia
may
suppress
h
##y
##pot
##hala
##mic
G
##n
##R
##H
,
resulting
in
reduced
pit
##uit
##ary
go
##nado
##tro
##pin
secret
##ion
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Not
for
acute
use
:
Not
for
use
as
a
rescue
medication
.
[SEP]
[CLS]
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
can
occur
and
may
include
generalized
r
##ash
/
er
##yt
##hem
##a
,
h
##y
##pot
##ens
##ion
and
br
##on
##cho
##sp
##as
##m
.
[SEP]
[CLS]
Pat
##ients
should
be
tested
for
late
##nt
tuberculosis
before
C
##IM
##Z
##IA
use
and
during
therapy
.
[SEP]
[CLS]
In
##fect
##ions
and
In
##fest
##ations
:
her
##pes
z
##ost
##er
.
[SEP]
[CLS]
Skin
and
sub
##cut
##aneous
tissue
disorders
-
Ra
##sh
,
al
##ope
##cia
,
photos
##ens
##iti
##vity
reaction
,
an
##gio
##ede
##ma
.
[SEP]
[CLS]
(
5
.
6
)
*
Laboratory
test
alterations
:
El
##eva
##tions
of
serum
c
##rea
##tin
##ine
may
occur
.
[SEP]
[CLS]
Of
the
patients
who
reported
ne
##uro
##pathy
,
51
%
had
residual
ne
##uro
##pathy
at
the
time
of
their
last
evaluation
.
[SEP]
[CLS]
One
patient
experienced
related
Grade
3
flush
##ing
.
[SEP]
[CLS]
S
##ym
##pt
##oma
##tic
h
##y
##pot
##ens
##ion
may
occur
after
in
##iti
##ating
J
##AR
##DI
##AN
##CE
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
particularly
in
patients
with
re
##nal
imp
##air
##ment
,
the
elderly
,
in
patients
with
low
s
##ys
##to
##lic
[SEP]
[CLS]
blood
pressure
,
and
in
patients
on
di
##ure
##tics
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Take
##da
Ph
##arma
##ce
##utical
##s
at
1
-
87
##7
-
T
##A
##KE
##DA
-
7
(
1
-
87
##7
-
82
##5
-
33
##27
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reaction
has
been
identified
during
post
-
approval
use
of
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
with
>
=
3
%
Inc
##iden
##ce
and
More
Common
than
Place
##bo
in
Sub
##jects
with
Ch
##ronic
O
##bs
##truct
##ive
P
##ul
##mona
##ry
Disease
Ad
##verse
Re
##action
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
(
n
[SEP]
[CLS]
=
410
)
%
V
##ila
##nter
##ol
25
m
##c
##g
(
n
=
40
##8
)
%
F
##lut
##ica
##son
##e
Fu
##roa
##te
100
m
##c
##g
(
n
=
410
)
%
Place
##bo
(
n
=
41
##2
)
%
[SEP]
[CLS]
In
##fect
##ions
and
in
##fest
##ations
Na
##so
##pha
##ryn
##git
##is
9
10
8
8
Upper
respiratory
tract
infection
7
5
4
3
Oro
##pha
##ryn
##ge
##al
can
##di
##dia
##sis
a
5
2
3
2
N
##er
##vous
system
disorders
Head
##ache
7
9
7
[SEP]
[CLS]
5
a
Includes
oral
can
##di
##dia
##sis
,
or
##op
##har
##yn
##ge
##al
can
##di
##dia
##sis
,
can
##di
##dia
##sis
,
and
fun
##gal
or
##op
##har
##yn
##git
##is
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
in
patients
who
develop
worse
##ning
of
liver
function
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Disco
##ntin
##ue
T
##I
##VI
##CA
##Y
and
other
suspect
agents
immediately
if
signs
or
symptoms
of
h
##yper
##sen
##si
##ti
##vity
reactions
develop
(
including
,
but
not
limited
to
,
severe
r
##ash
or
r
##ash
accompanied
by
fever
[SEP]
[CLS]
,
general
ma
##lai
##se
,
fatigue
,
muscle
or
joint
ache
##s
,
b
##list
##ers
or
p
##eel
##ing
of
the
skin
,
oral
b
##list
##ers
or
lesions
,
con
##junct
##iv
##itis
,
facial
ed
##ema
,
he
##pa
##titis
,
[SEP]
[CLS]
e
##os
##ino
##phi
##lia
,
an
##gio
##ede
##ma
,
difficulty
breathing
)
.
[SEP]
[CLS]
(
5
.
1
)
*
Q
##T
pro
##long
##ation
:
Pro
##long
##s
Q
##T
interval
and
may
be
associated
with
a
##rr
##hy
##th
##mia
and
sudden
death
-
consider
using
other
anti
##psy
##cho
##tics
first
.
[SEP]
[CLS]
(
6
.
1
)
The
most
common
adverse
drug
reactions
in
at
least
2
%
of
p
##ediatric
patients
are
r
##ash
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
In
total
,
from
the
281
subjects
treated
in
the
long
-
term
studies
and
tested
for
the
presence
of
neutral
##izing
antibodies
,
3
.
6
%
developed
neutral
##izing
antibodies
after
treatment
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Sun
##ov
##ion
at
1
-
87
##7
-
737
-
72
##26
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
A
total
of
1
,
224
patients
were
treated
with
D
##U
##AV
##EE
and
1
,
06
##9
patients
received
place
##bo
.
[SEP]
[CLS]
In
patients
who
develop
H
##B
##V
react
##ivation
,
T
##NF
-
block
##ers
should
be
stopped
and
anti
##vir
##al
therapy
with
appropriate
supportive
treatment
should
be
initiated
.
[SEP]
[CLS]
5
.
3
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
with
b
##ot
##ulin
##um
to
##xin
products
(
an
##aph
##yla
##xi
##s
,
serum
sickness
,
u
##rt
##ica
##ria
,
soft
tissue
ed
##ema
,
and
d
##ys
##p
##nea
)
.
[SEP]
[CLS]
Table
2
lists
adverse
reactions
that
occurred
in
>
=
0
.
2
%
patients
who
received
D
##OT
##AR
##EM
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
g
##eni
##tal
my
##cot
##ic
infections
were
more
likely
to
develop
g
##eni
##tal
my
##cot
##ic
infections
on
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
Monitor
EC
##G
##s
.
[SEP]
[CLS]
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
is
not
indicated
for
the
treatment
of
as
##th
##ma
.
[SEP]
[CLS]
*
119
patients
with
CP
C
##ML
previously
treated
with
both
im
##ati
##ni
##b
and
at
least
1
additional
T
##K
##I
who
had
a
median
duration
of
B
##OS
##U
##L
##IF
treatment
of
9
months
and
a
[SEP]
[CLS]
median
dose
intensity
of
47
##5
mg
/
day
.
[SEP]
[CLS]
In
males
,
disco
##ntin
##uations
due
to
g
##eni
##tal
my
##cot
##ic
infections
occurred
in
0
%
and
0
.
5
%
of
patients
treated
with
place
##bo
and
IN
##VO
##KA
##NA
,
respectively
.
[SEP]
[CLS]
Skin
infections
,
including
er
##ys
##ip
##ela
##s
and
cell
##uli
##tis
,
leading
to
hospital
##ization
were
reported
more
frequently
in
patients
treated
with
Pro
##lia
(
<
0
.
1
%
place
##bo
vs
.
0
.
4
%
Pro
##lia
)
[SEP]
[CLS]
.
[SEP]
[CLS]
Inc
##reased
Mortal
##ity
In
Study
1
,
there
was
a
statistical
##ly
significant
increased
mortality
risk
by
Week
120
in
the
S
##IR
##TU
##RO
treatment
group
compared
to
the
place
##bo
treatment
group
(
9
/
79
[SEP]
[CLS]
(
11
.
4
%
)
versus
2
/
81
(
2
.
5
%
)
,
p
-
value
=
0
.
03
,
an
exact
95
%
confidence
interval
of
the
difference
[
1
.
1
%
,
18
.
2
%
]
)
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
6
)
*
With
##dra
##wal
of
AP
##TI
##OM
:
With
##dra
##w
AP
##TI
##OM
gradually
to
minimize
the
risk
of
increased
seizure
frequency
and
status
e
##pile
##ptic
##us
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
My
##elo
##su
##pp
##ression
:
Del
##ay
or
reduce
dose
.
[SEP]
[CLS]
Overall
disco
##ntin
##uation
of
therapy
due
to
adverse
events
was
4
.
7
%
with
NE
##SI
##NA
25
mg
compared
to
4
.
5
%
with
place
##bo
or
6
.
2
%
with
active
com
##par
##ator
.
[SEP]
[CLS]
Because
all
patients
developed
anti
-
drug
antibodies
,
associations
between
anti
##body
t
##iter
##s
and
reduction
##s
in
treatment
effect
or
the
occurrence
of
an
##aph
##yla
##xi
##s
or
other
h
##yper
##sen
##si
##ti
##vity
reactions
could
not
be
determined
.
[SEP]
[CLS]
Life
-
threatening
an
##aph
##yla
##ctic
reactions
have
occurred
in
some
patients
during
V
##im
##iz
##im
in
##fusion
##s
.
[SEP]
[CLS]
5
.
7
El
##eva
##ted
Live
##r
En
##zy
##mes
Treatment
with
B
##L
##IN
##C
##Y
##TO
was
associated
with
trans
##ient
elevations
in
liver
enzymes
.
[SEP]
[CLS]
During
marketing
of
S
##NR
##I
##s
(
Ser
##oto
##nin
and
Nor
##ep
##ine
##ph
##rine
Re
##up
##take
In
##hibit
##ors
)
,
and
SSR
##I
##s
(
Select
##ive
Ser
##oto
##nin
Re
##up
##take
In
##hibit
##ors
)
,
there
have
been
spontaneous
reports
of
adverse
events
occurring
[SEP]
[CLS]
upon
disco
##ntin
##uation
of
these
drugs
,
particularly
when
abrupt
,
including
the
following
:
d
##ys
##ph
##ori
##c
mood
,
i
##rri
##ta
##bility
,
agitation
,
di
##zzi
##ness
,
sensory
disturbance
##s
(
e
.
g
.
,
par
##est
##hesia
,
[SEP]
[CLS]
such
as
electric
shock
sensations
)
,
anxiety
,
confusion
,
headache
,
let
##har
##gy
,
emotional
lab
##ility
,
ins
##om
##nia
,
h
##y
##po
##mani
##a
,
tin
##ni
##tus
,
and
seizure
##s
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Eli
Lilly
and
Company
at
1
-
800
-
Lilly
##R
##x
(
1
-
800
-
54
##5
-
59
##7
##9
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
[SEP]
[CLS]
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
[SEP]
[CLS]
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
The
adverse
reaction
of
first
degree
A
##V
block
occurred
more
frequently
in
patients
treated
with
T
##R
##U
##L
##IC
##IT
##Y
than
place
##bo
(
0
.
9
%
,
1
.
7
%
and
2
.
3
%
for
place
##bo
,
[SEP]
[CLS]
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
,
respectively
)
.
[SEP]
[CLS]
Case
##s
with
serum
sodium
lower
than
110
mm
##ol
/
L
have
been
reported
.
[SEP]
[CLS]
Ad
##verse
reactions
that
led
to
disco
##ntin
##uation
of
Z
##yd
##eli
##g
occurred
in
11
(
10
%
)
subjects
.
[SEP]
[CLS]
(
5
.
5
)
*
O
##ste
##one
##c
##rosis
of
the
jaw
:
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
.
[SEP]
[CLS]
Skin
and
sub
##cut
##aneous
tissue
disorders
:
Der
##mat
##itis
,
er
##yt
##hem
##a
nod
##os
##um
,
and
u
##rt
##ica
##ria
.
[SEP]
[CLS]
Do
##se
modification
due
to
di
##ar
##r
##hea
,
nausea
,
vomit
##ing
,
or
abdominal
pain
occurred
in
38
%
of
patients
.
[SEP]
[CLS]
The
use
of
CO
##Cs
increases
the
risk
of
ve
##nous
th
##rom
##boe
##mbo
##lis
##m
.
[SEP]
[CLS]
The
skin
disco
##lora
##tion
is
generally
described
as
blue
,
but
has
also
been
described
as
grey
-
blue
or
brown
.
[SEP]
[CLS]
If
pan
##cre
##ati
##tis
is
confirmed
,
T
##R
##U
##L
##IC
##IT
##Y
should
not
be
restart
##ed
.
[SEP]
[CLS]
The
radiation
dose
to
patients
with
severe
re
##nal
imp
##air
##ment
may
be
increased
due
to
the
delayed
elimination
of
the
drug
.
[SEP]
[CLS]
5
.
4
Ser
##ious
In
##fect
##ions
and
Op
##port
##uni
##stic
In
##fect
##ions
Ser
##ious
infections
and
op
##port
##uni
##stic
infections
such
as
pneumonia
,
b
##act
##ere
##mia
,
and
se
##psis
or
se
##ptic
shock
(
including
fatal
outcomes
)
have
been
reported
[SEP]
[CLS]
in
patients
treated
with
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
5
.
7
Transfer
##ring
Pat
##ients
from
System
##ic
Co
##rt
##ico
##ster
##oid
Therapy
Part
##icular
care
is
needed
for
patients
who
have
been
transferred
from
systemic
##ally
active
co
##rt
##ico
##ster
##oids
to
inhaled
co
##rt
##ico
##ster
##oids
because
deaths
due
to
ad
##rena
##l
ins
##uff
##iciency
[SEP]
[CLS]
have
occurred
in
patients
with
as
##th
##ma
during
and
after
transfer
from
systemic
co
##rt
##ico
##ster
##oids
to
less
systemic
##ally
available
inhaled
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
No
patients
developed
ma
##li
##gnant
h
##yper
##tens
##ion
.
[SEP]
[CLS]
In
place
##bo
-
controlled
studies
,
the
population
had
a
median
age
of
53
years
at
entry
;
approximately
80
%
were
females
,
93
%
were
Caucasian
and
all
patients
were
[SEP]
[CLS]
suffering
from
active
r
##he
##uma
##to
##id
art
##hr
##itis
,
with
a
median
disease
duration
of
6
.
2
years
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
seizure
##s
were
excluded
from
pre
-
marketing
clinical
studies
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
Across
four
Phase
2
and
five
Phase
3
clinical
studies
,
64
(
1
.
6
%
)
T
##R
##U
##L
##IC
##IT
##Y
treated
patients
developed
anti
-
drug
antibodies
(
AD
##As
)
to
the
active
ingredient
[SEP]
[CLS]
in
T
##R
##U
##L
##IC
##IT
##Y
(
i
.
e
.
,
du
##lag
##lut
##ide
)
.
[SEP]
[CLS]
The
population
with
R
##LS
ranged
from
18
to
82
years
of
age
,
with
60
%
being
female
and
95
%
being
Caucasian
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
incidence
greater
than
20
%
)
are
di
##ar
##r
##hea
,
nausea
,
th
##rom
##bo
##cy
##top
##enia
,
vomit
##ing
,
abdominal
pain
,
r
##ash
,
an
##emia
,
[SEP]
[CLS]
p
##yre
##xia
,
and
fatigue
.
[SEP]
[CLS]
(
5
.
5
)
*
N
##eur
##ological
Ad
##verse
Re
##actions
:
Monitor
for
di
##zzi
##ness
,
disturbance
in
g
##ait
and
coordination
,
so
##m
##no
##len
##ce
,
fatigue
,
cognitive
d
##ys
##function
,
and
visual
changes
.
[SEP]
[CLS]
Sc
##hi
##zophrenia
(
6
-
weeks
)
B
##ip
##olar
(
3
-
weeks
)
Place
##bo
SA
##P
##H
##RI
##S
Place
##bo
SA
##P
##H
##RI
##S
##5
or
10
mg
##t
##wi
##ce
daily
5
mg
##t
##wi
##ce
daily
10
mg
##t
##wi
##ce
daily
5
or
10
mg
##t
##wi
##ce
daily
S
Change
from
[SEP]
[CLS]
Basel
##ine
(
kg
)
(
N
*
)
0
.
0
(
34
##8
)
1
.
0
(
251
)
0
.
9
(
200
)
1
.
1
(
53
##2
)
0
.
2
(
171
)
1
.
3
(
33
##6
[SEP]
[CLS]
)
Pro
##port
##ion
of
Pat
##ients
with
a
>
=
7
%
Inc
##rease
in
Body
Weight
%
with
>
=
7
%
increase
in
body
weight
1
.
6
%
4
.
4
%
4
.
8
%
4
.
9
%
[SEP]
[CLS]
0
.
5
%
5
.
8
%
Adult
Pat
##ients
:
In
a
52
-
week
,
double
-
blind
,
com
##par
##ator
-
controlled
adult
trial
that
included
primarily
patients
with
s
##chi
##zophrenia
,
the
mean
weight
gain
from
base
##line
was
[SEP]
[CLS]
0
.
9
kg
.
[SEP]
[CLS]
One
death
occurred
during
the
24
-
week
S
##IR
##TU
##RO
treatment
period
.
[SEP]
[CLS]
These
subjects
did
not
receive
calcium
and
vitamin
D
supplement
##ation
.
[SEP]
[CLS]
Males
represented
73
%
and
53
%
of
the
adult
and
p
##ediatric
populations
,
respectively
.
[SEP]
[CLS]
(
5
.
6
,
5
.
7
)
5
.
1
As
##th
##ma
-
Re
##lated
Death
[
See
Box
##ed
Warning
]
*
Data
from
a
large
place
##bo
-
controlled
study
in
as
##th
##ma
patients
showed
that
long
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
##s
[SEP]
[CLS]
may
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
Media
##n
duration
of
treatment
was
5
.
2
months
for
patients
who
received
X
##AL
##KO
##RI
after
cross
over
from
ch
##em
##otherapy
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
at
an
Inc
##iden
##ce
of
2
%
or
More
Among
SA
##P
##H
##RI
##S
-
T
##reate
##d
(
Mon
##otherapy
)
patients
with
B
##ip
##olar
I
Di
##sor
##der
:
Ad
##verse
reactions
associated
with
the
use
of
SA
##P
##H
##RI
##S
[SEP]
[CLS]
(
incidence
of
2
%
or
greater
,
rounded
to
the
nearest
percent
,
and
SA
##P
##H
##RI
##S
incidence
greater
than
place
##bo
)
that
occurred
during
acute
mon
##otherapy
(
up
to
3
-
weeks
[SEP]
[CLS]
in
patients
with
bi
##pol
##ar
man
##ia
)
are
shown
in
Table
9
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
described
in
greater
detail
in
other
sections
:
*
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Adult
Pat
##ients
with
Sc
##hi
##zophrenia
:
The
following
findings
are
based
on
the
short
-
term
place
##bo
-
controlled
pre
-
marketing
trials
for
s
##chi
##zophrenia
(
a
pool
of
three
6
-
week
fixed
-
dose
trials
and
one
6
-
week
flexible
-
dose
[SEP]
[CLS]
trial
)
in
which
sub
##ling
##ual
SA
##P
##H
##RI
##S
was
administered
in
doses
ranging
from
5
to
10
mg
twice
daily
.
[SEP]
[CLS]
(
5
.
5
)
*
Weight
G
##ain
:
Weight
gain
has
been
reported
.
[SEP]
[CLS]
Ad
##vise
patients
to
contact
their
healthcare
provider
if
they
become
pregnant
,
or
if
pregnancy
is
suspected
,
while
taking
G
##IL
##OT
##RI
##F
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
##and
##8
.
6
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
The
adverse
reaction
profile
of
CE
##RD
##EL
##GA
is
based
on
two
controlled
studies
,
Trials
1
and
2
.
[SEP]
[CLS]
1
Neo
##nat
##al
To
##xi
##city
In
##tra
##ven
##ous
administration
of
products
containing
ben
##zy
##l
alcohol
has
been
associated
with
neon
##ata
##l
gasping
syndrome
consisting
of
severe
metabolic
acid
##osis
,
gasping
re
##spiration
##s
,
progressive
h
##y
##pot
##ens
##ion
,
[SEP]
[CLS]
seizure
##s
,
central
nervous
system
depression
,
in
##tra
##vent
##ric
##ular
hem
##or
##r
##hage
,
and
death
in
pre
##ter
##m
,
low
birth
weight
infants
.
[SEP]
[CLS]
*
Ser
##ious
infections
and
op
##port
##uni
##stic
infections
:
Close
##ly
monitor
patients
for
the
emergence
of
bacterial
,
fun
##gal
or
viral
infections
(
5
.
4
)
.
[SEP]
[CLS]
More
patients
experienced
these
events
during
PR
##IS
##TI
##Q
treatment
as
compared
to
place
##bo
.
[SEP]
[CLS]
Con
##com
##ita
##nt
use
of
P
-
g
##p
inhibitor
##s
in
patients
with
re
##nal
imp
##air
##ment
is
expected
to
produce
increased
exposure
of
da
##bi
##gat
##ran
compared
to
that
seen
with
either
factor
alone
.
[SEP]
[CLS]
One
patient
discontinued
treatment
due
to
potential
infection
.
[SEP]
[CLS]
Common
adverse
reactions
(
>
=
1
%
)
were
g
##ing
##ival
bleeding
,
e
##pis
##ta
##xi
##s
,
con
##tus
##ion
,
hem
##at
##uria
,
re
##ct
##al
hem
##or
##r
##hage
,
hem
##ato
##ma
,
men
##or
##r
##ha
##gia
,
and
hem
##op
##ty
##sis
.
[SEP]
[CLS]
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
,
Including
Ana
##phy
##lax
##is
Po
##ten
##tial
##ly
serious
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
,
have
occurred
in
patients
treated
with
K
##AL
##BI
##TO
##R
.
[SEP]
[CLS]
As
##ses
##s
L
##VE
##F
by
echo
##card
##io
##gram
or
multi
##gated
acquisition
(
M
##U
##GA
)
scan
before
initiation
of
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
,
one
month
after
initiation
,
and
then
at
2
-
to
[SEP]
[CLS]
3
-
month
intervals
while
on
treatment
with
the
combination
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
VI
##CT
##RE
##L
##IS
can
not
be
directly
compared
to
rates
[SEP]
[CLS]
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
*
Have
a
p
##el
##vic
exam
,
breast
exam
and
ma
##mm
##ogram
(
breast
X
-
ray
)
every
year
unless
your
healthcare
provider
tells
you
something
else
.
[SEP]
[CLS]
*
In
##vasive
fun
##gal
infections
,
including
his
##top
##las
##mos
##is
,
co
##cci
##dio
##ido
##my
##cos
##is
,
can
##di
##dia
##sis
,
as
##per
##gill
##osis
,
blast
##omy
##cos
##is
,
and
p
##ne
##um
##oc
##ys
##tosis
.
[SEP]
[CLS]
Ad
##verse
reactions
that
led
to
treatment
disco
##ntin
##uation
in
2
or
more
patients
were
peripheral
sensory
ne
##uro
##pathy
(
14
%
)
,
peripheral
motor
ne
##uro
##pathy
(
7
%
)
,
[SEP]
[CLS]
acute
respiratory
distress
syndrome
(
1
%
)
,
para
##est
##hesia
(
1
%
)
and
vomit
##ing
(
1
%
)
.
[SEP]
[CLS]
In
patients
with
chronic
he
##pa
##titis
C
,
PR
##OM
##AC
##TA
in
combination
with
inter
##fer
##on
and
rib
##avi
##rin
may
increase
the
risk
of
he
##pa
##tic
de
##com
##pen
##sation
.
[SEP]
[CLS]
In
the
wet
AM
##D
,
R
##VO
,
and
D
##ME
studies
,
the
pre
-
treatment
incidence
of
im
##mu
##nor
##ea
##ct
##ivity
to
E
##Y
##LE
##A
was
approximately
1
%
to
3
%
across
treatment
groups
.
[SEP]
[CLS]
A
ca
##usal
relationship
has
not
been
established
.
[SEP]
[CLS]
(
5
.
2
)
*
There
is
a
potential
risk
of
art
##erial
th
##rom
##boe
##mbo
##lic
events
following
in
##tra
##vi
##tre
##al
use
of
V
##EG
##F
inhibitor
##s
.
[SEP]
[CLS]
Long
-
standing
h
##yper
##p
##rol
##act
##ine
##mia
when
associated
with
h
##y
##po
##gon
##adi
##sm
may
lead
to
decreased
bone
density
in
both
female
and
male
subjects
.
[SEP]
[CLS]
These
include
as
##pi
##rin
and
other
anti
##plate
##let
agents
,
other
anti
##coa
##gu
##lants
,
he
##par
##in
,
th
##rom
##bol
##ytic
agents
,
selective
se
##rot
##oni
##n
re
##up
##take
inhibitor
##s
,
se
##rot
##oni
##n
nor
##ep
##ine
##ph
##rine
re
##up
##take
inhibitor
##s
,
and
non
##ster
##oid
##al
anti
-
inflammatory
drugs
[SEP]
[CLS]
(
NSA
##ID
##s
)
[
see
##D
##rug
Inter
##actions
(
7
.
3
)
]
.
[SEP]
[CLS]
Ph
##eo
##ch
##rom
##oc
##yt
##oma
and
N
##eur
##ob
##last
##oma
Ser
##ious
adverse
reactions
were
not
observed
in
the
Ad
##re
##V
##ie
##w
clinical
study
.
[SEP]
[CLS]
Use
with
caution
in
patients
with
severe
h
##yper
##sen
##si
##ti
##vity
to
milk
proteins
.
[SEP]
[CLS]
After
dos
##ing
with
E
##Y
##LE
##A
for
24
-
100
weeks
,
antibodies
to
E
##Y
##LE
##A
were
detected
in
a
similar
percentage
range
of
patients
.
[SEP]
[CLS]
83
.
9
%
of
patients
were
White
,
13
.
8
%
were
Black
,
1
.
4
%
Asian
,
and
<
1
%
Hispanic
.
[SEP]
[CLS]
In
##st
##ru
##ct
patients
to
consult
a
physician
immediately
should
any
of
these
signs
or
symptoms
develop
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
commonly
reported
adverse
reactions
were
:
injection
site
reaction
(
3
.
9
%
)
.
[SEP]
[CLS]
Ad
##verse
drug
reactions
listed
in
Table
2
showed
higher
rates
than
place
##bo
from
both
trials
.
[SEP]
[CLS]
The
reactions
either
resolved
spontaneous
##ly
or
following
the
administration
of
co
##rt
##ico
##ster
##oids
and
anti
##his
##tamine
##s
.
[SEP]
[CLS]
More
frequent
monitoring
is
recommended
in
patients
with
e
##G
##F
##R
below
60
m
##L
/
min
/
1
.
73
m
2
(
5
.
2
)
*
H
##y
##po
##gly
##ce
##mia
:
Consider
lowering
the
dose
of
insulin
secret
##ago
##gue
or
insulin
to
[SEP]
[CLS]
reduce
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
in
##iti
##ating
J
##AR
##DI
##AN
##CE
(
5
.
3
)
*
Gen
##ital
my
##cot
##ic
infections
:
Monitor
and
treat
as
appropriate
(
5
.
4
)
*
U
##rina
##ry
tract
infections
:
Monitor
[SEP]
[CLS]
and
treat
as
appropriate
(
5
.
5
)
*
Inc
##reased
L
##D
##L
-
C
:
Monitor
and
treat
as
appropriate
(
5
.
6
)
*
Mac
##rov
##as
##cular
outcomes
:
There
have
been
no
clinical
studies
establishing
[SEP]
[CLS]
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
J
##AR
##DI
##AN
##CE
(
5
.
7
)
5
.
1
H
##y
##pot
##ens
##ion
J
##AR
##DI
##AN
##CE
causes
in
##tra
##vas
##cular
volume
contraction
.
[SEP]
[CLS]
The
median
age
of
the
study
population
was
37
years
(
range
:
18
to
79
years
)
,
63
%
were
male
,
79
%
were
White
,
3
[SEP]
[CLS]
%
were
Asian
,
and
3
%
were
Black
or
African
American
.
[SEP]
[CLS]
(
6
.
1
,
6
.
2
,
6
.
3
)
Ren
##al
an
##gio
##my
##oli
##po
##ma
with
T
##SC
:
Most
common
adverse
reaction
(
incidence
>
=
30
%
)
is
s
##tom
##ati
##tis
.
[SEP]
[CLS]
Dec
##rease
##s
in
hem
##og
##lo
##bin
may
also
occur
.
[SEP]
[CLS]
This
trial
did
not
have
a
place
##bo
arm
.
[SEP]
[CLS]
Monitor
C
##r
##C
##l
at
least
daily
in
patients
with
changing
re
##nal
function
and
adjust
the
dose
of
Z
##ER
##BA
##X
##A
accordingly
.
[SEP]
[CLS]
D
##ys
##pha
##gia
may
per
##sist
for
several
weeks
,
and
require
use
of
a
feeding
tube
to
maintain
adequate
nutrition
and
h
##yd
##ration
.
[SEP]
[CLS]
(
5
.
5
)
*
D
##ys
##lip
##ide
##mia
:
Un
##des
##ira
##ble
alterations
have
been
observed
in
patients
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
.
[SEP]
[CLS]
The
most
common
adverse
reactions
to
CE
##RD
##EL
##GA
(
occurring
in
>
=
10
%
of
the
126
G
##D
##1
patients
treated
with
CE
##RD
##EL
##GA
across
Trials
1
and
2
)
were
fatigue
,
[SEP]
[CLS]
headache
,
nausea
,
di
##ar
##r
##hea
,
back
pain
,
pain
in
ex
##tre
##mit
##ies
,
and
upper
abdominal
pain
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
to
use
highly
effective
con
##tra
##ception
during
treatment
,
and
for
at
least
2
weeks
after
the
last
dose
of
G
##IL
##OT
##RI
##F
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Associated
with
Disco
##ntin
##uation
of
Treatment
:
A
total
of
9
%
of
SA
##P
##H
##RI
##S
-
treated
patients
and
10
%
of
place
##bo
-
treated
patients
discontinued
due
to
adverse
reactions
.
[SEP]
[CLS]
If
a
patient
requires
anti
##psy
##cho
##tic
drug
treatment
after
recovery
from
N
##MS
,
the
potential
re
##int
##rod
##uction
of
drug
therapy
should
be
carefully
considered
.
[SEP]
[CLS]
Her
##pes
V
##ira
##l
In
##fect
##ions
In
place
##bo
-
controlled
trials
,
the
rate
of
her
##pet
##ic
infections
was
9
%
in
patients
receiving
G
##IL
##EN
##Y
##A
0
.
5
mg
and
7
%
on
place
##bo
.
[SEP]
[CLS]
(
5
.
7
)
*
V
##eno
##us
T
##hr
##omb
##osis
:
T
##hr
##omb
##op
##rop
##hyl
##ax
##is
is
recommended
.
[SEP]
[CLS]
The
diagnostic
evaluation
of
patients
with
this
syndrome
is
complicated
.
[SEP]
[CLS]
5
.
5
Use
in
Elder
##ly
Pat
##ients
In
the
random
##ized
clinical
trial
,
3
of
131
(
2
%
)
patients
<
65
years
of
age
and
15
of
240
(
6
[SEP]
[CLS]
%
)
>
=
65
years
of
age
died
of
causes
other
than
disease
progression
within
30
days
of
the
last
cab
##azi
##ta
##xe
##l
dose
.
[SEP]
[CLS]
Pat
##ients
treated
with
K
##AL
##BI
##TO
##R
were
between
the
ages
of
10
and
78
years
.
[SEP]
[CLS]
Ad
##verse
reactions
of
any
toxicity
grade
reported
for
greater
than
20
%
of
patients
in
the
Phase
1
/
2
safety
population
(
n
=
54
##6
)
were
di
##ar
##r
##hea
(
82
%
)
,
[SEP]
[CLS]
nausea
(
46
%
)
,
th
##rom
##bo
##cy
##top
##enia
(
41
%
)
,
vomit
##ing
(
39
%
)
,
abdominal
pain
(
37
%
)
,
r
##ash
(
35
%
)
[SEP]
[CLS]
,
an
##emia
(
27
%
)
,
p
##yre
##xia
(
26
%
)
,
and
fatigue
(
24
%
)
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Pat
##ients
should
not
wear
contact
lenses
if
they
have
signs
or
symptoms
of
bacterial
con
##junct
##iv
##itis
or
during
the
course
of
therapy
with
Be
##si
##vance
(
5
.
3
)
5
.
1
Top
##ical
Op
##ht
##hal
##mic
Use
[SEP]
[CLS]
Only
NO
##T
F
##OR
IN
##J
##EC
##TI
##ON
IN
##TO
THE
E
##Y
##E
.
[SEP]
[CLS]
T
##EN
has
been
reported
for
r
##it
##ux
##ima
##b
(
see
r
##it
##ux
##ima
##b
package
insert
)
.
[SEP]
[CLS]
These
included
no
subjects
in
the
normal
re
##nal
function
group
,
10
%
of
subjects
in
the
c
##rea
##tin
##ine
clearance
50
to
80
m
##L
/
min
group
,
29
%
of
subjects
in
[SEP]
[CLS]
the
c
##rea
##tin
##ine
clearance
<
30
m
##L
/
min
group
,
and
29
%
of
subjects
in
the
hem
##od
##ial
##ys
##is
group
.
[SEP]
[CLS]
Among
E
##NT
##ER
##EG
-
treated
patients
undergoing
surge
##ries
that
included
a
bow
##el
re
##section
,
the
most
common
adverse
reaction
(
incidence
>
=
1
.
5
%
)
occurring
with
a
higher
frequency
than
place
##bo
was
[SEP]
[CLS]
d
##ys
##pe
##ps
##ia
(
E
##NT
##ER
##EG
,
1
.
5
%
;
place
##bo
,
0
.
8
%
)
.
[SEP]
[CLS]
The
median
time
to
death
for
the
remaining
eight
subjects
in
the
S
##IR
##TU
##RO
treatment
group
was
32
##9
days
after
last
intake
of
S
##IR
##TU
##RO
.
[SEP]
[CLS]
To
manage
gas
##tro
##int
##est
##inal
toxicity
,
with
##hold
,
dose
reduce
,
or
disco
##ntin
##ue
B
##OS
##U
##L
##IF
as
necessary
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Ad
##verse
Re
##actions
(
6
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
T
##RE
##AN
##DA
.
[SEP]
[CLS]
S
##ym
##pt
##oma
##tic
h
##y
##pot
##ens
##ion
can
occur
after
in
##iti
##ating
IN
##VO
##KA
##NA
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
particularly
in
patients
with
impaired
re
##nal
function
(
e
##G
##F
##R
less
than
60
m
##L
/
min
/
1
.
73
m
2
[SEP]
[CLS]
)
,
elderly
patients
,
patients
on
either
di
##ure
##tics
or
medications
that
interfere
with
the
re
##nin
-
an
##gio
##tens
##in
-
al
##dos
##tero
##ne
system
(
e
.
g
.
,
an
##gio
##tens
##in
-
converting
-
enzyme
[
AC
##E
]
inhibitor
##s
,
an
##gio
##tens
##in
receptor
block
##ers
[
[SEP]
[CLS]
AR
##B
##s
]
)
,
or
patients
with
low
s
##ys
##to
##lic
blood
pressure
.
[SEP]
[CLS]
(
5
.
3
)
*
H
##y
##po
##gly
##ce
##mia
:
When
an
insulin
secret
##ago
##gue
(
e
.
g
.
,
su
##lf
##ony
##lu
##rea
)
or
insulin
is
used
in
combination
with
NE
##SI
##NA
,
a
lower
dose
of
the
insulin
[SEP]
[CLS]
secret
##ago
##gue
or
insulin
may
be
required
to
minimize
the
risk
of
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
H
##yper
##gly
##ce
##mia
and
Di
##abe
##tes
Mel
##lit
##us
H
##yper
##gly
##ce
##mia
,
in
some
cases
extreme
and
associated
with
k
##eto
##ac
##ido
##sis
or
h
##yper
##os
##mo
##lar
coma
or
death
,
has
been
reported
in
patients
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
including
[SEP]
[CLS]
FA
##NA
##P
##T
.
[SEP]
[CLS]
Other
serious
or
significant
adverse
reactions
reported
in
controlled
and
un
##con
##tro
##lled
studies
in
C
##ro
##hn
'
s
disease
and
other
diseases
,
occurring
in
patients
receiving
C
##IM
##Z
##IA
at
doses
of
400
mg
[SEP]
[CLS]
or
other
doses
include
:
Blood
and
l
##ymph
##atic
system
disorders
:
An
##emia
,
le
##uk
##ope
##nia
,
l
##ymph
##ade
##no
##pathy
,
pan
##cy
##top
##enia
,
and
th
##rom
##bo
##phi
##lia
.
[SEP]
[CLS]
(
5
.
3
)
item
{
Ba
##cter
##ial
infections
-
Pro
##long
##ed
use
of
co
##rt
##ico
##ster
##oids
may
suppress
the
host
response
and
thus
increase
the
hazard
of
secondary
o
##cular
infections
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
5
%
)
in
patients
who
received
Y
##ER
##VO
##Y
at
3
mg
/
kg
were
fatigue
,
di
##ar
##r
##hea
,
p
##ru
##rit
##us
,
r
##ash
,
and
co
##lit
##is
.
[SEP]
[CLS]
Fund
##us
##copic
abnormal
##ities
have
most
commonly
been
described
as
per
##iva
##s
##cular
pig
##mentation
(
bone
s
##pic
##ule
pattern
)
in
the
re
##tina
##l
periphery
and
/
or
as
areas
of
focal
re
##tina
##l
pig
##ment
e
##pit
##hel
##ium
c
##lump
##ing
.
[SEP]
[CLS]
If
infectious
et
##iol
##ogies
are
not
considered
,
there
is
a
risk
that
patients
with
infectious
et
##iol
##ogies
will
not
receive
the
appropriate
therapy
and
their
disease
may
worse
##n
.
[SEP]
[CLS]
PR
##IS
##TI
##Q
has
not
been
systematically
evaluated
in
patients
with
a
seizure
disorder
.
[SEP]
[CLS]
The
risk
of
major
bleed
##s
was
similar
with
PR
##AD
##A
##X
##A
150
mg
and
war
##fari
##n
across
major
subgroup
##s
defined
by
base
##line
characteristics
(
see
Figure
1
)
,
with
the
exception
of
[SEP]
[CLS]
age
,
where
there
was
a
trend
towards
a
higher
incidence
of
major
bleeding
on
PR
##AD
##A
##X
##A
(
hazard
ratio
1
.
2
,
95
%
C
##I
:
1
.
0
to
1
.
5
)
for
[SEP]
[CLS]
patients
>
=
75
years
of
age
.
[SEP]
[CLS]
(
2
.
2
,
5
.
7
)
*
Em
##b
##ryo
##fe
##tal
To
##xi
##city
:
Z
##Y
##KA
##DI
##A
may
cause
f
##etal
harm
.
[SEP]
[CLS]
(
5
.
7
)
*
U
##ter
##ine
bleeding
:
Eva
##lu
##ate
irregular
bleeding
or
am
##eno
##rr
##hea
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
described
in
greater
detail
in
other
sections
:
*
Para
##dox
##ical
br
##on
##cho
##sp
##as
##m
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
[SEP]
[CLS]
W
##orse
##ning
of
narrow
-
angle
g
##lau
##com
##a
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
W
##orse
##ning
of
u
##rina
##ry
retention
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
[SEP]
[CLS]
I
##mme
##dia
##te
H
##yper
##sen
##si
##ti
##vity
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
=
3
%
incidence
and
greater
than
place
##bo
)
are
[SEP]
[CLS]
headache
,
na
##so
##pha
##ryn
##git
##is
and
cough
.
[SEP]
[CLS]
The
risk
of
post
##par
##tum
th
##rom
##boe
##mbo
##lis
##m
decreases
after
the
third
post
##par
##tum
week
,
whereas
the
risk
of
o
##vu
##lation
increases
after
the
third
post
##par
##tum
week
.
[SEP]
[CLS]
Inter
##rup
##t
or
adjust
dos
##age
until
recovery
,
or
permanently
disco
##ntin
##ue
Bel
##eo
##da
##q
based
on
the
severity
of
the
he
##pa
##tic
toxicity
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
If
the
Ad
##re
##V
##ie
##w
imaging
information
is
essential
for
clinical
care
,
consider
the
withdrawal
of
the
following
categories
of
medications
if
the
withdrawal
can
be
accomplished
safely
:
anti
##hy
##pert
##ens
##ives
that
[SEP]
[CLS]
de
##ple
##te
nor
##ep
##ine
##ph
##rine
stores
or
in
##hibit
re
##up
##take
(
e
.
g
.
,
re
##ser
##pine
,
lab
##etal
##ol
)
,
anti
##de
##press
##ants
that
in
##hibit
nor
##ep
##ine
##ph
##rine
transport
##er
function
(
e
.
g
.
,
am
##it
##rip
##ty
##line
and
derivatives
,
im
##ip
##ram
##ine
and
derivatives
[SEP]
[CLS]
,
selective
se
##rot
##oni
##n
re
##up
##take
inhibitor
##s
)
,
and
s
##ym
##path
##omi
##met
##ic
am
##ines
(
e
.
g
.
,
p
##hen
##yle
##ph
##rine
,
p
##hen
##yl
##p
##rop
##ano
##lam
##ine
,
pseudo
##ep
##hed
##rine
and
e
##phe
##dr
##ine
)
.
[SEP]
[CLS]
Out
of
71
##5
patients
who
received
two
concurrent
injection
##s
of
XI
##AF
##LE
##X
0
.
58
mg
in
the
same
hand
(
145
##0
XI
##AF
##LE
##X
injection
##s
)
in
Study
3
,
one
(
0
.
1
%
[SEP]
[CLS]
)
patient
experienced
a
tend
##on
r
##up
##ture
of
the
treated
finger
within
3
days
of
the
injection
.
[SEP]
[CLS]
(
5
.
2
)
*
He
##pa
##to
##to
##xi
##city
:
Inc
##rease
##s
in
liver
enzymes
have
led
to
drug
interrupt
##ion
,
dose
modification
and
/
or
disco
##ntin
##uation
.
[SEP]
[CLS]
(
2
.
2
,
5
.
1
)
*
In
##fect
##ion
:
Ser
##ious
and
fatal
infections
(
e
.
g
.
,
pneumonia
and
se
##psis
)
.
[SEP]
[CLS]
Both
the
loading
dose
of
400
mg
every
other
week
at
Weeks
0
,
2
and
4
and
con
##com
##ita
##nt
use
of
M
##T
##X
were
associated
with
reduced
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
Use
Z
##Y
##TI
##GA
with
caution
in
patients
with
a
history
of
card
##iovascular
disease
.
[SEP]
[CLS]
In
clinical
trials
,
patients
were
not
eligible
for
Ad
##re
##V
##ie
##w
imaging
if
they
were
receiving
medications
in
the
above
categories
and
the
risks
for
medication
withdrawal
were
unacceptable
or
if
[SEP]
[CLS]
they
were
not
clinical
##ly
stable
(
e
.
g
.
,
experiencing
continuing
chest
pain
,
hem
##ody
##nam
##ic
instability
,
or
clinical
##ly
significant
a
##rr
##hy
##th
##mia
)
.
[SEP]
[CLS]
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
the
adverse
reaction
rates
observed
can
not
be
directly
compared
to
rates
in
other
trials
and
may
not
reflect
the
[SEP]
[CLS]
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
and
initiate
systemic
high
-
dose
co
##rt
##ico
##ster
##oid
therapy
for
severe
immune
-
mediated
reactions
.
[SEP]
[CLS]
These
immune
-
mediated
reactions
may
involve
any
organ
system
;
however
,
the
most
common
severe
immune
-
mediated
adverse
reactions
are
enter
##oc
##oli
##tis
,
he
##pa
##titis
,
der
##mat
##itis
(
including
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
)
[SEP]
[CLS]
,
ne
##uro
##pathy
,
and
end
##oc
##rino
##pathy
.
[SEP]
[CLS]
Therefore
,
the
efficacy
and
safety
of
XI
##AF
##LE
##X
in
patients
receiving
anti
##coa
##gu
##lant
medications
(
other
than
low
-
dose
as
##pi
##rin
,
e
.
g
.
,
up
to
150
mg
per
day
)
within
7
[SEP]
[CLS]
days
prior
to
XI
##AF
##LE
##X
administration
is
not
known
.
[SEP]
[CLS]
(
5
.
6
,
8
.
1
,
8
.
3
)
5
.
1
He
##pa
##to
##to
##xi
##city
Drug
-
induced
he
##pa
##to
##to
##xi
##city
with
fatal
outcome
occurred
in
2
(
0
.
1
%
)
of
the
166
##9
patients
treated
with
X
##AL
##KO
##RI
across
clinical
[SEP]
[CLS]
trials
in
patients
with
N
##SC
##LC
.
[SEP]
[CLS]
pneumonia
,
systemic
infection
)
and
un
##tre
##ated
or
inadequate
##ly
treated
extra
##py
##ram
##idal
signs
and
symptoms
(
EP
##S
)
.
[SEP]
[CLS]
The
acute
reactions
requiring
intervention
were
managed
by
either
temporarily
interrupting
or
disco
##ntin
##uing
in
##fusion
,
and
administer
##ing
additional
anti
##his
##tamine
,
anti
##py
##ret
##ics
,
or
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
*
Ser
##ious
as
##th
##ma
-
related
events
,
including
death
,
were
reported
in
clinical
studies
with
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
.
[SEP]
[CLS]
Do
##ses
of
the
related
beta
##2
-
ago
##nist
al
##but
##ero
##l
,
when
administered
in
##tra
##ven
##ously
,
have
been
reported
to
a
##gg
##ra
##vate
pre
-
existing
diabetes
me
##lli
##tus
.
[SEP]
[CLS]
The
onset
of
vision
disorder
generally
was
within
the
first
week
of
drug
administration
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
the
disco
##ntin
##uation
of
C
##IM
##Z
##IA
(
for
at
least
2
patients
and
with
a
higher
incidence
than
place
##bo
)
were
abdominal
pain
(
0
.
4
[SEP]
[CLS]
%
C
##IM
##Z
##IA
,
0
.
2
%
place
##bo
)
,
di
##ar
##r
##hea
(
0
.
4
%
C
##IM
##Z
##IA
,
0
%
place
##bo
)
,
and
in
##test
##inal
o
##bs
##truction
(
0
.
4
%
C
##IM
##Z
##IA
,
0
%
place
##bo
[SEP]
[CLS]
)
.
[SEP]
[CLS]
5
.
6
Gas
##tro
##int
##est
##inal
Per
##fo
##ration
and
Fi
##st
##ula
Formation
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
gas
##tro
##int
##est
##inal
per
##fo
##ration
was
reported
in
1
/
35
##9
patients
(
<
[SEP]
[CLS]
1
%
)
receiving
IN
##L
##Y
##TA
and
none
of
the
patients
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
In
place
##bo
-
controlled
mon
##otherapy
trials
,
di
##ar
##r
##hea
was
reported
up
to
2
%
in
patients
treated
with
Ed
##ar
##bi
80
mg
daily
compared
with
0
.
5
%
of
patients
on
place
##bo
.
[SEP]
[CLS]
Disco
##ntin
##ue
for
life
-
threatening
cut
##aneous
reactions
.
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
O
##bs
##erve
##d
During
the
Pre
##market
##ing
Evaluation
of
SA
##P
##H
##RI
##S
:
Following
is
a
list
of
Me
##d
##DR
##A
terms
that
reflect
adverse
reactions
reported
by
patients
treated
with
sub
##ling
##ual
SA
##P
##H
##RI
##S
at
[SEP]
[CLS]
multiple
doses
of
>
=
5
mg
twice
daily
during
any
phase
of
a
trial
within
the
database
of
adult
patients
.
[SEP]
[CLS]
5
.
3
Mali
##gna
##ncy
The
impact
of
treatment
with
B
##EN
##L
##Y
##ST
##A
on
the
development
of
ma
##li
##gna
##ncies
is
not
known
.
[SEP]
[CLS]
If
involvement
of
the
tongue
,
h
##y
##pop
##har
##ynx
,
or
la
##ryn
##x
occurs
,
f
##es
##oter
##od
##ine
should
be
promptly
discontinued
and
appropriate
therapy
and
/
or
measures
to
ensure
a
patent
air
##way
should
be
promptly
[SEP]
[CLS]
provided
.
[SEP]
[CLS]
The
increased
risk
of
su
##icidal
thoughts
with
A
##ED
##s
was
observed
as
early
as
1
week
after
starting
drug
treatment
with
A
##ED
##s
and
persisted
for
the
duration
of
treatment
assessed
.
[SEP]
[CLS]
*
D
##U
##AV
##EE
should
be
swallowed
whole
.
[SEP]
[CLS]
Close
##ly
observe
patients
during
and
after
al
##g
##lu
##cos
##idas
##e
al
##fa
administration
and
be
prepared
to
manage
an
##aph
##yla
##xi
##s
and
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
Because
of
the
potential
risk
of
my
##oc
##ard
##ial
in
##far
##ction
with
long
-
term
use
,
E
##NT
##ER
##EG
is
available
only
through
a
restricted
program
for
short
-
term
use
(
15
doses
)
under
a
Risk
[SEP]
[CLS]
Evaluation
and
Mi
##ti
##gation
Strategy
(
R
##EM
##S
)
called
the
E
##NT
##ER
##EG
Access
Support
and
Education
(
E
.
A
.
S
.
E
.
[SEP]
[CLS]
Se
##vere
acute
ex
##ace
##rb
##ations
of
he
##pa
##titis
B
have
been
reported
in
patients
who
are
coin
##fected
with
H
##B
##V
and
HIV
-
1
and
have
discontinued
em
##tric
##ita
##bine
or
ten
##of
##ov
##ir
D
##F
,
two
of
the
components
[SEP]
[CLS]
of
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
A
majority
of
these
cases
have
been
in
women
.
[SEP]
[CLS]
Safety
results
are
based
on
a
median
follow
-
up
of
approximately
13
months
.
[SEP]
[CLS]
The
median
time
between
diagnosis
of
the
first
cu
##SC
##C
and
the
second
cu
##SC
##C
was
6
weeks
.
[SEP]
[CLS]
5
.
10
G
##lu
##cos
##e
-
6
-
Ph
##os
##phate
De
##hy
##dr
##ogen
##ase
De
##ficiency
T
##AF
##IN
##LA
##R
,
which
contains
a
su
##lf
##ona
##mi
##de
m
##oi
##ety
,
con
##fers
a
potential
risk
of
hem
##oly
##tic
an
##emia
in
patients
with
glucose
-
6
-
phosphate
de
##hy
##dr
##ogen
##ase
(
G
##6
##PD
)
deficiency
.
[SEP]
[CLS]
The
test
results
for
the
e
##cal
##lant
##ide
program
were
determined
using
one
of
two
ass
##ay
formats
:
E
##L
##IS
##A
and
br
##id
##ging
electro
##che
##mi
##lum
##ines
##cence
(
EC
##L
)
.
[SEP]
[CLS]
5
.
2
Tu
##mor
Promotion
in
BR
##AF
Wild
-
Type
Mel
##ano
##ma
In
v
##it
##ro
experiments
have
demonstrated
para
##dox
##ical
activation
of
MA
##P
-
kinase
signaling
and
increased
cell
proliferation
in
BR
##AF
wild
-
type
cells
which
are
exposed
to
BR
##AF
[SEP]
[CLS]
inhibitor
##s
.
[SEP]
[CLS]
The
incidence
of
the
following
grade
3
-
4
adverse
reactions
were
higher
in
patients
>
=
65
years
of
age
compared
to
younger
patients
;
ne
##ut
##rop
##enia
(
87
%
vs
.
74
[SEP]
[CLS]
%
)
,
and
f
##eb
##ril
##e
ne
##ut
##rop
##enia
(
8
%
vs
.
6
%
)
[
see
Use
in
S
##pecific
Population
##s
(
8
.
5
)
]
.
[SEP]
[CLS]
Eva
##lu
##ate
patients
who
develop
fever
and
lung
in
##fi
##lt
##rates
or
respiratory
distress
after
receiving
G
##RA
##NI
##X
,
for
AR
##DS
.
[SEP]
[CLS]
*
PR
##IS
##TI
##Q
is
not
approved
for
use
in
p
##ediatric
patients
(
8
.
4
)
.
[SEP]
[CLS]
The
possibility
that
G
##RA
##NI
##X
acts
as
a
growth
factor
for
any
tumor
type
,
including
my
##elo
##id
ma
##li
##gna
##ncies
and
my
##elo
##dy
##sp
##lasia
,
diseases
for
which
G
##RA
##NI
##X
is
not
approved
,
can
not
[SEP]
[CLS]
be
excluded
.
[SEP]
[CLS]
Monitor
blood
pressure
regularly
during
treatment
(
5
.
3
)
.
[SEP]
[CLS]
Pat
##ients
with
C
##ro
##hn
'
s
disease
that
require
chronic
exposure
to
im
##mu
##nos
##up
##press
##ant
the
##rap
##ies
may
be
at
higher
risk
than
the
general
population
for
the
development
of
l
##ymph
##oma
,
even
in
the
[SEP]
[CLS]
absence
of
T
##NF
block
##er
therapy
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
There
were
no
reports
of
seizure
##s
in
p
##ediatric
patients
treated
with
SA
##P
##H
##RI
##S
in
a
3
-
week
-
term
,
bi
##pol
##ar
man
##ia
trial
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
drug
reactions
to
ST
##RI
##BI
##LD
(
incidence
greater
than
or
equal
to
10
%
,
all
grades
)
are
nausea
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
It
is
generally
believed
(
though
not
established
in
controlled
studies
)
that
treating
such
an
episode
with
an
anti
##de
##press
##ant
alone
may
increase
the
likelihood
of
[SEP]
[CLS]
precipitation
of
a
mixed
/
man
##ic
episode
in
patients
at
risk
for
bi
##pol
##ar
disorder
.
[SEP]
[CLS]
Only
an
##emia
and
fatigue
were
reported
as
events
that
led
to
disco
##ntin
##uation
in
more
than
1
%
of
subjects
in
any
arm
.
[SEP]
[CLS]
The
useful
##ness
of
hem
##od
##ial
##ys
##is
in
the
prevention
of
N
##SF
is
unknown
.
[SEP]
[CLS]
In
a
large
,
random
##ized
,
place
##bo
-
controlled
clinical
study
,
a
generalized
effect
of
est
##rogen
##s
on
blood
pressure
was
not
seen
.
[SEP]
[CLS]
Of
the
patients
who
reported
ne
##uro
##pathy
,
59
%
had
complete
resolution
and
41
%
had
residual
ne
##uro
##pathy
(
26
%
partial
improvement
,
15
%
no
improvement
)
at
[SEP]
[CLS]
the
time
of
their
last
evaluation
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Gil
##ead
Sciences
,
Inc
.
at
1
-
800
-
G
##IL
##EA
##D
-
5
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
5
.
4
H
##yper
##sen
##si
##ti
##vity
Re
##actions
The
following
symptoms
that
could
be
compatible
with
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
rarely
following
C
##IM
##Z
##IA
administration
to
patients
:
an
##gio
##ede
##ma
,
d
##ys
##p
##nea
,
h
##y
##pot
##ens
##ion
,
[SEP]
[CLS]
r
##ash
,
serum
sickness
,
and
u
##rt
##ica
##ria
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
the
pre
##s
##cribing
information
.
[SEP]
[CLS]
As
with
other
anti
##psy
##cho
##tic
drugs
,
SA
##P
##H
##RI
##S
should
be
used
with
caution
in
patients
with
a
history
of
seizure
##s
or
with
conditions
that
potentially
lower
the
seizure
threshold
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
care
is
advised
when
pre
##s
##cribing
SA
##P
##H
##RI
##S
for
patients
who
will
be
experiencing
conditions
that
may
contribute
to
an
elevation
in
core
body
temperature
,
e
.
g
.
,
ex
##er
##cis
##ing
s
##tre
##nu
##ously
,
[SEP]
[CLS]
exposure
to
extreme
heat
,
receiving
con
##com
##ita
##nt
medication
with
anti
##cho
##liner
##gic
activity
,
or
being
subject
to
de
##hy
##dra
##tion
.
[SEP]
[CLS]
D
##AM
##PA
interfere
##s
with
the
measurement
of
met
##hot
##re
##xa
##te
concentration
using
im
##mu
##no
##ass
##ays
resulting
in
an
er
##rone
##ous
measurement
which
over
##est
##imate
##s
the
met
##hot
##re
##xa
##te
concentration
.
[SEP]
[CLS]
Laboratory
Tests
Inc
##rease
in
Low
-
Den
##sity
Li
##pop
##rote
##in
Cho
##les
##tero
##l
(
L
##D
##L
-
C
)
Do
##se
-
related
increases
in
low
-
density
lip
##op
##rote
##in
ch
##ole
##ster
##ol
(
L
##D
##L
-
C
)
were
observed
in
patients
treated
with
J
##AR
##DI
##AN
##CE
.
[SEP]
[CLS]
T
##AF
##IN
##LA
##R
and
tram
##eti
##ni
##b
may
be
resumed
at
lower
dose
levels
in
patients
with
improvement
or
recovery
from
skin
toxicity
within
3
weeks
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
The
following
symptoms
,
anxiety
,
agitation
,
panic
attacks
,
ins
##om
##nia
,
i
##rri
##ta
##bility
,
hostility
,
aggressive
##ness
,
imp
##ul
##si
##vity
,
aka
##thi
##sia
(
ps
##ych
##omo
##tor
restless
##ness
)
,
h
##y
##po
##mani
##a
,
and
[SEP]
[CLS]
man
##ia
,
have
been
reported
in
adult
and
p
##ediatric
patients
being
treated
with
anti
##de
##press
##ants
for
major
de
##pressive
disorder
as
well
as
for
other
indication
##s
,
both
psychiatric
and
non
##psy
##chia
##tric
.
[SEP]
[CLS]
G
##IL
##EN
##Y
##A
has
not
been
tested
in
MS
patients
with
compromised
respiratory
function
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
Similar
adverse
reactions
have
been
observed
post
##market
##ing
as
described
for
clinical
trial
experience
.
[SEP]
[CLS]
Additionally
,
the
observed
incidence
of
anti
##body
(
including
neutral
##izing
anti
##body
)
p
##os
##iti
##vity
in
an
ass
##ay
may
be
influenced
by
several
factors
including
ass
##ay
methodology
,
sample
handling
,
timing
[SEP]
[CLS]
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
(
r
)
)
Program
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
and
(
5
.
2
)
]
.
[SEP]
[CLS]
Side
effects
are
grouped
by
how
serious
they
are
and
how
often
they
happen
when
you
are
treated
.
[SEP]
[CLS]
E
##ti
##ologies
included
infection
,
card
##iovascular
disease
,
and
suicide
.
[SEP]
[CLS]
*
Gas
##tro
##int
##est
##inal
Ad
##verse
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
he
##pa
##titis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Disco
##ntin
##uations
due
to
adverse
events
were
reported
for
16
%
of
X
##TA
##ND
##I
-
treated
patients
and
18
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Consider
follow
-
up
re
##nal
function
assessments
for
patients
with
a
history
of
re
##nal
d
##ys
##function
.
[SEP]
[CLS]
4
##I
##nc
##lude
##s
the
preferred
terms
fatigue
and
let
##har
##gy
.
[SEP]
[CLS]
In
clinical
trials
with
IN
##L
##Y
##TA
,
ve
##nous
th
##rom
##boe
##mbo
##lic
events
were
reported
in
22
/
71
##5
patients
(
3
%
)
,
with
two
deaths
secondary
to
pulmonary
em
##bol
##ism
.
[SEP]
[CLS]
There
has
been
no
long
-
term
use
of
Ed
##ar
##bi
in
patients
with
un
##ila
##teral
or
bilateral
re
##nal
artery
s
##ten
##osis
,
but
similar
results
may
be
expected
.
[SEP]
[CLS]
The
most
common
(
per
patient
incidence
>
=
10
%
)
adverse
reactions
reported
with
Pro
##lia
in
patients
with
bone
loss
receiving
and
##rogen
de
##p
##ri
##vation
therapy
for
pro
##state
cancer
or
[SEP]
[CLS]
ad
##ju
##vant
a
##roma
##tase
inhibitor
therapy
for
breast
cancer
are
art
##hra
##l
##gia
and
back
pain
.
[SEP]
[CLS]
This
was
not
clinical
##ly
significant
among
patients
in
the
development
program
but
could
be
a
factor
in
patients
whose
diabetes
is
difficult
to
control
.
[SEP]
[CLS]
Free
T
##4
and
free
T
##3
concentrations
are
un
##altered
.
[SEP]
[CLS]
Based
on
the
Visual
S
##ym
##pt
##om
Assessment
Question
##naire
(
V
##SA
##Q
-
AL
##K
)
,
patients
treated
with
X
##AL
##KO
##RI
in
Studies
1
and
2
reported
a
higher
incidence
of
visual
disturbance
##s
compared
to
patients
[SEP]
[CLS]
treated
with
ch
##em
##otherapy
.
[SEP]
[CLS]
Other
important
considerations
in
the
differential
diagnosis
include
central
anti
##cho
##liner
##gic
toxicity
,
heat
stroke
,
drug
fever
,
and
primary
central
nervous
system
path
##ology
.
[SEP]
[CLS]
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
5
.
9
A
##b
##nor
##mal
T
##hy
##roid
Fun
##ction
Tests
Do
##se
-
dependent
decreases
in
serum
T
##3
and
T
##4
(
free
)
values
have
been
observed
in
patients
taking
AP
##TI
##OM
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
(
>
=
2
%
)
included
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
p
##yre
##xia
,
pneumonia
,
se
##psis
,
ne
##ut
##rop
##enia
,
device
-
related
infection
,
t
##rem
##or
,
[SEP]
[CLS]
en
##ce
##pha
##lop
##athy
,
infection
,
over
##dos
##e
,
confusion
,
St
##aph
##yl
##oc
##oc
##cal
b
##act
##ere
##mia
,
and
headache
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
during
therapy
.
[SEP]
[CLS]
Among
those
,
211
##0
patients
were
treated
with
the
recommended
dose
of
2
mg
.
Ser
##ious
adverse
reactions
related
to
the
injection
procedure
have
occurred
in
<
0
.
1
%
of
in
##tra
##vi
##tre
##al
[SEP]
[CLS]
injection
##s
with
E
##Y
##LE
##A
including
end
##op
##ht
##hal
##mit
##is
and
re
##tina
##l
detachment
.
[SEP]
[CLS]
I
##mm
##une
System
Di
##sor
##ders
:
sa
##rc
##oid
##osis
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
AND
MA
##L
##IG
##NA
##NC
##Y
WA
##R
##NI
##NG
:
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
AND
MA
##L
##IG
##NA
##NC
##Y
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
Pat
##ients
treated
with
C
##IM
##Z
##IA
are
at
increased
risk
[SEP]
[CLS]
for
developing
serious
infections
that
may
lead
to
hospital
##ization
or
death
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
N
##NR
##TI
-
related
r
##ash
did
not
appear
to
be
at
increased
risk
for
the
development
of
IN
##TE
##LE
##NC
##E
(
r
)
-
related
r
##ash
compared
to
patients
without
a
[SEP]
[CLS]
history
of
N
##NR
##TI
-
related
r
##ash
.
[SEP]
[CLS]
5
.
3
Inter
##st
##iti
##al
Lu
##ng
Disease
(
IL
##D
)
/
P
##ne
##um
##oni
##tis
Se
##vere
,
life
-
threatening
,
or
fatal
IL
##D
/
p
##ne
##um
##oni
##tis
can
occur
in
patients
treated
with
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
Table
5
shows
the
number
of
patients
experiencing
bleeding
events
in
the
study
.
[SEP]
[CLS]
The
mechanism
of
Fe
##rri
##p
##ro
##x
-
associated
a
##gra
##nu
##loc
##yt
##osis
is
unknown
.
[SEP]
[CLS]
Monitor
with
liver
laboratory
tests
including
AL
##T
,
as
##par
##tate
amino
##tra
##ns
##fer
##ase
(
AS
##T
)
,
and
total
bi
##li
##ru
##bin
once
a
month
and
as
clinical
##ly
indicated
,
with
more
frequent
testing
in
[SEP]
[CLS]
patients
who
develop
trans
##ami
##nas
##e
elevations
.
[SEP]
[CLS]
5
.
8
Em
##b
##ryo
##fe
##tal
To
##xi
##city
Based
on
its
mechanism
of
action
,
Z
##Y
##KA
##DI
##A
may
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
(
2
.
2
)
As
##ses
##s
patients
for
signs
and
symptoms
of
enter
##oc
##oli
##tis
,
der
##mat
##itis
,
ne
##uro
##pathy
,
and
end
##oc
##rino
##pathy
and
evaluate
clinical
chemist
##ries
including
liver
function
tests
and
thy
##roid
function
tests
[SEP]
[CLS]
at
base
##line
and
before
each
dose
.
[SEP]
[CLS]
Mean
percent
changes
from
base
##line
at
Week
24
,
were
0
.
0
%
versus
2
.
5
%
for
total
ch
##ole
##ster
##ol
,
in
the
place
##bo
and
FA
##R
##X
##IG
##A
10
mg
groups
,
respectively
.
[SEP]
[CLS]
5
.
11
He
##pa
##tic
I
##mp
##air
##ment
CO
##ME
##TR
##I
##Q
is
not
recommended
for
use
in
patients
with
moderate
or
severe
he
##pa
##tic
imp
##air
##ment
[
see
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
Based
on
patient
di
##aries
,
am
##eno
##rr
##hea
occurs
in
approximately
16
%
of
cycles
in
women
using
Nat
##azi
##a
.
[SEP]
[CLS]
In
addition
to
the
reactions
in
Table
1
,
the
following
adverse
reactions
were
reported
more
frequently
in
T
##R
##U
##L
##IC
##IT
##Y
-
treated
patients
than
place
##bo
(
frequencies
listed
,
respectively
,
as
:
[SEP]
[CLS]
place
##bo
;
0
.
75
mg
;
1
.
5
mg
)
:
con
##st
##ip
##ation
(
0
.
7
%
,
3
.
9
%
,
3
.
7
%
)
,
flat
##ule
##nce
(
1
.
4
%
,
1
.
4
%
,
3
.
4
[SEP]
[CLS]
%
)
,
abdominal
di
##sten
##sion
(
0
.
7
%
,
2
.
9
%
,
2
.
3
%
)
,
gas
##tro
##es
##op
##hage
##al
re
##f
##lux
disease
(
0
.
5
%
,
1
.
7
%
,
2
.
0
%
)
,
[SEP]
[CLS]
and
er
##uc
##tation
(
0
.
2
%
,
0
.
6
%
,
1
.
6
%
)
.
[SEP]
[CLS]
The
liver
transplant
recipient
was
treated
with
6
months
of
a
N
##U
##L
##O
##J
##IX
dos
##age
regime
##n
that
was
more
intensive
than
that
studied
in
kidney
transplant
recipients
,
M
##MF
at
doses
higher
[SEP]
[CLS]
than
the
recommended
dose
,
and
co
##rt
##ico
##ster
##oids
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
The
safety
profile
for
patients
with
P
##s
##A
treated
with
C
##IM
##Z
##IA
was
similar
to
the
safety
profile
seen
in
patients
with
RA
and
previous
experience
with
C
##IM
##Z
##IA
.
[SEP]
[CLS]
Gala
##ctor
##r
##hea
,
am
##eno
##rr
##hea
,
g
##yne
##com
##ast
##ia
,
and
imp
##ote
##nce
have
been
reported
with
pro
##la
##ct
##in
-
el
##eva
##ting
compounds
.
[SEP]
[CLS]
high
tumor
burden
)
.
[SEP]
[CLS]
The
sizes
of
these
studies
were
not
adequate
to
precisely
q
##uant
##ify
the
differences
in
serious
as
##th
##ma
ex
##ace
##rb
##ation
rates
between
treatment
groups
.
[SEP]
[CLS]
Ha
##zard
##ous
Activities
Pre
##s
##cribe
##rs
should
advise
patients
against
engaging
in
hazardous
activities
requiring
mental
alert
##ness
,
such
as
operating
motor
vehicles
or
dangerous
machinery
,
until
the
effect
of
AP
##TI
##OM
is
[SEP]
[CLS]
known
.
[SEP]
[CLS]
Pat
##ients
with
moderate
re
##nal
imp
##air
##ment
at
base
##line
had
larger
mean
changes
.
[SEP]
[CLS]
Close
##ly
super
##vise
high
-
risk
patients
.
[SEP]
[CLS]
Con
##current
elevations
in
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
)
greater
than
or
equal
to
three
times
the
upper
limit
of
normal
(
U
##L
##N
)
and
[SEP]
[CLS]
total
bi
##li
##ru
##bin
greater
than
or
equal
to
two
times
the
U
##L
##N
,
with
normal
al
##kal
##ine
p
##hos
##pha
##tase
,
occurred
in
10
patients
(
0
.
6
%
)
treated
with
X
##AL
##KO
##RI
.
[SEP]
[CLS]
Table
2
:
Shi
##ft
from
Basel
##ine
to
Lowe
##st
O
##bs
##erve
##d
e
##G
##F
##R
Group
During
Treatment
Safety
Population
in
Clinical
Studies
(
n
=
81
##8
)
Among
the
81
##8
patients
,
e
##G
##F
##R
was
missing
in
[SEP]
[CLS]
5
patients
at
base
##line
or
on
-
therapy
.
[SEP]
[CLS]
Ser
##ious
In
##fect
##ions
S
er
##ious
infection
was
reported
in
1
patient
(
0
.
8
%
)
in
the
place
##bo
group
and
no
patients
in
the
Pro
##lia
group
.
[SEP]
[CLS]
*
currently
have
or
have
had
liver
problems
*
have
been
diagnosed
with
a
bleeding
disorder
*
think
you
may
be
pregnant
.
[SEP]
[CLS]
*
Po
##ssi
##ble
clinical
##ly
significant
adverse
reactions
from
greater
exposure
##s
of
con
##com
##ita
##nt
drugs
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
below
and
also
elsewhere
in
the
label
##ing
:
*
H
##y
##po
##cal
##ce
##mia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
[SEP]
[CLS]
Ser
##ious
In
##fect
##ions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
*
Der
##mat
##olo
##gic
Ad
##verse
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
*
O
##ste
##one
##c
##rosis
of
the
J
##aw
[
[SEP]
[CLS]
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
At
##y
##pical
Sub
##tro
##chan
##ter
##ic
and
Di
##aph
##ys
##eal
Fe
##mor
##al
Fr
##act
##ures
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
The
most
common
adverse
reactions
reported
[SEP]
[CLS]
with
Pro
##lia
in
patients
with
post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
are
back
pain
,
pain
in
ex
##tre
##mity
,
m
##us
##cu
##los
##kel
##etal
pain
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
and
c
##ys
##titis
.
[SEP]
[CLS]
Do
not
use
to
treat
acute
symptoms
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
for
h
##yper
##tens
##ion
and
treated
as
needed
with
standard
anti
-
h
##yper
##tensive
therapy
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Seattle
Gene
##tics
,
Inc
.
at
1
-
85
##5
-
47
##3
-
243
##6
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Gala
##ctor
##r
##hea
or
d
##ys
##men
##or
##r
##hea
were
reported
in
0
%
of
patients
treated
with
SA
##P
##H
##RI
##S
2
.
5
mg
twice
daily
,
2
%
of
patients
treated
with
SA
##P
##H
##RI
##S
5
mg
twice
daily
,
[SEP]
[CLS]
and
1
%
of
patients
treated
with
SA
##P
##H
##RI
##S
10
mg
twice
daily
compared
to
1
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
mean
exposure
to
NE
##SI
##NA
was
40
weeks
with
more
than
240
##0
subjects
treated
for
more
than
one
year
.
[SEP]
[CLS]
*
Pan
##cre
##ati
##tis
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Di
##ar
##r
##hea
:
Di
##ar
##r
##hea
may
result
in
de
##hy
##dra
##tion
and
re
##nal
failure
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
in
greater
detail
in
another
section
of
the
label
:
*
Bone
Mar
##row
Su
##pp
##ression
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
[SEP]
[CLS]
5
.
1
)
]
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
incidence
>
=
50
%
)
were
h
##yper
##cho
##les
##tero
##lem
##ia
,
h
##yper
##gly
##ce
##mia
,
increased
as
##par
##tate
trans
##ami
##nas
##e
)
,
an
##emia
,
le
##uk
##ope
##nia
,
th
##rom
##bo
##cy
##top
##enia
,
l
##ymph
##ope
##nia
,
[SEP]
[CLS]
increased
al
##ani
##ne
trans
##ami
##nas
##e
)
,
and
h
##yper
##tri
##gly
##cer
##ide
##mia
.
[SEP]
[CLS]
The
most
common
adverse
reactions
in
the
221
patients
treated
with
K
##AL
##Y
##DE
##CO
were
headache
(
17
%
)
,
upper
respiratory
tract
infection
(
16
%
)
,
[SEP]
[CLS]
nasal
congestion
(
16
%
)
,
nausea
(
10
%
)
,
r
##ash
(
10
%
)
,
r
##hin
##itis
(
6
%
)
,
di
##zzi
##ness
(
5
%
)
[SEP]
[CLS]
,
art
##hra
##l
##gia
(
5
%
)
,
and
bacteria
in
s
##put
##um
(
5
%
)
.
[SEP]
[CLS]
Con
##fi
##rm
evidence
of
BR
##AF
V
##60
##0
##E
or
V
##60
##0
##K
mutation
status
prior
to
initiation
of
T
##AF
##IN
##LA
##R
as
a
single
agent
or
combination
therapy
[
see
In
##dication
##s
and
Us
##age
(
1
)
,
[SEP]
[CLS]
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
As
with
all
therapeutic
proteins
,
there
is
a
potential
for
im
##mu
##no
##genic
##ity
with
the
use
of
K
##AL
##BI
##TO
##R
.
[SEP]
[CLS]
In
Trial
1
,
the
incidence
of
new
primary
ma
##li
##gnant
me
##lan
##oma
##s
was
2
%
(
3
/
187
)
for
patients
receiving
T
##AF
##IN
##LA
##R
while
no
da
##car
##ba
##zine
-
treated
patient
was
diagnosed
with
new
primary
[SEP]
[CLS]
ma
##li
##gnant
me
##lan
##oma
.
[SEP]
[CLS]
Tu
##ber
##cu
##los
##is
Tu
##ber
##cu
##los
##is
was
more
frequently
observed
in
patients
receiving
N
##U
##L
##O
##J
##IX
than
c
##y
##c
##los
##por
##ine
in
clinical
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
*
A
##b
##nor
##mal
B
##lee
##ding
:
PR
##IS
##TI
##Q
may
increase
risk
of
bleeding
events
.
[SEP]
[CLS]
5
.
11
V
##ac
##cin
##ations
During
A
##FI
##NI
##TO
##R
treatment
,
avoid
the
use
of
live
vaccine
##s
and
avoid
close
contact
with
individuals
who
have
received
live
vaccine
##s
(
e
.
g
.
,
in
##tra
##nas
##al
in
##fluenza
,
me
##as
##les
[SEP]
[CLS]
,
mum
##ps
,
rub
##ella
,
oral
p
##olio
,
BC
##G
,
yellow
fever
,
var
##ice
##lla
,
and
T
##Y
##21
##a
t
##y
##ph
##oid
vaccine
##s
)
.
[SEP]
[CLS]
5
.
5
Over
##est
##imation
of
Ex
##ten
##t
of
Mali
##gnant
Disease
in
MR
##I
of
the
B
##rea
##st
G
##ada
##vist
MR
##I
of
the
breast
over
##est
##imated
the
his
##to
##logical
##ly
confirmed
extent
of
ma
##li
##gna
##ncy
in
the
disease
##d
breast
in
up
[SEP]
[CLS]
to
50
%
of
the
patients
[
see
Clinical
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
(
4
,
5
.
2
,
14
.
4
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Det
##er
##mine
cardiac
rhythm
at
least
once
every
3
months
.
[SEP]
[CLS]
5
.
2
C
##los
##tri
##dium
di
##ff
##ici
##le
-
Associated
Di
##ar
##r
##hea
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
(
CD
##AD
)
has
been
reported
for
nearly
all
systemic
anti
##ba
##cter
##ial
agents
,
including
Te
##f
##lar
##o
,
and
may
range
in
severity
from
[SEP]
[CLS]
mild
di
##ar
##r
##hea
to
fatal
co
##lit
##is
.
[SEP]
[CLS]
Media
##n
duration
of
treatment
was
7
cycles
(
range
,
1
-
16
)
[
see
Clinical
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
Have
re
##sus
##citation
equipment
and
trained
personnel
available
at
time
of
V
##iza
##my
##l
administration
(
5
.
1
)
*
Image
interpretation
errors
(
especially
false
positive
##s
)
have
been
observed
(
5
.
2
)
[SEP]
[CLS]
*
Ra
##diation
risk
:
V
##iza
##my
##l
,
similar
to
all
radio
##pha
##rma
##ce
##utical
##s
,
contributes
to
a
patient
'
s
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
When
Co
##arte
##m
Table
##ts
are
co
##ad
##mini
##stered
with
an
inhibitor
of
C
##YP
##3
##A
##4
,
including
grape
##f
##ruit
juice
it
may
result
in
increased
concentrations
of
art
##em
##eth
##er
and
/
or
l
##ume
##fant
##rine
and
potent
##iate
Q
##T
pro
##long
##ation
.
[SEP]
[CLS]
These
reactions
occurred
several
weeks
to
3
years
after
initiation
of
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
##s
.
[SEP]
[CLS]
Ser
##oto
##nin
syndrome
symptoms
may
include
mental
status
changes
(
e
.
g
.
,
agitation
,
hall
##uc
##ination
##s
,
del
##iri
##um
,
and
coma
)
,
auto
##no
##mic
instability
(
e
.
g
.
,
ta
##chy
##card
##ia
,
[SEP]
[CLS]
lab
##ile
blood
pressure
,
di
##zzi
##ness
,
di
##aph
##ores
##is
,
flush
##ing
,
h
##yper
##ther
##mia
)
,
ne
##uro
##mus
##cular
symptoms
(
e
.
g
.
,
t
##rem
##or
,
rigid
##ity
,
my
##oc
##lon
##us
,
h
##yper
##re
##fle
##xia
,
in
##co
##ordination
)
,
[SEP]
[CLS]
seizure
##s
,
and
/
or
gas
##tro
##int
##est
##inal
symptoms
(
e
.
g
.
,
nausea
,
vomit
##ing
,
di
##ar
##r
##hea
)
.
[SEP]
[CLS]
*
Before
E
##O
##VI
##ST
administration
,
assess
all
patients
for
any
history
of
a
reaction
to
contrast
media
,
br
##on
##chia
##l
as
##th
##ma
and
all
##ergic
disorders
.
[SEP]
[CLS]
Se
##vere
A
##p
##lastic
An
##emia
:
In
the
single
-
arm
,
open
-
label
trial
,
43
patients
with
severe
a
##p
##lastic
an
##emia
received
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
The
use
of
est
##rogen
-
alone
has
been
reported
to
result
in
an
increase
in
abnormal
ma
##mm
##ogram
##s
requiring
further
evaluation
.
[SEP]
[CLS]
Pre
##scription
##s
for
PR
##IS
##TI
##Q
should
be
written
for
the
smallest
quantity
of
tablets
consistent
with
good
patient
management
,
in
order
to
reduce
the
risk
of
over
##dos
##e
.
[SEP]
[CLS]
Safety
of
combined
use
of
PD
##E
##5
inhibitor
##s
and
alpha
-
block
##ers
may
be
affected
by
other
variables
,
including
in
##tra
##vas
##cular
volume
de
##ple
##tion
and
other
anti
-
h
##yper
##tensive
drugs
[
see
Do
##sa
##ge
and
Administration
(
[SEP]
[CLS]
2
)
and
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
Six
of
these
patients
again
experienced
liver
test
abnormal
##ities
(
predominantly
Grade
1
)
resulting
in
disco
##ntin
##uation
of
PR
##OM
##AC
##TA
in
one
patient
.
[SEP]
[CLS]
5
.
3
Drug
Inter
##actions
with
C
##YP
##3
##A
##4
When
Co
##arte
##m
Table
##ts
are
co
##ad
##mini
##stered
with
substrates
of
C
##YP
##3
##A
##4
it
may
result
in
decreased
concentrations
of
the
substrate
and
potential
loss
of
substrate
efficacy
.
[SEP]
[CLS]
Re
##fer
to
the
pre
##s
##cribing
information
for
rib
##avi
##rin
for
additional
information
.
[SEP]
[CLS]
5
.
14
Suicide
The
possibility
of
a
suicide
attempt
is
inherent
in
ps
##ych
##otic
illness
##es
and
bi
##pol
##ar
disorder
,
and
close
supervision
of
high
-
risk
patients
should
accompany
drug
therapy
.
[SEP]
[CLS]
If
an
all
##ergic
reaction
to
Te
##f
##lar
##o
occurs
,
disco
##ntin
##ue
Te
##f
##lar
##o
and
institute
appropriate
treatment
and
supportive
measures
.
[SEP]
[CLS]
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
.
[SEP]
[CLS]
Con
##ditions
that
lower
the
seizure
threshold
may
be
more
prevalent
in
patients
65
years
or
older
.
[SEP]
[CLS]
AL
##T
=
Alan
##ine
amino
##tra
##ns
##fer
##ase
;
AS
##T
=
As
##par
##tate
amino
##tra
##ns
##fer
##ase
;
G
##G
##T
=
Gamma
g
##lut
##am
##yl
##tra
##ns
##fer
##ase
.
[SEP]
[CLS]
Other
adverse
reactions
which
occurred
in
2
-
5
%
of
subjects
were
eye
irritation
,
headache
,
and
na
##so
##pha
##ryn
##git
##is
.
[SEP]
[CLS]
One
additional
patient
'
s
death
was
attributed
to
ne
##ut
##rop
##enia
without
a
documented
infection
.
[SEP]
[CLS]
S
##pi
##rome
##tric
evaluation
of
respiratory
function
and
evaluation
of
DL
##CO
should
be
performed
during
therapy
with
G
##IL
##EN
##Y
##A
if
clinical
##ly
indicated
.
[SEP]
[CLS]
Because
of
the
risk
of
an
##aph
##yla
##xi
##s
,
K
##AL
##BI
##TO
##R
should
only
be
administered
by
a
healthcare
professional
with
appropriate
medical
support
to
manage
an
##aph
##yla
##xi
##s
and
hereditary
an
##gio
##ede
##ma
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Ex
##clusive
of
an
uncommon
,
mild
injection
site
reaction
,
no
other
adverse
reactions
have
been
reported
(
6
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Ser
##ious
all
##ergic
reactions
,
including
an
##aph
##yla
##ctic
reactions
,
may
occur
.
[SEP]
[CLS]
Pat
##ients
who
are
coin
##fected
with
HIV
-
1
and
H
##B
##V
should
be
closely
monitored
with
both
clinical
and
laboratory
follow
-
up
for
at
least
several
months
after
stopping
treatment
with
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
In
all
open
-
label
trials
combined
,
85
##7
,
70
##1
,
52
##9
,
and
105
patients
received
To
##via
##z
for
at
least
6
months
,
1
year
,
2
years
,
and
[SEP]
[CLS]
3
years
,
respectively
.
[SEP]
[CLS]
Although
the
causes
of
death
were
varied
,
most
of
the
deaths
appeared
to
be
either
card
##iovascular
(
e
.
g
.
,
heart
failure
,
sudden
death
)
or
infectious
(
e
.
g
.
[SEP]
[CLS]
,
pneumonia
)
in
nature
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
,
whether
considered
drug
-
related
or
not
by
the
investigators
,
that
occurred
more
frequently
in
K
##AL
##Y
##DE
##CO
-
treated
patients
included
abdominal
pain
,
increased
he
##pa
##tic
enzymes
,
and
[SEP]
[CLS]
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
There
were
no
reports
of
g
##yne
##com
##ast
##ia
in
this
trial
.
[SEP]
[CLS]
S
##ym
##pt
##oms
of
taking
too
much
D
##U
##AV
##EE
include
:
nausea
##vo
##mit
##ing
##bre
##ast
tender
##ness
##di
##zzi
##ness
##ab
##dom
##inal
pain
##fe
##elin
##g
tired
##va
##gin
##al
bleeding
What
are
the
possible
side
effects
of
D
##U
##AV
##EE
?
[SEP]
[CLS]
Approximately
850
##0
patients
with
type
2
diabetes
have
been
treated
with
NE
##SI
##NA
in
14
random
##ized
,
double
-
blind
,
controlled
clinical
trials
with
approximately
290
##0
subjects
random
##ized
to
place
##bo
and
approximately
[SEP]
[CLS]
220
##0
to
an
active
com
##par
##ator
.
[SEP]
[CLS]
The
median
duration
of
treatment
was
8
.
3
months
with
X
##TA
##ND
##I
and
3
.
0
months
with
place
##bo
.
[SEP]
[CLS]
In
clinical
studies
of
g
##aba
##pent
##in
as
ad
##junct
##ive
therapy
in
e
##pile
##psy
comprising
2
,
08
##5
patient
-
years
of
exposure
in
patients
>
12
years
of
age
,
new
tumors
,
1
[SEP]
[CLS]
non
-
Ho
##d
##g
##kin
'
s
l
##ymph
##oma
,
1
end
##ome
##tri
##al
car
##cin
##oma
in
sit
##u
)
,
and
pre
##ex
##ist
##ing
tumors
worse
##ned
in
11
patients
(
9
brain
)
during
or
up
to
2
years
following
disco
##ntin
##uation
[SEP]
[CLS]
of
g
##aba
##pent
##in
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
drug
reactions
(
adverse
events
assessed
as
ca
##usal
##ly
related
by
the
investigator
or
AD
##R
##s
)
are
discussed
in
other
sections
of
the
label
##ing
:
[SEP]
[CLS]
*
H
##yper
##sen
##si
##ti
##vity
reactions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
who
experienced
bra
##dy
##card
##ia
were
generally
as
##ym
##pt
##oma
##tic
,
but
some
patients
experienced
h
##y
##pot
##ens
##ion
,
di
##zzi
##ness
,
fatigue
,
p
##al
##pit
##ations
,
and
/
or
chest
pain
that
usually
resolved
within
the
first
24
[SEP]
[CLS]
hours
on
treatment
.
[SEP]
[CLS]
Healthcare
providers
should
be
aware
of
the
risk
of
h
##yper
##sen
##si
##ti
##vity
reactions
,
which
may
present
as
in
##fusion
reactions
,
and
monitor
patients
closely
.
[SEP]
[CLS]
The
incidence
of
eye
##lid
p
##tosis
did
not
increase
in
the
long
-
term
safety
studies
with
multiple
re
-
treatments
at
intervals
>
=
three
months
.
[SEP]
[CLS]
Per
##form
he
##pa
##tic
enzyme
tests
monthly
for
the
first
three
months
of
B
##OS
##U
##L
##IF
treatment
and
as
clinical
##ly
indicated
.
[SEP]
[CLS]
There
were
no
patients
with
kidney
failure
at
base
##line
.
[SEP]
[CLS]
Use
caution
in
a
patient
with
a
history
of
an
##gio
##ede
##ma
with
another
D
##PP
-
4
inhibitor
because
it
is
unknown
whether
such
patients
will
be
pre
##dis
##posed
to
an
##gio
##ede
##ma
with
NE
##SI
##NA
.
[SEP]
[CLS]
5
.
1
Ana
##phy
##lax
##is
and
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Ana
##phy
##lax
##is
and
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
in
patients
treated
with
V
##im
##iz
##im
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
a
f
##etus
[SEP]
[CLS]
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Anyone
considering
pre
##s
##cribing
AP
##TI
##OM
or
any
other
A
##ED
must
balance
this
risk
with
the
risk
of
un
##tre
##ated
illness
.
[SEP]
[CLS]
E
##os
##ino
##phi
##lia
is
often
present
.
[SEP]
[CLS]
(
5
.
11
,
8
.
1
)
5
.
1
Per
##fo
##rations
and
Fi
##st
##ula
##s
G
##I
)
per
##fo
##rations
were
reported
in
3
%
and
1
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
,
respectively
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
R
##ET
##IN
##AL
AB
##N
##OR
##MA
##L
##IT
##IE
##S
AND
P
##OT
##EN
##TI
##AL
VI
##SI
##ON
L
##OS
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
5
.
3
Spin
##al
/
E
##pid
##ural
An
##est
##hesia
or
P
##un
##cture
When
ne
##ura
##xial
an
##est
##hesia
(
spinal
/
e
##pid
##ural
an
##est
##hesia
)
or
spinal
pu
##nc
##ture
is
employed
,
patients
treated
with
anti
##coa
##gu
##lant
agents
are
at
risk
of
developing
an
[SEP]
[CLS]
spinal
hem
##ato
##ma
which
can
result
in
long
-
term
or
para
##lysis
[
see
Box
##ed
Warning
]
.
[SEP]
[CLS]
As
##ses
##s
patients
for
signs
and
symptoms
of
enter
##oc
##oli
##tis
,
der
##mat
##itis
,
ne
##uro
##pathy
,
and
end
##oc
##rino
##pathy
and
evaluate
clinical
chemist
##ries
including
liver
function
tests
and
thy
##roid
function
tests
at
base
##line
and
[SEP]
[CLS]
before
each
dose
.
[SEP]
[CLS]
Monitor
patients
for
h
##yper
##tens
##ion
,
h
##y
##po
##kal
##emia
,
and
fluid
retention
at
least
once
a
month
.
[SEP]
[CLS]
In
this
situation
,
the
patient
requires
immediate
re
##eval
##uation
with
re
##ass
##ess
##ment
of
the
treatment
regime
##n
,
giving
special
consideration
to
the
possible
need
for
replacing
the
current
strength
of
BR
##E
##O
[SEP]
[CLS]
E
##LL
##IP
##TA
with
a
higher
strength
,
adding
additional
inhaled
co
##rt
##ico
##ster
##oid
,
or
in
##iti
##ating
systemic
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
In
patients
with
he
##pa
##to
##to
##xi
##city
,
rule
out
infectious
or
ma
##li
##gnant
causes
and
increase
frequency
of
liver
function
test
monitoring
until
resolution
.
[SEP]
[CLS]
Brady
##card
##ia
was
reported
as
an
adverse
drug
reaction
in
3
%
of
patients
in
Study
1
.
[SEP]
[CLS]
(
5
.
4
)
*
F
##ail
##ure
to
block
thy
##roid
i
##od
##ine
up
##take
may
result
in
i
##od
##ine
123
accumulation
in
the
thy
##roid
.
[SEP]
[CLS]
(
5
.
4
)
*
Em
##b
##ryo
-
f
##etal
toxicity
:
Bel
##eo
##da
##q
may
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
At
the
time
of
per
##fo
##ration
,
some
patients
had
moderate
to
severe
di
##ar
##r
##hea
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
to
avoid
becoming
pregnant
while
taking
Z
##yd
##eli
##g
.
[SEP]
[CLS]
Pat
##ients
treated
with
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ant
therapy
(
M
##T
##X
)
in
RA
-
I
,
RA
-
II
,
RA
-
III
had
a
lower
rate
of
neutral
##izing
anti
##body
formation
overall
than
patients
treated
with
C
##IM
##Z
##IA
mon
##otherapy
[SEP]
[CLS]
in
RA
-
IV
(
2
%
vs
.
8
%
)
.
[SEP]
[CLS]
Ad
##verse
Re
##action
Place
##bo
(
N
=
56
##8
)
%
T
##ru
##licity
0
.
75
mg
(
N
=
83
##6
)
%
T
##ru
##licity
1
.
5
mg
(
N
=
83
##4
)
%
Na
##use
##a
5
.
3
12
.
4
21
.
1
Di
##ar
##r
##hea
a
6
.
7
8
.
9
12
.
6
[SEP]
[CLS]
V
##omi
##ting
b
2
.
3
6
.
0
12
.
7
Abd
##omi
##nal
Pain
c
4
.
9
6
.
5
9
.
4
Dec
##reased
A
##ppe
##tite
1
.
6
4
.
9
8
.
6
D
##ys
##pe
##ps
##ia
2
.
3
4
.
1
5
.
8
Fat
##ig
##ue
d
2
.
6
4
.
2
5
.
6
Gas
##tro
##int
##est
##inal
Ad
##verse
Re
##actions
In
the
[SEP]
[CLS]
pool
of
place
##bo
-
controlled
trials
,
gas
##tro
##int
##est
##inal
adverse
reactions
occurred
more
frequently
among
patients
receiving
T
##R
##U
##L
##IC
##IT
##Y
than
place
##bo
(
place
##bo
21
.
3
%
,
0
.
75
mg
31
.
6
%
,
1
.
5
mg
41
.
0
[SEP]
[CLS]
%
)
.
[SEP]
[CLS]
The
adverse
reactions
with
>
=
10
%
incidence
for
any
grade
or
>
=
5
%
incidence
for
Grade
3
or
higher
are
summarized
in
Table
2
.
[SEP]
[CLS]
These
immune
-
mediated
reactions
may
involve
any
organ
system
;
however
,
the
most
common
severe
immune
-
mediated
adverse
reactions
are
enter
##oc
##oli
##tis
,
he
##pa
##titis
,
der
##mat
##itis
(
including
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
)
[SEP]
[CLS]
,
ne
##uro
##pathy
,
and
end
##oc
##rino
##pathy
.
[SEP]
[CLS]
Ad
##e
##qua
##tel
##y
supplement
patients
with
calcium
and
vitamin
D
(
5
.
3
)
*
O
##ste
##one
##c
##rosis
of
the
jaw
:
Has
been
reported
with
Pro
##lia
.
[SEP]
[CLS]
Therefore
,
a
lower
dose
of
insulin
or
insulin
secret
##ago
##gue
may
be
required
to
minimize
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
used
in
combination
with
NE
##SI
##NA
.
[SEP]
[CLS]
Table
4
:
Inc
##iden
##ce
of
He
##mat
##ology
Laboratory
A
##b
##nor
##mal
##ities
in
Pat
##ients
Who
Re
##ceived
T
##RE
##AN
##DA
in
the
NHL
Studies
Per
##cent
of
patients
He
##mat
##ology
variable
All
Grades
Grades
3
/
4
L
##ymph
##ocytes
Dec
##reased
99
94
[SEP]
[CLS]
Le
##uk
##ocytes
Dec
##reased
94
56
He
##mo
##g
##lo
##bin
Dec
##reased
88
11
N
##eu
##tro
##phi
##ls
Dec
##reased
86
60
Plate
##lets
Dec
##reased
86
25
In
both
studies
,
serious
adverse
reactions
,
regardless
of
ca
##usal
##ity
,
were
reported
[SEP]
[CLS]
in
37
%
of
patients
receiving
T
##RE
##AN
##DA
.
[SEP]
[CLS]
5
.
6
Mac
##rov
##as
##cular
Out
##come
##s
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
NE
##SI
##NA
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
leading
to
disco
##ntin
##uation
of
PR
##AD
##A
##X
##A
were
bleeding
and
gas
##tro
##int
##est
##inal
events
(
i
.
e
.
,
d
##ys
##pe
##ps
##ia
,
nausea
,
upper
abdominal
pain
,
gas
##tro
##int
##est
##inal
hem
##or
##r
##hage
,
and
[SEP]
[CLS]
di
##ar
##r
##hea
)
.
[SEP]
[CLS]
The
incidence
of
non
##fa
##tal
serious
adverse
events
was
7
.
5
%
in
the
place
##bo
group
and
8
.
3
%
in
the
Pro
##lia
group
.
[SEP]
[CLS]
An
increased
incidence
was
observed
in
patients
on
the
300
mg
dose
.
[SEP]
[CLS]
Inc
##rea
##sing
inhaled
beta
##2
-
ago
##nist
use
is
a
signal
of
de
##ter
##ior
##ating
disease
for
which
pro
##mpt
medical
attention
is
indicated
.
[SEP]
[CLS]
Five
patients
experienced
serious
adverse
reactions
of
h
##yper
##sen
##si
##ti
##vity
with
IN
##VO
##KA
##NA
,
which
included
4
patients
with
u
##rt
##ica
##ria
and
1
patient
with
a
di
##ff
##use
r
##ash
and
u
##rt
##ica
##ria
occurring
within
hours
of
[SEP]
[CLS]
exposure
to
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
*
Ra
##diation
risk
:
Amy
##vid
,
similar
to
all
radio
##pha
##rma
##ce
##utical
##s
,
contributes
to
a
patient
'
s
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
None
of
these
abnormal
##ities
were
reported
in
the
place
##bo
group
.
[SEP]
[CLS]
5
.
4
Extra
##vas
##ation
and
In
##jection
Site
Re
##actions
En
##sure
cat
##he
##ter
and
ve
##nous
pat
##ency
before
the
injection
of
D
##OT
##AR
##EM
.
[SEP]
[CLS]
IN
##L
##Y
##TA
has
not
been
studied
in
patients
who
had
an
art
##erial
th
##rom
##boe
##mbo
##lic
event
within
the
previous
12
months
.
[SEP]
[CLS]
Use
of
live
vaccine
##s
could
result
in
clinical
infections
,
including
di
##sse
##minated
infections
.
[SEP]
[CLS]
Two
suicide
##s
(
0
.
1
%
)
were
reported
in
patients
receiving
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Disco
##ntin
##ue
if
significant
liver
injury
occurs
.
[SEP]
[CLS]
In
pre
##market
##ing
controlled
trials
of
all
patient
populations
combined
the
most
common
adverse
reactions
(
>
=
8
%
)
were
upper
respiratory
infections
(
18
%
)
,
[SEP]
[CLS]
r
##ash
(
9
%
)
and
u
##rina
##ry
tract
infections
(
8
%
)
.
[SEP]
[CLS]
Other
Re
##actions
During
the
Pre
##market
##ing
Evaluation
of
FA
##NA
##P
##T
The
following
is
a
list
of
Me
##d
##DR
##A
terms
that
reflect
treatment
-
emerge
##nt
adverse
reactions
in
patients
treated
with
FA
##NA
##P
##T
at
multiple
doses
>
[SEP]
[CLS]
=
4
mg
/
day
during
any
phase
of
a
trial
with
the
database
of
321
##0
FA
##NA
##P
##T
-
treated
patients
.
[SEP]
[CLS]
Do
not
take
2
doses
at
the
same
time
unless
your
healthcare
provider
tells
you
to
.
[SEP]
[CLS]
More
G
##IL
##OT
##RI
##F
-
treated
patients
(
2
.
2
%
;
n
=
5
)
experienced
vent
##ric
##ular
d
##ys
##function
(
defined
as
di
##ast
##olic
d
##ys
##function
,
left
vent
##ric
##ular
d
##ys
##function
,
or
vent
##ric
##ular
di
##lation
;
all
<
Grade
3
[SEP]
[CLS]
)
compared
to
ch
##em
##otherapy
-
treated
patients
(
0
.
9
%
;
n
=
1
)
.
[SEP]
[CLS]
Do
##se
reduction
##s
were
reported
in
12
%
of
J
##E
##V
##TA
##NA
-
treated
patients
and
4
%
of
mit
##ox
##ant
##rone
-
treated
patients
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
screening
tests
should
be
performed
in
all
patients
.
[SEP]
[CLS]
5
.
3
All
##ergic
Re
##actions
Ser
##ious
all
##ergic
reactions
including
an
##aph
##yla
##xi
##s
can
occur
in
patients
receiving
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
EC
##G
Changes
and
Po
##ten
##tial
for
Card
##iac
A
##rr
##hy
##th
##mia
##s
:
Not
recommended
in
patients
with
pre
-
existing
cardiac
disease
,
long
Q
##T
syndrome
,
and
con
##com
##ita
##nt
[SEP]
[CLS]
use
of
Class
I
##A
and
Class
III
anti
##ar
##r
##hy
##th
##mic
##s
(
5
.
2
)
5
.
1
Drug
-
Drug
Inter
##actions
Eli
##g
##lus
##tat
is
a
C
##YP
##2
##D
##6
and
C
##YP
##3
##A
substrate
.
[SEP]
[CLS]
Data
from
a
large
place
##bo
-
controlled
US
trial
that
compared
the
safety
of
another
LA
##BA
(
sa
##lm
##eter
##ol
)
or
place
##bo
added
to
usual
as
##th
##ma
therapy
showed
an
increase
in
as
##th
##ma
-
related
[SEP]
[CLS]
deaths
in
subjects
receiving
sa
##lm
##eter
##ol
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Main
##tain
as
##ept
##ic
technique
.
[SEP]
[CLS]
Volume
De
##ple
##tion
J
##AR
##DI
##AN
##CE
causes
an
o
##smo
##tic
di
##ures
##is
,
which
may
lead
to
in
##tra
##vas
##cular
volume
contraction
and
adverse
reactions
related
to
volume
de
##ple
##tion
.
[SEP]
[CLS]
(
5
.
5
)
*
Pat
##ients
who
receive
prolonged
C
##lev
##ip
##re
##x
in
##fusion
##s
and
are
not
transitioned
to
other
anti
##hy
##pert
##ens
##ive
the
##rap
##ies
should
be
monitored
for
the
possibility
of
re
##bound
h
##yper
##tens
##ion
for
at
least
[SEP]
[CLS]
8
hours
after
the
in
##fusion
is
stopped
.
[SEP]
[CLS]
There
is
insufficient
information
to
determine
the
re
##vers
##ibility
of
the
decrease
of
DL
##CO
after
drug
disco
##ntin
##uation
.
[SEP]
[CLS]
PR
##IS
##TI
##Q
should
also
not
be
started
in
a
patient
who
is
being
treated
with
MA
##O
##I
##s
such
as
line
##zo
##lid
or
in
##tra
##ven
##ous
met
##hyl
##ene
blue
.
[SEP]
[CLS]
Anti
##mal
##aria
##ls
should
not
be
given
con
##com
##ita
##ntly
with
Co
##arte
##m
Table
##ts
,
unless
there
is
no
other
treatment
option
,
due
to
limited
safety
data
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
(
>
=
10
%
and
Greater
than
Place
##bo
)
from
Two
Place
##bo
-
controlled
Trials
in
Adults
with
Ch
##ronic
He
##pa
##titis
C
Ad
##verse
Re
##action
PR
##OM
##AC
##TA
+
P
##eg
##int
##er
##fer
##on
/
R
##iba
##vir
##in
n
=
95
##5
(
[SEP]
[CLS]
%
)
Place
##bo
+
P
##eg
##int
##er
##fer
##on
/
R
##iba
##vir
##in
n
=
48
##4
(
%
)
An
##emia
40
35
P
##yre
##xia
30
24
Fat
##ig
##ue
28
23
Head
##ache
21
20
Na
##use
##a
19
14
Di
##ar
##r
##hea
19
11
[SEP]
[CLS]
Dec
##reased
appetite
18
14
In
##fluenza
-
like
illness
18
16
As
##the
##nia
16
13
In
##so
##m
##nia
16
15
Co
##ugh
15
12
P
##ru
##rit
##us
15
13
Chi
##lls
14
9
My
##al
##gia
12
10
Al
##ope
##cia
10
6
[SEP]
[CLS]
Per
##ip
##her
##al
ed
##ema
10
5
In
the
two
controlled
clinical
trials
in
patients
with
chronic
he
##pa
##titis
C
,
h
##yper
##bil
##ir
##ubi
##ne
##mia
was
reported
in
8
%
of
patients
receiving
PR
##OM
##AC
##TA
compared
with
3
[SEP]
[CLS]
%
for
place
##bo
.
[SEP]
[CLS]
The
risks
and
benefits
of
re
-
administer
##ing
al
##g
##lu
##cos
##idas
##e
al
##fa
following
an
immune
-
mediated
reaction
should
be
considered
.
[SEP]
[CLS]
In
a
place
##bo
controlled
study
in
patients
with
permanent
A
##F
increased
rates
of
heart
failure
were
observed
in
patients
with
normal
left
vent
##ric
##ular
function
and
no
history
of
s
##ym
##pt
##oma
##tic
heart
[SEP]
[CLS]
failure
,
as
well
as
those
with
a
history
of
heart
failure
or
left
vent
##ric
##ular
d
##ys
##function
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
h
##yper
##sen
##si
##ti
##vity
reactions
with
card
##iovascular
,
respiratory
or
cut
##aneous
manifest
##ations
,
ranging
from
mild
to
severe
,
including
death
,
have
uncommon
##ly
occurred
following
G
##ada
##vist
administration
[
see
[SEP]
[CLS]
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Based
on
published
literature
,
the
annual
incidence
of
N
##A
##ION
is
2
.
5
-
11
.
8
cases
per
100
,
000
in
males
aged
>
=
50
.
[SEP]
[CLS]
The
most
common
in
##fusion
reaction
in
S
##IM
##PO
##NI
ARIA
treated
patients
was
r
##ash
.
[SEP]
[CLS]
Ad
##vise
patients
to
consult
a
physician
if
they
develop
signs
or
symptoms
of
heart
failure
,
such
as
weight
gain
,
dependent
ed
##ema
,
or
increasing
short
##ness
of
breath
.
[SEP]
[CLS]
The
E
##L
##IS
##A
ass
##ay
is
subject
to
interference
by
co
-
present
go
##lim
##uma
##b
and
thus
the
results
are
an
under
##est
##imate
of
the
rate
of
product
im
##mu
##no
##genic
##ity
and
are
in
addition
highly
dependent
on
[SEP]
[CLS]
the
sensitivity
and
specific
##ity
of
the
ass
##ay
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
drug
reactions
are
discussed
in
other
sections
of
the
label
##ing
:
*
Lac
##tic
A
##cid
##osis
/
Se
##vere
He
##pa
##tom
##eg
##aly
with
St
##eat
##osis
[
see
Box
##ed
Warning
,
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
St
##ric
##tly
avoid
in
##tra
##mus
##cular
administration
of
E
##O
##VI
##ST
because
it
may
cause
my
##oc
##yte
ne
##c
##rosis
and
inflammation
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
2
)
]
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
.
[SEP]
[CLS]
All
reports
with
met
##hyl
##ene
blue
that
provided
information
on
the
route
of
administration
involved
in
##tra
##ven
##ous
administration
in
the
dose
range
of
1
mg
/
kg
to
8
mg
/
kg
.
[SEP]
[CLS]
The
absolute
risk
of
probable
dem
##ent
##ia
for
CE
-
alone
versus
place
##bo
was
37
versus
25
cases
per
10
,
000
women
-
years
[
see
Use
in
S
##pecific
Population
##s
(
8
.
5
)
and
Clinical
Studies
[SEP]
[CLS]
(
14
.
6
)
]
.
[SEP]
[CLS]
P
##ul
##mona
##ry
To
##xi
##city
In
a
trial
in
patients
with
classical
H
##L
that
studied
AD
##CE
##TR
##IS
with
b
##leo
##my
##cin
as
part
of
a
combination
regime
##n
,
the
rate
of
non
-
infectious
pulmonary
toxicity
was
higher
[SEP]
[CLS]
than
the
historical
incidence
reported
with
AB
##VD
(
ad
##ria
##my
##cin
,
b
##leo
##my
##cin
,
v
##in
##blast
##ine
,
da
##car
##ba
##zine
)
.
[SEP]
[CLS]
In
MS
place
##bo
-
controlled
trials
,
d
##ys
##p
##nea
was
reported
in
9
%
of
patients
receiving
G
##IL
##EN
##Y
##A
0
.
5
mg
and
7
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
The
95
%
confidence
limits
that
are
shown
do
not
take
into
account
how
many
comparisons
were
made
,
nor
do
they
reflect
the
effect
of
a
particular
factor
after
[SEP]
[CLS]
adjustment
for
all
other
factors
.
[SEP]
[CLS]
As
in
controlled
clinical
trials
,
a
dose
-
dependent
increase
in
the
incidence
of
seizure
##s
has
been
observed
in
open
-
label
clinical
trials
with
AM
##P
##Y
##RA
in
patients
with
MS
as
follows
:
[SEP]
[CLS]
AM
##P
##Y
##RA
10
mg
twice
daily
0
.
41
per
100
person
-
years
(
95
%
confidence
interval
0
.
13
-
0
.
96
)
;
da
##lf
##amp
##rid
##ine
15
mg
twice
daily
1
.
7
per
100
person
-
years
(
95
%
confidence
[SEP]
[CLS]
interval
0
.
21
-
6
.
28
)
.
[SEP]
[CLS]
In
some
post
##market
##ing
cases
,
h
##y
##po
##cal
##ce
##mia
persisted
for
weeks
or
months
and
required
frequent
monitoring
and
in
##tra
##ven
##ous
and
/
or
oral
calcium
replacement
,
with
or
without
vitamin
D
.
H
##y
##po
##cal
##ce
##mia
following
Pro
##lia
[SEP]
[CLS]
administration
is
a
significant
risk
in
patients
with
severe
re
##nal
imp
##air
##ment
[
c
##rea
##tin
##ine
clearance
<
30
m
##L
/
min
]
or
receiving
dial
##ys
##is
.
[SEP]
[CLS]
U
##rina
##ry
T
##rac
##t
In
##fect
##ions
In
the
pool
of
five
place
##bo
-
controlled
clinical
trials
,
the
incidence
of
u
##rina
##ry
tract
infections
(
e
.
g
.
,
u
##rina
##ry
tract
infection
,
as
##ym
##pt
##oma
##tic
b
##act
##eri
##uria
,
and
[SEP]
[CLS]
c
##ys
##titis
)
was
increased
in
patients
treated
with
J
##AR
##DI
##AN
##CE
compared
to
place
##bo
(
see
Table
1
)
.
[SEP]
[CLS]
C
##aut
##ion
patients
about
risk
of
activation
of
man
##ia
/
h
##y
##po
##mani
##a
(
5
.
6
)
.
[SEP]
[CLS]
*
Use
in
Elder
##ly
Pat
##ients
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
5
.
4
Control
##led
Na
##rrow
-
Ang
##le
G
##lau
##com
##a
To
##via
##z
should
be
used
with
caution
in
patients
being
treated
for
narrow
-
angle
g
##lau
##com
##a
,
and
only
where
the
potential
benefits
out
##wei
##gh
the
risks
[
see
Con
##tra
##ind
##ica
##tions
[SEP]
[CLS]
(
4
)
]
.
[SEP]
[CLS]
The
most
frequent
serious
infections
included
pneumonia
,
u
##rina
##ry
tract
infection
,
cell
##uli
##tis
,
and
br
##on
##chi
##tis
.
[SEP]
[CLS]
*
Take
D
##U
##AV
##EE
with
or
without
food
.
[SEP]
[CLS]
The
proportion
of
patients
with
pro
##la
##ct
##in
elevations
>
=
4
times
U
##L
##N
(
at
End
##point
)
were
2
.
3
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
0
.
7
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
extended
normal
range
for
lowered
hem
##ato
##c
##rit
was
defined
in
each
of
these
trials
as
the
value
15
%
below
the
normal
range
for
the
centralized
laboratory
that
was
used
[SEP]
[CLS]
in
the
trial
.
[SEP]
[CLS]
Re
##sp
##ira
##tory
,
Thor
##ac
##ic
and
Media
##st
##inal
Di
##sor
##ders
:
In
##f
##re
##quent
-
e
##pis
##ta
##xi
##s
,
as
##th
##ma
,
r
##hino
##rr
##hea
,
sin
##us
congestion
,
nasal
dry
##ness
;
Rare
-
dry
throat
,
sleep
a
##p
##nea
syndrome
,
[SEP]
[CLS]
d
##ys
##p
##nea
ex
##ert
##ional
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
FA
##NA
##P
##T
:
re
##tro
##grade
e
##ja
##cula
##tion
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
for
immune
-
mediated
o
##cular
disease
that
is
un
##res
##po
##ns
##ive
to
local
im
##mu
##nos
##up
##pressive
therapy
.
[SEP]
[CLS]
In
clinical
trials
,
premature
disco
##ntin
##uation
because
of
adverse
reactions
occurred
in
11
.
8
%
of
the
drone
##dar
##one
-
treated
patients
and
in
7
.
7
%
of
the
place
##bo
-
treated
group
.
[SEP]
[CLS]
Extra
##py
##ram
##idal
symptoms
included
:
d
##ys
##ton
##ia
,
park
##ins
##oni
##sm
,
o
##cu
##logy
##ration
,
and
t
##rem
##or
(
excluding
aka
##thi
##sia
)
.
[SEP]
[CLS]
Do
not
use
BR
##E
##O
E
##LL
##IP
##TA
for
patients
whose
as
##th
##ma
is
adequately
controlled
on
low
-
or
medium
-
dose
I
##CS
.
[SEP]
[CLS]
Common
Ad
##verse
Events
(
>
=
10
%
)
The
adverse
events
in
the
first
12
cycles
of
therapy
that
occurred
at
a
rate
of
10
%
or
greater
in
[SEP]
[CLS]
the
K
##R
##d
arm
are
presented
in
Table
5
.
[SEP]
[CLS]
Per
##sist
##ent
or
worse
##ning
bone
pain
,
pain
in
ex
##tre
##mit
##ies
,
fracture
##s
and
/
or
muscular
pain
or
weakness
may
be
manifest
##ations
of
pro
##ximal
re
##nal
tub
##ulo
##pathy
and
should
pro
##mpt
an
evaluation
of
re
##nal
[SEP]
[CLS]
function
in
at
-
risk
patients
.
[SEP]
[CLS]
5
.
5
Card
##iac
F
##ail
##ure
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
cardiac
failure
was
reported
in
6
/
35
##9
patients
(
2
%
)
receiving
[SEP]
[CLS]
IN
##L
##Y
##TA
and
3
/
35
##5
patients
(
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Because
this
disorder
is
variable
in
its
expression
,
other
organ
systems
not
noted
here
may
be
involved
.
[SEP]
[CLS]
abnormal
plate
##let
and
W
##BC
counts
were
observed
in
<
0
.
1
%
of
subjects
.
[SEP]
[CLS]
Consider
dose
adjustment
in
patients
with
base
##line
and
treatment
emerge
##nt
re
##nal
imp
##air
##ment
[
see
Do
##sa
##ge
and
Administration
(
2
.
7
)
]
.
[SEP]
[CLS]
Per
##form
an
op
##ht
##hal
##mo
##logical
evaluation
.
[SEP]
[CLS]
Although
the
causes
of
death
were
varied
,
most
of
the
deaths
appeared
to
be
either
card
##iovascular
(
e
.
g
.
,
heart
failure
,
sudden
death
)
or
infectious
(
e
.
g
.
[SEP]
[CLS]
,
pneumonia
)
in
nature
.
[SEP]
[CLS]
Be
##ha
##vior
##s
of
concern
should
be
reported
immediately
to
healthcare
providers
.
[SEP]
[CLS]
(
5
.
2
)
*
H
##y
##po
##gly
##ce
##mia
:
In
patients
taking
insulin
or
an
insulin
secret
##ago
##gue
with
FA
##R
##X
##IG
##A
,
consider
a
lower
dose
of
insulin
or
the
insulin
secret
##ago
##gue
to
reduce
the
[SEP]
[CLS]
risk
of
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
5
.
13
P
##ria
##pis
##m
Three
cases
of
p
##ria
##pis
##m
were
reported
in
the
pre
##market
##ing
FA
##NA
##P
##T
program
.
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
H
##y
##po
##gly
##ce
##mia
Table
2
sum
##mar
##izes
the
incidence
of
documented
h
##y
##po
##gly
##ce
##mia
in
the
place
##bo
-
controlled
clinical
studies
.
[SEP]
[CLS]
Rate
##s
of
serious
infections
in
the
200
mg
every
other
week
dose
group
were
0
.
06
per
patient
-
year
and
in
the
400
mg
every
4
weeks
dose
group
were
0
.
04
per
[SEP]
[CLS]
patient
-
year
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
care
is
advised
when
pre
##s
##cribing
FA
##NA
##P
##T
for
patients
who
will
be
experiencing
conditions
which
may
contribute
to
an
elevation
in
core
body
temperature
,
e
.
g
.
,
ex
##er
##cis
##ing
s
##tre
##nu
##ously
,
[SEP]
[CLS]
exposure
to
extreme
heat
,
receiving
con
##com
##ita
##nt
medication
with
anti
##cho
##liner
##gic
activity
,
or
being
subject
to
de
##hy
##dra
##tion
.
[SEP]
[CLS]
(
5
.
4
)
*
Psychological
De
##pen
##dence
:
Monitor
patients
with
a
history
of
substance
abuse
for
signs
of
habit
##uation
and
dependence
(
5
.
5
,
9
)
*
Su
##icidal
Be
##ha
##vior
:
[SEP]
[CLS]
Monitor
for
su
##icidal
thoughts
or
behaviors
(
5
.
6
)
5
.
1
So
##m
##no
##len
##ce
or
Se
##dation
ON
##FI
causes
so
##m
##no
##len
##ce
and
se
##dation
.
[SEP]
[CLS]
c
Con
##fi
##dence
interval
Pat
##ients
Major
bleeding
event
a
B
##lee
##ding
sites
for
MBE
b
Clinical
##ly
relevant
non
-
major
bleeding
Any
bleeding
The
rate
of
any
gas
##tro
##int
##est
##inal
bleed
##s
in
patients
receiving
PR
##AD
##A
##X
##A
150
[SEP]
[CLS]
mg
in
the
full
treatment
period
was
3
.
1
%
(
2
.
4
%
on
war
##fari
##n
)
.
[SEP]
[CLS]
When
such
an
infection
develops
,
it
should
be
treated
with
appropriate
local
or
systemic
(
i
.
e
.
,
oral
)
anti
##fu
##nga
##l
therapy
while
treatment
with
BR
##E
##O
E
##LL
##IP
##TA
continues
,
but
[SEP]
[CLS]
at
times
therapy
with
BR
##E
##O
E
##LL
##IP
##TA
may
need
to
be
interrupted
.
[SEP]
[CLS]
Ra
##sh
generally
resolved
within
1
to
2
weeks
on
continued
therapy
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
If
infection
occurs
while
on
Fe
##rri
##p
##ro
##x
,
interrupt
therapy
and
monitor
the
AN
##C
more
frequently
.
[SEP]
[CLS]
There
were
63
(
12
%
)
patients
with
moderate
(
Grade
2
)
der
##mat
##itis
.
[SEP]
[CLS]
Across
the
development
program
of
Z
##Y
##KA
##DI
##A
,
one
of
304
patients
(
less
than
1
%
)
treated
with
Z
##Y
##KA
##DI
##A
doses
ranging
from
50
to
750
mg
was
found
to
[SEP]
[CLS]
have
a
Q
##T
##c
greater
than
500
m
##se
##c
and
3
%
of
patients
had
an
increase
from
base
##line
Q
##T
##c
greater
than
60
m
##se
##c
.
[SEP]
[CLS]
[
See
Ad
##verse
Re
##actions
(
6
.
1
)
.
]
[SEP]
[CLS]
(
5
.
3
)
*
Pat
##ients
with
severe
re
##nal
imp
##air
##ment
may
have
increased
radiation
exposure
and
decreased
quality
of
Ad
##re
##V
##ie
##w
images
.
[SEP]
[CLS]
V
##as
##cular
disorder
:
systemic
v
##as
##cu
##lit
##is
has
been
identified
during
post
-
approval
use
of
T
##NF
block
##ers
.
[SEP]
[CLS]
S
##ym
##pt
##oms
and
signs
of
ad
##ren
##oc
##ort
##ical
ins
##uff
##iciency
may
be
masked
by
adverse
reactions
associated
with
mineral
##oc
##ort
##ico
##id
excess
seen
in
patients
treated
with
Z
##Y
##TI
##GA
.
[SEP]
[CLS]
In
this
setting
a
re
##eval
##uation
of
the
patient
and
the
CO
##PD
treatment
regime
##n
should
be
undertaken
at
once
.
[SEP]
[CLS]
Expo
##sure
to
excessive
amounts
of
ben
##zy
##l
alcohol
has
been
associated
with
toxicity
(
h
##y
##pot
##ens
##ion
,
metabolic
acid
##osis
)
,
particularly
in
neon
##ates
,
and
an
increased
incidence
of
k
##ern
##ict
##erus
,
[SEP]
[CLS]
particularly
in
small
pre
##ter
##m
infants
.
[SEP]
[CLS]
Disco
##ntin
##ue
ON
##FI
gradually
.
[SEP]
[CLS]
Bel
##eo
##da
##q
may
cause
te
##rato
##genic
##ity
and
/
or
em
##b
##ryo
-
f
##etal
lethal
##ity
because
it
is
g
##eno
##to
##xi
##c
and
targets
actively
dividing
cells
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
BR
##E
##O
E
##LL
##IP
##TA
has
not
been
studied
in
the
relief
of
acute
symptoms
and
extra
doses
should
not
be
used
for
that
purpose
.
[SEP]
[CLS]
However
,
there
is
controversy
about
the
extent
to
which
these
findings
may
be
due
to
differences
in
sexual
behavior
and
other
factors
.
[SEP]
[CLS]
Seven
(
54
%
)
Y
##ER
##VO
##Y
-
treated
patients
with
severe
der
##mat
##itis
received
high
-
dose
co
##rt
##ico
##ster
##oids
(
median
dose
60
mg
pre
##dn
##ison
##e
/
day
or
equivalent
)
for
up
to
14
.
9
weeks
followed
by
co
##rt
##ico
##ster
##oid
[SEP]
[CLS]
tape
##r
.
[SEP]
[CLS]
Re
-
treatment
with
Z
##Y
##TI
##GA
at
a
reduced
dose
level
may
take
place
only
after
return
of
liver
function
tests
to
the
patient
'
s
base
##line
or
to
AS
##T
and
AL
##T
less
than
[SEP]
[CLS]
or
equal
to
2
.
5
*
U
##L
##N
and
total
bi
##li
##ru
##bin
less
than
or
equal
to
1
.
5
*
U
##L
##N
[
see
##D
##osa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
A
total
of
2
.
2
%
of
HIV
-
1
-
infected
subjects
in
Phase
3
trials
receiving
IN
##TE
##LE
##NC
##E
(
r
)
discontinued
due
to
r
##ash
.
[SEP]
[CLS]
In
the
place
##bo
group
,
no
serious
infection
occurred
in
more
than
one
subject
.
[SEP]
[CLS]
In
clinical
studies
,
less
than
1
%
of
patients
treated
with
B
##L
##IN
##C
##Y
##TO
tested
positive
for
binding
anti
-
b
##lina
##tum
##oma
##b
antibodies
.
[SEP]
[CLS]
In
Study
1
,
35
%
were
Black
,
17
.
5
%
were
Hispanic
,
12
.
5
%
were
White
,
9
.
4
%
were
Asian
,
and
25
.
6
%
were
of
another
[SEP]
[CLS]
race
.
[SEP]
[CLS]
5
.
4
W
##ou
##nd
Co
##mp
##lication
##s
W
##ou
##nd
complications
have
been
reported
with
CO
##ME
##TR
##I
##Q
.
[SEP]
[CLS]
Of
the
28
patients
with
moderate
enter
##oc
##oli
##tis
,
46
%
were
not
treated
with
systemic
co
##rt
##ico
##ster
##oids
,
29
%
were
treated
with
<
40
mg
pre
##dn
##ison
##e
or
equivalent
per
day
[SEP]
[CLS]
for
a
median
duration
of
5
.
1
weeks
,
and
25
%
were
treated
with
high
-
dose
co
##rt
##ico
##ster
##oids
for
a
median
duration
of
10
days
prior
to
co
##rt
##ico
##ster
##oid
tape
##r
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
to
X
##E
##OM
##IN
are
discussed
in
greater
detail
in
other
sections
of
the
label
##ing
:
*
H
##yper
##sen
##si
##ti
##vity
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
[SEP]
[CLS]
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
D
##ys
##pha
##gia
and
B
##reath
##ing
Di
##ff
##ic
##ult
##ies
in
Treatment
of
c
##er
##vic
##al
d
##ys
##ton
##ia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
[SEP]
[CLS]
S
##p
##read
of
Effects
from
To
##xin
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
E
##X
##CE
##RP
##T
:
Ce
##r
##vic
##al
D
##ys
##ton
##ia
:
The
most
commonly
observed
adverse
reactions
(
>
=
5
%
of
[SEP]
[CLS]
patients
and
>
place
##bo
)
are
d
##ys
##pha
##gia
,
neck
pain
,
muscle
weakness
,
injection
site
pain
,
and
m
##us
##cu
##los
##kel
##etal
pain
(
6
.
1
)
.
[SEP]
[CLS]
Fat
##al
adverse
events
occurred
in
15
%
of
patients
.
[SEP]
[CLS]
[
See
Box
##ed
Warning
.
]
[SEP]
[CLS]
Disco
##ntin
##ue
use
if
severe
symptoms
develop
(
5
.
8
)
*
Su
##pp
##ression
of
bone
turnover
:
Sign
##ificant
suppression
has
been
demonstrated
.
[SEP]
[CLS]
O
##bs
##erve
patients
closely
for
an
appropriate
period
of
time
after
administration
of
V
##im
##iz
##im
,
taking
into
account
the
time
to
onset
of
an
##aph
##yla
##xi
##s
seen
in
pre
##market
##ing
clinical
trials
.
[SEP]
[CLS]
The
mechanism
for
the
bleeding
events
is
not
well
understood
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
occurring
in
>
=
5
%
of
patients
were
f
##eb
##ril
##e
ne
##ut
##rop
##enia
and
pneumonia
.
[SEP]
[CLS]
Should
su
##icidal
thoughts
and
behavior
emerge
during
treatment
,
the
pre
##s
##cribe
##r
needs
to
consider
whether
the
emergence
of
these
symptoms
in
any
given
patient
may
be
related
to
the
illness
[SEP]
[CLS]
being
treated
.
[SEP]
[CLS]
Other
increased
(
an
##gio
##tens
##ino
##gen
)
.
[SEP]
[CLS]
The
extent
to
which
the
findings
of
increased
mortality
in
observation
##al
studies
may
be
attributed
to
the
anti
##psy
##cho
##tic
drug
as
opposed
to
some
characteristic
(
s
)
of
the
patients
[SEP]
[CLS]
is
not
clear
.
[SEP]
[CLS]
(
5
.
2
)
*
Q
##T
Inter
##val
Pro
##long
##ation
:
O
##cc
##ur
##red
in
2
.
1
%
of
patients
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Brady
##card
##ia
and
/
or
at
##rio
##vent
##ric
##ular
conduct
##ion
after
first
dose
:
Monitor
patients
.
[SEP]
[CLS]
The
following
co
##agu
##lation
proteins
were
decreased
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
of
moderate
to
severe
intensity
and
incidence
at
least
2
%
(
in
those
receiving
T
##I
##VI
##CA
##Y
in
any
one
adult
trial
)
are
[SEP]
[CLS]
ins
##om
##nia
,
fatigue
,
and
headache
.
[SEP]
[CLS]
In
un
##ap
##p
##roved
uses
,
including
spa
##stic
##ity
in
children
and
adults
,
and
in
approved
indication
##s
,
cases
of
spread
of
effect
have
been
reported
at
doses
comparable
to
those
used
[SEP]
[CLS]
to
treat
c
##er
##vic
##al
d
##ys
##ton
##ia
and
at
lower
doses
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Po
##ten
##tial
neon
##ata
##l
adverse
effects
.
[SEP]
[CLS]
Laboratory
Test
A
##b
##nor
##mal
##ities
in
Clinical
Trials
There
were
no
differences
between
FA
##NA
##P
##T
and
place
##bo
in
the
incidence
of
disco
##ntin
##uation
due
to
changes
in
hem
##ato
##logy
,
u
##rina
##lysis
,
or
serum
chemistry
[SEP]
[CLS]
.
[SEP]
[CLS]
For
patients
who
develop
moderate
to
severe
protein
##uria
,
reduce
the
dose
or
temporarily
interrupt
IN
##L
##Y
##TA
treatment
.
[SEP]
[CLS]
P
##sor
##ia
##tic
Art
##hr
##itis
Clinical
Trials
O
##TE
##Z
##LA
was
evaluated
in
3
multi
##cent
##er
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trials
[
Studies
P
##s
##A
-
1
,
P
##s
##A
-
2
,
and
P
##s
##A
-
3
]
of
similar
design
in
[SEP]
[CLS]
adult
patients
with
active
ps
##oria
##tic
art
##hr
##itis
[
see
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
Re
##actions
are
further
categorized
by
Me
##d
##DR
##A
system
organ
class
and
listed
in
order
of
decreasing
frequency
according
to
the
following
definitions
:
frequent
adverse
events
are
those
occurring
in
at
[SEP]
[CLS]
least
1
/
100
patients
(
only
those
not
listed
in
Table
7
appear
in
this
listing
)
;
in
##f
##re
##quent
adverse
reactions
are
those
occurring
in
1
/
100
to
1
/
1000
patients
;
rare
[SEP]
[CLS]
events
are
those
occurring
in
fewer
than
1
/
1000
patients
.
[SEP]
[CLS]
Pat
##ients
who
tested
positive
for
up
##take
in
##hibition
tended
to
have
higher
I
##g
##G
t
##iter
##s
than
patients
who
tested
negative
for
up
##take
in
##hibition
.
[SEP]
[CLS]
Table
2
shows
adverse
reactions
occurring
in
>
=
8
%
of
K
##AL
##Y
##DE
##CO
-
treated
patients
with
CF
who
have
a
G
##55
##1
##D
mutation
in
the
CF
##TR
gene
that
also
occurred
at
a
higher
[SEP]
[CLS]
rate
than
in
the
place
##bo
-
treated
patients
in
the
two
double
-
blind
,
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
There
were
no
as
##th
##ma
-
related
deaths
or
as
##th
##ma
-
related
in
##tub
##ations
observed
in
this
trial
.
[SEP]
[CLS]
If
you
are
not
sure
about
your
dos
##ing
,
call
your
healthcare
provider
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
*
CO
##PD
:
Most
common
adverse
reactions
(
incidence
greater
than
or
equal
to
3
%
)
are
na
##so
##pha
##ryn
##git
##is
,
upper
respiratory
tract
infection
,
headache
,
and
[SEP]
[CLS]
oral
can
##di
##dia
##sis
.
[SEP]
[CLS]
Any
type
of
hem
##or
##r
##ha
##gic
stroke
was
ad
##ju
##dicated
and
counted
as
an
in
##tra
##c
##rani
##al
major
bleed
.
[SEP]
[CLS]
More
frequent
monitoring
is
recommended
when
A
##FI
##NI
##TO
##R
is
co
-
administered
with
other
drugs
that
may
induce
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
*
Ra
##diation
risk
:
Cho
##line
C
11
In
##jection
contributes
to
a
patient
'
s
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
C
##lev
##ip
##re
##x
:
increased
blood
t
##rig
##ly
##cer
##ides
,
il
##eus
,
h
##yper
##sen
##si
##ti
##vity
,
h
##y
##pot
##ens
##ion
,
nausea
,
decreased
oxygen
sat
##uration
(
possible
[SEP]
[CLS]
pulmonary
s
##hun
##ting
)
and
reflex
ta
##chy
##card
##ia
.
[SEP]
[CLS]
Non
-
cut
##aneous
Mali
##gna
##ncies
:
Based
on
its
mechanism
of
action
,
T
##AF
##IN
##LA
##R
may
promote
the
growth
and
development
of
ma
##li
##gna
##ncies
with
activation
of
RA
##S
through
mutation
or
other
mechanisms
[
see
[SEP]
[CLS]
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
In
##st
##ru
##ct
all
patients
with
severe
re
##nal
imp
##air
##ment
,
including
those
receiving
dial
##ys
##is
,
about
the
symptoms
of
h
##y
##po
##cal
##ce
##mia
and
the
importance
of
maintaining
calcium
levels
with
adequate
calcium
and
vitamin
[SEP]
[CLS]
D
supplement
##ation
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Go
##ut
F
##lar
##e
After
initiation
of
U
##L
##OR
##IC
,
an
increase
in
go
##ut
flare
##s
is
frequently
observed
.
[SEP]
[CLS]
Such
monitoring
should
include
daily
observation
by
families
and
care
##gi
##vers
.
[SEP]
[CLS]
Of
the
patients
who
reported
ne
##uro
##pathy
,
51
%
had
residual
ne
##uro
##pathy
at
the
time
of
their
last
evaluation
.
[SEP]
[CLS]
Among
the
factors
that
may
increase
the
risk
for
N
##SF
are
repeated
or
higher
than
recommended
doses
of
a
GB
##CA
and
degree
of
re
##nal
imp
##air
##ment
at
the
time
of
exposure
[SEP]
[CLS]
.
[SEP]
[CLS]
Most
of
the
patients
were
receiving
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
.
[SEP]
[CLS]
Of
these
patients
,
one
S
##IM
##PO
##NI
ARIA
-
treated
patient
and
no
control
-
treated
patients
had
newly
positive
anti
-
d
##s
##D
##NA
antibodies
.
[SEP]
[CLS]
Pat
##ients
should
be
caution
##ed
about
performing
activities
requiring
mental
alert
##ness
,
such
as
operating
hazardous
machinery
or
operating
a
motor
vehicle
,
until
they
are
reasonably
certain
that
SA
##P
##H
##RI
##S
therapy
[SEP]
[CLS]
does
not
affect
them
adverse
##ly
.
[SEP]
[CLS]
Image
interpretation
is
performed
independently
of
the
patient
'
s
clinical
information
.
[SEP]
[CLS]
No
data
are
available
on
the
effectiveness
of
v
##ac
##cin
##ations
with
inactivated
(
killed
)
anti
##gens
in
patients
receiving
IL
##AR
##IS
[
see
Drug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
It
was
usually
trans
##ient
with
the
highest
incidence
reported
during
the
first
week
of
treatment
.
[SEP]
[CLS]
If
heart
failure
develops
or
worse
##ns
and
requires
hospital
##ization
,
disco
##ntin
##ue
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
For
patients
receiving
hem
##od
##ial
##ys
##is
,
consider
the
pro
##mpt
initiation
of
hem
##od
##ial
##ys
##is
following
the
administration
of
a
GB
##CA
in
order
to
enhance
the
contrast
agent
'
s
elimination
[
see
Use
in
[SEP]
[CLS]
S
##pecific
Population
##s
(
8
.
6
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Ad
##verse
events
(
regardless
of
investigator
'
s
ca
##usal
##ity
assessment
)
reported
in
greater
than
or
equal
to
10
%
of
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
and
reported
[SEP]
[CLS]
at
a
rate
of
greater
than
or
equal
to
5
%
than
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
in
SP
##RI
##NT
-
1
,
SP
##RI
##NT
-
2
,
and
R
##ES
##PO
##ND
-
2
are
presented
in
Table
3
.
[SEP]
[CLS]
*
Se
##vere
A
##cute
Ex
##ace
##rb
##ations
of
He
##pa
##titis
B
[
see
Box
##ed
Warning
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Live
##r
En
##zy
##me
El
##eva
##tions
There
have
been
reports
of
severe
he
##pa
##tic
reactions
including
acute
liver
failure
in
patients
receiving
T
##NF
-
block
##ers
.
[SEP]
[CLS]
5
.
4
Pro
##ba
##ble
De
##ment
##ia
In
the
W
##H
##IM
##S
est
##rogen
-
alone
an
##cilla
##ry
study
of
W
##H
##I
,
a
population
of
2
,
94
##7
h
##yster
##ec
##tom
##ized
women
65
to
79
years
of
age
was
random
##ized
to
daily
CE
(
[SEP]
[CLS]
0
.
625
mg
)
-
alone
or
place
##bo
.
[SEP]
[CLS]
Of
these
patients
,
49
%
had
complete
resolution
,
31
%
had
partial
improvement
,
and
20
%
had
no
improvement
.
[SEP]
[CLS]
5
.
8
Laboratory
Tests
and
Monitor
##ing
Ren
##al
Fun
##ction
El
##eva
##tions
of
serum
c
##rea
##tin
##ine
and
protein
##uria
have
been
reported
in
patients
taking
A
##FI
##NI
##TO
##R
[
see
Ad
##verse
Re
##actions
(
6
.
1
,
6
.
2
,
6
.
3
[SEP]
[CLS]
,
6
.
4
,
6
.
5
)
]
.
[SEP]
[CLS]
For
DL
##CO
,
the
reduction
from
base
##line
in
percent
of
predicted
values
at
the
time
of
last
assessment
on
drug
was
3
.
3
%
for
G
##IL
##EN
##Y
##A
0
.
5
mg
and
0
.
5
%
[SEP]
[CLS]
for
place
##bo
.
[SEP]
[CLS]
Do
not
administer
K
##AL
##BI
##TO
##R
to
patients
with
known
clinical
h
##yper
##sen
##si
##ti
##vity
to
K
##AL
##BI
##TO
##R
.
[SEP]
[CLS]
*
a
Data
presented
are
to
the
primary
end
##point
and
include
only
events
occurring
on
-
therapy
with
random
##ized
medications
and
exclude
##s
events
occurring
after
use
of
g
##ly
##ce
##mic
rescue
medications
(
i
.
e
.
[SEP]
[CLS]
,
primarily
met
##form
##in
or
insulin
)
.
[SEP]
[CLS]
Cut
##aneous
sq
##ua
##mous
cell
car
##cin
##oma
(
SC
##C
)
,
including
k
##era
##to
##aca
##nt
##hom
##a
,
occurred
in
7
%
of
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
and
19
%
of
patients
receiving
T
##AF
##IN
##LA
##R
[SEP]
[CLS]
as
a
single
agent
.
[SEP]
[CLS]
*
All
##ergic
reactions
:
have
emergency
re
##sus
##citation
equipment
and
personnel
readily
available
(
5
.
2
)
.
[SEP]
[CLS]
Pat
##ients
testing
positive
in
tuberculosis
screening
should
be
treated
according
to
standard
medical
practice
prior
to
therapy
with
IL
##AR
##IS
.
[SEP]
[CLS]
5
.
10
He
##pa
##tic
I
##mp
##air
##ment
Expo
##sure
to
ever
##oli
##mus
was
increased
in
patients
with
he
##pa
##tic
imp
##air
##ment
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ser
##ious
all
##ergic
reactions
,
including
an
##aph
##yla
##ctic
reactions
,
may
occur
.
[SEP]
[CLS]
In
the
controlled
clinical
trials
,
the
overall
incidence
of
infections
was
71
%
in
patients
treated
with
B
##EN
##L
##Y
##ST
##A
compared
with
67
%
in
patients
who
received
place
##bo
.
[SEP]
[CLS]
*
If
you
take
a
calcium
or
vitamin
D
supplement
,
you
may
take
it
at
the
same
time
you
take
D
##U
##AV
##EE
.
[SEP]
[CLS]
See
the
list
of
ingredients
in
D
##U
##AV
##EE
at
the
end
of
this
leaf
##let
.
[SEP]
[CLS]
5
.
4
He
##mor
##r
##hage
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
hem
##or
##r
##ha
##gic
events
were
reported
in
58
/
35
##9
patients
(
16
%
)
receiving
IN
##L
##Y
##TA
[SEP]
[CLS]
and
64
/
35
##5
patients
(
18
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
V
##ii
##V
Healthcare
at
1
-
87
##7
-
84
##4
-
88
##7
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
in
Adult
Sub
##jects
Treatment
-
emerge
##nt
[SEP]
[CLS]
Ad
##verse
Drug
Re
##actions
(
AD
##R
##s
)
Treatment
-
naive
Sub
##jects
:
The
safety
assessment
of
T
##I
##VI
##CA
##Y
in
HIV
-
1
-
infected
treatment
-
naive
subjects
is
based
on
the
analyses
of
96
-
week
data
from
2
international
,
[SEP]
[CLS]
multi
##cent
##er
,
double
-
blind
trials
,
SP
##RI
##NG
-
2
(
IN
##G
##11
##30
##86
)
and
S
##ING
##LE
(
IN
##G
##11
##44
##6
##7
)
and
48
-
week
data
from
the
international
,
multi
##cent
##er
,
open
-
label
FL
##AM
##ING
##O
(
IN
##G
##11
##4
##9
##15
)
trial
.
[SEP]
[CLS]
5
.
1
Risk
for
Image
Mi
##sin
##ter
##p
##reta
##tion
and
other
E
##rro
##rs
E
##rro
##rs
may
occur
in
the
Amy
##vid
est
##imation
of
brain
ne
##uri
##tic
plaque
density
during
image
interpretation
[
see
Clinical
Studies
(
14
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Clinical
manifest
##ations
of
N
##MS
are
h
##yper
##py
##re
##xia
,
muscle
rigid
##ity
,
altered
mental
status
,
and
evidence
of
auto
##no
##mic
instability
(
irregular
pulse
,
ta
##chy
##card
##ia
,
di
##aph
##ores
##is
,
and
[SEP]
[CLS]
cardiac
d
##ys
##r
##hy
##th
##mia
)
.
[SEP]
[CLS]
Pro
##long
##ed
exposure
to
elevated
plasma
am
##monia
levels
can
rapidly
result
in
injury
to
the
brain
or
death
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
in
>
=
5
%
of
men
with
o
##ste
##op
##oro
##sis
and
more
frequently
with
Pro
##lia
than
in
the
place
##bo
-
treated
patients
were
:
back
pain
(
6
.
7
%
place
##bo
[SEP]
[CLS]
vs
.
8
.
3
%
Pro
##lia
)
,
art
##hra
##l
##gia
(
5
.
8
%
place
##bo
vs
.
6
.
7
%
Pro
##lia
)
,
and
na
##so
##pha
##ryn
##git
##is
(
5
.
8
%
place
##bo
vs
.
6
.
7
%
Pro
##lia
)
.
[SEP]
[CLS]
5
.
13
Pre
##gna
##ncy
IN
##L
##Y
##TA
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
based
on
its
mechanism
of
action
.
[SEP]
[CLS]
5
.
3
Top
##ical
Op
##ht
##hal
##mic
Use
Only
B
##EP
##RE
##VE
is
for
topic
##al
op
##ht
##hal
##mic
use
only
.
[SEP]
[CLS]
Disco
##ntin
##ue
permanently
if
a
clinical
##ly
significant
reaction
occurs
(
5
.
2
)
*
H
##y
##po
##cal
##ce
##mia
:
Must
be
corrected
before
in
##iti
##ating
Pro
##lia
.
[SEP]
[CLS]
Period
##ically
monitor
patients
clinical
##ly
for
at
##rial
fi
##bri
##lla
##tion
.
[SEP]
[CLS]
An
earlier
onset
can
not
be
ruled
out
,
and
it
is
possible
that
re
##tina
##l
abnormal
##ities
were
present
earlier
in
the
course
of
exposure
to
P
##OT
##IG
##A
.
[SEP]
[CLS]
Stop
treatment
with
CO
##ME
##TR
##I
##Q
at
least
28
days
prior
to
scheduled
surgery
.
[SEP]
[CLS]
Table
2
:
Inc
##iden
##ce
(
%
)
of
Doc
##ume
##nted
H
##y
##po
##gly
##ce
##mia
Ad
##verse
Re
##actions
in
Place
##bo
-
Control
##led
Trials
Place
##bo
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
Ad
##d
-
on
to
Met
##form
##in
(
26
weeks
)
N
=
177
[SEP]
[CLS]
N
=
302
N
=
304
Doc
##ume
##nted
s
##ym
##pt
##oma
##tic
1
.
1
%
2
.
6
%
5
.
6
%
Se
##vere
0
0
0
Ad
##d
-
on
to
Met
##form
##in
+
Pi
##og
##lit
##az
##one
(
26
weeks
)
N
=
141
N
=
280
N
=
27
##9
Doc
##ume
##nted
s
##ym
##pt
##oma
##tic
1
.
4
%
[SEP]
[CLS]
4
.
6
%
5
.
0
%
Se
##vere
0
0
0
H
##y
##po
##gly
##ce
##mia
was
more
frequent
when
T
##R
##U
##L
##IC
##IT
##Y
was
used
in
combination
with
a
su
##lf
##ony
##lu
##rea
or
insulin
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
Pat
##ients
in
the
treatment
studies
who
rolled
over
into
the
R
##E
-
ME
##D
##Y
study
had
a
combined
treatment
duration
of
up
to
more
than
3
years
,
with
mean
exposure
of
47
##3
[SEP]
[CLS]
days
.
[SEP]
[CLS]
Stevens
-
Johnson
syndrome
,
drug
h
##yper
##sen
##si
##ti
##vity
reaction
and
er
##yt
##hem
##a
multi
##form
##e
were
reported
in
less
than
0
.
1
%
of
subjects
during
clinical
development
with
IN
##TE
##LE
##NC
##E
(
r
)
[
see
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
5
.
6
Em
##b
##ryo
-
f
##etal
To
##xi
##city
Bel
##eo
##da
##q
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
5
.
2
Ad
##ren
##oc
##ort
##ical
In
##su
##ff
##iciency
Ad
##rena
##l
ins
##uff
##iciency
occurred
in
the
two
random
##ized
clinical
studies
in
0
.
5
%
of
patients
taking
Z
##Y
##TI
##GA
and
in
0
.
2
%
of
patients
taking
place
##bo
.
[SEP]
[CLS]
In
Study
RA
-
IV
(
mon
##otherapy
)
,
the
AC
##R
##20
response
was
33
%
versus
56
%
,
anti
##body
-
positive
versus
anti
##body
-
negative
status
,
respectively
.
[SEP]
[CLS]
5
.
4
Ser
##ious
Der
##mat
##ological
Re
##actions
Ser
##ious
skin
reactions
,
including
Stevens
-
Johnson
syndrome
(
S
##J
##S
)
and
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
(
T
##EN
)
,
have
been
reported
with
ON
##FI
in
both
children
[SEP]
[CLS]
and
adults
during
the
post
-
marketing
period
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
Re
##actions
The
following
symptoms
that
could
be
compatible
with
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
rarely
following
C
##IM
##Z
##IA
administration
to
patients
:
an
##gio
##ede
##ma
,
der
##mat
##itis
all
##ergic
,
[SEP]
[CLS]
di
##zzi
##ness
(
post
##ural
)
,
d
##ys
##p
##nea
,
hot
flush
,
h
##y
##pot
##ens
##ion
,
injection
site
reactions
,
ma
##lai
##se
,
p
##yre
##xia
,
r
##ash
,
serum
sickness
,
and
(
[SEP]
[CLS]
v
##as
##ova
##gal
)
s
##ync
##ope
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
If
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
no
longer
controls
symptoms
of
br
##on
##cho
##con
##st
##ric
##tion
;
the
patient
'
s
inhaled
,
short
-
acting
,
beta
##2
-
ago
##nist
becomes
less
effective
;
or
the
patient
needs
more
short
-
acting
beta
##2
-
ago
##nist
[SEP]
[CLS]
than
usual
,
these
may
be
markers
of
de
##ter
##ior
##ation
of
disease
.
[SEP]
[CLS]
A
subset
of
patients
who
had
re
##cu
##rrence
of
contract
##ure
in
a
joint
that
was
previously
successfully
treated
with
XI
##AF
##LE
##X
in
Study
4
were
retreated
(
Study
5
)
.
[SEP]
[CLS]
However
,
the
at
##tri
##but
##able
risk
of
liver
cancer
##s
in
CO
##C
users
is
less
than
one
case
per
million
users
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
c
##ert
##oli
##zu
##ma
##b
p
##ego
##l
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
5
.
2
Per
##ip
##her
##al
N
##eur
##op
##athy
Grade
3
peripheral
ne
##uro
##pathy
occurred
in
8
%
(
40
/
50
##3
)
of
patients
,
and
Grade
4
in
0
.
4
%
(
2
/
50
##3
)
of
patients
in
Study
[SEP]
[CLS]
1
.
[SEP]
[CLS]
The
clinical
significance
of
C
##M
##V
se
##rol
##ogy
as
a
risk
factor
for
PT
##LD
remains
to
be
determined
;
however
,
these
findings
should
be
considered
when
pre
##s
##cribing
N
##U
##L
##O
##J
##IX
[
see
Warning
##s
[SEP]
[CLS]
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
(
5
.
5
)
5
.
1
I
##mm
##une
-
mediated
En
##tero
##co
##lit
##is
In
Study
1
,
severe
,
life
-
threatening
,
or
fatal
(
di
##ar
##r
##hea
of
7
or
more
stool
##s
above
base
##line
,
fever
,
il
##eus
,
[SEP]
[CLS]
per
##ito
##nea
##l
signs
;
Grade
3
-
5
)
immune
-
mediated
enter
##oc
##oli
##tis
occurred
in
34
(
7
%
)
Y
##ER
##VO
##Y
-
treated
patients
,
and
moderate
(
di
##ar
##r
##hea
with
up
to
6
stool
##s
above
base
##line
,
[SEP]
[CLS]
abdominal
pain
,
blood
in
stool
;
Grade
2
)
enter
##oc
##oli
##tis
occurred
in
28
(
5
%
)
Y
##ER
##VO
##Y
-
treated
patients
.
[SEP]
[CLS]
By
Week
24
,
hem
##ato
##c
##rit
values
>
55
%
were
reported
in
0
.
4
%
of
place
##bo
-
treated
patients
and
1
.
3
%
of
FA
##R
##X
##IG
##A
10
mg
-
treated
patients
.
[SEP]
[CLS]
Note
:
Per
##cent
##ages
reflect
the
number
of
patients
that
reported
at
least
1
treatment
-
emerge
##nt
occurrence
of
the
adverse
reaction
.
[SEP]
[CLS]
(
5
.
1
,
5
.
2
,
5
.
3
,
5
.
4
,
5
.
5
)
*
?
[SEP]
[CLS]
Monitor
urine
protein
regularly
during
CO
##ME
##TR
##I
##Q
treatment
.
[SEP]
[CLS]
Ad
##vise
patients
to
seek
pro
##mpt
medical
attention
if
they
develop
signs
or
symptoms
of
infection
,
including
cell
##uli
##tis
(
5
.
6
)
*
Der
##mat
##olo
##gic
reactions
:
Der
##mat
##itis
,
r
##ash
##es
,
and
[SEP]
[CLS]
e
##cz
##ema
have
been
reported
.
[SEP]
[CLS]
If
ne
##uro
##logical
compromise
is
noted
,
urgent
diagnosis
and
treatment
is
necessary
.
[SEP]
[CLS]
The
median
duration
of
treatment
was
2
cycles
(
range
1
-
33
cycles
)
.
[SEP]
[CLS]
Monitor
heart
rate
and
blood
pressure
regularly
.
[SEP]
[CLS]
Photo
##sen
##si
##ti
##vity
-
related
adverse
reactions
(
including
photos
##ens
##iti
##vity
reaction
,
p
##oly
##morphic
light
eruption
,
and
sun
##burn
)
occurred
in
0
.
1
%
,
0
.
2
%
,
and
0
.
2
%
of
patients
receiving
com
##par
##ator
[SEP]
[CLS]
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
*
are
breast
##fe
##eding
or
plan
to
breast
##fe
##ed
.
[SEP]
[CLS]
The
most
common
serious
adverse
events
were
:
pneumonia
(
8
%
)
,
acute
re
##nal
failure
(
5
%
)
,
disease
progression
(
4
%
)
,
[SEP]
[CLS]
p
##yre
##xia
(
3
%
)
,
h
##yper
##cal
##ce
##mia
(
3
%
)
,
con
##ges
##tive
heart
failure
(
3
%
)
,
multiple
my
##elo
##ma
(
3
%
)
,
an
##emia
(
2
[SEP]
[CLS]
%
)
,
and
d
##ys
##p
##nea
(
2
%
)
.
[SEP]
[CLS]
In
some
cases
glucose
into
##ler
##ance
may
be
i
##rre
##versible
.
[SEP]
[CLS]
estimated
c
##rea
##tin
##ine
clearance
less
than
70
m
##L
per
minute
)
at
base
##line
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
were
reported
in
29
%
of
patients
treated
with
G
##IL
##OT
##RI
##F
.
[SEP]
[CLS]
These
events
generally
occurred
within
hours
of
the
in
##fusion
;
however
,
they
may
occur
later
.
[SEP]
[CLS]
In
##form
patients
of
the
signs
and
symptoms
of
an
##aph
##yla
##xi
##s
,
h
##yper
##sen
##si
##ti
##vity
reactions
,
and
immune
-
mediated
reactions
and
have
them
seek
immediate
medical
care
should
signs
and
symptoms
occur
(
5
.
1
[SEP]
[CLS]
,
5
.
2
)
.
[SEP]
[CLS]
After
cross
-
over
to
open
-
label
A
##FI
##NI
##TO
##R
,
there
were
three
additional
deaths
,
one
due
to
h
##y
##po
##gly
##ce
##mia
and
cardiac
arrest
in
a
patient
with
insulin
##oma
,
one
due
to
[SEP]
[CLS]
my
##oc
##ard
##ial
in
##far
##ction
with
con
##ges
##tive
heart
failure
,
and
the
other
due
to
sudden
death
.
[SEP]
[CLS]
Fever
was
complicated
with
chill
##s
/
rig
##ors
in
51
%
(
28
/
55
)
,
de
##hy
##dra
##tion
in
9
%
(
5
/
55
)
,
re
##nal
failure
in
4
%
(
2
/
55
)
,
and
[SEP]
[CLS]
s
##ync
##ope
in
4
%
(
2
/
55
)
of
patients
in
Trial
2
.
[SEP]
[CLS]
Out
of
108
##2
patients
who
received
0
.
58
mg
of
XI
##AF
##LE
##X
in
the
controlled
and
un
##con
##tro
##lled
portions
of
the
XI
##AF
##LE
##X
studies
(
26
##30
XI
##AF
##LE
##X
injection
##s
)
,
3
(
0
.
3
%
[SEP]
[CLS]
)
patients
had
a
fl
##ex
##or
tend
##on
r
##up
##ture
of
the
treated
finger
within
7
days
of
the
injection
.
[SEP]
[CLS]
Pat
##ient
presenting
with
an
at
##y
##pical
f
##em
##ur
fracture
should
also
be
assessed
for
symptoms
and
signs
of
fracture
in
the
con
##tral
##ater
##al
limb
.
[SEP]
[CLS]
On
average
,
women
with
he
##pa
##tic
imp
##air
##ment
treated
with
b
##azed
##ox
##ife
##ne
alone
showed
a
4
.
3
-
fold
increase
in
overall
exposure
##s
compared
with
controls
[
see
Use
in
S
##pecific
Population
##s
(
8
.
7
)
[SEP]
[CLS]
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Mi
##ld
(
less
than
LL
##N
and
greater
than
75
##x
##10
9
/
L
)
and
trans
##ient
decreases
in
plate
##let
counts
were
observed
in
3
(
6
.
3
%
)
IL
##AR
##IS
treated
patients
versus
[SEP]
[CLS]
1
(
2
.
0
%
)
place
##bo
-
treated
patient
.
[SEP]
[CLS]
In
2
-
year
place
##bo
-
controlled
trials
,
the
reduction
from
base
##line
in
the
percent
of
predicted
values
for
F
##E
##V
##1
at
the
time
of
last
assessment
on
drug
was
2
.
8
%
for
G
##IL
##EN
##Y
##A
[SEP]
[CLS]
0
.
5
mg
and
1
.
0
%
for
place
##bo
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
S
##ple
##nic
R
##up
##ture
:
Disco
##ntin
##ue
G
##RA
##NI
##X
if
suspected
(
5
.
1
)
*
A
##cute
Re
##sp
##ira
##tory
Di
##st
##ress
S
##yn
##drome
(
AR
##DS
)
:
Monitor
for
and
manage
[SEP]
[CLS]
immediately
.
[SEP]
[CLS]
Ex
##er
##cise
caution
in
considering
the
use
of
C
##IM
##Z
##IA
in
patients
with
pre
-
existing
or
recent
-
onset
central
or
peripheral
nervous
system
dem
##ye
##lina
##ting
disorders
.
[SEP]
[CLS]
Table
2
:
B
##lee
##ding
Events
in
Pat
##ients
with
Non
##val
##vu
##lar
At
##rial
Fi
##bri
##lla
##tion
in
A
##VE
##R
##RO
##ES
E
##L
##I
##Q
##UI
##SN
=
27
##9
##8
##n
(
%
/
year
)
As
##pi
##rin
##N
=
278
##0
##n
(
%
/
year
)
Ha
##zard
Rat
##io
(
95
%
C
##I
)
[SEP]
[CLS]
P
-
value
Events
associated
with
each
end
##point
were
counted
once
per
subject
,
but
subjects
may
have
contributed
events
to
multiple
end
##points
.
[SEP]
[CLS]
11
C
-
ch
##olin
##e
up
##take
is
not
specific
for
pro
##state
cancer
and
may
occur
with
other
types
of
cancer
(
such
as
lung
car
##cin
##oma
and
brain
tumors
)
.
[SEP]
[CLS]
The
efficacy
and
safety
of
D
##U
##AV
##EE
in
pre
##men
##op
##aus
##al
women
have
not
been
established
,
and
its
use
is
not
recommended
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
*
receiving
other
medications
that
pro
##long
the
Q
##T
interval
,
such
as
class
I
##A
(
q
##uin
##id
##ine
,
pro
##ca
##ina
##mi
##de
,
di
##so
##py
##ram
##ide
)
,
or
class
III
(
am
##io
##dar
##one
,
so
##tal
##ol
)
[SEP]
[CLS]
anti
##ar
##r
##hy
##th
##mic
agents
;
anti
##psy
##cho
##tics
(
p
##imo
##zi
##de
,
z
##ip
##ras
##ido
##ne
)
;
anti
##de
##press
##ants
;
certain
anti
##biotics
(
mac
##rol
##ide
anti
##biotics
,
flu
##oro
##quin
##olo
##ne
anti
##biotics
,
im
##ida
##zo
##le
,
and
t
##ria
##zo
##le
anti
##fu
##nga
##l
agents
)
[
see
[SEP]
[CLS]
Clinical
Ph
##arma
##cology
(
12
.
6
)
]
.
[SEP]
[CLS]
5
.
3
Direct
Co
##omb
##s
'
Test
Ser
##oc
##on
##version
Ser
##oc
##on
##version
from
a
negative
to
a
positive
direct
Co
##omb
##s
'
test
result
occurred
in
120
/
111
##4
(
10
.
8
%
)
of
patients
receiving
Te
##f
##lar
##o
and
[SEP]
[CLS]
49
/
111
##6
(
4
.
4
%
)
of
patients
receiving
com
##par
##ator
drugs
in
the
four
pool
##ed
Phase
3
trials
.
[SEP]
[CLS]
IL
##AR
##IS
should
not
be
administered
to
any
patients
with
known
clinical
h
##yper
##sen
##si
##ti
##vity
to
IL
##AR
##IS
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
(
See
current
recommended
im
##mu
##ni
##zation
schedules
at
the
website
of
the
Centers
for
Disease
Control
,
http
:
/
/
www
.
c
##d
##c
.
go
##v
/
vaccine
##s
/
schedules
/
index
.
html
)
.
[SEP]
[CLS]
All
patients
who
were
positive
for
antibodies
to
go
##lim
##uma
##b
had
neutral
##izing
antibodies
based
on
an
in
v
##it
##ro
cell
-
based
ass
##ay
.
[SEP]
[CLS]
Dec
##rease
##s
in
ne
##ut
##rop
##hil
##s
or
plate
##lets
may
require
a
decrease
in
dos
##age
or
interrupt
##ion
of
p
##eg
##int
##er
##fer
##on
al
##fa
,
or
disco
##ntin
##uation
of
therapy
[
see
pre
##s
##cribing
information
for
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Table
2
:
Laboratory
data
/
EC
##G
parameters
not
necessarily
reported
as
adverse
events
Place
##bo
M
##U
##LT
##A
##Q
400
mg
twice
daily
(
N
=
287
##5
)
(
N
=
32
##8
##2
)
Early
increases
in
c
##rea
##tin
##ine
>
=
10
[SEP]
[CLS]
%
21
%
51
%
(
N
=
223
##7
)
(
N
=
270
##1
)
Q
##T
##c
prolonged
19
%
28
%
Assessment
of
demographic
factors
such
as
gender
or
age
on
the
incidence
of
[SEP]
[CLS]
treatment
-
emerge
##nt
adverse
events
did
not
suggest
an
excess
of
adverse
events
in
any
particular
sub
-
group
.
[SEP]
[CLS]
During
adult
pre
-
marketing
clinical
trials
with
SA
##P
##H
##RI
##S
,
including
long
-
term
trials
without
comparison
to
place
##bo
,
d
##ys
##pha
##gia
was
reported
in
0
.
1
%
(
2
/
1953
)
of
patients
treated
with
SA
##P
##H
##RI
##S
[SEP]
[CLS]
.
[SEP]
[CLS]
In
the
controlled
and
un
##con
##tro
##lled
portions
of
Trial
1
,
95
##8
total
patient
-
years
of
follow
-
up
with
a
median
follow
-
up
of
approximately
92
weeks
,
the
incidence
per
100
patient
-
years
of
[SEP]
[CLS]
all
serious
infections
was
4
.
07
(
C
##I
:
2
.
90
,
5
.
57
)
in
patients
receiving
S
##IM
##PO
##NI
ARIA
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
A
##ppa
##rent
ho
##mo
##gene
##ity
or
he
##tero
##gene
##ity
among
groups
should
not
be
over
-
interpreted
.
[SEP]
[CLS]
Do
not
administer
K
##AL
##BI
##TO
##R
to
patients
with
known
clinical
h
##yper
##sen
##si
##ti
##vity
to
K
##AL
##BI
##TO
##R
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
,
and
Ad
##verse
Re
##actions
(
[SEP]
[CLS]
6
)
]
.
[SEP]
[CLS]
No
dose
modifications
of
T
##AF
##IN
##LA
##R
or
tram
##eti
##ni
##b
are
required
in
patients
who
develop
new
primary
cut
##aneous
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
5
.
15
Pre
##men
##op
##aus
##al
Women
There
is
no
indication
for
pre
##men
##op
##aus
##al
use
of
D
##U
##AV
##EE
.
[SEP]
[CLS]
In
##jection
Site
Re
##actions
In
the
pool
of
place
##bo
-
controlled
trials
,
injection
site
reactions
occurred
more
frequently
on
T
##AN
##Z
##E
##UM
(
18
%
)
than
on
place
##bo
(
8
%
)
.
[SEP]
[CLS]
Therapy
with
le
##uc
##ovo
##rin
should
be
continued
until
the
met
##hot
##re
##xa
##te
concentration
has
been
maintained
below
the
le
##uc
##ovo
##rin
treatment
threshold
for
a
minimum
of
3
days
.
[SEP]
[CLS]
(
5
.
1
)
*
H
##y
##pot
##ens
##ion
and
reflex
ta
##chy
##card
##ia
are
potential
consequences
of
rapid
upward
t
##it
##ration
of
C
##lev
##ip
##re
##x
.
[SEP]
[CLS]
Death
##s
due
to
causes
other
than
disease
progression
within
30
days
of
last
study
drug
dose
were
reported
in
18
(
5
%
)
J
##E
##V
##TA
##NA
-
treated
patients
and
3
(
<
[SEP]
[CLS]
1
%
)
mit
##ox
##ant
##rone
-
treated
patients
.
[SEP]
[CLS]
Ex
##er
##cise
caution
with
the
use
of
A
##FI
##NI
##TO
##R
in
the
per
##i
-
surgical
period
.
[SEP]
[CLS]
Any
patient
who
presents
with
thigh
or
groin
pain
should
be
suspected
of
having
an
at
##y
##pical
fracture
and
should
be
evaluated
to
rule
out
an
incomplete
f
##em
##ur
fracture
.
[SEP]
[CLS]
All
patients
continued
and
##rogen
de
##p
##ri
##vation
therapy
.
[SEP]
[CLS]
Figure
##s
rounded
to
the
nearest
integer
.
[SEP]
[CLS]
This
im
##bal
##ance
has
not
been
observed
in
other
studies
of
E
##NT
##ER
##EG
in
patients
treated
with
op
##io
##ids
for
chronic
pain
,
nor
in
patients
treated
within
the
surgical
setting
,
including
[SEP]
[CLS]
patients
undergoing
surge
##ries
that
included
bow
##el
re
##section
who
received
E
##NT
##ER
##EG
12
mg
twice
daily
for
up
to
7
days
(
the
indicated
dose
and
patient
population
;
E
##NT
##ER
##EG
12
mg
[SEP]
[CLS]
,
n
=
1
,
142
;
place
##bo
,
n
=
1
,
120
)
.
[SEP]
[CLS]
Notable
requirements
of
the
E
.
A
.
S
.
E
.
[SEP]
[CLS]
None
of
the
59
e
##val
##ua
##ble
patients
tested
positive
for
in
##hibition
of
enzyme
activity
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
AS
##TH
##MA
-
R
##EL
##AT
##ED
DE
##AT
##H
WA
##R
##NI
##NG
:
AS
##TH
##MA
-
R
##EL
##AT
##ED
DE
##AT
##H
Long
-
acting
beta
##2
-
ad
##rene
##rg
##ic
ago
##nist
##s
(
LA
##BA
)
,
such
as
v
##ila
##nter
##ol
,
one
of
the
active
ingredients
in
BR
##E
##O
E
##LL
##IP
##TA
[SEP]
[CLS]
,
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
In
the
two
random
##ized
clinical
trials
,
Grade
1
-
4
ne
##ut
##rop
##enia
occurred
in
15
%
of
patients
treated
with
X
##TA
##ND
##I
(
1
%
Grade
3
-
4
)
and
in
6
[SEP]
[CLS]
%
of
patients
treated
with
place
##bo
(
0
.
5
%
Grade
3
-
4
)
.
[SEP]
[CLS]
*
Before
D
##OT
##AR
##EM
administration
,
assess
all
patients
for
any
history
of
a
reaction
to
contrast
media
,
br
##on
##chia
##l
as
##th
##ma
and
/
or
all
##ergic
disorders
.
[SEP]
[CLS]
5
.
9
V
##ac
##cin
##ations
/
The
##rap
##eu
##tic
In
##fect
##ious
Agents
Live
V
##ac
##cine
##s
Pat
##ients
treated
with
S
##IM
##PO
##NI
ARIA
may
receive
v
##ac
##cin
##ations
,
except
for
live
vaccine
##s
.
[SEP]
[CLS]
H
##OR
##I
##Z
##AN
##T
should
be
discontinued
if
an
alternative
et
##iology
for
the
signs
or
symptoms
can
not
be
established
.
[SEP]
[CLS]
Among
these
subjects
,
42
%
were
women
and
99
%
Caucasian
.
[SEP]
[CLS]
In
Study
3
,
the
most
common
adverse
reactions
(
>
=
20
%
)
in
the
AD
##CE
##TR
##IS
-
treatment
arm
,
regardless
of
ca
##usal
##ity
,
were
ne
##ut
##rop
##enia
,
peripheral
sensory
ne
##uro
##pathy
,
[SEP]
[CLS]
th
##rom
##bo
##cy
##top
##enia
,
an
##emia
,
upper
respiratory
tract
infection
,
fatigue
,
peripheral
motor
ne
##uro
##pathy
,
nausea
,
cough
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
has
not
been
studied
in
the
relief
of
acute
symptoms
and
extra
doses
should
not
be
used
for
that
purpose
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
and
Active
-
Control
##led
Trials
The
occurrence
of
adverse
reactions
for
can
##ag
##li
##f
##lo
##zin
was
evaluated
in
a
larger
pool
of
patients
participating
in
place
##bo
-
and
active
-
controlled
trials
.
[SEP]
[CLS]
In
these
patients
,
the
majority
of
l
##ymph
##oc
##yte
counts
remained
<
0
.
5
##x
##10
9
/
L
with
continued
therapy
.
[SEP]
[CLS]
5
.
2
Inter
##st
##iti
##al
Lu
##ng
Disease
(
P
##ne
##um
##oni
##tis
)
Se
##vere
,
life
-
threatening
,
or
fatal
inter
##st
##iti
##al
lung
disease
(
IL
##D
)
/
p
##ne
##um
##oni
##tis
can
occur
in
patients
treated
with
X
##AL
##KO
##RI
.
[SEP]
[CLS]
W
##orse
##ning
h
##yper
##tens
##ion
was
reported
in
4
patients
treated
with
T
##RE
##AN
##DA
in
the
C
##LL
trial
and
in
none
treated
with
ch
##lora
##mb
##uc
##il
.
[SEP]
[CLS]
5
.
10
Body
Te
##mper
##ature
Regulation
Di
##s
##rup
##tion
of
the
body
'
s
ability
to
reduce
core
body
temperature
has
been
attributed
to
anti
##psy
##cho
##tic
agents
.
[SEP]
[CLS]
The
most
frequently
reported
adverse
reactions
(
occurring
in
greater
than
1
%
of
patients
and
at
a
higher
rate
with
F
##IR
##A
##Z
##Y
##R
versus
place
##bo
)
are
shown
in
Table
1
[SEP]
[CLS]
.
[SEP]
[CLS]
All
cases
of
PT
##LD
reported
up
to
36
months
post
transplant
in
N
##U
##L
##O
##J
##IX
-
or
c
##y
##c
##los
##por
##ine
-
treated
patients
presented
within
18
months
of
transplant
##ation
.
[SEP]
[CLS]
Among
the
404
E
##B
##V
se
##rop
##os
##itive
recipients
treated
with
the
recommended
dos
##age
regime
##n
of
N
##U
##L
##O
##J
##IX
,
three
PT
##LD
cases
were
detected
among
99
C
##M
##V
se
##rone
##gat
##ive
patients
(
3
%
)
and
[SEP]
[CLS]
there
was
no
case
detected
among
303
C
##M
##V
se
##rop
##os
##itive
patients
.
[SEP]
[CLS]
Pat
##ients
with
ne
##ut
##rop
##enia
should
be
carefully
monitored
for
fever
or
other
symptoms
or
signs
of
infection
and
treated
promptly
if
such
symptoms
or
signs
occur
.
[SEP]
[CLS]
and
Minor
##M
##ino
##r
episodes
of
h
##y
##po
##gly
##ce
##mia
were
defined
as
either
a
s
##ym
##pt
##oma
##tic
episode
with
a
plasma
glucose
measurement
<
63
mg
/
d
##L
regardless
of
need
for
external
assistance
,
or
an
as
##ym
##pt
##oma
##tic
[SEP]
[CLS]
plasma
glucose
measurement
<
63
mg
/
d
##L
that
does
not
qualify
as
a
major
episode
.
[SEP]
[CLS]
Clinical
studies
of
H
##AL
##AV
##EN
did
not
include
patients
with
base
##line
ne
##ut
##rop
##hil
counts
below
1
,
500
/
mm
3
.
[SEP]
[CLS]
A
##vo
##id
H
##AL
##AV
##EN
in
patients
with
con
##gen
##ital
long
Q
##T
syndrome
.
[SEP]
[CLS]
If
clinical
##ly
indicated
,
perform
appropriate
tests
to
confirm
the
diagnosis
of
ad
##ren
##oc
##ort
##ical
ins
##uff
##iciency
.
[SEP]
[CLS]
Therefore
,
a
lower
dose
of
insulin
or
insulin
secret
##ago
##gue
may
be
required
to
minimize
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
these
agents
are
used
in
combination
with
FA
##R
##X
##IG
##A
.
[SEP]
[CLS]
ON
##FI
should
be
discontinued
at
the
first
sign
of
r
##ash
,
unless
the
r
##ash
is
clearly
not
drug
-
related
.
[SEP]
[CLS]
5
.
2
Se
##vere
Di
##ar
##r
##hea
or
Col
##itis
Se
##vere
di
##ar
##r
##hea
or
co
##lit
##is
(
Grade
3
or
higher
)
occurred
in
14
%
of
Z
##yd
##eli
##g
-
treated
patients
across
clinical
trials
[
see
Ad
##verse
Re
##actions
(
[SEP]
[CLS]
6
.
1
)
]
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Jazz
Ph
##arma
##ce
##utical
##s
,
Inc
.
at
1
-
800
-
520
-
55
##6
##8
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Studies
Because
clinical
trials
are
conducted
under
controlled
,
[SEP]
[CLS]
but
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
ER
##WI
##NA
##Z
##E
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
other
drugs
and
may
[SEP]
[CLS]
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
controlled
Trials
The
data
in
Table
1
are
derived
from
the
place
##bo
-
controlled
trials
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
At
Week
24
,
the
mean
changes
from
base
##line
in
hem
##ato
##c
##rit
were
-
0
.
33
%
in
the
place
##bo
group
and
2
.
30
%
in
the
FA
##R
##X
##IG
##A
10
mg
group
.
[SEP]
[CLS]
5
.
8
Pro
##tein
##uria
Pro
##tein
##uria
was
observed
in
4
(
2
%
)
of
patients
receiving
CO
##ME
##TR
##I
##Q
,
including
one
with
ne
##ph
##rot
##ic
syndrome
,
as
compared
to
none
of
the
patients
receiving
[SEP]
[CLS]
place
##bo
.
[SEP]
[CLS]
(
5
.
1
)
*
If
re
##tina
##l
pig
##mentary
abnormal
##ities
or
vision
changes
are
detected
,
P
##OT
##IG
##A
should
be
discontinued
unless
no
other
suitable
treatment
options
are
available
and
the
benefits
of
[SEP]
[CLS]
treatment
out
##wei
##gh
the
potential
risk
of
vision
loss
.
[SEP]
[CLS]
b
Includes
re
##tch
##ing
,
vomit
##ing
,
vomit
##ing
project
##ile
.
[SEP]
[CLS]
Con
##tra
##ception
and
Heavy
Men
##st
##ru
##al
B
##lee
##ding
Studies
A
total
of
2
,
131
women
,
18
to
54
years
of
age
,
who
took
at
least
one
dose
of
Nat
##azi
##a
were
enrolled
in
[SEP]
[CLS]
four
clinical
phase
3
trials
.
[SEP]
[CLS]
5
.
2
In
##fect
##ions
Fat
##al
and
non
-
fatal
infections
have
occurred
with
I
##MB
##R
##U
##VI
##CA
therapy
.
[SEP]
[CLS]
Ad
##verse
reactions
occurring
less
frequently
but
possibly
related
to
T
##RE
##AN
##DA
treatment
were
hem
##oly
##sis
,
d
##ys
##ge
##us
##ia
/
taste
disorder
,
at
##y
##pical
pneumonia
,
se
##psis
,
her
##pes
z
##ost
##er
,
er
##yt
##hem
##a
,
der
##mat
##itis
,
and
[SEP]
[CLS]
skin
ne
##c
##rosis
.
[SEP]
[CLS]
To
manage
my
##elo
##su
##pp
##ression
,
with
##hold
,
dose
reduce
,
or
disco
##ntin
##ue
B
##OS
##U
##L
##IF
as
necessary
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
5
.
2
Q
##T
Pro
##long
##ation
S
##IR
##TU
##RO
pro
##long
##s
the
Q
##T
interval
.
[SEP]
[CLS]
O
##cular
adverse
reactions
occurring
in
<
1
%
of
subjects
included
application
site
discomfort
,
corn
##eal
pig
##mentation
,
e
##pis
##cle
##rit
##is
,
eye
p
##ru
##rit
##is
,
eye
##lid
irritation
,
foreign
body
sensation
,
[SEP]
[CLS]
increased
la
##c
##rima
##tion
,
mac
##ular
ed
##ema
,
s
##cle
##ra
h
##yper
##emia
,
and
u
##ve
##itis
.
[SEP]
[CLS]
All
men
were
instructed
to
take
at
least
1000
mg
of
calcium
and
400
I
##U
of
vitamin
D
supplement
##ation
per
day
.
[SEP]
[CLS]
Ser
##ious
adverse
events
were
reported
,
regardless
of
ca
##usal
##ity
,
in
50
%
of
patients
in
the
pool
##ed
K
##y
##p
##rol
##is
mon
##otherapy
studies
(
n
=
59
##8
)
.
[SEP]
[CLS]
(
2
.
2
,
5
.
12
)
*
IN
##L
##Y
##TA
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
based
on
its
mechanism
of
action
.
[SEP]
[CLS]
Some
patients
experienced
c
##ir
##cula
##tory
collapse
and
died
.
[SEP]
[CLS]
Pat
##ients
with
diabetes
me
##lli
##tus
or
a
history
of
u
##ve
##itis
are
at
increased
risk
.
[SEP]
[CLS]
These
symptoms
have
been
reported
hours
to
weeks
after
injection
.
[SEP]
[CLS]
Case
##s
of
acute
re
##nal
failure
after
initiation
of
high
dose
or
multiple
NSA
##ID
##s
have
been
reported
in
HIV
-
infected
patients
with
risk
factors
for
re
##nal
d
##ys
##function
who
appeared
stable
on
ten
##of
##ov
##ir
[SEP]
[CLS]
D
##F
.
[SEP]
[CLS]
In
clinical
studies
,
cases
of
pan
##cy
##top
##enia
,
le
##uk
##ope
##nia
,
ne
##ut
##rop
##enia
,
and
th
##rom
##bo
##cy
##top
##enia
have
also
occurred
in
S
##IM
##PO
##NI
ARIA
-
treated
patients
.
[SEP]
[CLS]
(
5
.
1
,
5
.
2
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
A
higher
number
of
my
##oc
##ard
##ial
in
##far
##ctions
was
reported
in
patients
treated
with
al
##vi
##mo
##pan
0
.
5
mg
twice
daily
compared
[SEP]
[CLS]
with
place
##bo
in
a
12
-
month
study
in
patients
treated
with
op
##io
##ids
for
chronic
non
-
cancer
pain
,
although
a
ca
##usal
relationship
with
long
-
term
use
has
not
been
established
.
[SEP]
[CLS]
All
other
patients
tested
negative
for
in
##hibition
of
cellular
up
##take
.
[SEP]
[CLS]
Table
1
displays
adverse
reactions
more
common
with
drone
##dar
##one
400
mg
twice
daily
than
with
place
##bo
in
A
##F
or
AFL
patients
,
presented
by
system
organ
class
and
by
decreasing
[SEP]
[CLS]
order
of
frequency
.
[SEP]
[CLS]
(
5
.
7
)
5
.
1
Po
##ten
##tial
Risk
of
My
##oc
##ard
##ial
In
##far
##ction
with
Long
-
term
Use
There
were
more
reports
of
my
##oc
##ard
##ial
in
##far
##ctions
in
patients
treated
with
al
##vi
##mo
##pan
0
.
5
mg
twice
daily
compared
with
[SEP]
[CLS]
place
##bo
-
treated
patients
in
a
12
-
month
study
of
patients
treated
with
op
##io
##ids
for
chronic
non
-
cancer
pain
(
al
##vi
##mo
##pan
0
.
5
mg
,
n
=
53
##8
;
place
##bo
,
n
=
26
##7
)
[SEP]
[CLS]
.
[SEP]
[CLS]
If
it
is
almost
time
for
your
next
dose
,
skip
the
missed
dose
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Leading
to
Disco
##ntin
##uation
in
an
L
##GS
Place
##bo
Control
##led
Clinical
Trial
(
Study
1
)
The
adverse
reactions
associated
with
ON
##FI
treatment
disco
##ntin
##uation
in
>
=
1
%
of
patients
[SEP]
[CLS]
in
decreasing
order
of
frequency
included
let
##har
##gy
,
so
##m
##no
##len
##ce
,
at
##ax
##ia
,
aggression
,
fatigue
,
and
ins
##om
##nia
.
[SEP]
[CLS]
In
Trial
2
,
the
incidence
of
any
skin
toxicity
was
similar
for
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
(
65
%
[
36
/
55
]
)
compared
with
patients
[SEP]
[CLS]
receiving
T
##AF
##IN
##LA
##R
as
a
single
agent
(
68
%
[
36
/
53
]
)
.
[SEP]
[CLS]
Because
of
the
continuing
p
##har
##ma
##co
##dynamic
effects
of
fin
##gol
##imo
##d
,
in
##iti
##ating
other
drugs
during
this
period
warrant
##s
the
same
considerations
needed
for
con
##com
##ita
##nt
administration
(
e
.
g
.
,
risk
of
add
##itive
[SEP]
[CLS]
im
##mu
##nos
##up
##press
##ant
effects
)
[
see
Drug
Inter
##actions
(
7
)
]
.
[SEP]
[CLS]
AM
##P
##Y
##RA
should
be
discontinued
and
not
restart
##ed
in
patients
who
experience
a
seizure
while
on
treatment
.
[SEP]
[CLS]
All
patients
had
normal
values
at
the
next
visit
.
[SEP]
[CLS]
The
pool
##ed
analyses
of
place
##bo
-
controlled
studies
in
children
and
adolescent
##s
with
MD
##D
,
o
##bs
##ess
##ive
com
##pu
##lsive
disorder
(
O
##CD
)
,
or
other
psychiatric
disorders
included
a
total
of
24
short
-
term
[SEP]
[CLS]
studies
of
9
anti
##de
##press
##ant
drugs
in
over
4
,
400
patients
.
[SEP]
[CLS]
Beyond
48
hours
after
V
##OR
##A
##X
##A
##Z
##E
,
administer
le
##uc
##ovo
##rin
based
on
the
measured
met
##hot
##re
##xa
##te
concentration
.
[SEP]
[CLS]
5
.
10
Counsel
##ing
Pat
##ients
about
Sexual
##ly
Trans
##mit
##ted
Disease
##s
The
use
of
ST
##EN
##DR
##A
offers
no
protection
against
sexually
transmitted
diseases
.
[SEP]
[CLS]
The
relative
risk
of
probable
dem
##ent
##ia
for
CE
-
alone
versus
place
##bo
was
1
.
49
(
95
percent
C
##I
,
0
.
83
-
2
.
66
)
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Drug
Re
##actions
that
O
##cc
##ur
##red
in
at
Lea
##st
1
%
of
Pat
##ients
and
Were
More
Fr
##e
##quent
than
Place
##bo
Place
##bo
Dr
##oned
##aro
##ne
400
mg
twice
daily
(
N
=
287
##5
)
[SEP]
[CLS]
(
N
=
32
##8
##2
)
Gas
##tro
##int
##est
##inal
Di
##ar
##r
##hea
6
%
9
%
Na
##use
##a
3
%
5
%
Abd
##omi
##nal
pain
3
%
4
%
V
##omi
##ting
1
%
2
%
D
##ys
##pe
##ptic
signs
and
symptoms
1
[SEP]
[CLS]
%
2
%
General
As
##the
##nic
conditions
5
%
7
%
Card
##iac
Brady
##card
##ia
1
%
3
%
Skin
and
sub
##cut
##aneous
tissue
Including
r
##ash
##es
)
,
p
##ru
##rit
##us
,
e
##cz
##ema
,
der
##mat
##itis
,
[SEP]
[CLS]
der
##mat
##itis
all
##ergic
3
%
5
%
Photo
##sen
##si
##ti
##vity
reaction
and
d
##ys
##ge
##us
##ia
have
also
been
reported
at
an
incidence
less
than
1
%
in
patients
treated
with
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
This
increase
is
due
to
reduction
in
serum
u
##ric
acid
levels
,
resulting
in
mob
##ilization
of
u
##rate
from
tissue
deposits
.
[SEP]
[CLS]
Table
7
presents
the
most
common
adverse
drug
reactions
(
experienced
by
greater
than
or
equal
to
10
%
of
patients
receiving
PR
##OM
##AC
##TA
compared
with
place
##bo
)
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
for
the
development
of
systemic
immune
-
mediated
reactions
involving
skin
and
other
organs
while
receiving
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
The
use
of
clinical
information
in
the
interpretation
of
V
##iza
##my
##l
images
has
not
been
evaluated
and
may
lead
to
errors
.
[SEP]
[CLS]
Eleven
cases
of
MA
##S
were
observed
in
201
S
##J
##IA
patients
treated
with
can
##aki
##num
##ab
in
clinical
trials
.
[SEP]
[CLS]
Ever
##oli
##mus
caused
em
##b
##ryo
-
f
##etal
toxic
##ities
in
animals
at
maternal
exposure
##s
that
were
lower
than
human
exposure
##s
.
[SEP]
[CLS]
Blood
and
L
##ymph
##atic
System
Di
##sor
##ders
:
a
##gra
##nu
##loc
##yt
##osis
,
pan
##cy
##top
##enia
,
th
##rom
##bo
##cy
##top
##enia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
mouth
ul
##cer
##ation
,
s
##tom
##ati
##tis
In
##fect
##ions
and
In
##fest
##ations
[SEP]
[CLS]
:
pneumonia
,
se
##psis
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
an
##gio
##ede
##ma
,
u
##rt
##ica
##ria
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
;
DR
##ES
##S
)
syndrome
,
ex
##folia
##tive
r
##ash
,
[SEP]
[CLS]
ex
##folia
##tive
der
##mat
##itis
,
Stevens
-
Johnson
syndrome
,
toxic
skin
eruption
,
toxic
##ode
##rma
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
Use
of
VI
##CT
##RE
##L
##IS
with
R
##iba
##vir
##in
and
P
##eg
##int
##er
##fer
##on
al
##fa
:
*
Em
##b
##ryo
##fe
##tal
To
##xi
##city
(
[SEP]
[CLS]
Use
with
R
##iba
##vir
##in
and
P
##eg
##int
##er
##fer
##on
Alfa
)
:
R
##iba
##vir
##in
may
cause
birth
defects
and
f
##etal
death
;
avoid
pregnancy
in
female
patients
and
female
partners
of
male
patients
.
[SEP]
[CLS]
Consider
obtaining
periodic
he
##pa
##tic
serum
enzymes
,
especially
during
the
first
6
months
of
treatment
,
but
it
is
not
known
whether
routine
periodic
monitoring
of
serum
enzymes
will
prevent
[SEP]
[CLS]
the
development
of
severe
liver
injury
.
[SEP]
[CLS]
If
rib
##avi
##rin
is
permanently
discontinued
,
then
p
##eg
##int
##er
##fer
##on
al
##fa
and
VI
##CT
##RE
##L
##IS
must
also
be
discontinued
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
End
##ome
##tri
##al
h
##yper
##p
##lasia
may
be
a
precursor
to
end
##ome
##tri
##al
cancer
.
[SEP]
[CLS]
The
other
cases
represented
a
variety
of
different
ma
##li
##gna
##ncies
and
included
rare
ma
##li
##gna
##ncies
usually
associated
with
im
##mu
##nos
##up
##press
##ion
and
ma
##li
##gna
##ncies
that
are
not
usually
observed
in
children
and
adolescent
##s
.
[SEP]
[CLS]
If
immune
-
mediated
reactions
occur
,
consider
disco
##ntin
##uation
of
the
administration
of
al
##g
##lu
##cos
##idas
##e
al
##fa
,
and
initiate
appropriate
medical
treatment
.
[SEP]
[CLS]
5
.
16
Use
in
Pat
##ients
with
Con
##com
##ita
##nt
Il
##ln
##ess
Clinical
experience
with
SA
##P
##H
##RI
##S
in
patients
with
certain
con
##com
##ita
##nt
systemic
illness
##es
is
limited
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Cut
##aneous
Mali
##gna
##ncies
:
T
##AF
##IN
##LA
##R
results
in
an
increased
incidence
of
cut
##aneous
sq
##ua
##mous
cell
car
##cin
##oma
,
k
##era
##to
##aca
##nt
##hom
##a
,
and
me
##lan
##oma
.
[SEP]
[CLS]
In
order
to
prevent
go
##ut
flare
##s
when
U
##L
##OR
##IC
is
initiated
,
concurrent
prop
##hyl
##actic
treatment
with
an
NSA
##ID
or
co
##l
##chi
##cine
is
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
The
following
laboratory
data
/
EC
##G
parameters
were
reported
with
M
##U
##LT
##A
##Q
400
mg
twice
daily
.
[SEP]
[CLS]
For
the
first
48
hours
after
V
##OR
##A
##X
##A
##Z
##E
,
administer
the
same
le
##uc
##ovo
##rin
dose
as
given
prior
to
V
##OR
##A
##X
##A
##Z
##E
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
These
fracture
##s
can
occur
anywhere
in
the
f
##em
##oral
shaft
from
just
below
the
lesser
t
##ro
##chan
##ter
to
above
the
su
##pra
##con
##dy
##lar
flare
and
are
transverse
or
short
oblique
in
orientation
without
evidence
[SEP]
[CLS]
of
com
##min
##ution
.
[SEP]
[CLS]
End
##oc
##ard
##itis
was
also
reported
more
frequently
in
Pro
##lia
-
treated
patients
.
[SEP]
[CLS]
Red
##uction
##s
in
im
##mu
##nos
##up
##press
##ion
should
be
considered
for
patients
who
develop
evidence
of
P
##VA
##N
.
[SEP]
[CLS]
As
##ses
##s
c
##rea
##tin
##ine
clearance
(
C
##L
##c
##r
)
,
urine
glucose
and
urine
protein
before
in
##iti
##ating
treatment
with
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
Ren
##al
and
U
##rina
##ry
Di
##sor
##ders
:
Ren
##al
imp
##air
##ment
.
[SEP]
[CLS]
The
most
frequent
infections
(
>
5
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
)
were
upper
respiratory
tract
infection
,
u
##rina
##ry
tract
infection
,
na
##so
##pha
##ryn
##git
##is
,
sin
##us
##itis
,
br
##on
##chi
##tis
,
and
[SEP]
[CLS]
in
##fluenza
.
[SEP]
[CLS]
Ad
##vise
patients
not
to
drive
or
operate
heavy
machinery
until
they
know
how
To
##via
##z
affects
them
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
sa
##no
##fi
-
a
##vent
##is
U
.
S
.
LLC
at
1
-
800
-
63
##3
-
161
##0
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
During
the
12
-
week
,
controlled
study
in
patients
with
P
##H
##N
,
so
##m
##no
##len
##ce
was
reported
in
10
%
of
patients
treated
with
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
8
[SEP]
[CLS]
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
The
incidence
of
dry
mouth
was
higher
in
those
taking
8
mg
/
day
(
35
%
)
and
in
those
taking
4
mg
/
day
(
19
%
)
,
as
compared
to
[SEP]
[CLS]
place
##bo
(
7
%
)
.
[SEP]
[CLS]
(
5
.
1
)
*
Pat
##ients
recently
exposed
to
op
##io
##ids
are
expected
to
be
more
sensitive
to
the
effects
of
E
##NT
##ER
##EG
and
therefore
may
experience
abdominal
pain
,
nausea
and
[SEP]
[CLS]
vomit
##ing
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
*
Long
-
acting
beta
##2
-
ad
##rene
##rg
##ic
ago
##nist
##s
(
LA
##BA
)
,
such
as
v
##ila
##nter
##ol
,
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
In
##iti
##ation
of
ST
##RI
##BI
##LD
in
patients
with
estimated
c
##rea
##tin
##ine
clearance
below
70
m
##L
per
minute
is
not
recommended
.
[SEP]
[CLS]
(
5
.
9
)
5
.
1
Brady
##ar
##r
##hy
##th
##mia
and
At
##rio
##vent
##ric
##ular
Block
##s
Because
of
a
risk
for
bra
##dy
##ar
##r
##hy
##th
##mia
and
at
##rio
##vent
##ric
##ular
(
A
##V
)
blocks
,
patients
should
be
monitored
during
G
##IL
##EN
##Y
##A
treatment
initiation
[
[SEP]
[CLS]
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
The
risk
appears
lower
for
patients
with
chronic
,
moderate
kidney
disease
(
G
##F
##R
30
-
59
m
##L
/
min
/
1
.
73
m
2
)
and
little
,
if
any
,
for
patients
with
[SEP]
[CLS]
chronic
,
mild
kidney
disease
(
G
##F
##R
60
-
89
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
breathing
difficulties
can
be
life
threatening
and
there
have
been
reports
of
death
.
[SEP]
[CLS]
You
and
your
healthcare
provider
should
decide
if
you
will
take
D
##U
##AV
##EE
or
breast
##fe
##ed
.
[SEP]
[CLS]
Women
of
child
##be
##aring
potential
should
be
advised
of
the
potential
hazard
to
the
f
##etus
and
to
avoid
becoming
pregnant
while
receiving
IN
##L
##Y
##TA
.
[SEP]
[CLS]
If
such
signs
or
symptoms
are
present
,
the
patient
should
be
evaluated
immediately
.
[SEP]
[CLS]
Laboratory
Test
A
##b
##nor
##mal
##ities
:
Trans
##ami
##nas
##es
:
Trans
##ient
elevations
in
serum
trans
##ami
##nas
##es
)
in
the
short
-
term
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
adult
trials
were
more
common
in
treated
patients
.
[SEP]
[CLS]
Fat
##al
c
##ere
##bro
##vas
##cular
accident
was
reported
in
1
/
35
##9
patients
(
<
1
%
)
receiving
IN
##L
##Y
##TA
and
none
of
the
patients
receiving
so
##ra
##fen
##ib
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
.
2
Ce
##re
##bro
##vas
##cular
Ad
##verse
Events
,
Including
St
##roke
,
In
Elder
##ly
Pat
##ients
with
De
##ment
##ia
-
Re
##lated
P
##sy
##cho
##sis
In
place
##bo
-
controlled
trials
with
r
##is
##per
##ido
##ne
,
a
##rip
##ip
##raz
##ole
,
and
o
##lan
##za
##pine
in
elderly
subjects
with
dem
##ent
##ia
,
[SEP]
[CLS]
there
was
a
higher
incidence
of
c
##ere
##bro
##vas
##cular
adverse
reactions
(
c
##ere
##bro
##vas
##cular
accidents
and
trans
##ient
is
##che
##mic
attacks
)
including
fatalities
compared
to
place
##bo
-
treated
subjects
.
[SEP]
[CLS]
Specifically
,
9
patients
had
a
Grade
3
or
4
p
##le
##ural
e
##ff
##usion
,
3
patients
experienced
both
Grade
3
or
Grade
4
per
##ica
##rdi
##al
e
##ff
##usions
,
1
patient
experienced
Grade
3
[SEP]
[CLS]
pulmonary
ed
##ema
,
and
1
patient
had
a
Grade
3
ed
##ema
.
[SEP]
[CLS]
(
5
.
7
)
*
Le
##uk
##ope
##nia
,
N
##eu
##tro
##pen
##ia
,
and
A
##gra
##nu
##loc
##yt
##osis
have
been
reported
with
anti
##psy
##cho
##tics
.
[SEP]
[CLS]
Grade
3
or
higher
bleeding
events
(
sub
##du
##ral
hem
##ato
##ma
,
gas
##tro
##int
##est
##inal
bleeding
,
hem
##at
##uria
and
post
pro
##cedural
hem
##or
##r
##hage
)
have
occurred
in
up
to
6
%
of
patients
.
[SEP]
[CLS]
Ser
##ious
drug
-
related
adverse
reactions
reported
in
clinical
trials
included
my
##elo
##su
##pp
##ression
,
infection
,
pneumonia
,
tumor
l
##ys
##is
syndrome
and
in
##fusion
reactions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
Decision
##s
about
whether
or
not
to
restart
T
##EC
##FI
##DE
##RA
should
be
individual
##ized
based
on
clinical
circumstances
.
[SEP]
[CLS]
A
total
of
242
(
14
.
9
%
)
patients
had
a
heart
rate
less
than
50
beats
per
minute
.
[SEP]
[CLS]
In
patients
with
abnormal
liver
tests
,
NE
##SI
##NA
should
be
initiated
with
caution
.
[SEP]
[CLS]
Of
the
1
,
83
##4
patients
,
12
%
discontinued
treatment
due
to
an
adverse
reaction
,
compared
with
3
%
of
the
1
,
116
place
##bo
-
treated
patients
.
[SEP]
[CLS]
A
##gra
##nu
##loc
##yt
##osis
(
including
fatal
cases
)
has
also
been
reported
.
[SEP]
[CLS]
Study
1
C
##NS
PT
##LD
1
1
Non
-
C
##NS
##P
##TL
##D
1
2
1
Study
2
C
##NS
PT
##LD
1
1
1
1
Non
-
C
##NS
##P
##TL
##D
1
Study
3
C
##NS
PT
##LD
2
Non
-
C
##NS
##P
##TL
##D
1
Total
(
%
[SEP]
[CLS]
)
2
(
0
.
5
)
5
(
11
.
6
)
1
(
3
.
6
)
3
(
0
.
7
)
2
(
4
.
1
)
0
0
1
(
1
.
8
)
0
E
##B
##V
Ser
##op
##os
##itive
[SEP]
[CLS]
Sub
##pop
##ulation
Among
the
80
##6
E
##B
##V
se
##rop
##os
##itive
patients
with
known
C
##M
##V
se
##ros
##tat
##us
treated
with
either
N
##U
##L
##O
##J
##IX
regime
##n
in
Studies
1
,
2
,
and
3
,
two
percent
(
2
%
[SEP]
[CLS]
;
4
/
210
)
of
C
##M
##V
se
##rone
##gat
##ive
patients
developed
PT
##LD
compared
to
0
.
2
%
(
1
/
59
##6
)
of
C
##M
##V
se
##rop
##os
##itive
patients
.
[SEP]
[CLS]
Monitor
patients
for
signs
and
symptoms
of
enter
##oc
##oli
##tis
(
such
as
di
##ar
##r
##hea
,
abdominal
pain
,
m
##uc
##us
or
blood
in
stool
,
with
or
without
fever
)
and
of
bow
##el
[SEP]
[CLS]
per
##fo
##ration
(
such
as
per
##ito
##nea
##l
signs
and
il
##eus
)
.
[SEP]
[CLS]
5
.
3
P
##ne
##um
##oni
##tis
Fat
##al
and
serious
p
##ne
##um
##oni
##tis
occurred
in
patients
treated
with
Z
##yd
##eli
##g
.
[SEP]
[CLS]
Of
the
63
patients
with
moderate
der
##mat
##itis
,
25
(
40
%
)
were
treated
with
systemic
co
##rt
##ico
##ster
##oids
(
median
of
60
mg
/
day
of
pre
##dn
##ison
##e
or
equivalent
)
for
a
[SEP]
[CLS]
median
of
2
.
1
weeks
,
7
(
11
%
)
were
treated
with
only
topic
##al
co
##rt
##ico
##ster
##oids
,
and
31
(
49
%
)
did
not
receive
systemic
or
topic
##al
co
##rt
##ico
##ster
##oids
[SEP]
[CLS]
.
[SEP]
[CLS]
Ad
##vise
patients
to
promptly
report
any
new
or
worse
##ning
abdominal
pain
,
chill
##s
,
fever
,
nausea
,
or
vomit
##ing
.
[SEP]
[CLS]
*
Q
##T
interval
pro
##long
##ation
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
Monitor
and
treat
appropriately
.
[SEP]
[CLS]
AL
##T
abnormal
##ities
occurred
more
frequently
in
he
##pa
##titis
B
and
/
or
he
##pa
##titis
C
virus
co
-
infected
subjects
for
both
treatment
groups
.
[SEP]
[CLS]
If
bleeding
per
##sist
##s
or
occurs
after
previously
regular
cycles
,
check
for
causes
such
as
pregnancy
or
ma
##li
##gna
##ncy
.
[SEP]
[CLS]
5
.
3
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
There
are
no
adequate
and
well
-
controlled
studies
of
H
##AL
##AV
##EN
in
pregnant
women
.
[SEP]
[CLS]
In
the
place
##bo
-
controlled
portions
of
Studies
1
and
2
through
Day
90
,
98
%
and
51
%
of
XI
##AF
##LE
##X
-
treated
and
place
##bo
-
treated
patients
had
an
adverse
reaction
after
up
to
[SEP]
[CLS]
3
injection
##s
,
respectively
.
[SEP]
[CLS]
If
Fe
##rri
##p
##ro
##x
is
used
during
pregnancy
or
if
the
patient
becomes
pregnant
while
taking
Fe
##rri
##p
##ro
##x
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
.
[SEP]
[CLS]
5
.
7
Pan
##cre
##ati
##tis
Pan
##cre
##ati
##tis
,
including
one
fatal
##ity
,
has
been
reported
in
less
than
1
%
of
patients
receiving
Z
##Y
##KA
##DI
##A
in
clinical
trials
.
[SEP]
[CLS]
After
excluding
patients
in
whom
exposure
to
study
drug
was
less
than
one
year
at
the
time
of
diagnosis
of
bladder
cancer
,
there
were
4
cases
with
FA
##R
##X
##IG
##A
and
[SEP]
[CLS]
no
cases
with
place
##bo
/
com
##par
##ator
.
[SEP]
[CLS]
Poole
##d
analyses
of
199
place
##bo
-
controlled
clinical
trials
(
mon
##o
-
and
ad
##junct
##ive
therapy
)
of
11
different
A
##ED
##s
showed
that
patients
random
##ized
to
one
of
the
A
##ED
##s
had
approximately
twice
the
[SEP]
[CLS]
risk
(
adjusted
relative
risk
1
.
8
,
95
%
confidence
interval
[
C
##I
]
:
1
.
2
,
2
.
7
)
of
su
##icidal
thinking
compared
to
patients
random
##ized
to
place
##bo
.
[SEP]
[CLS]
Table
1
shows
common
adverse
reactions
,
excluding
h
##y
##po
##gly
##ce
##mia
,
associated
with
the
use
of
T
##R
##U
##L
##IC
##IT
##Y
in
the
pool
of
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
5
.
5
H
##yper
##tens
##ion
CO
##ME
##TR
##I
##Q
treatment
results
in
an
increased
incidence
of
treatment
-
emerge
##nt
h
##yper
##tens
##ion
with
Joint
National
Committee
on
Prevention
,
Det
##ec
##tion
,
Evaluation
,
and
Treatment
of
High
Blood
Press
##ure
(
[SEP]
[CLS]
modified
J
##NC
criteria
)
stage
1
or
2
h
##yper
##tens
##ion
identified
in
61
%
in
CO
##ME
##TR
##I
##Q
-
treated
patients
compared
with
30
%
of
place
##bo
-
treated
patients
in
the
random
##ized
trial
.
[SEP]
[CLS]
The
impact
of
long
-
term
treatment
with
C
##IM
##Z
##IA
on
the
development
of
auto
##im
##mu
##ne
diseases
is
unknown
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
9
)
]
.
[SEP]
[CLS]
1915
05
Skin
and
sub
##cut
##aneous
tissue
disorders
Ra
##sh
##R
##ash
includes
the
following
terms
:
er
##yt
##hem
##a
,
r
##ash
,
er
##yt
##hem
##ato
##us
r
##ash
,
generalized
r
##ash
,
mac
##ular
r
##ash
,
mac
##ulo
-
p
##ap
##ular
r
##ash
,
[SEP]
[CLS]
p
##ap
##ular
r
##ash
,
and
ve
##si
##cular
r
##ash
.
[SEP]
[CLS]
Whenever
clinical
judgment
di
##ct
##ates
,
the
patient
should
be
examined
with
the
aid
of
ma
##gni
##fication
,
such
as
slit
-
lamp
bio
##mic
##ros
##copy
,
and
,
where
appropriate
,
flu
##ores
##ce
##in
stain
##ing
.
[SEP]
[CLS]
The
incidence
of
infections
(
60
%
vs
58
%
)
and
serious
infections
(
2
%
vs
2
%
)
was
similar
in
patients
treated
with
T
##EC
##FI
##DE
##RA
or
place
##bo
[SEP]
[CLS]
,
respectively
.
[SEP]
[CLS]
Three
of
these
4
adverse
reactions
were
described
as
a
h
##yper
##tensive
crisis
and
were
managed
with
oral
medications
and
resolved
.
[SEP]
[CLS]
5
.
6
Q
##T
Inter
##val
Effect
A
study
of
cardiac
conduct
##ion
showed
that
P
##OT
##IG
##A
produced
a
mean
7
.
7
-
m
##se
##c
Q
##T
pro
##long
##ation
in
healthy
volunteers
t
##it
##rated
to
400
mg
3
times
daily
.
[SEP]
[CLS]
The
im
##bal
##ance
in
deaths
is
une
##x
##plain
##ed
.
[SEP]
[CLS]
Disco
##ntin
##ue
S
##IR
##TU
##RO
if
:
*
amino
##tra
##ns
##fer
##ase
elevations
are
accompanied
by
total
bi
##li
##ru
##bin
elevation
greater
than
two
times
the
upper
limit
of
normal
*
amino
##tra
##ns
##fer
##ase
elevations
are
greater
than
eight
times
[SEP]
[CLS]
the
upper
limit
of
normal
*
amino
##tra
##ns
##fer
##ase
elevations
are
greater
than
five
times
the
upper
limit
of
normal
and
per
##sist
beyond
two
weeks
5
.
4
Drug
Inter
##actions
C
##YP
##3
##A
##4
induce
##rs
/
inhibitor
##s
Bed
##aq
##uil
##ine
is
[SEP]
[CLS]
meta
##bol
##ized
by
C
##YP
##3
##A
##4
and
its
systemic
exposure
and
therapeutic
effect
may
therefore
be
reduced
during
co
-
administration
with
induce
##rs
of
C
##YP
##3
##A
##4
.
[SEP]
[CLS]
New
Mali
##gna
##ncies
New
ma
##li
##gna
##ncies
were
reported
in
no
patients
in
the
place
##bo
group
and
4
(
3
.
3
%
)
patients
(
3
pro
##state
cancer
##s
,
1
basal
cell
car
##cin
##oma
)
[SEP]
[CLS]
in
the
Pro
##lia
group
.
[SEP]
[CLS]
5
.
4
Pat
##ients
with
Pro
##st
##hetic
Heart
Val
##ves
The
safety
and
efficacy
of
E
##L
##I
##Q
##UI
##S
have
not
been
studied
in
patients
with
pro
##st
##hetic
heart
valves
.
[SEP]
[CLS]
Most
events
(
95
%
)
were
Grade
1
or
Grade
2
in
severity
.
[SEP]
[CLS]
For
patients
receiving
hem
##od
##ial
##ys
##is
,
physicians
may
consider
the
pro
##mpt
initiation
of
hem
##od
##ial
##ys
##is
following
the
administration
of
a
GB
##CA
in
order
to
enhance
the
contrast
agent
'
s
elimination
.
[SEP]
[CLS]
Features
of
acute
kidney
injury
consist
of
rapid
(
over
hours
to
days
)
and
usually
re
##versible
decrease
in
kidney
function
,
commonly
in
the
setting
of
surgery
,
severe
[SEP]
[CLS]
infection
,
injury
or
drug
-
induced
kidney
toxicity
.
[SEP]
[CLS]
After
resolution
,
treatment
with
ER
##WI
##NA
##Z
##E
may
be
resumed
.
[SEP]
[CLS]
En
##sure
that
appropriate
medical
support
measures
,
including
card
##io
##pu
##lm
##ona
##ry
re
##sus
##citation
equipment
,
are
readily
available
.
[SEP]
[CLS]
5
.
2
Ra
##diation
Risk
Amy
##vid
,
similar
to
other
radio
##pha
##rma
##ce
##utical
##s
,
contributes
to
a
patient
'
s
overall
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
(
5
.
4
)
*
Not
recommended
in
patients
with
end
-
stage
re
##nal
disease
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
for
severe
and
prolonged
cut
##aneous
reactions
.
[SEP]
[CLS]
For
more
information
,
ask
your
healthcare
provider
or
p
##har
##ma
##cist
.
[SEP]
[CLS]
program
may
use
E
##NT
##ER
##EG
.
[SEP]
[CLS]
He
##pa
##to
##bil
##iary
Di
##sor
##ders
:
He
##pa
##titis
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
,
including
serious
reactions
,
has
occurred
in
patients
who
have
previously
tolerate
##d
in
##fusion
##s
of
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
P
##sy
##chia
##tric
Di
##sor
##ders
N
##er
##vous
##ness
.
[SEP]
[CLS]
These
women
should
have
their
thy
##roid
function
monitored
in
order
to
maintain
their
free
thy
##roid
hormone
levels
in
an
acceptable
range
.
[SEP]
[CLS]
Con
##tin
##ue
h
##yd
##ration
and
al
##kal
##ini
##zation
of
the
urine
as
indicated
.
[SEP]
[CLS]
5
.
5
Ren
##al
F
##ail
##ure
Case
##s
of
re
##nal
failure
(
including
acute
re
##nal
failure
)
,
some
with
a
fatal
outcome
,
have
been
observed
in
patients
treated
with
A
##FI
##NI
##TO
##R
[
see
[SEP]
[CLS]
Laboratory
Tests
and
Monitor
##ing
(
5
.
8
)
]
.
[SEP]
[CLS]
Other
fatal
adverse
reactions
in
J
##E
##V
##TA
##NA
-
treated
patients
included
vent
##ric
##ular
fi
##bri
##lla
##tion
,
cerebral
hem
##or
##r
##hage
,
and
d
##ys
##p
##nea
.
[SEP]
[CLS]
U
##TI
##s
in
AM
##P
##Y
##RA
-
treated
patients
should
be
evaluated
and
treated
as
clinical
##ly
indicated
.
[SEP]
[CLS]
The
following
have
been
observed
with
B
##EN
##L
##Y
##ST
##A
and
are
discussed
in
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
:
*
Mortal
##ity
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
[SEP]
[CLS]
*
Ser
##ious
In
##fect
##ions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
Mali
##gna
##ncy
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
,
including
Ana
##phy
##lax
##is
[
[SEP]
[CLS]
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
In
##fusion
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
*
Depression
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
[SEP]
[CLS]
]
E
##X
##CE
##RP
##T
:
Common
adverse
reactions
(
>
=
5
%
)
in
clinical
trials
were
:
nausea
,
di
##ar
##r
##hea
,
p
##yre
##xia
,
na
##so
##pha
##ryn
##git
##is
,
br
##on
##chi
##tis
,
ins
##om
##nia
,
[SEP]
[CLS]
pain
in
ex
##tre
##mity
,
depression
,
mi
##gra
##ine
,
and
p
##har
##yn
##git
##is
.
[SEP]
[CLS]
Consider
the
benefit
-
risk
profile
in
such
patients
before
treating
with
Pro
##lia
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
is
discussed
in
more
detail
in
other
sections
of
the
label
##ing
:
*
Se
##iz
##ure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
E
##X
##CE
##RP
##T
:
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
10
%
)
are
as
##the
##nia
/
fatigue
,
back
pain
,
decreased
appetite
,
con
##st
##ip
##ation
,
art
##hra
##l
##gia
,
di
##ar
##r
##hea
,
hot
flush
,
[SEP]
[CLS]
upper
respiratory
tract
infection
,
peripheral
ed
##ema
,
d
##ys
##p
##nea
,
m
##us
##cu
##los
##kel
##etal
pain
,
weight
decreased
,
headache
,
h
##yper
##tens
##ion
,
and
di
##zzi
##ness
/
ve
##rt
##igo
.
[SEP]
[CLS]
The
median
number
of
treatment
cycles
in
each
study
arm
was
15
(
range
,
1
-
16
)
and
80
patients
(
48
%
)
in
the
AD
##CE
##TR
##IS
-
treatment
arm
received
16
[SEP]
[CLS]
cycles
[
see
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
Monitor
patients
for
new
ma
##li
##gna
##ncies
prior
to
initiation
of
therapy
,
while
on
therapy
,
and
following
disco
##ntin
##uation
of
T
##AF
##IN
##LA
##R
or
the
combination
therapy
.
[SEP]
[CLS]
Card
##iac
:
New
or
worse
##ning
heart
failure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
At
##rial
flutter
has
been
reported
very
rarely
.
[SEP]
[CLS]
In
clinical
studies
,
the
majority
of
patients
developed
I
##g
##G
antibodies
to
al
##g
##lu
##cos
##idas
##e
al
##fa
,
typically
within
3
months
of
treatment
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
(
>
=
10
%
)
from
One
Open
-
label
Trial
in
Adults
with
Se
##vere
A
##p
##lastic
An
##emia
Ad
##verse
Re
##action
PR
##OM
##AC
##TA
(
n
=
43
)
(
%
)
Na
##use
##a
33
[SEP]
[CLS]
Fat
##ig
##ue
28
Co
##ugh
23
Di
##ar
##r
##hea
21
Head
##ache
21
Pain
in
ex
##tre
##mity
19
D
##ys
##p
##nea
14
P
##yre
##xia
14
Di
##zzi
##ness
14
Oro
##pha
##ryn
##ge
##al
pain
14
Feb
##ril
##e
ne
##ut
##rop
##enia
14
Abd
##omi
##nal
pain
12
E
##cc
##hy
##mos
##is
12
[SEP]
[CLS]
Mu
##s
##cle
spa
##sm
##s
12
Trans
##ami
##nas
##es
increased
12
Art
##hra
##l
##gia
12
R
##hino
##rr
##hea
12
In
this
trial
,
patients
had
bone
ma
##rrow
as
##pi
##rates
evaluated
for
c
##yt
##ogen
##etic
abnormal
##ities
.
[SEP]
[CLS]
Because
of
the
risk
of
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
with
SA
##P
##H
##RI
##S
,
caution
should
be
observed
in
cardiac
patients
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
.
[SEP]
[CLS]
PR
##OM
##AC
##TA
was
administered
to
27
##7
patients
for
at
least
6
months
and
202
patients
for
at
least
1
year
.
[SEP]
[CLS]
If
an
##emia
develops
during
or
after
therapy
,
a
diagnostic
work
##up
for
drug
-
induced
hem
##oly
##tic
an
##emia
should
be
performed
and
consideration
given
to
disco
##ntin
##uation
of
Te
##f
##lar
##o
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
by
these
patients
who
received
the
additional
30
mg
sub
##cut
##aneous
dose
of
K
##AL
##BI
##TO
##R
were
consistent
with
those
reported
in
the
patients
receiving
a
single
dose
.
[SEP]
[CLS]
Ser
##ious
f
##eb
##ril
##e
reactions
and
fever
of
any
severity
complicated
by
h
##y
##pot
##ens
##ion
,
rig
##ors
or
chill
##s
occurred
in
25
%
(
14
/
55
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
[SEP]
[CLS]
tram
##eti
##ni
##b
compared
with
2
%
(
1
/
53
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
G
##IL
##EN
##Y
##A
should
be
discontinued
if
significant
liver
injury
is
confirmed
.
[SEP]
[CLS]
C
##aus
##ality
has
not
been
established
as
these
fracture
##s
also
occur
in
o
##ste
##op
##oro
##tic
patients
who
have
not
been
treated
with
anti
-
re
##sor
##pt
##ive
agents
.
[SEP]
[CLS]
In
clinical
trials
,
IL
##AR
##IS
has
not
been
administered
con
##com
##ita
##ntly
with
tumor
ne
##c
##rosis
factor
(
T
##NF
)
inhibitor
##s
.
[SEP]
[CLS]
The
second
most
commonly
reported
adverse
event
was
con
##st
##ip
##ation
.
[SEP]
[CLS]
Disco
##ntin
##ue
IN
##L
##Y
##TA
in
patients
developing
R
##PL
##S
.
[SEP]
[CLS]
Do
##se
reduction
##s
due
to
adverse
reactions
were
required
in
57
%
of
G
##IL
##OT
##RI
##F
-
treated
patients
.
[SEP]
[CLS]
A
##vo
##id
administer
##ing
ST
##RI
##BI
##LD
with
concurrent
or
recent
use
of
ne
##ph
##rot
##ox
##ic
drugs
.
[SEP]
[CLS]
Only
hospitals
that
have
enrolled
in
and
met
all
of
the
requirements
for
the
E
.
A
.
S
.
E
.
[SEP]
[CLS]
5
.
5
I
##mm
##une
-
mediated
End
##oc
##rino
##path
##ies
In
Study
1
,
severe
to
life
-
threatening
immune
-
mediated
end
##oc
##rino
##path
##ies
(
requiring
hospital
##ization
,
urgent
medical
intervention
,
or
interfering
with
activities
of
daily
living
;
Grade
3
-
4
[SEP]
[CLS]
)
occurred
in
9
(
1
.
8
%
)
Y
##ER
##VO
##Y
-
treated
patients
.
[SEP]
[CLS]
H
##yper
##tensive
crisis
was
reported
in
2
/
35
##9
patients
(
<
1
%
)
receiving
IN
##L
##Y
##TA
and
none
of
the
patients
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Before
you
take
D
##U
##AV
##EE
,
tell
your
healthcare
provider
if
you
:
*
have
any
unusual
v
##agi
##nal
bleeding
.
[SEP]
[CLS]
In
the
case
of
persistent
h
##yper
##tens
##ion
despite
use
of
anti
-
h
##yper
##tensive
medications
,
reduce
the
IN
##L
##Y
##TA
dose
.
[SEP]
[CLS]
5
.
3
G
##lu
##cos
##e
Into
##ler
##ance
G
##lu
##cos
##e
into
##ler
##ance
has
been
reported
in
5
%
of
patients
receiving
ER
##WI
##NA
##Z
##E
in
clinical
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
##I
##nc
##lude
##s
the
preferred
terms
h
##yper
##ins
##ulin
##emia
and
blood
insulin
increased
.
[SEP]
[CLS]
Ren
##al
replacement
therapy
was
not
required
for
these
subjects
.
[SEP]
[CLS]
(
5
.
4
)
*
Inc
##reased
risk
of
pneumonia
in
patients
with
CO
##PD
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
reported
during
post
-
approval
use
with
X
##E
##OM
##IN
.
[SEP]
[CLS]
For
patients
at
highest
risk
for
N
##SF
,
do
not
exceed
the
recommended
D
##OT
##AR
##EM
dose
and
allow
a
sufficient
period
of
time
for
elimination
of
the
drug
prior
to
re
-
administration
[SEP]
[CLS]
.
[SEP]
[CLS]
Clinical
##ly
notable
decreases
in
serum
potassium
or
changes
in
blood
glucose
were
in
##f
##re
##quent
during
clinical
studies
with
long
-
term
administration
of
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
with
the
rates
similar
to
those
for
place
##bo
[SEP]
[CLS]
controls
.
[SEP]
[CLS]
(
5
.
4
)
*
dispatch
:
unexpected
key
:
list
in
dispatch
table
:
{
'
cap
##tion
'
:
<
function
print
_
cap
##tion
at
0
##x
##1
##c
##6
##c
##8
##c
##0
>
,
'
text
'
:
<
function
[SEP]
[CLS]
print
_
text
at
0
##x
##1
##c
##6
##c
##500
>
}
Met
##ab
##olic
Changes
:
At
##y
##pical
anti
##psy
##cho
##tic
drugs
have
been
associated
with
metabolic
changes
that
may
increase
c
##ere
##bro
##vas
##cular
risk
.
[SEP]
[CLS]
With
##hold
,
dose
reduce
,
or
disco
##ntin
##ue
B
##OS
##U
##L
##IF
as
necessary
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
For
those
patients
continued
on
P
##OT
##IG
##A
,
di
##zzi
##ness
and
so
##m
##no
##len
##ce
appeared
to
dim
##ini
##sh
with
continued
use
.
[SEP]
[CLS]
Con
##current
h
##y
##po
##ch
##lore
##mia
was
also
present
in
patients
with
h
##y
##po
##nat
##rem
##ia
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
leading
to
study
withdrawal
for
patients
receiving
T
##RE
##AN
##DA
were
h
##yper
##sen
##si
##ti
##vity
(
2
%
)
and
p
##yre
##xia
(
1
%
)
.
[SEP]
[CLS]
It
is
unknown
whether
patients
with
a
history
of
pan
##cre
##ati
##tis
are
at
increased
risk
for
the
development
of
pan
##cre
##ati
##tis
while
using
NE
##SI
##NA
.
[SEP]
[CLS]
There
was
no
increased
incidence
of
serious
infections
observed
in
patients
with
l
##ymph
##oc
##yte
counts
<
0
.
8
##x
##10
9
/
L
or
0
.
5
##x
##10
9
/
L
in
controlled
trials
,
although
one
patient
in
[SEP]
[CLS]
an
extension
study
developed
PM
##L
in
the
setting
of
prolonged
l
##ymph
##ope
##nia
(
l
##ymph
##oc
##yte
counts
predominantly
<
0
.
5
##x
##10
9
/
L
for
3
.
5
years
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
Three
percent
(
3
%
)
of
patients
discontinued
T
##EC
##FI
##DE
##RA
for
flush
##ing
and
<
1
%
had
serious
flush
##ing
symptoms
that
were
not
life
-
threatening
but
led
to
hospital
##ization
.
[SEP]
[CLS]
The
adverse
reactions
occurring
in
at
least
5
%
of
the
NHL
patients
,
regardless
of
severity
,
are
shown
in
Table
3
.
[SEP]
[CLS]
Re
##mo
##ve
contact
lenses
prior
to
ins
##til
##lation
of
D
##UR
##E
##Z
##OL
.
[SEP]
[CLS]
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
(
e
.
g
.
,
an
##gio
##ede
##ma
,
u
##rt
##ica
##ria
,
h
##yper
##sen
##si
##ti
##vity
)
were
reported
with
FA
##R
##X
##IG
##A
treatment
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
Because
clinical
studies
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
studies
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
the
rates
in
the
clinical
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Two
of
the
5
cases
presented
with
C
##NS
involvement
.
[SEP]
[CLS]
A
total
of
35
%
were
Hispanic
or
Latino
.
[SEP]
[CLS]
Additional
testing
may
include
flu
##ores
##ce
##in
an
##gio
##gram
##s
(
FA
)
,
optical
co
##herence
to
##mo
##graphy
(
O
##CT
)
,
per
##ime
##try
,
and
electro
##ret
##ino
##gram
##s
(
ER
##G
)
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Per
##form
an
evaluation
for
R
##PL
##S
in
any
patient
presenting
with
seizure
##s
,
headache
,
visual
disturbance
##s
,
confusion
or
altered
mental
function
.
[SEP]
[CLS]
Therefore
,
XI
##AF
##LE
##X
should
be
injected
only
into
the
P
##ey
##ron
##ie
'
s
plaque
and
care
should
be
taken
to
avoid
in
##ject
##ing
into
the
u
##ret
##hra
,
nerves
,
blood
vessels
,
co
##rp
##ora
[SEP]
[CLS]
cavern
##osa
or
other
co
##lla
##gen
-
containing
structures
of
the
penis
.
[SEP]
[CLS]
Both
G
##RA
##NI
##X
and
the
non
-
US
-
approved
fi
##l
##gra
##st
##im
product
were
administered
at
5
m
##c
##g
/
kg
sub
##cut
##aneous
##ly
once
daily
beginning
one
day
after
ch
##em
##otherapy
for
at
least
five
days
and
continued
to
a
maximum
[SEP]
[CLS]
of
14
days
or
until
an
AN
##C
of
>
=
10
,
000
x
10
6
/
L
after
na
##dir
was
reached
.
[SEP]
[CLS]
6
.
2
Clinical
Trials
Experience
:
P
##ediatric
Sub
##jects
(
6
years
to
less
than
18
years
of
age
)
The
safety
assessment
in
children
and
adolescent
##s
is
based
on
the
Week
[SEP]
[CLS]
24
analysis
of
the
single
-
arm
,
Phase
2
trial
T
##MC
##12
##5
-
C
##21
##3
in
which
101
anti
##ret
##rov
##ira
##l
treatment
-
experienced
HIV
-
1
infected
subjects
6
years
to
less
than
18
years
of
age
and
weighing
at
[SEP]
[CLS]
least
16
kg
received
IN
##TE
##LE
##NC
##E
(
r
)
in
combination
with
other
anti
##ret
##rov
##ira
##l
agents
[
see
Clinical
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
Treatment
disco
##ntin
##uation
due
to
liver
enzyme
increases
occurred
in
1
%
of
patients
taking
Z
##Y
##TI
##GA
.
[SEP]
[CLS]
With
##hold
Y
##ER
##VO
##Y
in
patients
with
Grade
2
he
##pa
##to
##to
##xi
##city
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##yper
##sen
##si
##ti
##vity
reactions
have
followed
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
Physicians
should
remain
v
##igi
##lant
for
the
possible
development
of
pneumonia
in
patients
with
CO
##PD
as
the
clinical
features
of
such
infections
overlap
with
the
symptoms
of
CO
##PD
ex
##ace
##rb
##ations
.
[SEP]
[CLS]
*
Per
##ip
##her
##al
ne
##uro
##pathy
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Twenty
-
two
percent
(
109
/
50
##3
)
of
patients
developed
a
new
or
worse
##ning
ne
##uro
##pathy
that
had
not
recovered
within
a
median
follow
-
up
duration
of
26
##9
days
(
range
25
-
66
##2
days
)
[SEP]
[CLS]
.
[SEP]
[CLS]
(
5
.
16
)
5
.
1
As
##th
##ma
-
Re
##lated
Death
LA
##BA
,
such
as
v
##ila
##nter
##ol
,
one
of
the
active
ingredients
in
BR
##E
##O
E
##LL
##IP
##TA
,
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
No
apparent
correlation
of
anti
##body
development
to
adverse
events
or
efficacy
was
observed
.
[SEP]
[CLS]
Healthcare
providers
should
be
prepared
to
address
severe
all
##ergic
reactions
following
XI
##AF
##LE
##X
injection
##s
.
[SEP]
[CLS]
Sign
##s
or
symptoms
that
may
reflect
serious
injury
to
the
penis
should
be
promptly
evaluated
in
order
to
assess
for
co
##rp
##oral
r
##up
##ture
or
severe
pen
##ile
hem
##ato
##ma
,
which
may
require
[SEP]
[CLS]
surgical
intervention
.
[SEP]
[CLS]
One
of
the
1
,
56
##4
C
##ro
##hn
'
s
disease
patients
treated
with
C
##IM
##Z
##IA
developed
symptoms
of
a
l
##up
##us
-
like
syndrome
.
[SEP]
[CLS]
Place
##ment
or
removal
of
an
e
##pid
##ural
cat
##he
##ter
or
l
##umba
##r
pu
##nc
##ture
is
best
performed
when
the
anti
##coa
##gu
##lant
effect
of
da
##bi
##gat
##ran
is
low
;
however
,
the
exact
timing
to
reach
a
[SEP]
[CLS]
sufficiently
low
anti
##coa
##gu
##lant
effect
in
each
patient
is
not
known
.
[SEP]
[CLS]
There
are
insufficient
data
to
support
meaningful
analyses
of
adverse
reactions
by
age
or
race
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
b
##lina
##tum
##oma
##b
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
Two
fatal
cases
of
progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
have
been
reported
among
109
##6
patients
treated
with
a
N
##U
##L
##O
##J
##IX
-
containing
regime
##n
:
one
patient
in
clinical
trials
[SEP]
[CLS]
of
kidney
transplant
(
Studies
1
,
2
,
and
3
described
above
)
and
one
patient
in
a
trial
of
liver
transplant
(
trial
of
250
patients
)
.
[SEP]
[CLS]
Other
common
adverse
reactions
occurring
in
greater
than
1
%
of
patients
included
p
##yre
##xia
,
trans
##ami
##nas
##e
increase
,
di
##zzi
##ness
,
and
r
##ash
.
[SEP]
[CLS]
These
reactions
include
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
and
severe
cut
##aneous
adverse
reactions
,
including
Stevens
-
Johnson
syndrome
.
[SEP]
[CLS]
Clinical
##ly
significant
card
##iovascular
effects
and
fatalities
have
been
reported
in
association
with
excessive
use
of
inhaled
s
##ym
##path
##omi
##met
##ic
drugs
.
[SEP]
[CLS]
Su
##mma
##ry
of
Treatment
-
Em
##er
##gent
Laboratory
A
##b
##nor
##mal
##ities
with
Grade
3
or
4
Inc
##iden
##ce
of
>
=
4
%
in
X
##AL
##KO
##RI
-
T
##reate
##d
Pat
##ients
in
Study
2
Laboratory
A
##b
##nor
##mal
##ity
X
##AL
##KO
##RI
Ch
##em
##otherapy
Any
Grade
(
%
)
[SEP]
[CLS]
Grade
3
/
4
(
%
)
Any
Grade
(
%
)
Grade
3
/
4
(
%
)
He
##mat
##ology
N
##eu
##tro
##pen
##ia
49
12
28
12
L
##ymph
##ope
##nia
51
9
60
25
Chemistry
AL
##T
elevation
76
[SEP]
[CLS]
17
38
4
AS
##T
elevation
61
9
33
0
H
##y
##po
##kal
##emia
18
4
10
1
H
##y
##pop
##hos
##phate
##mia
28
5
25
6
Des
##cription
of
Selected
Ad
##verse
Drug
Re
##actions
Vision
disorders
Vision
disorders
,
[SEP]
[CLS]
most
commonly
visual
imp
##air
##ment
,
photo
##ps
##ia
,
blurred
vision
,
or
v
##it
##re
##ous
float
##ers
,
occurred
in
103
##8
(
62
%
)
of
166
##9
patients
.
[SEP]
[CLS]
5
.
7
S
##witch
##ing
Between
Biological
Disease
Mo
##di
##fying
Anti
##r
##he
##umatic
Drugs
(
D
##MA
##RD
##s
)
Care
should
be
taken
when
switching
from
one
bio
##log
##ic
product
to
another
bio
##log
##ic
product
since
overlapping
biological
activity
may
[SEP]
[CLS]
further
increase
the
risk
of
infection
.
[SEP]
[CLS]
*
Na
##use
##a
*
Mu
##s
##cle
spa
##sm
##s
*
Ra
##sh
*
P
##ru
##rit
##us
*
Ang
##io
##ede
##ma
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
F
##ET
##AL
TO
##X
##IC
##IT
##Y
WA
##R
##NI
##NG
:
F
##ET
##AL
TO
##X
##IC
##IT
##Y
*
When
pregnancy
is
detected
,
disco
##ntin
##ue
Ed
##ar
##bi
[SEP]
[CLS]
as
soon
as
possible
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
In
the
safety
population
in
controlled
studies
,
a
total
of
620
patients
with
C
##ro
##hn
'
s
disease
received
C
##IM
##Z
##IA
at
a
dose
of
400
mg
,
and
61
##4
subjects
received
[SEP]
[CLS]
place
##bo
(
including
subjects
random
##ized
to
place
##bo
in
Study
CD
##2
following
open
label
dos
##ing
of
C
##IM
##Z
##IA
at
Weeks
0
,
2
,
4
)
.
[SEP]
[CLS]
ST
##RI
##BI
##LD
should
be
avoided
with
concurrent
or
recent
use
of
a
ne
##ph
##rot
##ox
##ic
agent
.
[SEP]
[CLS]
Ad
##verse
reactions
of
any
cause
occurred
in
48
%
of
the
D
##Y
##SP
##OR
##T
(
r
)
-
treated
patients
and
33
%
of
the
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
in
X
##E
##OM
##IN
treated
subjects
were
:
headache
29
(
5
.
4
%
)
,
facial
par
##esis
4
(
0
.
7
%
)
,
injection
site
hem
##ato
##ma
3
[SEP]
[CLS]
(
0
.
6
%
)
and
eye
##lid
ed
##ema
2
(
0
.
4
%
)
.
[SEP]
[CLS]
5
.
7
Tu
##mor
##ige
##nic
Po
##ten
##tial
In
an
oral
car
##cin
##ogenic
##ity
study
,
g
##aba
##pent
##in
en
##aca
##rb
##il
increased
the
incidence
of
pan
##cre
##atic
a
##cin
##ar
cell
ad
##eno
##ma
in
male
and
female
rats
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
Unless
an
alternate
et
##iology
has
been
identified
,
signs
or
symptoms
of
der
##mat
##itis
should
be
considered
immune
-
mediated
.
[SEP]
[CLS]
The
clinical
relevance
of
this
finding
is
unknown
.
[SEP]
[CLS]
5
.
2
Pat
##ients
Co
##in
##fected
with
HIV
-
1
and
H
##B
##V
It
is
recommended
that
all
patients
with
HIV
-
1
be
tested
for
the
presence
of
chronic
he
##pa
##titis
B
virus
(
H
##B
##V
)
before
in
##iti
##ating
[SEP]
[CLS]
anti
##ret
##rov
##ira
##l
therapy
.
[SEP]
[CLS]
The
most
common
Grade
3
/
4
laboratory
abnormal
##ities
(
incidence
>
=
3
%
)
were
l
##ymph
##ope
##nia
,
h
##yper
##gly
##ce
##mia
,
an
##emia
,
decreased
potassium
,
increased
AS
##T
,
increased
AL
##T
,
[SEP]
[CLS]
and
th
##rom
##bo
##cy
##top
##enia
.
[SEP]
[CLS]
5
.
8
W
##ou
##nd
He
##aling
Co
##mp
##lication
##s
No
formal
studies
of
the
effect
of
IN
##L
##Y
##TA
on
wound
healing
have
been
conducted
.
[SEP]
[CLS]
In
the
remaining
patients
,
symptoms
resolved
within
4
to
5
weeks
.
[SEP]
[CLS]
Mi
##ld
to
severe
h
##yper
##tens
##ion
may
be
present
.
[SEP]
[CLS]
In
##iti
##ate
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
1
to
2
mg
/
kg
/
day
of
pre
##dn
##ison
##e
or
equivalent
,
and
initiate
appropriate
hormone
replacement
therapy
.
[SEP]
[CLS]
In
a
multi
##cent
##er
,
open
-
label
trial
(
FL
##AM
##ING
##O
)
,
243
subjects
received
T
##I
##VI
##CA
##Y
50
mg
once
daily
versus
242
subjects
who
received
da
##run
##avi
##r
800
mg
/
r
##ito
##na
##vir
100
mg
once
daily
[SEP]
[CLS]
,
both
in
combination
with
investigator
-
selected
N
##RT
##I
background
regime
##n
(
either
EP
##Z
##IC
##OM
or
T
##R
##U
##VA
##DA
)
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
K
##AL
##BI
##TO
##R
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
5
.
10
H
##y
##pot
##hy
##roid
##ism
E
##stro
##gen
administration
leads
to
increased
thy
##roid
-
binding
g
##lo
##bul
##in
(
T
##B
##G
)
levels
.
[SEP]
[CLS]
Disco
##ntin
##ue
treatment
with
IL
##AR
##IS
if
a
patient
develops
a
serious
infection
.
[SEP]
[CLS]
The
safety
of
re
##suming
T
##NF
block
##er
therapy
after
H
##B
##V
react
##ivation
is
controlled
is
not
known
.
[SEP]
[CLS]
In
AR
##IS
##TO
##TL
##E
,
the
mean
duration
of
exposure
was
89
weeks
(
>
15
,
000
patient
-
years
)
.
[SEP]
[CLS]
He
##mo
##g
##lo
##bin
Dec
##rease
##s
in
hem
##og
##lo
##bin
may
require
a
decrease
in
dos
##age
or
disco
##ntin
##uation
of
rib
##avi
##rin
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
and
Clinical
Studies
(
14
)
]
[
[SEP]
[CLS]
see
pre
##s
##cribing
information
for
rib
##avi
##rin
]
.
[SEP]
[CLS]
Neo
##p
##las
##m
Ben
##ign
and
Mali
##gnant
:
Mel
##ano
##ma
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
I
##mm
##une
System
Di
##sor
##ders
:
Ser
##ious
systemic
h
##yper
##sen
##si
##ti
##vity
reactions
(
including
an
##aph
##yla
##ctic
reaction
)
[
see
[SEP]
[CLS]
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
10
)
]
,
sa
##rc
##oid
##osis
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
and
media
##st
##inal
disorders
:
Inter
##st
##iti
##al
lung
disease
Skin
and
sub
##cut
##aneous
tissue
disorders
:
Skin
ex
##folia
##tion
,
[SEP]
[CLS]
bull
##ous
skin
reactions
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
AND
MA
##L
##IG
##NA
##NC
##Y
WA
##R
##NI
##NG
:
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
AND
MA
##L
##IG
##NA
##NC
##Y
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
AND
MA
##L
##IG
##NA
##NC
##Y
See
full
pre
##s
##cribing
information
[SEP]
[CLS]
for
complete
box
##ed
warning
.
[SEP]
[CLS]
5
.
3
H
##yper
##sen
##si
##ti
##vity
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
with
IL
##AR
##IS
therapy
.
[SEP]
[CLS]
There
are
currently
no
marketed
tests
for
antibodies
against
al
##g
##lu
##cos
##idas
##e
al
##fa
;
however
,
a
testing
service
is
provided
by
Gen
##zy
##me
.
[SEP]
[CLS]
If
E
##O
##VI
##ST
is
used
in
these
patients
,
complete
MR
##I
no
later
than
60
minutes
after
E
##O
##VI
##ST
administration
and
use
a
paired
non
-
contrast
and
contrast
MR
##I
set
for
diagnosis
.
[SEP]
[CLS]
5
.
3
Heart
F
##ail
##ure
Case
##s
of
worse
##ning
con
##ges
##tive
heart
failure
)
and
new
onset
CH
##F
have
been
reported
with
T
##NF
block
##ers
,
including
C
##IM
##Z
##IA
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
event
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
any
other
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
5
.
3
Ra
##diation
Risk
V
##iza
##my
##l
,
similar
to
other
radio
##pha
##rma
##ce
##utical
##s
,
contributes
to
a
patient
'
s
overall
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
C
##ubi
##st
Ph
##arma
##ce
##utical
##s
at
1
-
87
##7
-
C
##U
##BI
##ST
-
6
(
1
-
87
##7
-
28
##2
-
47
##86
)
or
FDA
at
(
1
-
800
-
FDA
-
108
##8
)
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
In
##fect
##ions
Ser
##ious
infections
observed
in
S
##IM
##PO
##NI
ARIA
-
treated
patients
included
se
##psis
,
pneumonia
,
cell
##uli
##tis
,
a
##bs
##cess
,
op
##port
##uni
##stic
infections
,
tuberculosis
(
T
##B
)
,
and
invasive
fun
##gal
infections
.
[SEP]
[CLS]
(
14
.
3
)
M
##U
##LT
##A
##Q
is
con
##tra
##ind
##ica
##ted
in
patients
with
s
##ym
##pt
##oma
##tic
heart
failure
with
recent
de
##com
##pen
##sation
requiring
hospital
##ization
or
NY
##HA
Class
IV
heart
failure
.
[SEP]
[CLS]
*
Ad
##mini
##ster
E
##O
##VI
##ST
only
in
situations
where
trained
personnel
and
the
##rap
##ies
are
promptly
available
for
the
treatment
of
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
personnel
trained
in
re
##sus
##citation
.
[SEP]
[CLS]
(
5
.
7
,
2
.
3
)
*
Ser
##ious
Skin
To
##xi
##city
:
Monitor
for
skin
toxic
##ities
and
for
secondary
infections
.
[SEP]
[CLS]
Ad
##verse
reactions
collected
in
clinical
trials
included
signs
and
symptoms
at
base
##line
but
only
treatment
emerge
##nt
adverse
events
,
defined
as
events
that
appeared
or
worse
##ned
after
the
start
of
[SEP]
[CLS]
treatment
,
are
presented
below
.
[SEP]
[CLS]
D
##U
##AV
##EE
contains
an
est
##rogen
ago
##nist
/
antagonist
.
[SEP]
[CLS]
When
feasible
,
the
decision
to
administer
em
##pi
##ric
anti
##fu
##nga
##l
therapy
in
these
patients
should
be
made
in
consultation
with
a
physician
with
expertise
in
the
diagnosis
and
treatment
of
invasive
[SEP]
[CLS]
fun
##gal
infections
and
should
take
into
account
both
the
risk
for
severe
fun
##gal
infection
and
risks
of
anti
##fu
##nga
##l
therapy
.
[SEP]
[CLS]
If
such
symptoms
occur
,
disco
##ntin
##ue
PR
##IS
##TI
##Q
and
initiate
supportive
treatment
.
[SEP]
[CLS]
Pro
##phy
##lax
##is
for
c
##yt
##ome
##gal
##ov
##ir
##us
is
recommended
for
at
least
3
months
after
transplant
##ation
.
[SEP]
[CLS]
5
.
7
Der
##mat
##olo
##gic
Ad
##verse
Re
##actions
In
a
large
clinical
trial
of
over
78
##00
women
with
post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
,
der
##mal
adverse
events
such
as
der
##mat
##itis
,
e
##cz
##ema
,
and
r
##ash
##es
occurred
at
[SEP]
[CLS]
a
significantly
higher
rate
in
the
Pro
##lia
group
compared
to
the
place
##bo
group
.
[SEP]
[CLS]
Common
adverse
reactions
in
place
##bo
-
controlled
per
##io
##per
##ative
studies
.
[SEP]
[CLS]
In
patients
who
develop
H
##B
##V
react
##ivation
,
disco
##ntin
##ue
C
##IM
##Z
##IA
and
initiate
effective
anti
-
viral
therapy
with
appropriate
supportive
treatment
.
[SEP]
[CLS]
In
2
-
year
place
##bo
-
controlled
clinical
trials
,
elevation
of
liver
trans
##ami
##nas
##es
to
3
-
fold
the
upper
limit
of
normal
(
U
##L
##N
)
or
greater
occurred
in
14
%
of
patients
treated
with
[SEP]
[CLS]
G
##IL
##EN
##Y
##A
0
.
5
mg
and
3
%
of
patients
on
place
##bo
.
[SEP]
[CLS]
In
such
cases
,
topic
##al
treatments
are
recommended
,
but
alcohol
-
,
hydrogen
per
##oxide
-
,
i
##od
##ine
-
,
or
thy
##me
-
containing
mouth
##wash
##es
should
be
avoided
as
they
may
ex
##ace
##rb
##ate
the
condition
[SEP]
[CLS]
.
[SEP]
[CLS]
Women
with
normal
thy
##roid
function
can
compensate
for
the
increased
T
##B
##G
by
making
more
thy
##roid
hormone
,
thus
maintaining
free
T
##4
and
T
##3
serum
concentrations
in
the
normal
range
.
[SEP]
[CLS]
R
##PL
##S
is
a
ne
##uro
##logical
disorder
which
can
present
with
headache
,
seizure
,
let
##har
##gy
,
confusion
,
blind
##ness
and
other
ne
##uro
##log
##ic
disturbance
##s
.
[SEP]
[CLS]
These
events
were
not
treatment
limiting
.
[SEP]
[CLS]
This
finding
with
sa
##lm
##eter
##ol
is
considered
a
class
effect
of
all
LA
##BA
.
[SEP]
[CLS]
Furthermore
,
CR
##IM
-
negative
infants
have
shown
reduced
clinical
effect
in
the
presence
of
high
sustained
I
##g
##G
anti
##body
t
##iter
##s
with
inhibitor
##y
activity
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
Mu
##s
##cle
spa
##sm
##s
.
[SEP]
[CLS]
Fat
##al
adverse
reactions
occurred
more
frequently
in
patients
who
received
A
##FI
##NI
##TO
##R
plus
ex
##em
##esta
##ne
(
2
%
)
compared
to
patients
on
the
place
##bo
plus
ex
##em
##esta
##ne
arm
(
0
.
4
%
)
[SEP]
[CLS]
.
[SEP]
[CLS]
5
.
3
Drug
Inter
##actions
Co
-
administration
of
strong
c
##yt
##och
##rome
P
##45
##0
enzyme
induce
##r
,
r
##if
##amp
##in
,
resulted
in
a
reduction
of
systemic
exposure
of
a
##p
##rem
##ila
##st
,
which
may
result
in
a
loss
of
[SEP]
[CLS]
efficacy
of
O
##TE
##Z
##LA
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
LA
##CT
##IC
AC
##ID
##OS
##IS
/
SE
##VE
##RE
H
##EP
##AT
##OM
##EG
##AL
##Y
W
##IT
##H
ST
##EA
##TO
##SI
##S
and
P
##OS
##T
T
##RE
##AT
##ME
##NT
AC
##UT
##E
E
##X
##AC
##ER
##BA
##TI
##ON
OF
H
##EP
##AT
##IT
##IS
B
WA
##R
##NI
##NG
:
LA
##CT
##IC
AC
##ID
##OS
##IS
/
SE
##VE
##RE
H
##EP
##AT
##OM
##EG
##AL
##Y
W
##IT
##H
ST
##EA
##TO
##SI
##S
and
P
##OS
##T
T
##RE
##AT
##ME
##NT
[SEP]
[CLS]
AC
##UT
##E
E
##X
##AC
##ER
##BA
##TI
##ON
OF
H
##EP
##AT
##IT
##IS
B
Lac
##tic
acid
##osis
and
severe
he
##pa
##tom
##eg
##aly
with
s
##te
##ato
##sis
,
including
fatal
cases
,
have
been
reported
with
the
use
of
n
##uc
##leo
##side
analog
##s
,
including
ten
##of
##ov
##ir
di
##so
##p
##ro
##xi
##l
[SEP]
[CLS]
f
##uma
##rate
,
a
component
of
ST
##RI
##BI
##LD
,
in
combination
with
other
anti
##ret
##rov
##ira
##ls
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
At
48
weeks
,
the
rates
of
adverse
events
leading
to
disco
##ntin
##uation
were
3
%
in
subjects
receiving
T
##I
##VI
##CA
##Y
50
mg
once
daily
+
background
regime
##n
and
4
%
in
[SEP]
[CLS]
subjects
receiving
r
##al
##te
##gra
##vir
400
mg
twice
daily
+
background
regime
##n
.
[SEP]
[CLS]
Some
patients
have
been
re
##chal
##len
##ged
and
have
continued
to
receive
al
##g
##lu
##cos
##idas
##e
al
##fa
under
close
clinical
supervision
.
[SEP]
[CLS]
Tell
your
healthcare
provider
about
all
the
medicines
you
take
,
including
prescription
and
over
-
the
-
counter
medicines
,
vitamin
##s
,
and
herb
##al
supplement
##s
.
[SEP]
[CLS]
d
H
##yper
##tens
##ion
includes
the
preferred
terms
of
h
##yper
##tens
##ion
,
h
##yper
##tensive
crisis
,
and
h
##yper
##tensive
emergency
.
[SEP]
[CLS]
*
I
##mm
##une
-
Media
##ted
Re
##actions
:
Monitor
patients
for
the
development
of
systemic
immune
-
mediated
reactions
involving
skin
and
other
organs
(
5
.
2
)
.
[SEP]
[CLS]
In
a
3
-
week
,
place
##bo
-
controlled
p
##ediatric
trial
with
bi
##pol
##ar
I
disorder
,
trans
##ient
elevations
in
serum
trans
##ami
##nas
##es
)
were
more
common
in
treated
patients
.
[SEP]
[CLS]
5
.
3
I
##mp
##aire
##d
Ren
##al
Fun
##ction
As
a
consequence
of
in
##hibit
##ing
the
re
##nin
-
an
##gio
##tens
##in
system
,
changes
in
re
##nal
function
may
be
anticipated
in
susceptible
individuals
treated
with
Ed
##ar
##bi
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
across
products
in
this
class
may
be
misleading
.
[SEP]
[CLS]
Control
##led
Studies
with
C
##ro
##hn
'
s
Disease
The
data
described
below
reflect
exposure
to
C
##IM
##Z
##IA
at
400
mg
sub
##cut
##aneous
dos
##ing
in
studies
of
patients
with
C
##ro
##hn
'
s
disease
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
e
.
g
.
,
age
>
60
years
,
diabetes
me
##lli
##tus
or
chronic
h
##yper
##tens
##ion
)
,
estimate
the
G
##F
##R
through
laboratory
testing
[SEP]
[CLS]
.
[SEP]
[CLS]
Table
1
shows
common
adverse
reactions
associated
with
the
use
of
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
The
majority
of
patients
on
the
X
##AL
##KO
##RI
arms
in
Studies
1
and
2
(
>
50
%
)
reported
visual
disturbance
##s
which
occurred
at
a
frequency
of
4
-
7
days
each
[SEP]
[CLS]
week
,
lasted
up
to
1
minute
,
and
had
mild
or
no
impact
(
scores
0
to
3
out
of
a
maximum
score
of
10
)
on
daily
activities
[SEP]
[CLS]
as
captured
in
the
V
##SA
##Q
-
AL
##K
question
##naire
.
[SEP]
[CLS]
5
.
8
H
##y
##po
##kal
##emia
and
H
##yper
##gly
##ce
##mia
Beta
##2
-
ago
##nist
medications
may
produce
significant
h
##y
##po
##kal
##emia
in
some
patients
,
possibly
through
in
##tra
##cellular
s
##hun
##ting
,
which
has
the
potential
to
produce
adverse
card
##iovascular
effects
[
see
[SEP]
[CLS]
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
Twenty
percent
of
the
patients
experienced
an
increase
in
either
AL
##T
.
[SEP]
[CLS]
Other
o
##cular
adverse
reactions
occurring
in
1
-
5
%
of
subjects
included
reduced
visual
a
##cu
##ity
,
pu
##nc
##tate
k
##era
##titis
,
eye
inflammation
,
and
i
##rit
##is
.
[SEP]
[CLS]
5
.
8
Drug
In
##duced
Live
##r
In
##ju
##ry
He
##pa
##tic
effects
,
ranging
from
mild
to
moderate
elevations
in
trans
##ami
##nas
##es
(
>
3
times
the
upper
limit
of
normal
)
to
rare
cases
with
[SEP]
[CLS]
con
##com
##ita
##nt
elevations
of
total
bi
##li
##ru
##bin
(
>
2
times
the
upper
limit
of
normal
)
have
been
reported
with
AP
##TI
##OM
use
.
[SEP]
[CLS]
5
.
4
Brady
##card
##ia
S
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
can
occur
in
patients
receiving
X
##AL
##KO
##RI
.
[SEP]
[CLS]
Pat
##ients
with
type
2
diabetes
may
have
fatty
liver
disease
,
which
may
cause
liver
test
abnormal
##ities
,
and
they
may
also
have
other
forms
of
liver
disease
,
many
[SEP]
[CLS]
of
which
can
be
treated
or
managed
.
[SEP]
[CLS]
In
clinical
trials
,
40
%
of
T
##EC
##FI
##DE
##RA
treated
patients
experienced
flush
##ing
.
[SEP]
[CLS]
Case
##s
of
progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
have
occurred
in
patients
treated
with
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
*
Second
Primary
Mali
##gna
##ncies
:
Other
ma
##li
##gna
##ncies
have
occurred
in
patients
,
including
skin
cancer
##s
,
and
other
car
##cin
##oma
##s
(
5
.
5
)
.
[SEP]
[CLS]
Therefore
,
administration
of
higher
than
the
recommended
doses
or
more
frequent
dos
##ing
of
N
##U
##L
##O
##J
##IX
is
not
recommended
.
[SEP]
[CLS]
Across
the
clinical
program
,
serious
an
##aph
##yla
##ctic
reactions
and
severe
cut
##aneous
adverse
reactions
and
an
##gio
##ede
##ma
were
reported
in
0
.
2
%
of
com
##par
##ator
-
treated
patients
and
0
.
3
%
of
FA
##R
##X
##IG
##A
-
treated
patients
.
[SEP]
[CLS]
Co
##mp
##aris
##on
of
Gender
,
Age
,
and
Race
The
overall
adverse
reaction
profile
of
P
##OT
##IG
##A
was
similar
for
females
and
males
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
in
patients
who
develop
R
##PL
##S
.
[SEP]
[CLS]
Y
##ER
##VO
##Y
can
result
in
severe
and
fatal
immune
-
mediated
adverse
reactions
due
to
T
-
cell
activation
and
proliferation
.
[SEP]
[CLS]
(
5
.
2
)
N
##utrition
##al
Management
:
In
the
initial
treatment
of
N
##AG
##S
deficiency
,
protein
restriction
is
recommended
.
[SEP]
[CLS]
(
B
)
SP
##IN
##AL
/
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##As
##pina
##l
hem
##ato
##mas
may
occur
in
patients
treated
with
PR
##AD
##A
##X
##A
who
are
receiving
ne
##ura
##xial
an
##est
##hesia
or
undergoing
spinal
pu
##nc
##ture
.
[SEP]
[CLS]
The
adverse
reactions
reported
most
frequently
as
the
reason
for
disco
##ntin
##uation
of
treatment
included
an
##emia
,
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
fatigue
,
and
multi
-
organ
failure
.
[SEP]
[CLS]
Women
with
un
##con
##tro
##lled
h
##yper
##tens
##ion
or
h
##yper
##tens
##ion
with
vascular
disease
should
not
use
CO
##Cs
.
[SEP]
[CLS]
The
following
adverse
reactions
are
discussed
in
detail
in
other
sections
of
the
label
##ing
:
*
N
##eu
##tro
##pen
##ia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
In
replica
##te
12
-
month
trials
in
3
,
255
subjects
with
CO
##PD
who
had
experienced
a
CO
##PD
ex
##ace
##rb
##ation
in
the
previous
year
,
there
was
a
higher
incidence
of
pneumonia
reported
in
subjects
[SEP]
[CLS]
receiving
flu
##tica
##son
##e
fur
##oat
##e
/
v
##ila
##nter
##ol
50
m
##c
##g
/
25
m
##c
##g
:
6
%
(
48
of
82
##0
subjects
)
;
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
:
6
%
(
51
of
80
##6
subjects
)
;
or
[SEP]
[CLS]
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
:
7
%
(
55
of
81
##1
subjects
)
than
in
subjects
receiving
v
##ila
##nter
##ol
25
m
##c
##g
:
3
%
(
27
of
81
##8
subjects
)
.
[SEP]
[CLS]
of
at
least
Mode
##rate
In
##tens
##ity
##I
##nte
##ns
##ities
are
defined
as
follows
:
Mode
##rate
(
discomfort
enough
to
cause
interference
with
usual
activity
)
;
Se
##vere
(
in
##cap
##ac
##itating
with
inability
to
work
or
[SEP]
[CLS]
do
usual
activity
)
.
[SEP]
[CLS]
E
##rro
##rs
may
also
occur
due
to
motion
artifacts
that
result
in
image
distortion
.
[SEP]
[CLS]
In
addition
,
patients
should
be
observed
for
signs
and
symptoms
of
ad
##rena
##l
ins
##uff
##iciency
,
such
as
fatigue
,
las
##si
##tude
,
weakness
,
nausea
and
vomit
##ing
,
and
h
##y
##pot
##ens
##ion
.
[SEP]
[CLS]
c
Includes
:
injection
site
pain
,
pen
##ile
pain
,
and
injection
site
discomfort
.
[SEP]
[CLS]
5
.
5
Tu
##mor
L
##ys
##is
S
##yn
##drome
Pat
##ients
with
rapidly
pro
##life
##rating
tumor
and
high
tumor
burden
may
be
at
increased
risk
of
tumor
l
##ys
##is
syndrome
.
[SEP]
[CLS]
Disco
##ntin
##ue
BR
##E
##O
E
##LL
##IP
##TA
if
such
reactions
occur
.
[SEP]
[CLS]
The
treatment
emerge
##nt
adverse
events
leading
to
disco
##ntin
##uation
of
at
least
2
patients
treated
with
AM
##P
##Y
##RA
and
that
led
to
disco
##ntin
##uation
more
frequently
compared
to
place
##bo
were
headache
(
AM
##P
##Y
##RA
[SEP]
[CLS]
0
.
5
%
,
place
##bo
0
%
)
,
balance
disorder
(
AM
##P
##Y
##RA
0
.
5
%
,
place
##bo
0
%
)
,
di
##zzi
##ness
(
AM
##P
##Y
##RA
0
.
5
%
,
place
##bo
0
%
)
[SEP]
[CLS]
,
and
confusion
##al
state
(
AM
##P
##Y
##RA
0
.
3
%
,
place
##bo
0
%
)
.
[SEP]
[CLS]
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
described
in
greater
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
[SEP]
[CLS]
*
C
##los
##tri
##dium
di
##ff
##ici
##le
-
Associated
di
##ar
##r
##hea
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
Direct
Co
##omb
##s
'
Test
Ser
##oc
##on
##version
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
E
##X
##CE
##RP
##T
[SEP]
[CLS]
:
The
most
common
adverse
reactions
occurring
in
>
2
%
of
patients
are
di
##ar
##r
##hea
,
nausea
,
and
r
##ash
.
[SEP]
[CLS]
Thirty
-
nine
subjects
(
35
%
)
had
dose
interrupt
##ions
and
sixteen
subjects
(
15
%
)
had
dose
reduction
##s
due
to
adverse
reactions
or
laboratory
abnormal
##ities
.
[SEP]
[CLS]
Across
these
13
studies
,
236
##0
patients
were
treated
once
daily
with
FA
##R
##X
##IG
##A
10
mg
for
a
mean
duration
of
exposure
of
22
weeks
.
[SEP]
[CLS]
For
these
reasons
,
the
incidence
of
antibodies
to
du
##lag
##lut
##ide
can
not
be
directly
compared
with
the
incidence
of
antibodies
of
other
products
.
[SEP]
[CLS]
na
##so
##pha
##ryn
##git
##is
,
la
##ryn
##git
##is
,
viral
infection
)
in
20
%
of
C
##IM
##Z
##IA
-
treated
patients
and
13
%
of
place
##bo
-
treated
patients
,
u
##rina
##ry
tract
infections
(
e
.
g
.
[SEP]
[CLS]
Grade
3
-
4
adverse
reactions
and
laboratory
abnormal
##ities
which
occurred
in
>
=
5
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
occurring
more
frequently
in
the
CO
##ME
##TR
##I
##Q
arm
with
a
between
-
arm
difference
of
>
[SEP]
[CLS]
=
2
%
included
,
in
order
of
decreasing
frequency
;
di
##ar
##r
##hea
,
PP
##ES
,
l
##ymph
##ope
##nia
,
h
##y
##po
##cal
##ce
##mia
,
fatigue
,
h
##yper
##tens
##ion
,
as
##the
##nia
,
increased
AL
##T
,
[SEP]
[CLS]
decreased
weight
,
s
##tom
##ati
##tis
,
and
decreased
appetite
(
see
Table
1
,
Table
2
)
.
[SEP]
[CLS]
(
5
.
8
)
5
.
1
Su
##icidal
Be
##ha
##vior
and
I
##dea
##tion
Anti
##ep
##ile
##ptic
drugs
(
A
##ED
##s
)
,
including
AP
##TI
##OM
,
increase
the
risk
of
su
##icidal
thoughts
in
patients
taking
these
drugs
for
any
[SEP]
[CLS]
indication
.
[SEP]
[CLS]
Therefore
,
remove
Q
##ute
##nza
patches
gently
and
slowly
by
rolling
the
ad
##hesive
side
inward
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Of
this
total
,
78
##2
received
To
##via
##z
4
mg
/
day
,
and
78
##5
received
To
##via
##z
8
mg
/
day
in
Phase
2
or
3
studies
with
treatment
periods
of
8
or
12
weeks
[SEP]
[CLS]
.
[SEP]
[CLS]
If
skin
not
intended
to
be
treated
comes
into
contact
with
Q
##ute
##nza
,
apply
Clean
##sing
G
##el
and
then
wipe
off
with
dry
g
##au
##ze
.
[SEP]
[CLS]
Among
patients
treated
with
Q
##ute
##nza
,
1
%
discontinued
premature
##ly
due
to
an
adverse
event
.
[SEP]
[CLS]
6
.
2
Clinical
Studies
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rate
observed
in
practice
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
If
the
following
occur
,
disco
##ntin
##ue
ER
##WI
##NA
##Z
##E
:
Ser
##ious
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
(
5
.
1
)
Se
##vere
or
pan
##cre
##ati
##tis
(
5
.
2
)
[SEP]
[CLS]
*
G
##lu
##cos
##e
into
##ler
##ance
can
occur
and
,
in
some
cases
,
may
be
i
##rre
##versible
.
[SEP]
[CLS]
For
persistent
h
##yper
##tens
##ion
despite
use
of
anti
-
h
##yper
##tensive
medications
,
reduce
the
IN
##L
##Y
##TA
dose
.
[SEP]
[CLS]
The
diagnosis
of
probable
PM
##L
was
based
on
MR
##I
findings
and
the
detection
of
J
##C
##V
DNA
in
the
CS
##F
in
the
absence
of
clinical
signs
or
symptoms
specific
to
[SEP]
[CLS]
PM
##L
.
[SEP]
[CLS]
(
5
.
3
)
*
P
##ul
##mona
##ry
To
##xi
##city
:
including
A
##cute
Re
##sp
##ira
##tory
Di
##st
##ress
S
##yn
##drome
,
acute
respiratory
failure
,
and
acute
di
##ff
##use
in
##fi
##lt
##rative
pulmonary
disease
:
With
##hold
K
##y
##p
##rol
##is
and
evaluate
promptly
(
[SEP]
[CLS]
5
.
4
)
*
P
##ul
##mona
##ry
H
##yper
##tens
##ion
:
With
##hold
K
##y
##p
##rol
##is
and
evaluate
(
5
.
5
)
*
D
##ys
##p
##nea
:
For
severe
or
life
threatening
d
##ys
##p
##nea
,
with
##hold
K
##y
##p
##rol
##is
and
evaluate
.
[SEP]
[CLS]
breathing
difficulties
can
be
life
threatening
and
there
have
been
reports
of
death
related
to
spread
of
to
##xin
effects
.
[SEP]
[CLS]
For
this
same
group
of
A
##FI
##NI
##TO
##R
-
treated
females
,
the
following
men
##st
##ru
##al
abnormal
##ities
were
reported
:
d
##ys
##men
##or
##r
##hea
(
6
%
)
,
men
##or
##r
##ha
##gia
(
6
%
)
,
metro
##rr
##ha
##gia
(
6
[SEP]
[CLS]
%
)
,
and
un
##sp
##ec
##ified
men
##st
##ru
##al
irregular
##ity
(
6
%
)
.
[SEP]
[CLS]
5
.
4
I
##mm
##une
Re
##con
##st
##itution
S
##yn
##drome
I
##mm
##une
re
##con
##st
##itution
syndrome
has
been
reported
in
patients
treated
with
combination
anti
##ret
##rov
##ira
##l
therapy
,
including
T
##I
##VI
##CA
##Y
.
[SEP]
[CLS]
5
.
4
P
##ul
##mona
##ry
To
##xi
##city
A
##cute
Re
##sp
##ira
##tory
Di
##st
##ress
S
##yn
##drome
(
AR
##DS
)
,
acute
respiratory
failure
,
and
acute
di
##ff
##use
in
##fi
##lt
##rative
pulmonary
disease
such
as
p
##ne
##um
##oni
##tis
and
inter
##st
##iti
##al
lung
disease
have
occurred
[SEP]
[CLS]
in
less
than
1
%
of
patients
receiving
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
If
this
product
is
to
be
given
to
a
patient
with
a
c
##ep
##hal
##os
##por
##in
,
pen
##ici
##llin
,
or
other
beta
-
la
##ct
##am
all
##er
##gy
,
exercise
caution
because
cross
sensitivity
has
been
established
.
[SEP]
[CLS]
5
.
13
Post
##eri
##or
Rev
##ers
##ible
En
##ce
##pha
##lop
##athy
S
##yn
##drome
(
PR
##ES
)
Case
##s
of
PR
##ES
have
been
reported
in
patients
receiving
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
The
safety
data
described
below
are
based
on
the
confirm
##atory
6
-
and
12
-
month
trials
.
[SEP]
[CLS]
(
B
)
SP
##IN
##AL
/
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##A
spinal
hem
##ato
##mas
may
occur
in
patients
treated
with
E
##L
##I
##Q
##UI
##S
who
are
receiving
ne
##ura
##xial
an
##est
##hesia
or
undergoing
spinal
pu
##nc
##ture
.
[SEP]
[CLS]
Data
in
Table
1
are
for
all
A
##Es
for
all
CA
##PS
patients
receiving
can
##aki
##num
##ab
.
[SEP]
[CLS]
In
Study
2
only
V
##OR
##A
##X
##A
##Z
##E
-
related
adverse
reactions
were
collected
and
severity
was
graded
according
to
NC
##I
CT
##CA
##E
version
3
.
[SEP]
[CLS]
The
significance
of
these
findings
and
the
effect
of
long
-
term
treatment
with
Pro
##lia
are
unknown
.
[SEP]
[CLS]
Local
##ized
and
systemic
infections
,
including
pneumonia
,
my
##co
##ba
##cter
##ial
infections
,
other
bacterial
infections
,
invasive
fun
##gal
infections
,
such
as
as
##per
##gill
##osis
,
can
##di
##dia
##sis
,
or
p
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
pneumonia
(
[SEP]
[CLS]
P
##JP
)
and
viral
infections
including
react
##ivation
of
he
##pa
##titis
B
virus
have
occurred
in
patients
taking
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
Pi
##cat
##o
(
r
)
(
ing
##eno
##l
me
##but
##ate
)
gel
,
0
.
01
##5
%
and
0
.
05
%
[SEP]
[CLS]
:
h
##yper
##sen
##si
##ti
##vity
,
all
##ergic
contact
der
##mat
##itis
,
her
##pes
z
##ost
##er
,
chemical
con
##junct
##iv
##itis
,
and
corn
##eal
burn
.
[SEP]
[CLS]
Ad
##vise
patients
to
report
promptly
any
new
or
worse
##ning
respiratory
symptoms
.
[SEP]
[CLS]
(
5
.
1
)
*
A
##cute
h
##yper
##sen
##si
##ti
##vity
reactions
(
an
##gio
##ede
##ma
,
d
##ys
##p
##nea
,
p
##ru
##rit
##us
,
and
r
##ash
)
have
been
reported
.
[SEP]
[CLS]
The
im
##mu
##no
##genic
##ity
of
E
##Y
##LE
##A
was
evaluated
in
serum
samples
.
[SEP]
[CLS]
A
ca
##usal
relationship
with
U
##L
##OR
##IC
has
not
been
established
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
additional
adverse
reactions
have
been
reported
during
the
post
##market
##ing
use
of
E
##O
##VI
##ST
.
[SEP]
[CLS]
A
total
of
58
patient
samples
that
were
either
trans
##ient
##ly
or
persistent
##ly
positive
for
anti
-
br
##ent
##ux
##ima
##b
ve
##do
##tin
antibodies
were
tested
for
the
presence
of
neutral
##izing
antibodies
.
[SEP]
[CLS]
Should
any
of
these
occur
or
be
suspected
,
D
##U
##AV
##EE
should
be
discontinued
immediately
.
[SEP]
[CLS]
The
risks
and
benefits
of
treatment
should
be
considered
prior
to
in
##iti
##ating
therapy
in
patients
:
*
with
chronic
or
re
##current
infection
*
who
have
been
exposed
to
tuberculosis
*
[SEP]
[CLS]
with
a
history
of
an
op
##port
##uni
##stic
infection
*
who
have
resided
or
traveled
in
areas
of
endemic
tuberculosis
or
endemic
my
##cos
##es
,
such
as
his
##top
##las
##mos
##is
,
co
##cci
##dio
##ido
##my
##cos
##is
,
or
blast
##omy
##cos
##is
[SEP]
[CLS]
*
with
underlying
conditions
that
may
pre
##dis
##pose
them
to
infection
Tu
##ber
##cu
##los
##is
Case
##s
of
react
##ivation
of
tuberculosis
or
new
tuberculosis
infections
have
been
observed
in
patients
receiving
C
##IM
##Z
##IA
,
including
patients
[SEP]
[CLS]
who
have
previously
received
treatment
for
late
##nt
or
active
tuberculosis
.
[SEP]
[CLS]
CD
##AD
must
be
considered
in
all
patients
who
present
with
di
##ar
##r
##hea
following
anti
##ba
##cter
##ial
use
.
[SEP]
[CLS]
5
.
2
An
##emia
(
Use
with
R
##iba
##vir
##in
and
P
##eg
##int
##er
##fer
##on
Alfa
)
An
##emia
has
been
reported
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
therapy
.
[SEP]
[CLS]
In
addition
to
the
adverse
reactions
presented
in
Table
1
,
di
##zzi
##ness
was
reported
in
more
than
1
%
of
U
##L
##OR
##IC
-
treated
subjects
although
not
at
a
rate
more
than
0
.
5
[SEP]
[CLS]
%
greater
than
place
##bo
.
[SEP]
[CLS]
The
values
did
not
exceed
more
than
3
times
the
base
##line
values
and
returned
to
base
##line
within
1
to
4
days
.
[SEP]
[CLS]
The
risk
of
portal
ve
##nous
th
##rom
##bos
##is
was
increased
in
th
##rom
##bo
##cy
##top
##eni
##c
patients
with
chronic
liver
disease
treated
with
75
mg
of
PR
##OM
##AC
##TA
once
daily
for
2
weeks
in
preparation
for
invasive
[SEP]
[CLS]
procedures
.
[SEP]
[CLS]
The
incidence
of
adverse
events
resulting
in
permanent
disco
##ntin
##uation
of
study
medication
in
Trial
1
was
3
%
for
patients
treated
with
T
##AF
##IN
##LA
##R
and
3
%
for
patients
treated
with
[SEP]
[CLS]
da
##car
##ba
##zine
.
[SEP]
[CLS]
Ser
##ious
infections
(
e
.
g
.
,
pneumonia
,
var
##ice
##lla
,
gas
##tro
##enter
##itis
,
me
##as
##les
,
se
##psis
,
o
##titis
media
,
sin
##us
##itis
,
ad
##eno
##virus
,
l
##ymph
node
a
##bs
##cess
,
p
##har
##yn
##git
##is
)
were
observed
[SEP]
[CLS]
in
approximately
4
%
to
5
%
(
0
.
02
to
0
.
17
per
100
patient
-
days
)
of
patients
receiving
IL
##AR
##IS
in
both
studies
.
[SEP]
[CLS]
5
.
4
Use
in
Children
U
##LE
##SF
##IA
(
r
)
Lot
##ion
should
only
be
used
on
children
(
6
months
of
age
and
older
)
under
the
direct
supervision
of
an
adult
[SEP]
[CLS]
.
[SEP]
[CLS]
Common
adverse
reactions
in
place
##bo
-
controlled
MD
##D
studies
The
most
commonly
observed
adverse
reactions
in
PR
##IS
##TI
##Q
treated
MD
##D
patients
in
pre
-
marketing
pool
##ed
8
-
week
,
place
##bo
-
controlled
,
fixed
-
dose
studies
(
incidence
>
[SEP]
[CLS]
=
5
%
and
at
least
twice
the
rate
of
place
##bo
in
the
50
or
100
mg
dose
groups
)
were
:
nausea
,
di
##zzi
##ness
,
ins
##om
##nia
,
h
##yper
##hi
##dr
##osis
,
[SEP]
[CLS]
con
##st
##ip
##ation
,
so
##m
##no
##len
##ce
,
decreased
appetite
,
anxiety
,
and
specific
male
sexual
function
disorders
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
D
##IF
##IC
##ID
should
not
be
used
for
systemic
infections
.
[SEP]
[CLS]
Op
##port
##uni
##stic
infections
such
as
p
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
pneumonia
(
P
##JP
)
should
be
considered
in
the
differential
diagnosis
.
[SEP]
[CLS]
5
.
2
In
##fect
##ions
A
##FI
##NI
##TO
##R
has
im
##mu
##nos
##up
##pressive
properties
and
may
pre
##dis
##pose
patients
to
pro
##to
##zo
##al
infections
,
including
infections
with
op
##port
##uni
##stic
path
##ogen
##s
[
see
Ad
##verse
Re
##actions
(
6
.
1
,
6
.
2
,
6
.
3
,
[SEP]
[CLS]
6
.
4
,
6
.
5
)
]
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
[SEP]
[CLS]
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
The
physician
responsible
for
the
maintenance
therapy
should
have
complete
information
re
##quisite
for
the
follow
-
up
of
the
patient
[
see
Box
##ed
Warning
]
.
[SEP]
[CLS]
These
hem
##ato
##mas
may
result
in
permanent
para
##lysis
.
[SEP]
[CLS]
5
.
2
I
##mp
##air
##ment
in
Ren
##al
Fun
##ction
J
##AR
##DI
##AN
##CE
increases
serum
c
##rea
##tin
##ine
and
decreases
e
##G
##F
##R
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Mac
##ular
ed
##ema
generally
partially
or
completely
resolved
with
or
without
treatment
after
drug
disco
##ntin
##uation
.
[SEP]
[CLS]
Consider
whether
to
restart
K
##y
##p
##rol
##is
based
on
a
benefit
/
risk
assessment
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
O
##bs
##erve
patients
carefully
when
the
dos
##age
of
NO
##RT
##H
##ER
##A
is
changed
or
when
con
##com
##ita
##nt
le
##vo
##do
##pa
is
reduced
abruptly
or
discontinued
,
especially
if
the
patient
is
receiving
ne
##uro
##le
##ptic
##s
.
[SEP]
[CLS]
Period
##ic
skin
examination
is
recommended
for
all
patients
,
particularly
those
with
risk
factors
for
skin
cancer
.
[SEP]
[CLS]
Other
adverse
reactions
involving
the
female
reproductive
system
were
men
##or
##r
##ha
##gia
(
10
%
)
,
men
##st
##ru
##al
irregular
##ities
(
10
%
)
,
and
v
##agi
##nal
hem
##or
##r
##hage
(
8
%
)
.
[SEP]
[CLS]
The
management
of
this
syndrome
should
include
:
(
1
)
immediate
disco
##ntin
##uation
of
the
anti
##psy
##cho
##tic
drugs
and
other
drugs
not
essential
to
concurrent
therapy
,
(
2
)
intensive
[SEP]
[CLS]
s
##ym
##pt
##oma
##tic
treatment
and
medical
monitoring
,
and
(
3
)
treatment
of
any
con
##com
##ita
##nt
serious
medical
problems
for
which
specific
treatments
are
available
.
[SEP]
[CLS]
(
2
.
1
,
5
.
9
)
*
T
##hr
##omb
##oc
##yt
##ope
##nia
:
Monitor
plate
##let
counts
;
interrupt
or
reduce
K
##y
##p
##rol
##is
dos
##ing
as
clinical
##ly
indicated
.
[SEP]
[CLS]
5
.
8
Inc
##rease
##s
in
Low
-
Den
##sity
Li
##pop
##rote
##in
(
L
##D
##L
-
C
)
Do
##se
-
related
increases
in
L
##D
##L
-
C
occur
with
IN
##VO
##KA
##NA
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
stated
frequencies
of
adverse
reactions
represent
the
proportion
of
individuals
who
experienced
a
treatment
-
emerge
##nt
adverse
event
of
the
type
listed
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reaction
reported
in
2
%
of
patients
treated
with
Be
##si
##vance
was
con
##junct
##ival
red
##ness
.
[SEP]
[CLS]
All
women
were
instructed
to
take
at
least
1000
mg
of
calcium
and
400
I
##U
of
vitamin
D
supplement
##ation
per
day
.
[SEP]
[CLS]
P
##ediatric
Pat
##ients
:
Data
from
the
short
-
term
,
place
##bo
-
controlled
trial
in
p
##ediatric
patients
with
bi
##pol
##ar
I
disorder
are
shown
in
Table
2
.
[SEP]
[CLS]
Given
these
con
##found
##ers
,
the
relationship
between
at
##y
##pical
anti
##psy
##cho
##tic
use
and
h
##yper
##gly
##ce
##mia
-
related
adverse
reactions
is
not
completely
understood
.
[SEP]
[CLS]
Therefore
,
a
RA
##N
##K
##L
inhibitor
such
as
Pro
##lia
may
increase
the
risk
of
infection
.
[SEP]
[CLS]
If
irritation
of
eyes
or
air
##ways
occurs
,
remove
the
affected
individual
from
the
vicinity
of
Q
##ute
##nza
.
[SEP]
[CLS]
The
adverse
event
information
from
clinical
trials
does
,
however
,
provide
a
basis
for
identifying
the
adverse
events
that
appear
to
be
related
to
drug
use
and
for
approx
##imating
[SEP]
[CLS]
rates
.
[SEP]
[CLS]
In
two
clinical
trials
,
122
##7
subjects
were
treated
with
J
##U
##BL
##IA
,
116
##1
for
at
least
24
weeks
and
78
##0
for
48
weeks
.
[SEP]
[CLS]
Ask
patients
about
symptoms
suggest
##ive
of
in
##fusion
reactions
after
their
first
cycle
of
therapy
.
[SEP]
[CLS]
(
5
.
2
)
*
He
##pa
##tic
effects
:
Post
##market
##ing
reports
of
he
##pa
##tic
failure
,
sometimes
fatal
.
[SEP]
[CLS]
5
.
1
Risk
of
T
##hy
##roid
C
-
cell
Tu
##mor
##s
In
male
and
female
rats
,
du
##lag
##lut
##ide
causes
a
dose
-
related
and
treatment
-
duration
-
dependent
increase
in
the
incidence
of
thy
##roid
C
-
cell
tumors
)
after
lifetime
exposure
[SEP]
[CLS]
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
In
double
-
blind
place
##bo
-
controlled
short
-
term
studies
,
where
the
dose
was
increased
slowly
,
as
recommended
above
,
s
##ync
##ope
was
reported
in
0
.
4
%
(
5
/
134
##4
)
of
patients
treated
with
[SEP]
[CLS]
FA
##NA
##P
##T
,
compared
with
0
.
2
%
(
1
/
58
##7
)
on
place
##bo
.
[SEP]
[CLS]
Data
from
a
4
-
week
,
fixed
-
dose
study
in
adult
subjects
with
s
##chi
##zophrenia
,
in
which
fast
##ing
blood
samples
were
drawn
,
are
presented
in
Table
1
.
[SEP]
[CLS]
This
pool
combined
13
place
##bo
-
controlled
studies
,
including
3
mon
##otherapy
studies
,
9
add
-
on
to
background
anti
##dia
##bet
##ic
therapy
studies
,
and
an
initial
combination
with
met
##form
##in
study
.
[SEP]
[CLS]
In
##fect
##ions
not
meeting
these
criteria
are
considered
non
-
serious
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
System
##ic
h
##yper
##sen
##si
##ti
##vity
adverse
reactions
sometimes
severe
(
e
.
g
.
,
severe
u
##rt
##ica
##ria
,
systemic
r
##ash
,
facial
ed
##ema
,
lip
swelling
)
occurred
in
0
.
5
%
of
patients
on
T
##R
##U
##L
##IC
##IT
##Y
[SEP]
[CLS]
in
the
four
Phase
2
and
five
Phase
3
studies
.
[SEP]
[CLS]
(
5
.
6
)
.
[SEP]
[CLS]
The
median
duration
of
exposure
to
Z
##yd
##eli
##g
was
5
months
.
[SEP]
[CLS]
The
most
common
adverse
reactions
that
led
to
treatment
disco
##ntin
##uations
were
he
##pa
##to
##to
##xi
##city
and
di
##ar
##r
##hea
/
co
##lit
##is
.
[SEP]
[CLS]
C
##lev
##id
##ip
##ine
was
evaluated
in
15
studies
in
h
##yper
##tensive
patients
:
109
##9
patients
with
per
##io
##per
##ative
h
##yper
##tens
##ion
,
126
with
severe
h
##yper
##tens
##ion
and
82
patients
with
essential
h
##yper
##tens
##ion
.
[SEP]
[CLS]
b
Includes
:
injection
site
swelling
,
pen
##ile
ed
##ema
,
pen
##ile
swelling
,
local
swelling
,
s
##c
##rot
##al
swelling
,
and
injection
site
ed
##ema
.
[SEP]
[CLS]
Transfer
of
patients
from
systemic
co
##rt
##ico
##ster
##oid
therapy
to
BR
##E
##O
E
##LL
##IP
##TA
may
un
##mas
##k
all
##ergic
conditions
previously
suppressed
by
the
systemic
co
##rt
##ico
##ster
##oid
therapy
(
e
.
g
.
,
r
##hin
##itis
,
con
##junct
##iv
##itis
,
e
##cz
##ema
,
[SEP]
[CLS]
art
##hr
##itis
,
e
##os
##ino
##phi
##lic
conditions
)
.
[SEP]
[CLS]
The
most
frequent
adverse
drug
reactions
that
led
to
disco
##ntin
##uation
in
1
%
or
more
of
patients
in
Study
1
were
pneumonia
,
IL
##D
/
p
##ne
##um
##oni
##tis
,
and
decreased
appetite
.
[SEP]
[CLS]
Pool
of
12
Place
##bo
-
Control
##led
Studies
for
FA
##R
##X
##IG
##A
5
and
10
mg
The
data
in
Table
1
is
derived
from
12
place
##bo
-
controlled
studies
ranging
from
12
to
24
weeks
.
[SEP]
[CLS]
At
three
years
after
transplant
##ation
,
s
##ys
##to
##lic
blood
pressures
were
6
mm
##H
##g
lower
and
di
##ast
##olic
blood
pressures
were
3
mm
##H
##g
lower
in
N
##U
##L
##O
##J
##IX
-
treated
patients
compared
to
c
##y
##c
##los
##por
##ine
-
treated
patients
.
[SEP]
[CLS]
The
safety
of
Z
##Y
##TI
##GA
in
patients
with
L
##VE
##F
<
50
%
or
NY
##HA
Class
III
or
IV
heart
failure
in
Study
1
or
L
##VE
##F
<
50
%
or
NY
##HA
Class
[SEP]
[CLS]
II
to
IV
heart
failure
in
Study
2
was
not
established
.
[SEP]
[CLS]
Lu
##ng
function
(
F
##E
##V
##1
##or
peak
ex
##pi
##rator
##y
flow
)
,
beta
-
ago
##nist
use
,
and
CO
##PD
or
as
##th
##ma
symptoms
should
be
carefully
monitored
during
withdrawal
of
oral
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
No
fracture
##s
occurred
in
the
place
##bo
group
,
5
occurred
in
the
FA
##R
##X
##IG
##A
5
mg
group
,
and
8
occurred
in
the
FA
##R
##X
##IG
##A
10
mg
group
.
[SEP]
[CLS]
A
total
of
48
##14
patients
were
evaluated
for
safety
when
treated
with
Ed
##ar
##bi
at
doses
of
20
,
40
,
or
80
mg
in
clinical
trials
.
[SEP]
[CLS]
5
.
3
Del
##ay
##ed
He
##aling
The
use
of
s
##tero
##ids
after
cat
##ara
##ct
surgery
may
delay
healing
and
increase
the
incidence
of
b
##le
##b
formation
.
[SEP]
[CLS]
Table
2
.
[SEP]
[CLS]
Disco
##ntin
##uations
due
to
elevated
he
##pa
##tic
trans
##ami
##nas
##es
were
<
1
%
and
were
similar
in
patients
treated
with
T
##EC
##FI
##DE
##RA
or
place
##bo
.
[SEP]
[CLS]
Approximately
five
percent
of
patients
receiving
I
##MB
##R
##U
##VI
##CA
in
Study
1
and
Study
2
discontinued
treatment
due
to
adverse
events
.
[SEP]
[CLS]
5
.
2
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
A
fatal
case
of
progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
occurred
in
a
patient
with
MS
who
received
T
##EC
##FI
##DE
##RA
for
4
years
while
enrolled
in
a
[SEP]
[CLS]
clinical
trial
.
[SEP]
[CLS]
Pat
##ients
receiving
SA
##P
##H
##RI
##S
should
receive
regular
monitoring
of
weight
[
see
Pat
##ient
Counsel
##ing
Information
(
17
)
]
.
[SEP]
[CLS]
The
majority
of
patients
(
78
%
)
were
non
-
Hispanic
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
that
led
to
dose
reduction
in
these
patients
were
nausea
(
1
.
8
%
)
and
elevated
trans
##ami
##nas
##es
(
1
.
8
%
)
.
[SEP]
[CLS]
Op
##io
##ids
may
affect
the
ability
to
perform
potentially
hazardous
activities
such
as
driving
or
operating
machinery
.
[SEP]
[CLS]
In
the
open
-
label
Study
3
,
6
.
9
%
(
16
/
233
)
subjects
died
.
[SEP]
[CLS]
Among
patients
with
moderate
re
##nal
imp
##air
##ment
,
approximately
84
%
were
taking
medications
that
interfere
with
potassium
ex
##cre
##tion
,
such
as
potassium
-
spa
##ring
di
##ure
##tics
,
an
##gio
##tens
##in
-
converting
-
enzyme
inhibitor
##s
,
and
an
##gio
##tens
##in
-
receptor
block
##ers
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
and
5
.
3
)
and
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
Pre
##cise
risk
estimates
for
h
##yper
##gly
##ce
##mia
-
related
adverse
events
in
patients
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
are
not
available
.
[SEP]
[CLS]
(
5
.
6
)
*
H
##yper
##tens
##ion
including
h
##yper
##tensive
crisis
:
Monitor
blood
pressure
regularly
.
[SEP]
[CLS]
(
5
.
2
,
5
.
3
)
*
He
##mor
##r
##ha
##gic
events
,
including
fatal
events
,
have
been
reported
.
[SEP]
[CLS]
With
##hold
K
##y
##p
##rol
##is
if
suspected
.
[SEP]
[CLS]
The
following
additional
adverse
reactions
occurred
in
less
than
10
%
of
A
##FI
##NI
##TO
##R
-
treated
patients
:
nausea
(
8
%
)
,
pain
in
ex
##tre
##mity
(
8
%
)
,
[SEP]
[CLS]
ins
##om
##nia
(
6
%
)
,
pneumonia
(
6
%
)
,
e
##pis
##ta
##xi
##s
(
5
%
)
,
h
##yper
##sen
##si
##ti
##vity
(
3
%
)
,
[SEP]
[CLS]
increased
blood
l
##ute
##ini
##zing
hormone
(
L
##H
)
levels
(
1
%
)
and
p
##ne
##um
##oni
##tis
(
1
%
)
.
[SEP]
[CLS]
These
may
include
as
##the
##nia
,
generalized
muscle
weakness
,
dip
##lop
##ia
,
blurred
vision
,
p
##tosis
,
d
##ys
##pha
##gia
,
d
##ys
##phon
##ia
,
d
##ys
##art
##hr
##ia
,
u
##rina
##ry
in
##con
##tine
##nce
and
breathing
difficulties
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
adverse
reactions
(
incidence
>
=
2
%
)
were
s
##tom
##ati
##tis
and
am
##eno
##rr
##hea
.
[SEP]
[CLS]
Six
out
of
107
(
6
%
)
patients
treated
with
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
discontinued
treatment
due
to
adverse
events
compared
with
12
of
the
95
(
13
%
[SEP]
[CLS]
)
patients
who
received
place
##bo
.
[SEP]
[CLS]
FA
##NA
##P
##T
should
also
be
avoided
in
patients
with
con
##gen
##ital
long
Q
##T
syndrome
and
in
patients
with
a
history
of
cardiac
a
##rr
##hy
##th
##mia
##s
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
in
these
three
12
week
studies
in
<
2
%
of
patients
treated
with
600
mg
of
H
##OR
##I
##Z
##AN
##T
and
numerical
##ly
greater
than
place
##bo
were
balance
disorder
,
[SEP]
[CLS]
blurred
vision
,
di
##sor
##ient
##ation
,
feeling
drunk
,
let
##har
##gy
,
and
ve
##rt
##igo
.
[SEP]
[CLS]
P
##sor
##ias
##is
:
During
the
0
to
16
week
place
##bo
-
controlled
period
of
the
3
controlled
clinical
trials
,
1
.
3
%
(
12
/
92
##0
)
of
subjects
treated
with
O
##TE
##Z
##LA
reported
depression
compared
[SEP]
[CLS]
to
0
.
4
%
(
2
/
50
##6
)
treated
with
place
##bo
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##UE
##RB
##ET
LLC
at
1
-
87
##7
-
72
##9
-
66
##7
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Studies
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
[SEP]
[CLS]
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
[SEP]
[CLS]
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
5
.
2
Ana
##phy
##lax
##is
and
In
##fusion
Re
##actions
In
##fusion
-
related
reactions
,
including
an
##aph
##yla
##xi
##s
,
have
occurred
with
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
P
-
g
##p
in
##hibition
and
impaired
re
##nal
function
are
the
major
independent
factors
that
result
in
increased
exposure
to
da
##bi
##gat
##ran
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
in
at
least
2
%
and
at
a
rate
greater
than
place
##bo
of
the
PR
##IS
##TI
##Q
treated
patients
in
the
short
-
term
studies
,
[SEP]
[CLS]
up
to
8
weeks
,
were
:
nausea
(
4
%
)
;
di
##zzi
##ness
,
headache
and
vomit
##ing
(
2
%
each
)
.
[SEP]
[CLS]
5
.
7
Mac
##rov
##as
##cular
Out
##come
##s
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
J
##AR
##DI
##AN
##CE
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
Grade
3
-
4
ne
##ut
##rop
##enia
has
been
observed
in
82
%
of
patients
treated
with
J
##E
##V
##TA
##NA
in
the
random
##ized
trial
.
[SEP]
[CLS]
Complete
blood
count
(
with
white
blood
cell
differential
counts
)
should
be
obtained
at
pre
##tre
##at
##ment
,
and
at
Treatment
Weeks
2
,
4
,
8
,
and
12
,
[SEP]
[CLS]
and
should
be
monitored
closely
at
other
time
points
,
as
clinical
##ly
appropriate
.
[SEP]
[CLS]
For
patients
who
require
use
of
co
##rt
##ico
##ster
##oids
for
treatment
of
non
-
infectious
p
##ne
##um
##oni
##tis
,
prop
##hyl
##ax
##is
for
P
##JP
may
be
considered
.
[SEP]
[CLS]
However
,
re
##lap
##sing
malaria
caused
by
P
.
v
##iva
##x
requires
additional
treatment
with
other
anti
##mal
##aria
##l
agents
to
achieve
radical
cure
i
.
e
.
,
era
##dicate
any
h
##y
##p
##no
##zo
##ites
forms
that
may
remain
dormant
in
[SEP]
[CLS]
the
liver
.
[SEP]
[CLS]
In
clinical
trials
,
the
median
time
to
onset
of
hem
##og
##lo
##bin
less
than
10
g
per
d
##L
from
the
initiation
of
therapy
was
similar
among
subjects
treated
with
the
combination
[SEP]
[CLS]
of
VI
##CT
##RE
##L
##IS
and
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
(
71
days
with
a
range
of
15
-
33
##7
days
)
,
compared
to
those
who
received
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
(
71
days
with
a
range
of
8
-
33
##7
days
[SEP]
[CLS]
)
.
[SEP]
[CLS]
If
liver
test
abnormal
##ities
per
##sist
,
worse
##n
or
re
##cu
##r
,
then
permanently
disco
##ntin
##ue
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
Therefore
,
treatments
for
E
##D
,
including
ST
##EN
##DR
##A
,
should
not
be
used
in
men
for
whom
sexual
activity
is
in
##ad
##vis
##able
because
of
their
underlying
card
##iovascular
status
.
[SEP]
[CLS]
Complete
blood
counts
(
with
white
blood
cell
differential
counts
)
should
be
obtained
pre
##tre
##at
##ment
,
and
at
Treatment
Weeks
2
,
4
,
8
,
and
12
,
and
[SEP]
[CLS]
should
be
monitored
closely
at
other
time
points
,
as
clinical
##ly
appropriate
.
[SEP]
[CLS]
No
new
safety
findings
were
reported
compared
to
the
place
##bo
controlled
trials
.
[SEP]
[CLS]
Pat
##ients
with
a
`
`
crowded
'
'
op
##tic
disc
may
also
be
at
an
increased
risk
of
N
##A
##ION
(
5
.
4
,
6
.
2
)
*
Pat
##ients
should
stop
taking
ST
##EN
##DR
##A
and
seek
pro
##mpt
medical
[SEP]
[CLS]
attention
in
the
event
of
sudden
decrease
or
loss
of
hearing
(
5
.
5
)
5
.
1
Card
##iovascular
Risk
##s
There
is
a
potential
for
cardiac
risk
during
sexual
activity
in
patients
with
[SEP]
[CLS]
pre
-
existing
card
##iovascular
disease
.
[SEP]
[CLS]
What
are
the
ingredients
in
D
##U
##AV
##EE
?
[SEP]
[CLS]
Approximately
7
%
of
patients
in
these
trials
developed
persistent
##ly
positive
antibodies
(
positive
test
at
more
than
2
time
##points
)
and
30
%
developed
trans
##ient
##ly
positive
antibodies
(
positive
[SEP]
[CLS]
in
1
or
2
post
-
base
##line
time
##points
)
.
[SEP]
[CLS]
Pat
##ients
with
tuberculosis
disease
.
[SEP]
[CLS]
A
##gra
##nu
##loc
##yt
##osis
(
including
fatal
cases
)
has
been
reported
with
other
agents
in
the
class
.
[SEP]
[CLS]
Ad
##verse
reactions
were
all
mild
to
moderate
in
severity
and
were
predominantly
isolated
occurrence
##s
(
<
=
2
patients
)
of
one
of
the
following
reactions
:
di
##zzi
##ness
,
[SEP]
[CLS]
r
##ash
,
p
##ru
##rit
##us
,
flush
##ing
or
injection
site
hem
##or
##r
##hage
.
[SEP]
[CLS]
Pat
##ients
were
treated
and
followed
for
3
years
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
Re
##action
Rate
(
%
)
n
=
63
##30
Head
##ache
1
.
5
Na
##use
##a
1
.
2
Di
##zzi
##ness
0
.
5
D
##ys
##ge
##us
##ia
0
.
4
Feeling
Hot
0
.
4
In
##jection
site
reactions
0
.
4
V
##omi
##ting
0
.
4
Ra
##sh
)
[SEP]
[CLS]
0
.
3
P
##ru
##rit
##us
)
0
.
2
E
##ry
##them
##a
0
.
2
H
##yper
##sen
##si
##ti
##vity
/
Ana
##phy
##la
##ct
##oid
*
0
.
1
D
##ys
##p
##nea
0
.
1
Pa
##rest
##hesia
0
.
1
*
H
##yper
##sen
##si
##ti
##vity
/
an
##aph
##yla
##ct
##oid
reaction
may
occur
with
one
or
more
of
the
following
adverse
reactions
:
for
example
,
[SEP]
[CLS]
h
##y
##pot
##ens
##ion
,
u
##rt
##ica
##ria
,
face
ed
##ema
,
eye
##lid
ed
##ema
,
flush
##ing
Ad
##verse
reactions
that
occurred
with
a
frequency
of
<
0
.
1
%
in
subjects
who
received
G
##ada
##vist
include
:
[SEP]
[CLS]
loss
of
consciousness
,
con
##vu
##ls
##ion
,
par
##os
##mia
,
ta
##chy
##card
##ia
,
p
##al
##pit
##ation
,
dry
mouth
,
ma
##lai
##se
and
feeling
cold
.
[SEP]
[CLS]
Table
7
:
Change
in
Body
Weight
in
P
##ediatric
Sub
##jects
from
Basel
##ine
N
*
=
Number
of
subjects
who
had
assessments
at
both
Basel
##ine
and
End
##point
.
[SEP]
[CLS]
*
c
P
##las
##ma
glucose
concentration
<
=
70
mg
/
d
##L
and
presence
of
h
##y
##po
##gly
##ce
##mic
symptoms
.
[SEP]
[CLS]
In
a
longer
-
term
study
,
up
to
9
months
,
the
most
common
was
vomit
##ing
(
2
%
)
.
[SEP]
[CLS]
3
Contact
Der
##mat
##itis
U
##LE
##SF
##IA
(
r
)
Lot
##ion
may
cause
i
##rri
##tant
der
##mat
##itis
.
[SEP]
[CLS]
Monitor
patients
during
in
##fusion
.
[SEP]
[CLS]
In
patients
of
all
ages
who
are
started
on
anti
##de
##press
##ant
therapy
,
monitor
closely
for
worse
##ning
,
and
for
emergence
of
su
##icidal
thoughts
and
behaviors
.
[SEP]
[CLS]
Monitor
patients
for
these
consequences
.
[SEP]
[CLS]
Basel
##ine
and
follow
-
up
op
##ht
##hal
##mo
##logical
examinations
are
recommended
in
p
##ediatric
patients
in
##iti
##ating
K
##AL
##Y
##DE
##CO
treatment
.
[SEP]
[CLS]
Clinical
Trials
in
Late
-
On
##set
Po
##mp
##e
Disease
Assessment
of
adverse
reactions
in
patients
with
late
-
onset
Po
##mp
##e
disease
is
based
on
the
exposure
of
90
patients
(
45
male
,
45
female
[SEP]
[CLS]
)
,
aged
10
to
70
years
,
to
20
mg
/
kg
al
##g
##lu
##cos
##idas
##e
al
##fa
or
place
##bo
in
a
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trial
.
[SEP]
[CLS]
The
co
##bic
##ista
##t
component
of
ST
##RI
##BI
##LD
has
been
shown
to
increase
serum
c
##rea
##tin
##ine
and
decrease
estimated
c
##rea
##tin
##ine
clearance
due
to
in
##hibition
of
tub
##ular
secret
##ion
of
c
##rea
##tin
##ine
without
[SEP]
[CLS]
affecting
re
##nal
g
##lo
##mer
##ular
function
.
[SEP]
[CLS]
Certain
circumstances
may
increase
the
risk
of
to
##rsa
##de
de
point
##es
and
/
or
sudden
death
in
association
with
the
use
of
drugs
that
pro
##long
the
Q
##T
##c
interval
,
including
(
1
)
[SEP]
[CLS]
bra
##dy
##card
##ia
;
(
2
)
h
##y
##po
##kal
##emia
or
h
##y
##po
##ma
##gne
##se
##mia
;
(
3
)
con
##com
##ita
##nt
use
of
other
drugs
that
pro
##long
the
Q
##T
##c
interval
;
and
(
4
)
presence
of
con
##gen
##ital
[SEP]
[CLS]
pro
##long
##ation
of
the
Q
##T
interval
;
(
5
)
recent
acute
my
##oc
##ard
##ial
in
##far
##ction
;
and
/
or
(
6
)
un
##com
##pen
##sat
##ed
heart
failure
.
[SEP]
[CLS]
The
following
adverse
reactions
were
dose
-
related
:
so
##m
##no
##len
##ce
/
se
##dation
,
di
##zzi
##ness
,
feeling
drunk
,
l
##ibi
##do
decreased
,
depression
,
headache
,
peripheral
ed
##ema
,
and
ve
##rt
##igo
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Driving
imp
##air
##ment
:
War
##n
patients
not
to
drive
until
they
have
gained
sufficient
experience
with
H
##OR
##I
##Z
##AN
##T
to
assess
whether
it
will
imp
##air
their
[SEP]
[CLS]
ability
to
drive
.
[SEP]
[CLS]
The
median
age
of
patients
was
9
.
5
years
(
range
0
.
8
to
26
years
)
,
93
%
were
Caucasian
,
and
57
%
were
male
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
D
##IS
##TA
##NT
SP
##RE
##AD
OF
TO
##X
##IN
E
##FF
##EC
##T
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Auto
##im
##mu
##ne
disorders
(
such
as
Graves
'
disease
,
p
##oly
##my
##os
##itis
,
and
G
##uil
##lain
-
Barr
##e
syndrome
)
have
also
been
reported
to
occur
in
the
setting
of
immune
re
##con
##st
##itution
;
however
,
[SEP]
[CLS]
the
time
to
onset
is
more
variable
and
can
occur
many
months
after
initiation
of
treatment
.
[SEP]
[CLS]
A
reaction
was
considered
treatment
emerge
##nt
if
it
occurred
for
the
first
time
or
worse
##ned
while
receiving
therapy
following
base
##line
evaluation
.
[SEP]
[CLS]
None
of
these
4
patients
had
neutral
##izing
antibodies
.
The
presence
of
AD
##A
to
ER
##WI
##NA
##Z
##E
is
associated
with
a
higher
risk
of
h
##yper
##sen
##si
##ti
##vity
reactions
in
patients
who
received
ER
##WI
##NA
##Z
##E
through
in
##tra
##ven
##ous
in
##fusion
[SEP]
[CLS]
compared
to
in
##tra
##mus
##cular
administration
of
ER
##WI
##NA
##Z
##E
.
I
##mm
##uno
##genic
##ity
ass
##ay
are
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
and
may
be
influenced
by
several
factors
such
as
:
ass
##ay
methodology
[SEP]
[CLS]
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
Overall
,
the
most
common
adverse
reactions
in
255
patients
with
H
##A
##E
were
headache
(
16
%
)
,
nausea
(
13
%
)
,
fatigue
(
12
%
)
[SEP]
[CLS]
,
di
##ar
##r
##hea
(
11
%
)
,
upper
respiratory
tract
infection
(
8
%
)
,
injection
site
reactions
(
7
%
)
,
na
##so
##pha
##ryn
##git
##is
(
6
%
)
,
[SEP]
[CLS]
vomit
##ing
(
6
%
)
,
p
##ru
##rit
##us
(
5
%
)
,
upper
abdominal
pain
(
5
%
)
,
and
p
##yre
##xia
(
5
%
)
.
[SEP]
[CLS]
(
5
.
2
)
Inc
##reased
Mortal
##ity
*
An
increased
risk
of
death
was
seen
in
the
S
##IR
##TU
##RO
treatment
group
(
9
/
79
,
11
.
4
%
)
compared
to
the
place
##bo
treatment
group
[SEP]
[CLS]
(
2
/
81
,
2
.
5
%
)
in
one
place
##bo
-
controlled
trial
.
[SEP]
[CLS]
Inc
##reased
Mortal
##ity
*
An
increased
risk
of
death
was
seen
in
the
S
##IR
##TU
##RO
treatment
group
(
9
/
79
,
11
.
4
%
)
compared
to
the
place
##bo
treatment
group
(
2
/
81
,
[SEP]
[CLS]
2
.
5
%
)
in
one
place
##bo
-
controlled
trial
.
[SEP]
[CLS]
These
adverse
reactions
are
presented
by
system
organ
class
and
are
ranked
by
frequency
.
[SEP]
[CLS]
Overall
,
approximately
4
%
of
subjects
reported
one
or
more
adverse
reactions
during
a
follow
-
up
period
that
ranged
from
24
hours
to
7
days
after
G
##ada
##vist
administration
.
[SEP]
[CLS]
Pre
##par
##e
to
treat
acute
pain
during
and
following
the
application
procedure
with
local
cooling
(
such
as
an
ice
pack
)
and
/
or
appropriate
anal
##ges
##ic
medication
,
such
as
op
##io
##ids
.
[SEP]
[CLS]
Ad
##verse
reactions
and
laboratory
abnormal
##ities
described
below
in
Table
##s
7
and
8
reflect
exposure
to
I
##MB
##R
##U
##VI
##CA
with
a
median
duration
of
11
.
7
months
in
the
W
##M
trial
.
[SEP]
[CLS]
Pat
##ients
with
acute
respiratory
illness
may
be
at
risk
of
serious
acute
ex
##ace
##rb
##ation
of
their
respiratory
compromise
due
to
h
##yper
##sen
##si
##ti
##vity
reactions
,
and
require
additional
monitoring
(
5
.
1
,
5
.
2
[SEP]
[CLS]
,
6
)
.
[SEP]
[CLS]
Inc
##iden
##ce
and
Rate
of
H
##y
##po
##gly
##ce
##mia
##A
##d
##verse
reactions
of
h
##y
##po
##gly
##ce
##mia
were
based
on
all
reports
of
s
##ym
##pt
##oma
##tic
and
as
##ym
##pt
##oma
##tic
h
##y
##po
##gly
##ce
##mia
;
a
concurrent
glucose
measurement
was
not
required
;
intent
-
to
-
treat
population
.
[SEP]
[CLS]
In
this
analysis
,
6
.
9
%
of
58
e
##val
##ua
##ble
patients
,
who
were
treated
with
0
.
3
mg
/
kg
dose
,
tested
positive
for
binding
antibodies
against
i
##pi
##lim
##uma
##b
.
[SEP]
[CLS]
Monitor
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
(
AL
##T
)
,
as
##par
##tate
amino
##tra
##ns
##fer
##ase
(
AS
##T
)
,
gamma
-
g
##lut
##am
##yl
transfer
##ase
(
G
##G
##T
)
,
and
total
blood
bi
##li
##ru
##bin
prior
to
the
start
of
and
during
[SEP]
[CLS]
B
##L
##IN
##C
##Y
##TO
treatment
.
[SEP]
[CLS]
Fat
##al
adverse
reactions
occurred
in
5
%
of
patients
receiving
place
##bo
and
resulted
from
se
##ptic
##emia
,
pneumonia
,
and
general
de
##ter
##ior
##ation
.
[SEP]
[CLS]
5
.
3
El
##eva
##ted
Blood
Press
##ure
Pat
##ients
receiving
PR
##IS
##TI
##Q
should
have
regular
monitoring
of
blood
pressure
since
increases
in
blood
pressure
were
observed
in
clinical
studies
[
see
Ad
##verse
Re
##actions
(
6
.
1
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
This
includes
170
##4
patients
treated
for
at
least
six
months
;
of
these
,
58
##8
were
treated
for
at
least
one
year
.
[SEP]
[CLS]
Eight
of
these
13
fracture
##s
were
in
patients
who
had
a
base
##line
e
##G
##F
##R
of
30
to
45
m
##L
/
min
/
1
.
73
m
2
.
[SEP]
[CLS]
FA
##NA
##P
##T
should
be
used
with
caution
in
patients
with
known
card
##iovascular
disease
(
e
.
g
.
,
heart
failure
,
history
of
my
##oc
##ard
##ial
in
##far
##ction
,
is
##che
##mia
,
or
conduct
##ion
abnormal
##ities
)
,
[SEP]
[CLS]
c
##ere
##bro
##vas
##cular
disease
,
or
conditions
that
pre
##dis
##pose
the
patient
to
h
##y
##pot
##ens
##ion
(
de
##hy
##dra
##tion
,
h
##y
##po
##vo
##lem
##ia
,
and
treatment
with
anti
##hy
##pert
##ens
##ive
medications
)
.
[SEP]
[CLS]
Man
##age
with
dose
delay
and
adjustment
(
2
.
2
,
5
.
2
,
6
)
*
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
:
Fe
##tal
harm
can
occur
when
administered
to
a
pregnant
woman
(
5
.
3
)
[SEP]
[CLS]
(
8
.
1
)
*
Q
##T
Pro
##long
##ation
:
Monitor
for
prolonged
Q
##T
intervals
in
patients
with
con
##ges
##tive
heart
failure
,
bra
##dy
##ar
##r
##hy
##th
##mia
##s
,
drugs
known
to
pro
##long
the
Q
##T
interval
,
and
[SEP]
[CLS]
electro
##ly
##te
abnormal
##ities
.
[SEP]
[CLS]
(
5
.
8
)
*
C
##YP
##3
##A
##4
induction
:
Women
taking
strong
C
##YP
##3
##A
##4
induce
##rs
(
for
example
,
car
##ba
##ma
##ze
##pine
,
p
##hen
##yt
##oi
##n
,
r
##if
##amp
##ici
##n
,
and
St
.
John
'
s
w
##ort
)
should
not
[SEP]
[CLS]
choose
Nat
##azi
##a
as
their
oral
con
##tra
##ceptive
due
to
the
possibility
of
decreased
con
##tra
##ceptive
efficacy
.
[SEP]
[CLS]
Feb
##ril
##e
ne
##ut
##rop
##enia
occurred
in
5
%
(
23
/
50
##3
)
of
patients
;
two
patients
(
0
.
4
%
)
died
from
complications
of
f
##eb
##ril
##e
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
5
.
2
Pan
##cre
##ati
##tis
In
Phase
2
and
Phase
3
clinical
studies
,
12
(
3
.
4
cases
per
1000
patient
years
)
pan
##cre
##ati
##tis
related
adverse
reactions
were
reported
in
patients
exposed
to
[SEP]
[CLS]
T
##R
##U
##L
##IC
##IT
##Y
versus
3
in
non
-
in
##cre
##tin
com
##par
##ators
(
2
.
7
cases
per
1000
patient
years
)
.
[SEP]
[CLS]
Monitor
patients
for
fever
.
[SEP]
[CLS]
H
##yper
##tens
##ion
was
reported
as
an
adverse
reaction
in
32
%
of
N
##U
##L
##O
##J
##IX
-
treated
patients
and
37
%
of
c
##y
##c
##los
##por
##ine
-
treated
patients
(
see
Table
4
)
.
[SEP]
[CLS]
For
this
reason
,
CO
##Cs
should
not
be
used
by
women
who
are
over
35
years
of
age
and
smoke
.
[SEP]
[CLS]
G
-
CS
##F
(
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factor
)
or
GM
-
CS
##F
(
g
##ran
##ulo
##cy
##te
-
mac
##rop
##hage
colony
-
s
##ti
##mulating
factor
)
was
used
in
19
%
of
patients
who
received
H
##AL
##AV
##EN
.
[SEP]
[CLS]
1
)
]
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
a
drug
can
not
be
compared
directly
to
[SEP]
[CLS]
rates
from
clinical
trials
of
another
drug
and
may
not
reflect
rates
observed
in
practice
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
Nat
##azi
##a
.
[SEP]
[CLS]
The
clinical
significance
of
these
imaging
changes
is
unknown
.
[SEP]
[CLS]
b
Including
in
##test
##inal
per
##fo
##ration
.
[SEP]
[CLS]
Pat
##ients
should
be
caution
##ed
about
the
risk
of
bleeding
associated
with
the
con
##com
##ita
##nt
use
of
PR
##IS
##TI
##Q
and
NSA
##ID
##s
,
as
##pi
##rin
,
or
other
drugs
that
affect
co
##agu
##lation
or
bleeding
.
[SEP]
[CLS]
The
overall
number
of
infections
,
serious
infections
,
and
select
infections
with
identified
et
##iology
reported
in
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
or
the
c
##y
##c
##los
##por
##ine
control
in
Studies
[SEP]
[CLS]
1
and
2
are
shown
in
Table
3
.
[SEP]
[CLS]
Such
patients
should
undergo
a
pro
##mpt
medical
evaluation
,
and
disco
##ntin
##uation
of
PR
##IS
##TI
##Q
should
be
considered
.
[SEP]
[CLS]
Close
##r
monitoring
is
recommended
for
patients
who
have
other
risk
factors
for
u
##rina
##ry
retention
(
e
.
g
.
,
ben
##ign
pro
##static
h
##yper
##p
##lasia
[
BP
##H
]
)
,
patients
who
are
unable
to
[SEP]
[CLS]
communicate
clinical
symptoms
(
e
.
g
.
,
cognitive
##ly
impaired
patients
)
,
or
patients
who
use
con
##com
##ita
##nt
medications
that
may
affect
void
##ing
(
e
.
g
.
,
anti
##cho
##liner
##gic
##s
)
.
[SEP]
[CLS]
In
other
XI
##AF
##LE
##X
-
treated
patients
(
9
of
104
##4
;
0
.
9
%
)
,
a
combination
of
pen
##ile
e
##cc
##hy
##mos
##es
,
sudden
pen
##ile
de
##tum
##es
##cence
,
and
/
or
a
pen
##ile
`
`
popping
'
'
[SEP]
[CLS]
sound
was
reported
,
and
in
these
cases
,
a
diagnosis
of
co
##rp
##oral
r
##up
##ture
can
not
be
excluded
.
[SEP]
[CLS]
Because
these
studies
did
not
include
a
place
##bo
control
group
,
ca
##usal
##ity
could
not
be
established
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
elsewhere
in
the
label
##ing
:
Application
-
Associated
Pain
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
[SEP]
[CLS]
Inc
##rease
in
Blood
Press
##ure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
5
%
and
greater
than
control
)
[SEP]
[CLS]
are
application
site
er
##yt
##hem
##a
,
application
site
pain
,
application
site
p
##ru
##rit
##us
and
application
site
p
##ap
##ules
.
[SEP]
[CLS]
Inc
##rease
##s
in
blood
pressure
were
unrelated
to
the
pre
##tre
##at
##ment
blood
pressure
but
were
related
to
treatment
-
related
increases
in
pain
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
P
##fi
##zer
Inc
at
1
-
800
-
43
##8
-
1985
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Females
of
reproductive
potential
should
avoid
becoming
pregnant
while
being
treated
with
B
##OS
##U
##L
##IF
.
[SEP]
[CLS]
The
mean
base
##line
L
##D
##L
-
C
levels
were
104
to
110
mg
/
d
##L
across
treatment
groups
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
8
)
]
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
*
Most
common
adverse
reactions
(
incidence
>
=
0
.
5
%
)
are
headache
,
nausea
,
and
di
##zzi
##ness
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
[SEP]
[CLS]
contact
Bay
##er
Health
##C
##are
Ph
##arma
##ce
##utical
##s
Inc
.
at
1
-
88
##8
-
84
##2
-
29
##37
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
[SEP]
[CLS]
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
[SEP]
[CLS]
clinical
practice
.
[SEP]
[CLS]
(
2
.
3
,
5
.
1
)
*
My
##elo
##su
##pp
##ression
:
Monitor
blood
counts
and
manage
as
necessary
.
[SEP]
[CLS]
A
total
of
131
##4
SA
##P
##H
##RI
##S
-
treated
patients
were
treated
for
at
least
24
weeks
and
78
##5
SA
##P
##H
##RI
##S
-
treated
patients
had
at
least
52
weeks
of
exposure
at
therapeutic
doses
.
[SEP]
[CLS]
Ce
##r
##vic
##al
D
##ys
##ton
##ia
(
5
.
4
)
:
*
Pat
##ients
with
smaller
neck
muscle
mass
and
patients
who
require
bilateral
injection
##s
into
the
stern
##oc
##le
##ido
##mas
##to
##id
muscles
are
at
greater
risk
of
d
##ys
##pha
##gia
.
[SEP]
[CLS]
In
controlled
clinical
trials
,
first
-
degree
A
##V
block
after
the
first
dose
occurred
in
4
.
7
%
of
patients
receiving
G
##IL
##EN
##Y
##A
and
1
.
6
%
of
patients
on
place
##bo
.
[SEP]
[CLS]
Under
conditions
of
metabolic
in
##hibition
for
both
2D
##6
and
3
##A
##4
,
FA
##NA
##P
##T
12
mg
twice
daily
was
associated
with
a
mean
Q
##T
##c
##F
increase
from
base
##line
of
about
19
m
##se
##c
.
[SEP]
[CLS]
Depression
was
reported
as
serious
in
0
.
2
%
(
3
/
144
##1
)
of
subjects
exposed
to
O
##TE
##Z
##LA
,
compared
to
none
in
place
##bo
-
treated
subjects
(
0
/
49
##5
)
.
[SEP]
[CLS]
The
mean
age
of
the
population
was
56
years
and
2
%
were
older
than
75
years
of
age
.
[SEP]
[CLS]
6
.
2
I
##mm
##uno
##genic
##ity
As
with
all
therapeutic
proteins
,
there
is
potential
for
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
All
patients
were
naive
to
enzyme
replacement
therapy
.
[SEP]
[CLS]
A
##ED
##s
increase
the
risk
of
su
##icidal
thoughts
.
[SEP]
[CLS]
I
##maging
appears
to
over
##est
##imate
the
incidence
of
clinical
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
The
##rap
##eu
##tic
use
of
G
-
CS
##F
and
secondary
prop
##hyl
##ax
##is
should
be
considered
in
all
patients
considered
to
be
at
increased
risk
for
ne
##ut
##rop
##enia
complications
.
[SEP]
[CLS]
Please
refer
to
Table
5
for
established
and
other
potentially
significant
drug
interactions
[
see
Drug
Inter
##actions
(
7
.
3
)
]
.
[SEP]
[CLS]
In
##jection
Site
Re
##actions
In
CA
##PS
Study
1
,
sub
##cut
##aneous
injection
site
reactions
were
observed
in
9
%
of
patients
in
Part
1
with
mild
to
##ler
##ability
reactions
;
in
Part
2
[SEP]
[CLS]
,
one
patient
each
(
7
%
)
had
a
mild
or
a
moderate
to
##ler
##ability
reaction
and
,
in
Part
3
,
one
patient
had
a
mild
[SEP]
[CLS]
local
to
##ler
##ability
reaction
.
[SEP]
[CLS]
Ad
##verse
reactions
were
similar
in
patients
who
received
doses
greater
than
250
mg
daily
.
[SEP]
[CLS]
To
reduce
this
risk
,
consider
coverage
with
another
anti
##coa
##gu
##lant
if
E
##L
##I
##Q
##UI
##S
is
discontinued
for
a
reason
other
than
path
##ological
bleeding
or
completion
of
a
course
of
therapy
.
[SEP]
[CLS]
Since
C
##M
##V
se
##rone
##gat
##ive
patients
are
at
increased
risk
for
C
##M
##V
disease
(
a
known
risk
factor
for
PT
##LD
)
,
the
clinical
significance
of
C
##M
##V
se
##rol
##ogy
for
PT
##LD
remains
to
[SEP]
[CLS]
be
determined
;
however
,
these
findings
should
be
considered
when
pre
##s
##cribing
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
5
.
4
T
##hr
##omb
##oe
##mbo
##lic
and
B
##lee
##ding
Events
in
Pat
##ients
with
th
##rom
##boe
##mbo
##lic
events
,
trans
##ient
is
##che
##mic
attack
,
and
my
##oc
##ard
##ial
in
##far
##ction
)
and
an
excess
of
major
bleeding
(
predominantly
post
-
operative
[SEP]
[CLS]
per
##ica
##rdi
##al
e
##ff
##usions
requiring
intervention
for
hem
##ody
##nam
##ic
compromise
)
in
the
PR
##AD
##A
##X
##A
treatment
arm
as
compared
to
the
war
##fari
##n
treatment
arm
.
[SEP]
[CLS]
E
##ps
##tein
-
Barr
virus
se
##rol
##ogy
should
be
as
##cer
##tain
##ed
before
starting
administration
of
N
##U
##L
##O
##J
##IX
,
and
only
patients
who
are
E
##B
##V
se
##rop
##os
##itive
should
receive
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
The
safety
of
X
##AL
##KO
##RI
is
based
primarily
on
34
##3
patients
with
AL
##K
-
positive
meta
##static
N
##SC
##LC
who
received
X
##AL
##KO
##RI
250
mg
twice
daily
in
two
open
-
label
,
random
##ized
,
active
-
controlled
trials
(
[SEP]
[CLS]
Studies
1
and
2
)
.
[SEP]
[CLS]
(
5
.
1
)
*
Pan
##cre
##ati
##tis
:
Disco
##ntin
##ue
promptly
if
suspected
.
[SEP]
[CLS]
To
minimize
the
risk
for
th
##rom
##bot
##ic
/
th
##rom
##boe
##mbo
##lic
complications
,
do
not
use
PR
##OM
##AC
##TA
in
an
attempt
to
normal
##ize
plate
##let
counts
.
[SEP]
[CLS]
Therefore
,
patients
may
require
a
lower
dose
of
su
##lf
##ony
##lu
##rea
or
insulin
to
reduce
the
risk
of
h
##y
##po
##gly
##ce
##mia
in
this
setting
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
,
[SEP]
[CLS]
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
*
H
##yper
##sen
##si
##ti
##vity
reactions
(
an
##aph
##yla
##ctic
##sh
##ock
,
h
##y
##pot
##ens
##ion
,
p
##har
##yn
##gol
##ary
##nge
##al
ed
##ema
,
u
##rt
##ica
##ria
,
face
ed
##ema
,
r
##hin
##itis
,
con
##junct
##iv
##itis
,
abdominal
pain
,
h
##y
##po
##est
##hesia
,
s
##nee
##zing
,
cough
and
[SEP]
[CLS]
p
##allo
##r
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
Ta
##chy
##card
##ia
*
Rest
##lessness
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
(
N
##SF
)
WA
##R
##NI
##NG
:
[SEP]
[CLS]
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
(
N
##SF
)
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
N
##SF
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
This
Pat
##ient
Information
has
been
approved
by
the
U
.
S
.
Food
and
Drug
Administration
.
[SEP]
[CLS]
MA
##L
##IG
##NA
##NC
##Y
L
##ymph
##oma
and
other
ma
##li
##gna
##ncies
,
some
fatal
,
have
been
reported
in
children
and
adolescent
patients
treated
with
T
##NF
block
##ers
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
[
[SEP]
[CLS]
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Two
of
these
trials
were
extensions
of
the
3
-
month
trials
,
and
one
was
a
dedicated
long
term
safety
trial
.
[SEP]
[CLS]
The
median
duration
on
treatment
was
4
.
9
months
for
patients
treated
with
T
##AF
##IN
##LA
##R
and
2
.
8
months
for
da
##car
##ba
##zine
-
treated
patients
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Am
##gen
Medical
Information
at
1
-
800
-
77
-
AM
##GE
##N
(
1
-
800
-
77
##2
-
64
##36
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Two
random
##ized
place
##bo
-
controlled
,
multi
##cent
##er
clinical
trials
enrolled
patients
who
had
meta
##static
cast
##ration
-
resistant
pro
##state
cancer
who
were
using
a
go
##nado
##tro
##pin
-
releasing
hormone
(
G
##n
##R
##H
)
ago
##nist
or
were
previously
treated
with
[SEP]
[CLS]
or
##chi
##ec
##tom
##y
.
[SEP]
[CLS]
In
both
Study
1
and
Study
2
Z
##Y
##TI
##GA
was
administered
at
a
dose
of
1
,
000
mg
daily
in
combination
with
pre
##dn
##ison
##e
5
mg
twice
daily
in
the
active
treatment
arms
[SEP]
[CLS]
.
[SEP]
[CLS]
*
H
##yper
##sen
##si
##ti
##vity
reactions
:
Ser
##ious
systemic
h
##yper
##sen
##si
##ti
##vity
reactions
including
an
##aph
##yla
##xi
##s
may
occur
(
5
.
10
)
.
[SEP]
[CLS]
(
5
.
4
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Ser
##ious
skin
reactions
have
been
reported
in
patients
treated
with
D
##AL
##VA
##NC
##E
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
[SEP]
[CLS]
.
[SEP]
[CLS]
ST
##EN
##DR
##A
200
mg
resulted
in
trans
##ient
decreases
in
sitting
blood
pressure
in
healthy
volunteers
of
8
.
0
mm
##H
##g
s
##ys
##to
##lic
and
3
.
3
mm
##H
##g
di
##ast
##olic
[
see
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
2
)
]
,
[SEP]
[CLS]
with
the
maximum
decrease
observed
at
1
hour
after
dos
##ing
.
[SEP]
[CLS]
5
.
2
Card
##iovascular
Di
##sor
##ders
E
##stro
##gen
ago
##nist
/
antagonist
##s
(
including
b
##azed
##ox
##ife
##ne
,
a
component
of
D
##U
##AV
##EE
)
and
est
##rogen
##s
individually
are
known
to
increase
the
risk
of
V
##TE
.
[SEP]
[CLS]
The
use
of
er
##yt
##hr
##op
##oi
##esis
s
##ti
##mulating
agents
(
E
##SA
##s
)
was
permitted
for
management
of
an
##emia
,
at
the
investigator
'
s
discretion
,
with
or
without
rib
##avi
##rin
dose
reduction
in
the
[SEP]
[CLS]
Phase
2
and
3
clinical
trials
.
[SEP]
[CLS]
Re
##sume
T
##AF
##IN
##LA
##R
at
the
same
dose
level
upon
recovery
of
cardiac
function
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
These
bleeding
and
th
##rom
##boe
##mbo
##lic
events
were
seen
both
in
patients
who
were
initiated
on
PR
##AD
##A
##X
##A
post
-
operative
##ly
within
three
days
of
mechanical
bi
##leaf
##let
valve
imp
##lant
##ation
,
as
well
as
in
patients
[SEP]
[CLS]
whose
valves
had
been
imp
##lanted
more
than
three
months
prior
to
enrollment
.
[SEP]
[CLS]
*
Ang
##io
##ede
##ma
with
con
##com
##ita
##nt
use
of
AC
##E
inhibitor
##s
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Results
from
these
studies
did
not
change
the
safety
profile
of
Pi
##cat
##o
(
r
)
gel
.
[SEP]
[CLS]
No
severe
injection
-
site
reactions
were
reported
and
none
led
to
disco
##ntin
##uation
of
treatment
.
[SEP]
[CLS]
Anti
##bo
##dies
against
IL
##AR
##IS
were
observed
in
approximately
1
.
5
%
and
3
.
1
%
of
the
patients
treated
with
IL
##AR
##IS
for
CA
##PS
and
S
##J
##IA
,
respectively
.
[SEP]
[CLS]
Monitor
plate
##let
counts
frequently
during
treatment
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
In
the
event
of
drug
-
induced
pulmonary
toxicity
,
disco
##ntin
##ue
K
##y
##p
##rol
##is
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
(
5
.
14
)
*
See
Full
Pre
##s
##cribing
Information
for
additional
WA
##R
##NI
##NG
##S
and
PR
##EC
##A
##UT
##ION
##S
.
[SEP]
[CLS]
He
##pa
##titis
B
and
/
or
He
##pa
##titis
C
V
##ir
##us
Co
-
infection
:
In
Phase
3
trials
,
subjects
with
he
##pa
##titis
B
and
/
or
C
virus
co
-
infection
were
permitted
to
en
##roll
provided
that
base
##line
liver
chemistry
[SEP]
[CLS]
tests
did
not
exceed
5
times
the
upper
limit
of
normal
.
[SEP]
[CLS]
Skin
,
scalp
,
and
o
##cular
irritation
were
monitored
in
the
clinical
trials
.
[SEP]
[CLS]
(
5
.
1
)
*
Weight
Dec
##rease
:
Monitor
weight
regularly
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
incidence
>
=
50
%
)
were
an
##emia
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
h
##yper
##tri
##gly
##cer
##ide
##mia
,
h
##yper
##gly
##ce
##mia
,
l
##ymph
##ope
##nia
,
and
increased
c
##rea
##tin
##ine
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
from
Clinical
Trials
of
the
Co
##mpo
##nent
##s
of
ST
##RI
##BI
##LD
Em
##tric
##ita
##bine
and
Ten
##of
##ov
##ir
Di
##so
##p
##ro
##xi
##l
Fu
##mara
##te
:
In
addition
to
the
adverse
reactions
observed
with
ST
##RI
##BI
##LD
,
the
following
adverse
reactions
[SEP]
[CLS]
occurred
in
at
least
5
%
of
treatment
-
experienced
or
treatment
-
naive
subjects
receiving
em
##tric
##ita
##bine
or
ten
##of
##ov
##ir
D
##F
with
other
anti
##ret
##rov
##ira
##l
agents
in
other
clinical
trials
:
depression
,
abdominal
pain
,
[SEP]
[CLS]
d
##ys
##pe
##ps
##ia
,
vomit
##ing
,
fever
,
pain
,
na
##so
##pha
##ryn
##git
##is
,
pneumonia
,
sin
##us
##itis
,
upper
respiratory
tract
infection
,
art
##hra
##l
##gia
,
back
pain
,
my
##al
##gia
,
par
##est
##hesia
,
[SEP]
[CLS]
peripheral
ne
##uro
##pathy
(
including
peripheral
ne
##uri
##tis
)
,
anxiety
,
increased
cough
,
and
r
##hin
##itis
.
[SEP]
[CLS]
While
subjects
aged
12
to
17
years
were
included
in
these
trials
,
BR
##E
##O
E
##LL
##IP
##TA
is
not
approved
for
use
in
this
age
-
group
[
see
Use
in
S
##pecific
Population
##s
(
[SEP]
[CLS]
8
.
4
)
]
.
[SEP]
[CLS]
breathing
difficulties
can
be
life
threatening
and
there
have
been
reports
of
death
.
[SEP]
[CLS]
These
reactions
can
occur
within
hours
to
weeks
after
injection
with
b
##ot
##ulin
##um
to
##xin
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
IN
##L
##Y
##TA
if
signs
or
symptoms
of
R
##PL
##S
occur
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
adverse
reactions
(
incidence
>
=
2
%
)
were
s
##tom
##ati
##tis
,
p
##yre
##xia
,
pneumonia
,
gas
##tro
##enter
##itis
,
aggression
,
agitation
,
and
am
##eno
##rr
##hea
.
[SEP]
[CLS]
Pat
##ients
with
active
acute
or
chronic
infections
should
not
start
treatment
until
the
infection
(
s
)
is
resolved
.
[SEP]
[CLS]
In
a
study
of
69
##7
patients
with
available
24
-
hour
Holt
##er
monitoring
data
after
their
first
dose
(
N
=
35
##1
receiving
G
##IL
##EN
##Y
##A
and
N
=
34
##6
on
place
##bo
)
,
second
-
degree
A
##V
blocks
]
[SEP]
[CLS]
or
2
:
1
A
##V
blocks
)
occurred
in
4
%
(
N
=
14
)
of
patients
receiving
G
##IL
##EN
##Y
##A
and
2
%
(
N
=
7
)
of
patients
on
place
##bo
.
[SEP]
[CLS]
(
2
.
3
,
5
.
4
)
*
Ren
##al
To
##xi
##city
Monitor
patients
for
re
##nal
function
at
base
##line
and
during
therapy
with
B
##OS
##U
##L
##IF
(
5
.
5
)
*
Em
##b
##ryo
##fe
##tal
To
##xi
##city
:
May
cause
[SEP]
[CLS]
f
##etal
harm
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
The
safety
of
To
##via
##z
was
evaluated
in
Phase
2
and
3
controlled
trials
in
a
total
of
285
##9
patients
with
over
##active
bladder
,
of
which
228
##8
[SEP]
[CLS]
were
treated
with
f
##es
##oter
##od
##ine
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
5
mg
or
10
mg
twice
daily
with
flexible
dos
##ing
.
[SEP]
[CLS]
Treatment
of
Post
##men
##op
##aus
##al
Women
with
O
##ste
##op
##oro
##sis
The
safety
of
Pro
##lia
in
the
treatment
of
post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
was
assessed
in
a
3
-
year
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
,
multinational
study
[SEP]
[CLS]
of
78
##0
##8
post
##men
##op
##aus
##al
women
aged
60
to
91
years
.
[SEP]
[CLS]
Se
##vere
elevations
(
greater
than
or
equal
to
6
.
5
m
##E
##q
/
L
)
occurred
in
0
.
4
%
of
patients
treated
with
place
##bo
,
no
patients
treated
with
IN
##VO
##KA
##NA
100
mg
,
and
[SEP]
[CLS]
1
.
3
%
of
patients
treated
with
IN
##VO
##KA
##NA
300
mg
.
[SEP]
[CLS]
Disco
##ntin
##ue
S
##IR
##TU
##RO
if
significant
vent
##ric
##ular
a
##rr
##hy
##th
##mia
or
if
Q
##T
##c
##F
interval
pro
##long
##ation
of
greater
than
500
m
##s
develops
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
The
most
frequently
reported
o
##cular
adverse
reaction
was
con
##junct
##ival
red
##ness
,
reported
in
approximately
2
%
of
patients
.
[SEP]
[CLS]
Fat
##al
adverse
events
in
X
##AL
##KO
##RI
-
treated
patients
occurred
in
2
.
3
%
patients
,
consisting
of
se
##ptic
shock
,
acute
respiratory
failure
,
and
di
##abe
##tic
k
##eto
##ac
##ido
##sis
.
[SEP]
[CLS]
(
5
.
1
)
*
H
##yper
##sen
##si
##ti
##vity
:
There
have
been
post
##market
##ing
reports
of
serious
h
##yper
##sen
##si
##ti
##vity
reactions
in
patients
treated
with
NE
##SI
##NA
such
as
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
and
severe
[SEP]
[CLS]
cut
##aneous
adverse
reactions
.
[SEP]
[CLS]
Ad
##verse
events
leading
to
dose
reduction
occurred
in
approximately
6
%
of
patients
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
Report
##ed
by
at
Lea
##st
1
%
of
Sub
##jects
T
##reate
##d
for
up
to
48
Weeks
Ad
##verse
Event
,
n
(
%
)
J
##U
##BL
##IA
##N
=
122
##7
Vehicle
##N
[SEP]
[CLS]
=
41
##3
In
##grown
toe
##nail
28
(
2
.
3
%
)
3
(
0
.
7
%
)
Application
site
der
##mat
##itis
27
(
2
.
2
%
)
1
(
0
.
2
%
)
[SEP]
[CLS]
Application
site
ve
##si
##cles
20
(
1
.
6
%
)
0
(
0
.
0
%
)
Application
site
pain
13
(
1
.
1
%
)
1
(
0
.
2
%
)
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
(
>
=
20
%
)
adverse
reactions
are
di
##ar
##r
##hea
,
h
##yper
##tens
##ion
,
fatigue
,
decreased
appetite
,
nausea
,
d
##ys
##phon
##ia
,
hand
-
foot
)
syndrome
,
[SEP]
[CLS]
weight
decreased
,
vomit
##ing
,
as
##the
##nia
,
and
con
##st
##ip
##ation
.
[SEP]
[CLS]
The
possibility
of
these
adverse
events
should
be
considered
in
patients
treated
with
PR
##IS
##TI
##Q
who
present
with
progressive
d
##ys
##p
##nea
,
cough
,
or
chest
discomfort
.
[SEP]
[CLS]
Disco
##ntin
##ue
promptly
if
pan
##cre
##ati
##tis
is
suspected
.
[SEP]
[CLS]
5
.
4
H
##yper
##sen
##si
##ti
##vity
Re
##actions
System
##ic
h
##yper
##sen
##si
##ti
##vity
reactions
were
observed
in
patients
receiving
T
##R
##U
##L
##IC
##IT
##Y
in
clinical
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
If
such
effects
occur
,
BR
##E
##O
E
##LL
##IP
##TA
should
be
reduced
slowly
,
consistent
with
accepted
procedures
for
reducing
systemic
co
##rt
##ico
##ster
##oids
,
and
other
treatments
for
management
of
CO
##PD
or
as
##th
##ma
[SEP]
[CLS]
symptoms
should
be
considered
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
ass
##ay
results
are
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
used
in
detection
and
may
be
influenced
by
several
factors
,
including
sample
handling
,
timing
[SEP]
[CLS]
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
*
Blood
and
L
##ymph
##atic
System
Di
##sor
##ders
:
l
##ymph
##ope
##nia
*
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
pan
##cre
##ati
##tis
*
He
##pa
##to
##bil
##iary
Di
##sor
##ders
:
he
##pa
##to
##to
##xi
##city
*
I
##mm
##une
System
Di
##sor
##ders
:
drug
h
##yper
##sen
##si
##ti
##vity
*
In
##fect
##ions
and
In
##fest
##ations
:
[SEP]
[CLS]
pneumonia
,
se
##psis
/
ne
##ut
##rop
##eni
##c
se
##psis
*
Met
##ab
##olis
##m
and
N
##utrition
Di
##sor
##ders
:
h
##y
##po
##ma
##gne
##se
##mia
,
de
##hy
##dra
##tion
*
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
and
media
##st
##inal
disorders
:
inter
##st
##iti
##al
lung
disease
*
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
[SEP]
[CLS]
:
p
##ru
##rit
##us
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
N
##eu
##tro
##pen
##ia
:
Monitor
peripheral
blood
cell
counts
and
adjust
dose
as
appropriate
(
2
.
2
,
5
.
1
,
6
)
*
[SEP]
[CLS]
Per
##ip
##her
##al
N
##eur
##op
##athy
:
Monitor
for
signs
of
ne
##uro
##pathy
.
[SEP]
[CLS]
Pat
##ients
treated
with
Te
##f
##lar
##o
were
predominantly
male
(
63
%
)
and
Caucasian
(
82
%
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Common
##ly
observed
adverse
reactions
(
incidence
>
=
5
%
and
2
-
fold
greater
than
place
##bo
)
were
:
di
##zzi
##ness
,
dry
mouth
,
fatigue
,
[SEP]
[CLS]
nasal
congestion
,
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
so
##m
##no
##len
##ce
,
ta
##chy
##card
##ia
,
and
weight
increased
.
[SEP]
[CLS]
However
,
exceeding
the
recommended
dos
##age
or
co
##ad
##mini
##stra
##tion
with
a
strong
c
##yt
##och
##rome
P
##45
##0
3
##A
##4
(
C
##YP
##3
##A
##4
)
inhibitor
may
result
in
HP
##A
d
##ys
##function
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
9
[SEP]
[CLS]
)
,
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
The
finding
of
increased
risk
with
A
##ED
##s
of
varying
mechanisms
of
action
and
across
a
range
of
indication
##s
suggests
that
the
risk
applies
to
all
A
##ED
##s
used
for
any
indication
[SEP]
[CLS]
.
[SEP]
[CLS]
Due
to
higher
MMA
##E
exposure
,
>
=
Grade
3
adverse
reactions
may
be
more
frequent
in
patients
with
severe
re
##nal
imp
##air
##ment
compared
to
patients
with
normal
re
##nal
function
.
[SEP]
[CLS]
5
.
5
Ang
##le
C
##losure
G
##lau
##com
##a
Ang
##le
-
C
##losure
G
##lau
##com
##a
:
The
pupil
##lary
di
##lation
that
occurs
following
use
of
many
anti
##de
##press
##ant
drugs
including
P
##rist
##iq
may
trigger
an
angle
closure
attack
in
a
patient
with
[SEP]
[CLS]
an
##ato
##mic
##ally
narrow
angles
who
does
not
have
a
patent
i
##ride
##ct
##omy
.
[SEP]
[CLS]
In
controlled
and
un
##con
##tro
##lled
studies
,
1
,
56
##4
patients
received
C
##IM
##Z
##IA
at
some
dose
level
,
of
whom
1
,
350
patients
received
400
mg
C
##IM
##Z
##IA
.
[SEP]
[CLS]
At
base
##line
,
17
%
of
the
population
in
these
studies
reported
peripheral
ne
##uro
##pathy
and
4
%
reported
re
##tino
##pathy
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
T
##hy
##roid
C
-
cell
Tu
##mor
##s
:
See
Box
##ed
Warning
(
5
.
1
)
.
[SEP]
[CLS]
The
dose
was
reduced
in
79
%
of
patients
receiving
CO
##ME
##TR
##I
##Q
compared
to
9
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Fun
##gus
invasion
must
be
considered
in
any
persistent
corn
##eal
ul
##cer
##ation
where
a
s
##tero
##id
has
been
used
or
is
in
use
.
[SEP]
[CLS]
Pat
##ients
should
be
closely
monitored
for
signs
or
symptoms
of
these
events
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
diabetes
for
an
average
of
9
years
,
had
a
mean
H
##b
##A
##1
##c
of
8
.
2
%
,
and
30
%
had
established
micro
##vas
##cular
disease
.
[SEP]
[CLS]
In
patients
with
normal
or
mildly
impaired
re
##nal
function
at
base
##line
,
serum
c
##rea
##tin
##ine
and
e
##G
##F
##R
returned
to
base
##line
values
at
Week
24
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
He
##mor
##r
##hage
:
Monitor
for
bleeding
(
5
.
1
)
.
[SEP]
[CLS]
The
most
common
Grade
3
or
4
non
-
hem
##ato
##logical
adverse
reactions
(
>
=
5
%
)
were
pneumonia
,
abdominal
pain
,
at
##rial
fi
##bri
##lla
##tion
,
di
##ar
##r
##hea
,
fatigue
,
and
[SEP]
[CLS]
skin
infections
.
[SEP]
[CLS]
These
adverse
reactions
are
included
based
on
clinical
relevance
and
ranked
in
order
of
decreasing
serious
##ness
within
each
category
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
worldwide
post
-
approval
use
of
in
##da
##cate
##rol
,
the
active
ingredient
in
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
.
[SEP]
[CLS]
The
mean
base
##line
non
-
HD
##L
-
C
levels
were
140
to
147
mg
/
d
##L
across
treatment
groups
.
[SEP]
[CLS]
Do
##se
adjustments
(
interrupt
##ions
or
reduction
##s
)
due
to
adverse
reactions
occurred
in
55
%
of
A
##FI
##NI
##TO
##R
-
treated
patients
.
[SEP]
[CLS]
Pat
##ients
with
symptoms
and
signs
consistent
with
cry
##pt
##oc
##oc
##cal
men
##ing
##itis
should
undergo
pro
##mpt
diagnostic
evaluation
and
treatment
.
[SEP]
[CLS]
5
.
6
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
(
e
.
g
.
,
generalized
u
##rt
##ica
##ria
)
,
some
serious
,
were
reported
with
IN
##VO
##KA
##NA
treatment
;
these
reactions
generally
occurred
within
hours
to
days
after
[SEP]
[CLS]
in
##iti
##ating
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
A
decision
on
whether
or
not
to
disco
##ntin
##ue
G
##IL
##EN
##Y
##A
therapy
should
include
an
assessment
of
the
potential
benefits
and
risks
for
the
individual
patient
.
[SEP]
[CLS]
No
cases
of
to
##rsa
##de
de
point
##es
or
other
severe
cardiac
a
##rr
##hy
##th
##mia
##s
were
observed
during
the
pre
-
marketing
clinical
program
.
[SEP]
[CLS]
Pat
##ients
receiving
more
than
3
doses
of
an
op
##io
##id
within
the
week
prior
to
surgery
were
not
studied
in
the
post
##oper
##ative
il
##eus
clinical
trials
.
[SEP]
[CLS]
(
5
.
6
)
*
I
##mm
##uni
##zation
:
Live
vaccine
##s
should
not
be
given
concurrently
with
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Depression
:
Ad
##vise
patients
,
their
care
##gi
##vers
,
and
families
to
be
alert
for
the
emergence
or
worse
##ning
of
depression
,
su
##icidal
thoughts
[SEP]
[CLS]
or
other
mood
changes
and
if
such
changes
occur
to
contact
their
healthcare
provider
.
[SEP]
[CLS]
Death
##s
due
to
acute
respiratory
failure
(
0
.
7
%
)
,
infection
(
0
.
7
%
)
,
and
acute
re
##nal
failure
(
0
.
4
%
)
were
observed
on
the
A
##FI
##NI
##TO
##R
[SEP]
[CLS]
arm
but
none
on
the
place
##bo
arm
.
[SEP]
[CLS]
Monitor
blood
pressure
,
both
in
the
su
##pine
position
and
in
the
recommended
head
-
elevated
sleeping
position
.
[SEP]
[CLS]
6
.
2
Clinical
Trials
Experience
in
As
##th
##ma
In
a
6
-
month
random
##ized
,
active
controlled
as
##th
##ma
safety
trial
,
80
##5
adult
patients
with
moderate
to
severe
persistent
as
##th
##ma
were
treated
with
AR
##CA
##P
##TA
[SEP]
[CLS]
NE
##OH
##AL
##ER
300
m
##c
##g
(
n
=
26
##8
)
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
600
m
##c
##g
(
n
=
26
##8
)
,
and
sa
##lm
##eter
##ol
(
n
=
26
##9
)
,
all
con
##com
##ita
##nt
with
inhaled
co
##rt
##ico
##ster
##oids
,
which
were
not
[SEP]
[CLS]
co
-
random
##ized
.
[SEP]
[CLS]
The
data
reflect
the
percentage
of
patients
whose
test
results
were
considered
positive
for
antibodies
to
al
##g
##lu
##cos
##idas
##e
al
##fa
using
an
enzyme
-
linked
im
##mu
##nos
##or
##bent
ass
##ay
(
E
##L
##IS
##A
)
and
confirmed
by
a
[SEP]
[CLS]
radio
##im
##mu
##no
##p
##re
##ci
##pit
##ation
(
R
##IP
)
ass
##ay
for
al
##g
##lu
##cos
##idas
##e
al
##fa
-
specific
I
##g
##G
antibodies
.
[SEP]
[CLS]
The
safety
of
H
##OR
##I
##Z
##AN
##T
in
doses
ranging
from
1
,
200
to
3
,
600
mg
has
been
evaluated
in
41
##7
patients
with
P
##H
##N
in
3
clinical
studies
.
[SEP]
[CLS]
Man
##age
fluid
and
electro
##ly
##te
levels
as
appropriate
,
supplement
protein
intake
,
monitor
anti
##ba
##cter
##ial
treatment
of
C
.
di
##ff
##ici
##le
,
and
institute
surgical
evaluation
as
clinical
##ly
indicated
.
[SEP]
[CLS]
(
5
.
6
)
*
Graf
##t
Loss
with
Co
##rt
##ico
##ster
##oid
Mini
##mi
##zation
:
co
##rt
##ico
##ster
##oid
u
##til
##ization
should
be
consistent
with
the
N
##U
##L
##O
##J
##IX
clinical
trial
experience
.
[SEP]
[CLS]
If
U
##LE
##SF
##IA
(
r
)
Lot
##ion
comes
in
contact
with
the
eyes
,
flush
them
immediately
with
water
.
[SEP]
[CLS]
Con
##sist
##ent
with
the
high
ho
##mology
of
al
##bi
##g
##lut
##ide
with
human
G
##LP
-
1
,
the
majority
of
patients
(
approximately
79
%
)
with
anti
-
al
##bi
##g
##lut
##ide
antibodies
also
tested
positive
for
anti
-
G
##LP
-
1
antibodies
;
[SEP]
[CLS]
none
were
neutral
##izing
.
[SEP]
[CLS]
Previously
Un
##tre
##ated
AL
##K
-
Po
##sitive
Met
##ast
##atic
N
##SC
##LC
-
Study
1
The
data
in
Table
3
are
derived
from
340
patients
with
AL
##K
-
positive
meta
##static
N
##SC
##LC
who
had
not
received
previous
systemic
treatment
for
[SEP]
[CLS]
advanced
disease
who
received
treatment
in
a
random
##ized
,
multi
##cent
##er
,
open
-
label
,
active
-
controlled
trial
(
Study
1
)
.
[SEP]
[CLS]
Consider
the
benefits
and
risks
before
ne
##ura
##xial
intervention
in
patients
anti
##coa
##gu
##lated
or
to
be
anti
##coa
##gu
##lated
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
The
time
to
onset
of
symptoms
varied
from
one
day
to
several
months
after
starting
Pro
##lia
.
[SEP]
[CLS]
Seven
th
##rom
##bot
##ic
complications
(
six
patients
)
were
reported
in
the
group
that
received
PR
##OM
##AC
##TA
and
three
th
##rom
##bot
##ic
complications
were
reported
in
the
place
##bo
group
(
two
patients
)
.
[SEP]
[CLS]
Active
In
##g
##red
##ients
:
con
##ju
##gated
est
##rogen
##s
and
b
##azed
##ox
##ife
##ne
.
[SEP]
[CLS]
The
following
groups
of
patients
were
not
included
in
clinical
safety
and
efficacy
trials
for
ST
##EN
##DR
##A
,
and
therefore
until
further
information
is
available
,
ST
##EN
##DR
##A
is
not
recommended
for
[SEP]
[CLS]
the
following
groups
:
*
Pat
##ients
who
have
suffered
a
my
##oc
##ard
##ial
in
##far
##ction
,
stroke
,
life
-
threatening
a
##rr
##hy
##th
##mia
,
or
co
##rona
##ry
re
##vas
##cular
##ization
within
the
last
6
months
;
*
Pat
##ients
with
[SEP]
[CLS]
resting
h
##y
##pot
##ens
##ion
(
blood
pressure
less
than
90
/
50
mm
##H
##g
)
or
h
##yper
##tens
##ion
(
blood
pressure
greater
than
170
/
100
mm
##H
##g
)
;
*
Pat
##ients
with
unstable
an
##gin
##a
,
an
##gin
##a
with
sexual
[SEP]
[CLS]
intercourse
,
or
New
York
Heart
Association
Class
2
or
greater
con
##ges
##tive
heart
failure
.
[SEP]
[CLS]
The
next
dose
of
E
##L
##I
##Q
##UI
##S
should
not
be
administered
earlier
than
5
hours
after
the
removal
of
the
cat
##he
##ter
.
[SEP]
[CLS]
A
patient
who
develops
a
new
infection
during
treatment
with
C
##IM
##Z
##IA
should
be
closely
monitored
,
undergo
a
pro
##mpt
and
complete
diagnostic
work
##up
appropriate
for
an
im
##mu
##no
##com
##p
##rom
##ised
patient
,
and
[SEP]
[CLS]
appropriate
anti
##mic
##ro
##bial
therapy
should
be
initiated
.
[SEP]
[CLS]
5
.
4
C
##los
##tri
##dium
di
##ff
##ici
##le
-
Associated
Di
##ar
##r
##hea
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
(
CD
##AD
)
has
been
reported
in
users
of
nearly
all
systemic
anti
##ba
##cter
##ial
drugs
,
including
D
##AL
##VA
##NC
##E
,
with
severity
ranging
from
[SEP]
[CLS]
mild
di
##ar
##r
##hea
to
fatal
co
##lit
##is
.
[SEP]
[CLS]
During
adult
pre
-
marketing
clinical
trials
with
SA
##P
##H
##RI
##S
,
including
long
-
term
trials
without
comparison
to
place
##bo
,
s
##ync
##ope
was
reported
in
0
.
6
%
(
11
/
1953
)
of
patients
treated
with
SA
##P
##H
##RI
##S
[SEP]
[CLS]
.
[SEP]
[CLS]
*
The
risk
for
N
##SF
appears
highest
among
patients
with
:
Ch
##ronic
,
severe
kidney
disease
(
G
##F
##R
<
30
m
##L
/
min
/
1
.
73
##m
##2
)
,
or
##A
##cute
kidney
injury
.
[SEP]
[CLS]
Trial
1
,
a
multi
##cent
##er
,
international
,
open
-
label
,
random
##ized
(
3
:
1
)
,
controlled
trial
allocated
250
patients
with
un
##res
##ec
##table
or
meta
##static
BR
##AF
V
##60
##0
##E
mutation
-
positive
me
##lan
##oma
to
receive
[SEP]
[CLS]
T
##AF
##IN
##LA
##R
150
mg
oral
##ly
twice
daily
(
n
=
187
)
or
da
##car
##ba
##zine
1
,
000
mg
/
m
2
in
##tra
##ven
##ously
every
3
weeks
(
n
=
63
)
.
[SEP]
[CLS]
5
.
8
Q
##T
Inter
##val
Pro
##long
##ation
Dr
##oned
##aro
##ne
induce
##s
a
moderate
(
average
of
about
10
m
##s
but
much
greater
effects
have
been
observed
)
Q
##T
##c
(
Ba
##ze
##tt
)
pro
##long
##ation
[
see
Clinical
[SEP]
[CLS]
Ph
##arma
##cology
(
12
.
2
)
and
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
with
left
vent
##ric
##ular
out
##flow
o
##bs
##truction
(
e
.
g
.
,
a
##ort
##ic
s
##ten
##osis
,
id
##io
##pathic
h
##yper
##tro
##phic
sub
##ao
##rt
##ic
s
##ten
##osis
)
and
those
with
severely
impaired
auto
##no
##mic
control
of
blood
pressure
can
be
particularly
[SEP]
[CLS]
sensitive
to
the
actions
of
v
##as
##od
##ila
##tors
,
including
ST
##EN
##DR
##A
.
[SEP]
[CLS]
All
of
the
th
##rom
##bot
##ic
complications
reported
in
the
group
that
received
PR
##OM
##AC
##TA
were
portal
vein
th
##rom
##bos
##is
(
P
##V
##T
)
.
[SEP]
[CLS]
Met
##ab
##olis
##m
and
nutrition
disorders
:
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
In
Trial
2
,
op
##ht
##hal
##mo
##log
##ic
examinations
including
re
##tina
##l
evaluation
were
performed
pre
##tre
##at
##ment
and
at
regular
intervals
during
treatment
.
[SEP]
[CLS]
If
ne
##uro
##logical
compromise
is
noted
,
urgent
treatment
is
necessary
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
In
##st
##ru
##ct
patients
to
immediately
report
if
they
experience
any
of
the
above
signs
or
symptoms
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
connect
##ive
tissue
disorders
-
Mu
##s
##cu
##los
##kel
##etal
stiff
##ness
.
[SEP]
[CLS]
(
2
.
2
)
Death
##s
have
occurred
due
to
gas
##tro
##int
##est
##inal
hem
##or
##r
##hage
and
ne
##ut
##rop
##eni
##c
enter
##oc
##oli
##tis
.
[SEP]
[CLS]
In
CA
##PS
trials
one
patient
discontinued
and
in
S
##J
##IA
trials
no
patients
discontinued
due
to
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
Ad
##verse
reactions
that
occurred
in
>
=
2
%
of
subjects
treated
with
Pi
##cat
##o
(
r
)
gel
and
at
a
higher
frequency
than
the
vehicle
are
presented
in
Table
3
[SEP]
[CLS]
and
Table
4
.
[SEP]
[CLS]
(
5
.
1
,
5
.
4
,
5
.
5
)
*
Live
##r
transplant
:
use
is
not
recommended
.
[SEP]
[CLS]
5
.
5
P
##ul
##mona
##ry
H
##yper
##tens
##ion
P
##ul
##mona
##ry
art
##erial
h
##yper
##tens
##ion
(
PA
##H
)
was
reported
in
approximately
1
%
of
patients
treated
with
K
##y
##p
##rol
##is
and
was
Grade
3
or
greater
in
less
than
1
[SEP]
[CLS]
%
of
patients
.
[SEP]
[CLS]
These
data
reflect
exposure
of
166
##7
patients
to
IN
##VO
##KA
##NA
and
a
mean
duration
of
exposure
to
IN
##VO
##KA
##NA
of
24
weeks
.
[SEP]
[CLS]
With
K
##y
##p
##rol
##is
mon
##otherapy
,
the
incidence
of
ve
##nous
th
##rom
##boe
##mbo
##lic
events
was
2
%
.
[SEP]
[CLS]
Treatment
-
experienced
,
In
##te
##gra
##se
Strand
Transfer
In
##hibit
##or
-
naive
Sub
##jects
:
Laboratory
abnormal
##ities
observed
in
SA
##IL
##ING
were
generally
similar
compared
with
observations
seen
in
the
treatment
-
naive
(
SP
##RI
##NG
-
2
and
S
##ING
##LE
)
trials
.
[SEP]
[CLS]
The
use
of
FA
##NA
##P
##T
should
be
avoided
in
combination
with
other
drugs
that
are
known
to
pro
##long
Q
##T
##c
including
Class
1A
(
e
.
g
.
,
q
##uin
##id
##ine
,
pro
##ca
##ina
##mi
##de
)
or
Class
[SEP]
[CLS]
III
(
e
.
g
.
,
am
##io
##dar
##one
,
so
##tal
##ol
)
anti
##ar
##r
##hy
##th
##mic
medications
,
anti
##psy
##cho
##tic
medications
(
e
.
g
.
,
ch
##lor
##p
##roma
##zine
,
th
##ior
##ida
##zine
)
,
anti
##biotics
(
e
.
g
.
,
g
##ati
##f
##lo
##xa
##cin
,
m
##ox
##if
##lo
##xa
##cin
)
,
[SEP]
[CLS]
or
any
other
class
of
medications
known
to
pro
##long
the
Q
##T
##c
interval
(
e
.
g
.
,
pen
##tam
##id
##ine
,
le
##vo
##met
##hady
##l
ace
##tate
,
met
##had
##one
)
.
[SEP]
[CLS]
The
risk
of
re
##cu
##rrence
after
re
##chal
##len
##ge
has
not
been
evaluated
.
[SEP]
[CLS]
5
.
3
Cat
##ara
##cts
Case
##s
of
non
-
con
##gen
##ital
lens
op
##ac
##ities
have
been
reported
in
p
##ediatric
patients
treated
with
K
##AL
##Y
##DE
##CO
.
[SEP]
[CLS]
N
##SF
has
not
been
reported
in
patients
with
a
clear
history
of
exposure
to
D
##OT
##AR
##EM
alone
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
additional
adverse
reactions
have
been
identified
during
post
##market
##ing
use
of
D
##OT
##AR
##EM
.
[SEP]
[CLS]
Cry
##pt
##oc
##oc
##cal
infections
Cry
##pt
##oc
##oc
##cal
infections
,
including
cases
of
cry
##pt
##oc
##oc
##cal
men
##ing
##itis
,
have
been
reported
with
G
##IL
##EN
##Y
##A
in
the
post
##market
##ing
setting
.
[SEP]
[CLS]
If
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
disco
##ntin
##ue
use
of
IN
##VO
##KA
##NA
;
treat
and
monitor
until
signs
and
symptoms
resolve
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
With
continued
dos
##ing
,
the
heart
rate
returns
to
base
##line
within
1
month
of
chronic
treatment
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
(
N
##SF
)
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
N
##SF
among
[SEP]
[CLS]
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
Blood
pressure
should
be
well
-
controlled
prior
to
in
##iti
##ating
IN
##L
##Y
##TA
.
[SEP]
[CLS]
Therefore
,
Units
of
biological
activity
of
X
##E
##OM
##IN
can
not
be
compared
to
or
converted
into
Units
of
any
other
b
##ot
##ulin
##um
to
##xin
products
(
5
.
2
)
.
[SEP]
[CLS]
S
Also
includes
the
F
##lex
##ible
-
dose
trial
(
N
=
90
)
.
[SEP]
[CLS]
Su
##mma
##ry
of
Treatment
-
Em
##er
##gent
Laboratory
A
##b
##nor
##mal
##ities
with
Grade
3
or
4
Inc
##iden
##ce
of
>
=
4
%
in
X
##AL
##KO
##RI
-
T
##reate
##d
Pat
##ients
in
Study
1
Laboratory
A
##b
##nor
##mal
##ity
X
##AL
##KO
##RI
Ch
##em
##otherapy
Any
Grade
(
%
)
[SEP]
[CLS]
Grade
3
/
4
(
%
)
Any
Grade
(
%
)
Grade
3
/
4
(
%
)
He
##mat
##ology
N
##eu
##tro
##pen
##ia
52
11
59
16
L
##ymph
##ope
##nia
48
7
53
13
Chemistry
AL
##T
elevation
79
[SEP]
[CLS]
15
33
2
AS
##T
elevation
66
8
28
1
H
##y
##pop
##hos
##phate
##mia
32
10
21
6
Previously
T
##reate
##d
AL
##K
-
Po
##sitive
Met
##ast
##atic
N
##SC
##LC
-
Study
2
The
data
in
Table
5
are
derived
from
[SEP]
[CLS]
34
##3
patients
with
AL
##K
-
positive
meta
##static
N
##SC
##LC
enrolled
in
a
random
##ized
,
multi
##cent
##er
,
active
-
controlled
,
open
-
label
trial
(
Study
2
)
.
[SEP]
[CLS]
5
.
5
Inc
##rease
in
Blood
Press
##ure
In
clinical
trials
,
increases
in
blood
pressure
occurred
during
or
shortly
after
exposure
to
Q
##ute
##nza
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reaction
(
incidence
>
=
1
.
5
%
)
occurring
with
a
higher
frequency
than
place
##bo
among
E
##NT
##ER
##EG
-
treated
patients
undergoing
surge
##ries
that
included
[SEP]
[CLS]
a
bow
##el
re
##section
was
d
##ys
##pe
##ps
##ia
.
[SEP]
[CLS]
In
the
pool
of
four
place
##bo
controlled
trials
,
the
mean
percent
change
in
serum
phosphate
levels
were
3
.
6
%
and
5
.
1
%
with
IN
##VO
##KA
##NA
100
mg
and
IN
##VO
##KA
##NA
300
[SEP]
[CLS]
mg
,
respectively
,
compared
to
1
.
5
%
with
place
##bo
.
[SEP]
[CLS]
While
all
of
the
drugs
in
the
class
have
been
shown
to
produce
some
metabolic
changes
,
each
drug
has
its
own
specific
risk
profile
.
[SEP]
[CLS]
In
the
mon
##otherapy
study
,
the
incidence
of
h
##y
##po
##gly
##ce
##mia
was
1
.
5
%
in
patients
treated
with
NE
##SI
##NA
compared
to
1
.
6
%
with
place
##bo
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
in
patients
with
per
##fo
##ration
or
fist
##ula
.
[SEP]
[CLS]
Management
of
these
events
may
require
either
temporary
interrupt
##ion
or
disco
##ntin
##uation
of
B
##L
##IN
##C
##Y
##TO
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Table
4
:
Change
in
Cho
##les
##tero
##l
Mean
Change
from
Basel
##ine
(
mg
/
d
##L
)
3
-
6
months
6
-
12
months
>
12
months
FA
##NA
##P
##T
10
-
16
mg
/
day
-
3
.
9
(
N
=
78
##3
)
-
3
.
9
(
N
=
72
##6
[SEP]
[CLS]
)
-
7
.
7
(
N
=
42
##8
)
FA
##NA
##P
##T
20
-
24
mg
/
day
-
19
.
4
(
N
=
34
)
-
23
.
2
(
N
=
31
)
-
19
.
4
(
N
=
20
)
Table
5
:
Change
in
Tri
##gly
##cer
##ides
Mean
Change
from
Basel
##ine
[SEP]
[CLS]
(
mg
/
d
##L
)
3
-
6
months
6
-
12
months
>
12
months
FA
##NA
##P
##T
10
-
16
mg
/
day
-
8
.
9
(
N
=
78
##3
)
-
8
.
9
(
N
=
72
##6
)
-
17
.
7
(
N
=
42
##8
)
FA
##NA
##P
##T
20
-
24
mg
/
day
-
26
.
6
(
[SEP]
[CLS]
N
=
34
)
-
35
.
4
(
N
=
31
)
-
17
.
7
(
N
=
20
)
Weight
G
##ain
Weight
gain
has
been
observed
with
at
##y
##pical
anti
##psy
##cho
##tic
use
.
[SEP]
[CLS]
In
the
place
##bo
-
controlled
e
##pile
##psy
trials
,
`
`
u
##rina
##ry
retention
,
'
'
`
`
u
##rina
##ry
hesitation
,
'
'
and
`
`
d
##ys
##uria
'
'
were
reported
in
0
.
9
%
,
2
.
2
%
,
and
[SEP]
[CLS]
2
.
3
%
of
patients
on
P
##OT
##IG
##A
,
respectively
,
and
in
0
.
5
%
,
0
.
9
%
,
and
0
.
7
%
of
patients
on
place
##bo
,
respectively
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
type
2
diabetes
for
an
average
of
7
years
and
had
a
mean
H
##b
##A
##1
##c
of
8
.
1
%
.
[SEP]
[CLS]
*
H
##y
##po
##gly
##ce
##mia
:
When
T
##R
##U
##L
##IC
##IT
##Y
is
used
with
an
insulin
secret
##ago
##gue
(
e
.
g
.
,
a
su
##lf
##ony
##lu
##rea
)
or
insulin
,
consider
lowering
the
dose
of
the
su
##lf
##ony
##lu
##rea
or
insulin
to
[SEP]
[CLS]
reduce
the
risk
of
h
##y
##po
##gly
##ce
##mia
(
5
.
3
)
.
[SEP]
[CLS]
Approximately
55
%
of
subjects
were
female
,
45
%
were
male
,
and
94
%
were
Caucasian
.
[SEP]
[CLS]
In
some
cases
,
h
##yper
##gly
##ce
##mia
has
resolved
when
the
at
##y
##pical
anti
##psy
##cho
##tic
was
discontinued
;
however
,
some
patients
required
continuation
of
anti
##dia
##bet
##ic
treatment
despite
disco
##ntin
##uation
of
the
suspect
drug
.
[SEP]
[CLS]
At
one
year
after
transplant
##ation
,
s
##ys
##to
##lic
blood
pressures
were
8
mm
##H
##g
lower
and
di
##ast
##olic
blood
pressures
were
3
mm
##H
##g
lower
in
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
compared
[SEP]
[CLS]
to
the
c
##y
##c
##los
##por
##ine
control
regime
##n
.
[SEP]
[CLS]
A
##vo
##id
the
use
of
AD
##CE
##TR
##IS
in
patients
with
severe
re
##nal
imp
##air
##ment
[
c
##rea
##tin
##ine
clearance
(
C
##L
##c
##r
)
<
30
m
##L
/
min
]
[
see
Use
in
S
##pecific
Population
##s
(
8
.
6
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
V
##as
##cular
disorders
:
art
##erial
th
##rom
##boe
##mbo
##lic
events
(
including
pulmonary
em
##bol
##i
,
deep
vein
th
##rom
##bos
##is
,
cerebral
th
##rom
##bos
##is
,
my
##oc
##ard
##ial
in
##far
##ction
and
stroke
)
,
h
##yper
##tens
##ion
He
##pa
##to
##bil
##iary
disorders
:
[SEP]
[CLS]
G
##all
##bla
##dder
disease
,
he
##pa
##titis
I
##mm
##une
system
disorders
:
H
##yper
##sen
##si
##ti
##vity
Met
##ab
##olis
##m
and
nutrition
disorders
:
F
##lu
##id
retention
,
h
##yper
##tri
##gly
##cer
##ide
##mia
N
##er
##vous
system
disorders
:
Di
##zzi
##ness
Skin
and
sub
##cut
##aneous
tissue
disorders
:
[SEP]
[CLS]
Ch
##lo
##as
##ma
,
an
##gio
##ede
##ma
,
er
##yt
##hem
##a
nod
##os
##um
,
er
##yt
##hem
##a
multi
##form
##e
Gas
##tro
##int
##est
##inal
disorders
:
Gas
##tro
##int
##est
##inal
symptoms
(
for
example
,
abdominal
pain
)
In
##fect
##ions
and
in
##fest
##ations
:
V
##ul
##vo
##va
##gin
##al
can
##di
##dia
##sis
B
##OX
##ED
WA
##R
##NI
##NG
:
[SEP]
[CLS]
WA
##R
##NI
##NG
:
C
##IG
##AR
##ET
##TE
SM
##OK
##ING
AND
SE
##RI
##O
##US
CA
##RD
##IO
##VA
##SC
##U
##LA
##R
E
##VE
##NT
##S
WA
##R
##NI
##NG
:
C
##IG
##AR
##ET
##TE
SM
##OK
##ING
AND
SE
##RI
##O
##US
CA
##RD
##IO
##VA
##SC
##U
##LA
##R
E
##VE
##NT
##S
C
##iga
##ret
##te
smoking
increases
the
risk
of
serious
card
##iovascular
events
from
combination
oral
con
##tra
##ceptive
##s
(
[SEP]
[CLS]
CO
##C
)
use
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
were
ass
##ay
##ed
for
all
patients
(
204
)
in
Study
1
.
[SEP]
[CLS]
Eye
disorders
:
dip
##lop
##ia
,
p
##ap
##ille
##de
##ma
,
re
##tina
##l
toxicity
.
[SEP]
[CLS]
Ra
##sh
occurred
most
commonly
during
the
first
6
weeks
of
therapy
.
[SEP]
[CLS]
(
2
.
2
,
5
.
5
)
*
Brady
##card
##ia
:
Z
##Y
##KA
##DI
##A
can
cause
bra
##dy
##card
##ia
.
[SEP]
